[
  {
    "id": 1,
    "question": "ä»¥ä¸‹é—œæ–¼é ­é ¸ç™Œæ ¹æ²»æ€§æ”¾å°„ç·šåŒ–å­¸æ²»ç™‚,ä½•è€…æ­£ç¢º?",
    "options": [
      "é‡å° locally advanced HPV-positive oropharyngeal cancer,å› å…¶é å¾Œè¼ƒä½³,ä¸”å°æ”¾å°„ç·šæ²»ç™‚æ•ˆæœè‰¯å¥½,æ‡‰å„ªå…ˆè€ƒæ…®ä½¿ç”¨ cetuximab åˆä½µæ”¾å°„æ²»ç™‚ã€‚",
      "é‡å° locally advanced HPV-positive oropharyngeal cancer,ä½¿ç”¨ cetuximab åˆä½µæ”¾å°„æ²»ç™‚ç›¸è¼ƒæ–¼ cisplatin åˆä½µæ”¾å°„æ²»ç™‚,overall survival ç„¡é¡¯è‘—å·®ç•°ã€‚",
      "é‡å° locally advanced head and neck squamous cell carcinoma, ä½¿ç”¨ pembrolizumab åˆä½µplatinum-based CCRT ç›¸è¼ƒæ–¼åƒ…æ¥å—platinum-based CCRT,ç„¡æ³•é¡¯ç¤ºæœ‰è¼ƒä½³çš„ progression free survivalã€‚",
      "é‡å° locally advanced head and neck squamous cell carcinoma, ä½¿ç”¨ avelumab åˆä½µ platinum-based CCRT ç›¸è¼ƒæ–¼åƒ…æ¥å— platinum-based CCRT,æœ‰è¼ƒä½³çš„ progression free survivalã€‚",
      "ä»¥ä¸Šçš†é"
    ],
    "correctAnswer": 4,
    "explanation": "(A)(B) for HPV+ (p16+) oropharyngeal cancer, æ˜¯å¦å¯ä»¥downgrade tx to Cetuximab-RT\r\n\r\n\r\næ ¹æ“šä¸‰å€‹è‡¨åºŠè©¦é©—: \r\n(Triweekly Cis vs Cetuximab)RTOG 1016, De-ESCALaTE\r\n(Weekly Cis vs Cetuximab)TROG 12.01\r\nçµæœå‡é¡¯ç¤º Cetuximab-RT OSè¼ƒå·®, Locoregional failure rateè¼ƒé«˜\r\n\r\n(C) Keynote 412 => Pembrolizumab + CRT vs CRT, primary endpoint: EFSæ²’å·® \r\n\r\n(D) JAVELINE head and neck 100 => Avelumab + CRT vs CRT, PFSæ²’å·®\r\n\r\n=> (A)(B)(D) çµè«–éŒ¯èª¤, (C)æ‡‰æ˜¯EFSä¸æ˜¯PFS\r\n=> ç­”æ¡ˆç‚ºE\r\n\r\n[Ref.]\r\n*RTOG 1016: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32779-X/abstract\r\n*De-ESCALaTE\r\nhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32752-1/fulltext\r\n*TROG 12.01https://www.redjournal.org/article/S0360-3016(21)00376-X/abstract\r\n*Keynote 412\r\nhttps://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00100-1/abstract\r\n*Javeline head and neck 100\r\nhttps://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30737-3/abstract",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 2,
    "question": "ä¸€ä½ 53 æ­²çš„ç”·æ€§ç—…æ‚£ç½¹æ‚£ hypopharyngeal squamous cell carcinoma,cT4aN0M0,ç¶“éæ‰‹è¡“ä¹‹å¾Œä¹‹å¾Œå†æ¥å— adjuvant CCRT ç²å¾—ç·©è§£ã€‚æ”¾å°„æ²»ç™‚çµæŸå¾Œç´„ä¸€å¹´ç™¼ç”Ÿ multiple lung metastasis,ä»¥ä¸‹æ²»ç™‚ä¸­,ä½•è€…è­‰æ“šæœ€å¼±?",
    "options": [
      "Clinical trial",
      "EXTREME regimen",
      "Pembrolizumab alone",
      "Durvalumab plus Tremelimumab",
      "Pembrolizumab plus platinum/5-FU"
    ],
    "correctAnswer": 3,
    "explanation": "é€™é¡Œè€ƒäº†å¹¾å€‹è‡¨åºŠè©¦é©—\r\n(B) EXTREME (æ”¶no prior tx for 6 months)\r\n(C) (E) Keynote 048 (æ”¶no prior tx for 6 months)\r\n(D) KESTREL =>Durvalumab + Tremelimumab not superior to the EXTREME regimen characterized by high PD-L1 expression (TC â‰¥50% or IC â‰¥25%)\r\n\r\nPS: å…¶å¯¦ä¸çŸ¥é“(A)ä¾†å¹¹å˜›çš„...ä¸é(D)ç¢ºå®šæ˜¯å¤±æ•—çš„è‡¨åºŠè©¦é©—ï¼Œæ•…é¸(D)\r\n\r\n[Ref.]\r\n*KESTREL study\r\nhttps://www.annalsofoncology.org/article/S0923-7534(22)04778-0/fulltext",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 3,
    "question": "é—œæ–¼ nasopharyngeal carcinoma ,ä¸‹åˆ—æ•˜è¿°ä½•è€…æ­£ç¢º?",
    "options": [
      "WHO type I NPC çš„ç—…ç†æª¢é«”, EBER æª¢é©—å¤šç‚ºé™½æ€§ã€‚",
      "WHO type III NPC ç‚º non-keratinizing differentiated typeã€‚",
      "Locally advanced NPC (Stage III-IVA) ç´„ä½”æ•´é«” NPC çš„ 30-40%ã€‚",
      "De novo metastatic NPC (Stage IVB) ç´„ä½”æ•´é«” NPC çš„ 10-20%ã€‚",
      "é¼»å’½ç™Œå¥½ç™¼çš„å¹´é½¡æ—ç¾¤è¼ƒå…¶ä»–é ­é ¸ç™Œå¤§ã€‚"
    ],
    "correctAnswer": 3,
    "explanation": "(A) éŒ¯èª¤, æ‡‰æ˜¯WHO type 3\r\n(B) éŒ¯èª¤, WHO type 3 æ‡‰æ˜¯ non-keratinizing â€œundifferentiatedâ€ type\r\n(C) éŒ¯èª¤, LA-NPC æ¯”ä¾‹ æ–‡ç»ä¸Šæåˆ° ~70%\r\n(https://www.sciencedirect.com/science/article/pii/S0305737224001683)\r\n(D) æ­£ç¢º, prospective PET screening for NPC, de novo metastatic NPC  14.8%\r\n(https://ascopubs.org/doi/10.1200/JCO.2012.46.0816?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed)\r\n(E) éŒ¯èª¤, é¼»å’½ç™Œå¥½ç™¼å¹´é½¡æ—ç¾¤è¼ƒå…¶ä»–é ­é ¸ç™Œå° (111å¹´ç™Œç™»å¹´å ±)\r\n*é ­é ¸ç™Œ(Figure 1)\r\n*é¼»å’½ç™Œ(Figure 2)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/003/explain_figures/Figure 1.jpg",
      "/qabank/003/explain_figures/Figure 2.jpg"
    ]
  },
  {
    "id": 4,
    "question": "é—œæ–¼ nasopharyngeal carcinoma çš„ induction chemotherapy ,ä¸‹åˆ—æ•˜è¿°ä½•è€…æ­£ç¢º?",
    "options": [
      "3 cycles of gemcitabine/cisplatin following by standard chemoradiotherapy èˆ‡ standard chemoradiotherapy ç›¸è¼ƒ,å¯æ˜é¡¯æ”¹å–„ locally advanced NPC çš„ overall survival, distant recurrence-free survival,ä½†å°æ–¼ locoregional recurrence-free survival æ²’æœ‰å¹«åŠ©ã€‚",
      "Gemcitabine/ cisplatin ä½œç‚º NPC induction chemotherapy or adjuvant chemotherapy çš†æœ‰è‰¯å¥½çš„æ•ˆæœã€‚",
      "ä½œç‚º Induction chemotherapy,gemcitabine/cisplatin èˆ‡ cisplatin/5-FU æ•ˆæœç›¸ç•¶ã€‚",
      "ä½œç‚º Induction chemotherapy,gemcitabine/cisplatin é¡¯è‘—å„ªæ–¼ cisplatin/5-FUã€‚",
      "ä½œç‚º Induction chemotherapy,docetaxel/cisplatin/5-FU é¡¯è‘—å„ªæ–¼ docetaxel/cisplatinã€‚"
    ],
    "correctAnswer": 0,
    "explanation": "(A) æ­£ç¢º\r\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa1905287\r\n\r\n(B) éŒ¯èª¤, adjuvant GP no RFS benefit\r\nhttps://ascopubs.org/doi/10.1200/JCO.2018.77.7847?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed\r\n\r\n(C) (D) éŒ¯èª¤ ç›®å‰æ‡‰æ²’æœ‰induction GP vs PFçš„è‡¨åºŠè©¦é©—\r\n(E) éŒ¯èª¤  ç›®å‰æ²’æœ‰induction TPF vs TPçš„è‡¨åºŠè©¦é©—\r\n\r\n**é™„ä¸ŠIC for NPC studyé€£çµ\r\n> Induction PF: Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial\r\nhttps://pubmed.ncbi.nlm.nih.gov/31425966/\r\n\r\n> Induction TPF: Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial\r\nhttps://pubmed.ncbi.nlm.nih.gov/27686945/\r\n\r\n> Induction TP: Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma\r\nhttps://pubmed.ncbi.nlm.nih.gov/19064973/\r\n\r\n**PS: é€™é¡Œ(A)æ˜é¡¯æ­£ç¢º\r\n(C)(D)(E)æ»¿æ€ªçš„...å¦‚æœcross-trial comparison, (D)å¯èƒ½å‹‰å¼·ä¹Ÿå°..\r\né™„ä¸Šæ‰€æœ‰induction therapy 3-y OSæ¯”è¼ƒåœ–",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/004/explain_figures/Figure 1.jpg"
    ]
  },
  {
    "id": 5,
    "question": "é—œæ–¼ recurrent or metastatic nasopharyngeal carcinoma æ²»ç™‚ï¼Œä¸‹åˆ—æ•˜è¿°ä½•è€…æ­£ç¢º?",
    "options": [
      "Locally recurrent nasopharyngeal carcinoma åœ¨æ‰‹è¡“å¯è¡Œçš„æƒ…å½¢ä¸‹ï¼Œå¯ä»¥è€ƒæ…®ç›´æ¥ä»¥æ‰‹è¡“åˆ‡é™¤ã€‚",
      "ä½œç‚ºç¬¬ä¸€ç·šæ²»ç™‚ï¼Œgemcitabine/cisplatin versus cisplatin/5-FU ä¸¦æœªé¡¯ç¾å‡ºè¼ƒå¥½çš„æ²»ç™‚æˆæ•ˆã€‚",
      "Gemcitabine/ cisplatin å’Œ cisplatin/5-FU ç›¸æ¯”ï¼Œé€ æˆè¼ƒå°‘çš„ hematologic adverse eventsã€‚",
      "ä½œç‚ºç¬¬ä¸€ç·šæ²»ç™‚ï¼Œtoripalimab plus chemotherapy versus chemotherapy alone ç„¡æ³•é¡¯è‘—æ”¹å–„ progression free survivalã€‚",
      "ä½œç‚ºç¬¬ä¸€ç·šæ²»ç™‚ï¼Œpembrolizumab plus chemotherapy versus chemotherapy alone å¯ä»¥é¡¯è‘—æ”¹å–„overall survivalã€‚"
    ],
    "correctAnswer": 0,
    "explanation": "(B)(C)æ ¹æ“šGEM20110714ï¼ŒGCæœ‰é¡¯è‘—è¼ƒé•·çš„PFSå’ŒOSï¼Œä½†æœ‰è¼ƒå¤šçš„grade 3 and 4 hematologic adverse events\n(D)æ ¹æ“šJUPITER-02ï¼Œtoripalimab+GP vs GPæœ‰PFSå¥½è™•(Final OSä¹Ÿæœ‰å¥½è™•: not reached vs 33.7m, HR 0.63)\n(E)Pembroåœ¨recurrent/metastatic NPCåªæœ‰KN-122ï¼ˆcisplatin pretreated recurrent NPCï¼‰ç ”ç©¶Pembro mono therapy vs physician choice chemotherapy, å³ä¾¿åœ¨trialæ”¶éŒ„ç—…äººPD-L1 CPS>1ä½”7æˆçš„æƒ…æ³ä¸‹OSä¹Ÿæ²’æœ‰benefit (ORRä¹Ÿæ²’æœ‰)ã€‚ç›®å‰ä¹Ÿç„¡ç¬¬ä¸€ç·šæ²»ç™‚æ¯”è¼ƒPembro + Chemo vs Chemo alone in NPCã€‚",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 6,
    "question": "ä¾æ“šç¾æœ‰ä¹‹è­‰æ“šï¼Œä»¥ä¸‹é ­é ¸è…«ç˜¤ä¸­ä½¿ç”¨ next-generation sequencingï¼Œä½•è€…ç™¼ç¾ druggable mutation çš„æ©Ÿæœƒæœ€ä½?",
    "options": [
      "Adenoid cystic carcinoma of salivary gland",
      "Salivary duct carcinoma of salivary gland",
      "Myoepithelial carcinoma of salivary gland",
      "Follicular thyroid cancer",
      "Papillary thyroid cancer"
    ],
    "correctAnswer": 0,
    "explanation": "(A)Adenoid cystic carcinoma: MYB-NFIB gene fusion(é‚„æœªæœ‰é‡å°è©²gene fusionçš„è—¥ç‰©)ï¼ŒNOTCH1ï¼Œlow TMB\n(B)Salivary duct carcinoma: PIK3CA(50%), HER2 amplification(15-40%)\n(C)Myoepithelial carcinoma: BRAF(5%), PIK3CA\n(D)Follicular thyroid cancer: PI3K/Akt\n(E)Papillary thyroid cancer: RET gene rearrangements(10-20%), BRAF V600E(60%)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 7,
    "question": "é—œæ–¼å”¾æ¶²è…ºè…«ç˜¤ï¼Œä¸‹åˆ—ä½•è€…ç‚ºçœŸ?",
    "options": [
      "Histology prevalence æœ€é«˜çš„æ˜¯ salivary duct carcinoma",
      "å°æ–¼ adenoid cystic carcinomaï¼Œcisplatin/doxorubicin/cyclophosphamide å¯ä»¥æä¾›ç´„ 50-60%çš„\nresponse rate",
      "å°æ–¼ adenoid cystic carcinomaï¼Œæ‡‰å¸¸è¦ä½¿ç”¨ next-generation sequencing screening for druggable\nmutation",
      "å°æ–¼ adenoid cystic carcinomaï¼Œlenvatinib æ˜¯ä¸€å€‹å¯ä»¥è€ƒæ…®çš„æ²»ç™‚æ–¹å¼",
      "å°æ–¼ salivary duct carcinoma ä»¥åŠ mucoepidermoid carcinomaï¼Œplatinum-based chemotherapy\nç‚ºæ²»ç™‚é¦–é¸"
    ],
    "correctAnswer": 3,
    "explanation": "(A)æœ€å¸¸è¦‹çš„æƒ¡æ€§salivary gland tumoræ˜¯mucoepidermoid carcinoma(30-35%)ï¼Œsalivary duct carcinomaå 1-3%\n(B)ACCå°åŒ–ç™‚çš„åæ‡‰å·®ï¼Œå°±ä¸åŒåŒ–ç™‚è™•æ–¹response rateç‚º10-30% (å¸¸è¦‹chemotherapyç‚ºCAP in combination or å–®ç”¨anthracycline, vinorebline; Paclitaxelå¯ç”¨åœ¨éACCä¹‹å¤–çš„å…¶ä»–salivary cancerè€Œä¸ç”¨åœ¨ACCå› ç‚ºæ•ˆæœå¤ªå·®)\n(C)ACCè¼ƒå¸¸è¦‹MYB-NFIB gene fusionï¼ŒNOTCH1ï¼Œlow TMBï¼Œæ²’æœ‰æ˜ç¢ºdruggable targetï¼ŒNGSéå¸¸è¦å»ºè­°\n(D)åœ¨R/M ACCçš„phase II trialä¸­DCR 88% (PR 15.6%, SD 75%)(J Clin Oncol 2019;37:1529-1537)\n(E)æ‡‰å…ˆæª¢é©—HER2æ˜¯å¦é™½æ€§(30% mucoepidermoid carcinoma, 40% salivary duct carcinoma), è‹¥æœ‰HER2é™½æ€§æ‡‰å…ˆä½¿ç”¨HER2 directed therapy",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 8,
    "question": "ä»¥ä¸‹æœ‰é—œè—¥ç‰©åŠå…¶ä¸»è¦æˆ–ç‰¹æœ‰å‰¯ä½œç”¨çš„é…å°ä¸­ï¼Œä½•è€…ä¸æ­£ç¢º?",
    "options": [
      "CDK4/6 inhibitor: neutropenic fever",
      "PI3K inhibitor: hyperglycemia",
      "Trastuzumab deruxtecan (TDXd): interstitial pneumonitis",
      "PARP inhibitor: anemia",
      "Aromatase inhibitor: joint pain"
    ],
    "correctAnswer": 0,
    "explanation": "ä½¿ç”¨CDK4/6 inhibitorså®¹æ˜“é€ æˆneutropeniaï¼Œè‡¨åºŠè©¦é©—ä¸­ribociclib or palbociclibç”¢ç”Ÿgrade 3 neutropeniaçš„æ¯”ä¾‹å¤§æ–¼50%ï¼Œabemaciclibç´„20%ï¼Œç„¶è€Œçµ±è¨ˆç™¼ç”Ÿneutropenic feverçš„é¢¨éšªç›¸å°ä½(ç´„1-2%)ã€‚",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 9,
    "question": "46 æ­² de novo stage IV ä¹³ç™Œï¼ŒcT2N3M1ï¼ŒER+ PR+ HER2-ï¼Œè‚ºéƒ¨æœ‰å…©å€‹ 1-2 cm nodulesï¼Œè‚è‡Ÿä¹Ÿæœ‰ä¸€å€‹ 3 cm è½‰ç§»ç—…ç¶ï¼Œç„¡å…¶ä»–è‡Ÿå™¨è½‰ç§»ç—‡ç‹€ï¼Œä¸ƒå€‹æœˆå‰é‚„æœ‰æœˆç¶“ä¾†ã€‚ä»¥ä¸‹æœ‰é—œç¬¬ä¸€ç·šæ²»ç™‚çš„æ•˜è¿°ä¸­ï¼Œä½•è€…éŒ¯èª¤ï¼Ÿ",
    "options": [
      "å¯æª¢æ¸¬ FSH/LH/estrodiol æ±ºå®šæ˜¯å¦è¦ åŠ ä¸Š GnRHa æ²»ç™‚",
      "è…«ç˜¤æª¢æ¸¬å¦‚æœæœ‰ PIK3CA çªè®Šï¼Œæ‡‰è©²ç¬¬ä¸€ç·šä½¿ç”¨ CDK4/6 inhibitor+PI3K inhibitor æ²»ç™‚",
      "å¯è€ƒæ…®åµå·¢åˆ‡é™¤ï¼ŒåŠ ä¸Š aromatase inhibitor+CDK4/6 inhibitor",
      "ä¸æƒ³åˆ‡é™¤åµå·¢ï¼Œå¯ä»¥ç”¨ GnRHa+tamoxifen/AI+CDK4/6 inhibitor",
      "é™¤éæœ‰è‡Ÿå™¨å±è±¡(visceral crisis)ï¼Œå¦å‰‡åŒ–å­¸æ²»ç™‚æ‡‰è©²åœ¨ç¬¬äºŒæˆ–ä¸‰ç·šå†è€ƒé‡"
    ],
    "correctAnswer": 1,
    "explanation": "æ­¤é¡Œè€ƒè½‰ç§»æ€§è·çˆ¾è’™å—é«”é™½æ€§ä¹³ç™Œçš„æ²»ç™‚æ¶æ§‹\nACDEé¸é …è€ƒOvary function suppression, ETåŠCDK4/6içš„æ‡‰ç”¨\nBé¸é …è€ƒäºŒç·šå¾Œçš„æ²»ç™‚é¸é …\n\né™„ä¸Š2024 ASCO education book æ¶æ§‹åœ–(https://ascopubs.org/doi/10.1200/EDBK_432442), éœ€æ³¨æ„åœ–ä¸­4L+æœªåŒ…å«Dato-Dxd (TROPION Breast 01, PFS benefit+, OS benefit-, æ–¼2025/01 FDA approved, å¯èƒ½ç‚ºä»Šå¹´è€ƒé»)\n\nç›®å‰è·çˆ¾è’™å—é«”é™½æ€§è½‰ç§»æ€§ä¹³ç™Œç¬¬ä¸€ç·šæ²»ç™‚\nEndocrine therapyï¼ˆSERM or Aromatase inhibitorï¼‰ + CDK4/6i\nCDK4/6ié¸æ“‡å¯ä»¥æ˜¯\n- Palbociclibï¼ˆPALOMA-2)\n- Ribociclibï¼ˆMONALEESA-2ï¼‰\n- Abemaciclibï¼ˆMONARCH-3ï¼‰\nPALOMA-2, MONALEESA-2, MONARCH-3çš†æ”¶éŒ„åœç¶“å¾Œä¹³ç™Œæ‚£è€…ï¼Œè€Œç”±MONALESSA-7ï¼ˆRibociclibä½¿ç”¨æ–¼Pre- or Peri-menopauseï¼‰å°‡CDK4/6iä½¿ç”¨ç¯„åœæ‹“å±•åˆ°åœç¶“å‰æ‚£è€…ä¹Ÿå¯ä½¿ç”¨ã€‚\n\nä¾ç…§é¡Œå¹¹\nA: Postmenopauseéœ€è¦é€£çºŒç„¡æœˆç¶“é”12å€‹æœˆï¼Œ7å€‹æœˆå‰ä»æœ‰æœˆç¶“ä¾†ä¸Šå°šç„¡æ³•åˆ¤å®šå·²å±¬æ–¼Postmenopauseï¼Œå¯æª¢æ¸¬FSH/Estradiolåˆ¤æ–·åµå·¢åŠŸèƒ½æ˜¯å¦å°šæœªç¬¦åˆåœç¶“å¾Œæ¨™æº–è©•ä¼°éœ€ä¸éœ€è¦é€²è¡ŒOvary function suppressionï¼ˆOFSï¼‰ã€‚\nB: éŒ¯èª¤, äºŒç·šæ¨™æº–æ²»ç™‚ç‚ºSERDç‚ºä¸»å¹¹(å¦‚Fulvestrant), å†ä¾ç…§PI3k-Akt pathway alterationæœ‰ç„¡é¸ç”¨PI3K inhibitorï¼ˆå¦‚alpelisib in SOLAR-1 study and BYlieve studyï¼‰æˆ–AKT inhibitorï¼ˆcapivasertib in capitello-291ï¼‰, ç›®å‰PI3k-Akt pathway alterationç›¸é—œçš„æŠ‘åˆ¶åŠ‘çš†æ˜¯åœ¨äºŒç·šï¼ˆå«ï¼‰ä»¥å¾Œã€‚\nC, D: å¦‚æœä¸é©—FSH/E2, åªä»¥é€£çºŒç„¡æœˆç¶“æœˆä»½åˆ¤æ–·ç—…æ‚£ä»ä¸ç®—é€²å…¥Postmenopauseæ•…éœ€è¦OFSï¼Œæ–¹å¼å¯ä»¥æ¡æ‰‹è¡“ï¼ˆåµå·¢åˆ‡é™¤ï¼‰æˆ–æ˜¯è—¥ç‰©ï¼ˆGnRHaï¼‰ã€‚é€²è¡ŒOFSå¾Œæ²»ç™‚å°±åŒPostmenopausalï¼Œä½¿ç”¨Endocrine therapy + CDK4/6iã€‚\nE: æ²’æœ‰Visceral crisiså„ªå…ˆç”¨ET+CDK4/6iï¼Œåªæ˜¯å› ç‚ºä¹‹å‰çš„ç ”ç©¶æ²’æœ‰æ”¶Visceral crisisç—…æ‚£ã€‚æœ‰Visceral crisisä¹Ÿä¸¦éå°±éœ€æŠŠåŒ–ç™‚æ‹‰åˆ°ç¬¬ä¸€ç·š, æ­¤è§€å¿µå·²åœ¨RIGHTCHOICE studyå¾Œè¢«æ¨ç¿»ï¼ˆET+Ribociclib vs Chemotherapy, ORRçš†ç´„6æˆ, ä¸”PFSèˆ‡Adverse eventè¡¨ç¾éƒ½æ˜¯CDK4/6içµ„æ›´å¥½, æ•…ä¸ç®¡æœ‰ç„¡Visceral crisis, ET+CDK4/6iéƒ½å¯ä»¥ä½œç‚ºç¬¬ä¸€ç·šé¸é …)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/009/explain_figures/Treatment of HR+ Breast cancer algorithm.png"
    ]
  },
  {
    "id": 10,
    "question": "å°æ–¼æ—©æœŸä¹³ç™Œçš„æ²»ç™‚ï¼Œgene expression profile å¯ä»¥ç”¨ä¾†è©•ä¼°å¾©ç™¼æ©Ÿç‡ï¼Œä»¥åŠæ˜¯å¦ä½¿ç”¨adjuvant chemotherapy ä¾†é é˜²å¾©ç™¼ã€‚ä¸‹åˆ—å“ªä¸€ç¨®æª¢æŸ¥ä¸æ‡‰è©²æ‡‰ç”¨æ–¼æ—©æœŸä¹³ç™Œç—…æ‚£ adjuvant treatment çš„æ±ºå®šï¼Ÿ",
    "options": [
      "21-Gene Recurrence Score (Oncotype DX)",
      "70-Gene Assay (Mammaprint)",
      "Tumor tissue NGS (Next generation gene sequencing)",
      "Prediction Analysis of Microarray-50 (PAM50, PAM50 Risk of Recurrence Score, or Prosigna)",
      "12-Gene Risk Score (Endopredict)"
    ],
    "correctAnswer": 2,
    "explanation": "é™¤NGSå¤–å››å€‹é¸é …çš†å¯ï¼ŒHR+ HER2-æ—©æœŸä¹³ç™Œ, å¯ä»¥ä¸‹åˆ—å››ç¨®åŸºå› æª¢æ¸¬ç¶œåˆåˆ¤æ–·æ˜¯å¦éœ€è¦åŠ ä¸ŠåŒ–ç™‚ã€‚\n\næª¢æ¸¬å¹³å°         LN          æª¢æ¸¬åƒæ•¸åŠåˆ¤å®š\nOncoType DX ->   -    | 21 geneåŠå«é‡åˆ¤å®šrecurrence score\nMammaPrint  -> - or + | 70 gene åˆ¤æ–·é¢¨éšª(éœ€åˆä½µclinical riskè©•ä¼°è‡¨åºŠé¢¨éšª)\nPAM50       ->   -    | 50 gene åˆ¤æ–·å±¬æ–¼å“ªç¨®subtype(Luminal A, B, HER2, basal-like)åŠé¢¨éšª\nEndopredict -> - or + | 12 gene åˆ¤æ–·EPclin Score",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 11,
    "question": "Which of the following description regarding uveal melanoma is wrong?",
    "options": [
      "Uveal melanomas can arise anywhere in the uveal tract, with less than 75% arising in the choroid, and the remainder arising in the iris or ciliary body",
      "Molecular markers common in uveal melanomas include chromosomal abnormalities (particularly chromosomes 3 and 8), and mutations in GNAQ or GNA11 (>80% of uveal cases), BAP1, SF3B1, and EIFAX",
      "Treatment efficacy of immune checkpoint inhibitors in uveal melanoma is similar to cutaneous\nmelanoma",
      "Uveal melanoma most often metastasizes to the liver (90% of the time). Other common sites\nof metastasis, listed in order of decreasing prevalence, are lung, bone, skin/soft tissue, and\nlymph nodes",
      "Tebentafusp, a TCR/Anti-CD3 bispecific fusion protein targeting gp100, may provide benefit\nto patients with metastatic uveal melanoma"
    ],
    "correctAnswer": 0,
    "explanation": "Aå¯èƒ½æœ‰çˆ­è­°ä½†Cæ˜é¡¯éŒ¯èª¤ï¼Œæ•…æ‡‰é¸C\n\nAï¼šå¤§å¤šæ•¸çµ±è¨ˆè³‡æ–™Uveal melanomaä¸­Choroidä½”85-90%ï¼Œå‰©é¤˜æ˜¯irisåŠciliary bodyåˆè¨ˆä½”å‰©é¤˜10%ã€‚ç„¡æ³•ç¢ºå®šè€ƒé¡Œç”¨çš„æ˜¯å“ªä»½è³‡æ–™ã€‚éœ€è¦çŸ¥é“æœ€å¤šçš„æ˜¯Choroidå³å¯ã€‚\n\nB: uveal melanoma\nè…«ç˜¤ç™¼å±•æ—©æœŸçš„çªè®Šè·ŸG-protein Î± subunitsç›¸é—œ, ä½”85% (GNAQ and GNA11, mutually exclusive), æœƒæ´»åŒ–ä¸‹æ¸¸MAPK pathwayã€‚\nè…«ç˜¤ç™¼å±•æ™šæœŸçš„çªè®Šç‚ºBAP1, SF3B1 (splicing factor 3B subunit 1), EIF1AX (eukaryotic translation initiation factor 1A X-linked)ã€‚æœ‰SF3B1, EIF1AXçªè®Šé å¾Œæ¯”è¼ƒå¥½ã€‚BAP1å¯ä»¥æ˜¯germline (äº¦å®¹æ˜“é€ æˆmesothelioma)ã€‚\nRef: Devita 12th p. 1605\n\nCéŒ¯èª¤ï¼šImmunotherapyåœ¨Cutaneous melanomaçš„æˆåŠŸæ²’æœ‰è¾¦æ³•è¤‡è£½åœ¨Uveal melanoma, èˆ‰ä¾‹ä»¥CheckMate-067ç‚ºä¾‹ï¼ˆRef C2ï¼‰ï¼ŒORRåˆ†åˆ¥ç‚ºIpi 19%, Nivo 44.9%, Ipi+Nivo 58.3%ã€‚è€ŒUveal melanomaå³ä¾¿ç”¨Ipi+Nivo combined IO therapy ORRä¹Ÿåªæœ‰13.7%ï¼ˆMeta-analysis, Ref C2ï¼‰, å…¶æ–¼å¤§å¤šè³‡æ–™Nivoå–®ç”¨ç´„5%, Ipiå–®ç”¨ç‚º0%ã€‚Devitaäº¦æœ‰æå‡ºå¯èƒ½åŸå› ç‚ºUveal melanoma TMBæ˜é¡¯ä¸å¦‚Cutaneous melanomaã€‚\n\nRef C1: https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.9506\nRef C2: https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.9534\n\nD: æœ€å¸¸è¦‹metastasisåˆ†ç‚ºliver (>90%), Lung (24%), Bone (16%), æœ€å°‘çš„æ˜¯LN & Brain (<6%)\n\nE: Metastatic uveal melanomaçš„ICIæ²»ç™‚æ•ˆæœæ˜é¡¯ä¸å¦‚cutaneous melanoma, æ‡‰ä¾ç…§IMCgp100-202 trialçµæœå„ªå…ˆè€ƒæ…®æ–¼HLA-A*02:01 positiveç—…äººä½¿ç”¨Tebentafusp (BiTE targeting gp100 & CD3), æ–¼trialä¸­ä½¿ç”¨Tebentafuspå°æ¯”æ–¼physician choice therapy (Pembro, Ipi or DTIC)æœ‰OS benefit, æ­¤è—¥ç‰©å¦ä¸€å€‹ç‰¹è‰²æ˜¯å³ä½¿ç”¨Tebentafuspå¾Œbest reponseæ˜¯PDçš„ç—…äººå­˜æ´»ä¹Ÿæ¯”ä½¿ç”¨physician choice therapyå¾Œbest responseæ˜¯PDçš„ç—…äººä¾†å¾—é•·ï¼ˆè¡¨ç¤ºæ­¤è—¥ç‰©çš„æ©Ÿè½‰ç‰¹åˆ¥, responseå³ä¾¿é€£SDéƒ½ç„¡æ³•é”åˆ°ä¹Ÿèƒ½å»¶é•·å­˜æ´»ï¼‰ã€‚\n\nè‹¥ç—…æ‚£ç‚ºHLA-A*02:01 negativeå‰‡æ‰è€ƒæ…®IO, è‹¥ç—…æ‚£ç‚ºliver dominant diseaseå‰‡æ‡‰è©²ç©æ¥µè€ƒæ…®local therapyã€‚é™„ä¸Šuptodateæµç¨‹åœ–æ›´åˆ©æ–¼ç†è§£ã€‚",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/011/explain_figures/Metastatic uveal melanoma treatment.png"
    ]
  },
  {
    "id": 12,
    "question": "According to NCCN guidelines, which of the following therapies can be considered for patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) that is borderline resectable or unresectable, or for whom surgery may carry high morbidity?",
    "options": [
      "Curative radiation therapy",
      "Neoadjuvant cemiplimab",
      "Neoadjuvant cisplatin",
      "Neoadjuvant pembrolizumab",
      "Neoadjuvant nivolumab"
    ],
    "correctAnswer": 0,
    "explanation": "é‡å°ä¸é©åˆæ‰‹è¡“æˆ–ç„¡æ³•æ‰‹è¡“ç—…æ‚£, curative RTç‚ºæœ€å»ºè­°æ–¹å¼ã€‚åŒ–ç™‚å¯è€ƒæ…®èˆ‡RTä¸¦ç”¨ä½œçˆ²CCRT (with cisplatin, PF, TP, cetuximabç­‰radiosensitizer)ã€‚åƒ…åœ¨ä¸é©åˆæ‰‹è¡“æˆ–RTçš„ç—…æ‚£ä½¿ç”¨immunotherapy (å¦‚Cemiplimab, Pembrolizumab)ä½œç‚ºsystemic treatmentã€‚\n\né™„2025 Ver2 NCCN guideline for Squamous Cell Skin Cancerä¾›åƒè€ƒ",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/012/explain_figures/Agents combined with RT.png",
      "/qabank/012/explain_figures/NCCN guideline.png"
    ]
  },
  {
    "id": 13,
    "question": "Which of the following statements about Merkel cell carcinoma (MCC) are INCORRECT?",
    "options": [
      "Sun exposure is believed to be a major risk factor for MCC.",
      "MCC is rarely clinically suspected at presentation because the primary tumor lacks distinguishing features and is often asymptomatic. In a study of 195 patients with pathologically confirmed MCC, 88% of MCC tumors were asymptomatic and correct clinical diagnosis was rare (only 1%).",
      "Merkel cell polyomavirus (MCPyV) is detected in 43% to 100% of tumors, and a much higher mutational burden is found in MCPyV-positive tumors.",
      "Cytokeratin 20 (CK20) and TTF-1 are two useful markers in differential diagnosis between MCC and small cell lung cancer (SCLC) since CK20 is positive in 75% to 100% of MCC and rarely positive in SCLC. TTF-1 is never positive in MCC, but is often positive in SCLC (>80%).",
      "Avelumab, nivolumab, and pembrolizumab are included as recommended systemic therapy options for treatment of disseminated disease."
    ],
    "correctAnswer": 2,
    "explanation": "æ­¤é¡Œå®Œå…¨å‡ºè‡ªNCCN guidelineçš„discussion\r\n\r\n(A) æ­£ç¢ºã€‚UV-mediated somatic mutation, oncogenic viral infection (Merkel cell polyomavirus (MCPyV)), immunosuppressionç‚ºoncogenesisä¸‰å¤§æ©Ÿè½‰ã€‚è…«ç˜¤è¼ƒå¸¸ç™¼ç”Ÿåœ¨sun exposure areaï¼Œç™½äººã€è€å¹´äººé¢¨éšªè¼ƒé«˜ã€‚\r\n\r\n(B) æ­£ç¢ºã€‚é€™æ®µå¾Œçš„å…§æ–‡ç‚º: æ ¹æ“šè‡¨åºŠè¨ºæ–·56% of MCCå‰›é–‹å§‹éƒ½è¢«èªç‚ºæ˜¯benign cysts/lesionsï¼Œå…¶ä»–æ–‡ç»è­‰å¯¦MCCå¸¸è¢«èª¤è¨ºæˆbenign lesionsæˆ–non-melanoma skin cancers (NMSCs)ã€other rare malignant skin tumorsã€‚\r\n\r\n(C) éŒ¯èª¤ã€‚MCPyV is detected in 43% to 100% of tumoræ˜¯æ­£ç¢ºçš„ï¼Œä½†MCPyV-negative tumorçš„mutational burdenæ‰æ˜¯è¼ƒé«˜çš„ï¼Œæ¨æ¸¬æ˜¯è·ŸUV damageæœ‰é—œã€‚\r\n\r\n(D) æ­£ç¢ºã€‚MCCæ˜¯neuroendocrine cell origin (æ­£å¸¸çš®è†šçµ„ç¹”å…§Merkel cellåŠŸèƒ½æ˜¯slowly adapting type I mechanoreceptor)ï¼Œç™ŒåŒ–å¾Œçµ„ç¹”å­¸ä¸‹è·Ÿå…¶ä»–small round cell tumorsç›¸ä¼¼ã€‚å…¶ä¸­æœ€é›£åˆ†è¾¨çš„æ˜¯ç—…ç¶æ˜¯primary MCCæˆ–metastatic SCLCï¼Œå¯è—‰ç”±CK20èˆ‡TTF-1é‘‘åˆ¥ã€‚\r\n\r\n(E) æ­£ç¢ºã€‚NCCNå°æ–¼disseminated diseaseé¦–é¸ç‚ºclinical trialsåŠIO (è¦‹figure 1)\r\nğŸ“JAVELIN Merkel 200 (phase 2): æ”¶éŒ„fresh M1ï¼Œavelumabï¼ŒORR 39.7%, PFS 4.1 mo, OS 20.3 moã€‚\r\nğŸ“KN-017 (phase 2): æ”¶éŒ„fresh advancedï¼Œpembrolizumabï¼ŒORR 58%, PFS 16.8 mo, OS (3y) not reachedã€‚\r\nğŸ“CM-358 (phase 1/2): æ”¶éŒ„â€resectableâ€ï¼Œneoadjuvant nivolumabï¼ŒpCR 47.2%, ORR 54.5%ã€‚é›–æ˜¯åšåœ¨neoadjuvantä½†å…¶æ•ˆæœæ–¼å…¶ä»–IOç›¸ä¼¼ï¼Œå› æ­¤ä¹Ÿåˆ—åœ¨NCCNçš„å»ºè­°ä¸Šã€‚\r\nğŸ“POD1UM-201 (phase 2): æ”¶éŒ„fresh advancedï¼Œretifanlimab (anti-PD1)ï¼ŒORR 52%\r\n\r\nReferences: Devita (12th Ed.) Section 9 Cancer of Skin - Merkel cell carcinomaã€NCCN guideline - Merkel cell carcinoma",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/013/explain_figures/Figure 1.jpg"
    ]
  },
  {
    "id": 14,
    "question": "ä¸‹åˆ—é—œæ–¼NivoCUPçš„è‡¨åºŠè©¦é©—æ•˜è¿°ï¼Œä½•è€…éŒ¯èª¤ï¼Ÿ",
    "options": [
      "A phase 2, single-arm, multicenter study in Japan",
      "å—è©¦è€…åŒ…å«previously untreatedåŠtreatedçš„åŸç™¼éƒ¨ä½ä¸æ˜è½‰ç§»ç™Œç—…æ‚£",
      "æ•´é«”åæ‡‰ç‡ç‚º22.2%ï¼Œå…¶ä¸­PD-L1 TPS â‰¥1%çš„åæ‡‰ç‡ç‚º41%ï¼Œæ˜é¡¯æ¯”PD-L1 TPS <1%çš„åæ‡‰ç‡é«˜",
      "TMBåœ¨æœ¬è©¦é©—çš„ä¸­ä½æ•¸ç‚º7.75 mut/Mbï¼Œå…¶ä¸­TMB â‰¥7.75 mut/Mbçš„åæ‡‰ç‡ç‚º28%ï¼Œæ˜é¡¯æ¯”TMB <7.75 mut/Mbçš„åæ‡‰ç‡é«˜",
      "ç›®å‰NCCN guideline å»ºè­°å¯ä½¿ç”¨nivolumabåœ¨PD-L1 TPS â‰¥1%çš„åŸç™¼éƒ¨ä½ä¸æ˜è½‰ç§»ç™Œçš„ç—…æ‚£"
    ],
    "correctAnswer": 4,
    "explanation": "NivoCUPæ˜¯åœ¨æ—¥æœ¬é€²è¡Œçš„phase 2 study\r\nğŸ“Œ æ”¶éŒ„CUP (æ’é™¤favorable prognosisåŠçµ„ç¹”å­¸æ˜¯melanoma, sarcoma, lymphoma)ï¼Œå…¶ä¸­adenocarcinomaç´„å 64%, SqCCç´„10%, undifferentiated (ä¸€çµ„11.1%, ä¸€çµ„0%)\r\nğŸ“Œ æ¥å—nivolumab 240 mg q2w\r\nğŸ“Œ Primary endpoint: ORR in previously treated group\r\nğŸ“Œ Results\r\nğŸ“ In previous treated group (N=45): ORR 22.2%, DCR 53.3%, PFS 4 mo, OS 15.9 mo\r\nğŸ“ In previous untreated group (N=10): ORR 18.2%, DCR 54.5%, PFS 2.8 mo, OS NR\r\n\r\n(A) æ­£ç¢ºã€‚\r\n\r\n(B) æ­£ç¢ºã€‚previously untreated 10ä½ã€treated 45ä½\r\n\r\n(C) æ­£ç¢ºã€‚å¦‚Figure 1, Figure 2\r\n\r\n(D) æ­£ç¢ºã€‚ä»¥median TMB 7.75 mut/Mbç‚ºåˆ‡é»\r\nHigh (â‰¥7.75 mut/Mb) vs Low (< 7.75 mut/Mb) : ORR 28 vs 12%, DCR 60 vs 36%, PFS 5.1 vs 19% (HR 0.34), OS 20.4 vs 8.4 (HR 0.57)\r\n\r\n(E) éŒ¯èª¤ã€‚ç›®å‰NCCN (2025 Ver.2)å°æ–¼IOåœ¨CUPï¼Œåªå»ºè­°tumor-agnostic therapyçš„pembrolizumab in dMMR/MSI-H, TMB-H (KN-158) (NCCNæ”¾åœ¨adenocarcinoma, SqCC)åŠdostarlimab in dMMR (GARNET trial) (NCCNåªæ”¾åœ¨adenocarcinoma, SqCCç„¡)\r\n\r\nReferences: Ann Oncol. 2022 Feb;33(2):216-226.ã€NCCN guideline - Occult Primary",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/014/explain_figures/Figure 1.jpg",
      "/qabank/014/explain_figures/Figure 2.jpg",
      "/qabank/014/explain_figures/Figure 3.jpg",
      "/qabank/014/explain_figures/Figure 4.jpg"
    ]
  },
  {
    "id": 15,
    "question": "ä¸‹åˆ—æœ‰é—œVon Hippel Lindau (VHL) disease çš„æ•˜è¿°ï¼Œä½•è€…æœ‰èª¤ï¼Ÿ",
    "options": [
      "VHL disease æ˜¯autosomal dominant syndromeã€‚",
      "ç™¼ç”Ÿç‡ç‚º1/36000ï¼Œå¥½ç™¼å¹´é½¡ç‚º60æ­²å·¦å³ã€‚",
      "VHL ç›¸é—œç–¾ç—…ç‚ºhemangioblastoma, neuroendocrine tumor, pheochromocytoma/paraganglioma åŠrenal cell carcinomaã€‚",
      "VHL gene åœ¨chromosome 3ï¼Œå±¬æ–¼tumor suppressor geneã€‚",
      "Belzutifan å¯ç”¨ä¾†æ²»ç™‚VHL ç›¸é—œçš„pancreas neuroendocrine tumor åŠrenal cell carcinomaï¼Œå…¶æ©Ÿè½‰ç‚ºæŠ‘åˆ¶VHL geneã€‚"
    ],
    "correctAnswer": 1,
    "explanation": "ğŸ“Pathophysiology\r\nå¦‚Figure 1ï¼Œä¸€èˆ¬ç”Ÿç†ç‹€æ³ä¸‹ï¼ŒVHL proteinä»¥oxygen-dependentæ–¹å¼æ°´è§£HIF-Î± (hypoxia-inducible factor)ï¼Œç¼ºæ°§æ™‚VHL proteinç„¡æ³•æ°´è§£HIF-Î±é€ æˆå…¶ç´¯ç©ï¼Œå°è‡´HIF-mediated gene expressionçš„target (VEGF, GLUT1, PDGF)å¢åŠ ä¾†å› æ‡‰ç¼ºæ°§æ™‚çš„ç’°å¢ƒ (vascularization, enhancing glucose utilization, increasing red-cell production through transcriptional signals)ã€‚\r\nVHL diseaseçªè®Šçš„VHL proteinç„¡æ³•æ¥ä¸ŠHIF-Î±(oxygen-independent)ï¼Œé€ æˆHIF-Î± stabilizationå¤§é‡ç´¯ç©ï¼Œå°è‡´tumor growth, neovascularizationã€‚\r\n\r\n(A) æ­£ç¢ºã€‚\r\n\r\n(B) éŒ¯èª¤ã€‚ç™¼ç”Ÿç‡ç‚º1/36000æ˜¯å°çš„ï¼Œä½†å¥½ç™¼åœ¨20-40æ­²ã€‚\r\n\r\n(C) æ­£ç¢ºã€‚VHL diseaseç›¸é—œç–¾ç—…ç‚ºclear cell renal tumors, retinal angiomas, central nervous system, hemangioblastomas, tumors of the adrenal gland (pheochromocytoma), endolymphatic sac and pancreatic islet cell, cysts in the pancreas and kidneyã€‚\r\n\r\n(D) æ­£ç¢ºã€‚ä½åœ¨chromosome 3p25-26ï¼Œæ˜¯å…¸å‹çš„â€two-hitâ€tumor suppressor geneï¼Œå…©å€‹alleleéƒ½inactivatedæ‰æœƒè‡´ç™Œã€‚\r\n\r\n(E) é€™é¸é …ç•¥æœ‰çˆ­è­°ã€‚Belzutifanæ˜¯HIF 2-Î± inhibitorï¼ŒFDAæ ¹æ“šLITESPARK-004 (phase 2)æ ¸å‡†ä½¿ç”¨åœ¨VHL associated RCC, CNS hemangioblastoma, pNET not requiring immediate surgeryã€‚æ©Ÿè½‰æ˜¯çµåˆåœ¨HIF 2-Î±ä¸Šï¼Œä½¿å…¶ç„¡æ³•æ´»åŒ–é€ æˆä¸Šè¿°ç›¸é—œVEGFç­‰ç”¢å‡ºï¼Œä¸¦ä¸èˆ‡VHL geneç›´æ¥ç›¸é—œã€‚ç„¶è€Œç›¸è¼ƒä¹‹ä¸‹(B)ç‚ºæ˜é¡¯çš„éŒ¯èª¤ï¼Œæ•…ä»é¸(B)è¼ƒæ°ç•¶ã€‚\r\n\r\nReferences: Devita (12th Ed.) p.733-735, Lancet Oncol. 2024 Oct;25(10):1325-1336.",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/015/explain_figures/Figure 1.jpg"
    ]
  },
  {
    "id": 16,
    "question": "ä¸‹åˆ—æœ‰é—œMultiple Endocrine Neoplasia (MEN) çš„æ•˜è¿°ï¼Œä½•è€…æœ‰èª¤ï¼Ÿ",
    "options": [
      "MEN1 å¤§å¤šæ˜¯ autosomal dominant syndromeã€‚",
      "MEN1 æ˜¯å› ç‚º MEN1 gene çªè®Šå°è‡´ã€‚",
      "MEN2 ä¸»è¦çªè®Šåœ¨ RET oncogene çš„ exon 10 å’Œ 11ï¼ŒMEN3 ä¸»è¦åœ¨ RET M918T çš„é»çªè®Šã€‚",
      "MEN3 çš„ç™¼ç”Ÿç‡æ¯” MEN2 é«˜ä¸”é å¾Œæ¯”è¼ƒå¥½ã€‚",
      "MEN4 çªè®Šåœ¨ CDKN1B geneï¼Œæ˜¯ MEN1 çš„äºå‹ã€‚"
    ],
    "correctAnswer": 3,
    "explanation": "ğŸ“æ•´ç†è¡¨æ ¼è«‹è¦‹Table 1\r\n\r\n(A), (B), (C) æ­£ç¢º\r\n\r\n(D) éŒ¯èª¤ã€‚MEN2B (MEN3)éå¸¸å°‘è¦‹ï¼Œä¸”å› RET M918T mutationæœƒé€ æˆaggressive, early-onset medullary thyroid carcinoma (MTC)ï¼Œæ‰€ä»¥é å¾Œè¼ƒå·®ã€‚\r\n\r\n(E) MEN4èˆ‡MEN1è‡¨åºŠè¡¨ç¾ç›¸ä¼¼ï¼Œä½†è‡´ç—…åŸºå› ä¸åŒï¼Œåœ¨HarrisonåŠç›¸é—œpaperå¤§å¤šæ˜¯ç¨ç«‹å‡ºä¾†ï¼Œä¸é(D)é¸é …æ˜é¡¯éŒ¯èª¤ï¼Œæ•…é¸(D)è¼ƒé©ç•¶ã€‚\r\n\r\nReferences: NCCN guideline - Neuroendocrine and Adrenal Tumorsã€Harrison Ch. 388 Multiple Endocrine Neoplasia Syndromesã€Intern Med J. 2019 Aug;49(8):954-961.ã€Ann Transl Med. 2021 Jun;9(11):944",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/016/explain_figures/Table 1.jpg"
    ]
  },
  {
    "id": 17,
    "question": "One 55 year-old male patient got metastatic urothelial carcinoma. He received gemzar-carboplatin treatment. Initially, the response was stable disease; however, disease progression developed 1 month later. After disease progression, his kidney function was still cisplatin-ineligible. The\nECOG status was 1. The PD-L1 was less than 10 % in the CPS score. The next-generation sequencing data from the cancer tissue showed FGFR3â€“TACC3_V1 fusion. In the current situation, what is the best-recommended treatment for his disease, and what is its evidence?",
    "options": [
      "Enfortumab vedotin (EV-301)",
      "Avelumab (JAVELIN Bladder 100)",
      "Erdafitinib (THOR)",
      "Pembrolizumab (KEYNOTE-052)",
      "re-challenge with gemcitabine"
    ],
    "correctAnswer": 2,
    "explanation": "(C)ç‚ºæ­£è§£ã€‚ æ ¹æ“š THOR study (2023 NEJM), â‰¥2 lines setting, åœ¨æœ‰FGFR3/2 alteration çš„unresectable/metastatic UCç—…äººï¼ŒErdafitinibå‹éChT (cohort 1), ç„¶è€Œåœ¨cohort 2ä¸­Erdafitinib vs pembrolzumabä¸¦ç„¡é”åˆ°çµ±è¨ˆå·®ç•°ã€‚å›é¡§é¡Œå¹¹ï¼Œæ­¤ç—…äººæœ‰FGFR3â€“TACC3_V1 fusionï¼Œç‚ºTHOR study includeçš„FGFR alterationä¹‹ä¸€ï¼ˆFGFR3 S249C mutations (47 percent), FGFR3 Y373C mutation (17 percent), FGFR3TACC3_V1 fusion (10 percent)ï¼‰ï¼Œæ•…äºŒç·šdå¯ä½¿ç”¨Erdafitinibåšç‚ºæ²»ç™‚ï¼ŒæƒŸç—…äººå°šæœªæ¥å—éå…ç–«æ²»ç™‚ï¼Œè‹¥å¯ã€‚æ­¤ç—…äººä½¿ç”¨pembrolizumabäº¦ç„¡ä¸å¯ï¼Œä½†å¼•ç”¨çš„evidenceæ˜¯KN-045è€ŒéKN-052ã€‚[KN-052ç‚º 1st-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic UC]\nè‹¥ç—…äººç„¡FGFR alterations, ä¾ç…§guidelineå¯ä»¥ç‚ºç—…äººé¸æ“‡pembrolizumab (KN-045) éé¸é …(D)Pembrolizumab (KEYNOTE-052) ã€‚\n(A) Enfortumab vedotin (EV-301)å‰‡é©ç”¨æ–¼PD after anti-PD-(L)1çš„æƒ…æ³ã€‚\n(B) Avelumab (JAVELIN Bladder 100)é©ç”¨æ™‚æ©Ÿå‰‡æ‡‰æ˜¯ç—…äººCR/PR/SD after GP or GCï¼Œæ¥ä¸Šmaintenance avelumabã€‚",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/017/explain_figures/ESMO_UC.jpg",
      "/qabank/017/explain_figures/THOR_trial.jpg",
      "/qabank/017/explain_figures/THOR_trial_2.jpg"
    ]
  },
  {
    "id": 18,
    "question": "Recently, the combination of new hormonal agents (NHA) with PARP inhibitors can be used to treat metastatic prostate cancer (PC). The following statements are incorrect:",
    "options": [
      "The target population is metastatic castration-resistant prostate cancer.",
      "There are several studies that demonstrated positive results, such as talazoparib+enzalutamide  and olaparib+abiraterone.",
      "EMA agrees that olaparib can be in combination with abiraterone as 1st-line treatment in  all comer setting.",
      "EMA agrees that combination of talazoparib and enzalutamide for the treatment of patients   with metastatic prostate cancer.",
      "Denosumab can not reduce the risk of bone side effects."
    ],
    "correctAnswer": 4,
    "explanation": "é€™é¡Œä¸»è¦æ˜¯è¦è€ƒPROpel study (olaparib+abiraterone+prednisone /prednisolone)åŠTALAPRO-2 study (talazoparib + enzalutamide)ï¼Œå…©è€…çš†æ˜¯mCRPC 1st lineçš„studyã€‚\n(E)é¸é …éŒ¯èª¤ã€‚æ•´é«”è€Œè¨€FDAæ¯”EMAåš´æ ¼ï¼ŒFDA approve olaparibç”¨æ–¼BRCA mutationç—…äººï¼Œè€Œtalazoparibé€šéçš„æ˜¯HRR mutationï¼›EMAå‰‡éƒ½æ˜¯all comerã€‚ å•Šä¸éé€™å…©å€‹trialå…¶å¯¦åœ¨all comers populationçš†ç‚ºpositive trials.\n((è€ƒå¾—ä¹Ÿå¤ªç´°æƒ¹æ‹”QQ\n(A)æ­£ç¢ºï¼Œtarget populationç‚ºmCRPCã€‚\n(B)æ­£ç¢ºï¼ŒPROpel study (olaparib+abiraterone+prednisone /prednisolone)åŠTALAPRO-2 study (talazoparib + enzalutamide)çš†ç‚ºpositive trialã€‚\n(C)æ­£ç¢ºï¼Œæ ¹æ“šä¸Šè¡¨EMAé©æ‡‰ç—‡æœ‰é€šé olaparib in combination with abiraterone as 1st-line treatment in all comer setting.\n(D)æ­£ç¢ºï¼Œæ ¹æ“šTALAPRO-2 studyï¼ŒEMAé€šétalazoparib+enzalutamide in mCRPC 1st line treatment. æ­¤å¤–ï¼Œä»Šå¹´ASCO GUç™¼è¡¨äº†OSçš„dataï¼Œ\nâ€œAmong the 805 unselected patients followed for a median of approximately 53 months, median OS reached 45.8 months with talazoparib plus enzalutamide versus 37.0 months with placebo plus enzalutamideâ€”about a 9-month survival advantage (HR 0.796, 95% CI [0.661, 0.958]; 2-sided P = .0155)â€”which met the threshold for statistical significance (P â‰¤ .022)â€",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/018/explain_figures/EMA_PARP.jpg",
      "/qabank/018/explain_figures/PROpel.jpg",
      "/qabank/018/explain_figures/PROpel_rPFS.jpg",
      "/qabank/018/explain_figures/TALAPRO2_OS.jpg",
      "/qabank/018/explain_figures/TARLAPRO_2.jpg"
    ]
  },
  {
    "id": 19,
    "question": "One 29 year-old male patient got testicular seminoma. Initial tumor marker was within normal limit. After staging work-up, he received orchiectomy. The pathological stage is stage I seminoma. Which of the following statements regarding the treatment is correct ?",
    "options": [
      "Active surveillance",
      "Adjuvant treatment with radiotherapy to para-aortic lymph nodes",
      "Adjuvant 20 Gy administered in 10 daily 2.0 fractions to para-aortic and/or ipsilateral iliac  lymph nodes",
      "Adjuvant 1-2 cycles of chemotherapy with carboplatin, dosed at the area under the curve  (AUC) of 7",
      "All of above"
    ],
    "correctAnswer": 4,
    "explanation": "æ ¹æ“šNCCN guideline, stage I testicular seminomaå¯ä»¥æ¡å–(A)Active surveillance (B)(C) Adjuvant RT (D) Adjuvant 2 cycles of chemotherapy with carboplatin (AUC=7); å› æ­¤ç­”æ¡ˆç‚ºä»¥ä¸Šçš†æ˜¯(E)ã€‚\n(B)æ­£ç¢ºï¼Œå¦‚é™„åœ–ï¼Œseminomaæœ€å®¹æ˜“æ“´æ•£çš„LNç‚ºpara-aortic nodes, å› æ­¤RTå»ºè­°ç¸®å°ç¯„åœåŒ…å«åœ–ç¤ºä¸­çš„å€åŸŸä»¥æ¸›å°‘ä½µç™¼ç—‡ã€‚",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/019/explain_figures/NCCN_seminoma.jpg",
      "/qabank/019/explain_figures/NCCN_seminoma_RT.jpg",
      "/qabank/019/explain_figures/para_aorticRT.jpg"
    ]
  },
  {
    "id": 20,
    "question": "About bone targeting agents in the treatment of metastatic prostate cancer, which of the following statements is correct ?",
    "options": [
      "Use of Radium-223 in mCRPC with bone metastasis by Phase III ALSYMPCA Trial via   beta particle effect.",
      "The addition of radium-223 to abiraterone or enzalutamide may improve symptomatic skeletal  event-free survival in patients with castration-resistant prostate cancer and bone metastases.",
      "Lutetium-177 (177Lu)â€“PSMA-617 is a radioligand therapy that delivers alpha-particle   radiation to kill cancer cells.",
      "177Lu-PSMA-617 can be used to treat PSMA PET-positive bone metastasis of CRPC by VISION trial.",
      "éŒ¯èª¤ã€‚Denosumab å¯ä»¥ reduce the risk of bone side effectsã€‚"
    ],
    "correctAnswer": 3,
    "explanation": "æ­£ç¢ºç­”æ¡ˆç‚ºDã€‚\n(D)æ­£ç¢ºã€‚æè¿°é›–ç„¶æ­£ç¢ºï¼Œä½†æ‡‰æ³¨æ„VISION trialä¸­Lutetium-177 (177Lu)â€“PSMA-617å°æ–¼mCRPCç—…äººï¼Œå¯æ²»ç™‚å…¨èº«PSMA-positive lesionsï¼Œè€Œä¸åƒ…æ˜¯bone metastasisã€‚(177Lu)â€“PSMA-617 + SOC vs SOCå¯ä»¥å»¶é•·PSMA-positive mCRPCç—…äººçš„rPFSåŠOSã€‚\n\n(A)éŒ¯èª¤ã€‚Radium-223ç‚ºalpha emitterã€‚ALSYMPCAè­‰å¯¦Radium-223èƒ½å»¶é•·mCRPC with bone metastasesç—…äººçš„overall survivalä»¥åŠå»¶ç·©time to first skeletal-related event (SRE)ã€‚\n(B)éŒ¯èª¤ã€‚PEACE-3 trial (Ra-223+enzalutamide) è­‰å¯¦æ¯”èµ·å°ç…§çµ„enzalutamide aloneèƒ½å»¶é•·mCRPC with bone metastasesç—…äººçš„rPFS and OSã€‚ç„¶è€ŒERA-223 trial (Ra-223+abiraterone)åœ¨mCRPC with bone metastasesç—…äººï¼Œå‰‡ç„¡æ³•å»¶é•·OS or symptomatic skeletal event-free survivalï¼Œç”šè‡³æœ‰æ›´é«˜çš„incidence of bone fracturesã€‚\n(C)éŒ¯èª¤ã€‚Lutetium-177 (177Lu)â€“PSMA-617ç‚ºbeta emitterè€Œä¸æ˜¯deliver alpha-particle radiationã€‚\n(E)éŒ¯èª¤ã€‚Denosumab å¯ä»¥ reduce the risk of bone side effectsã€‚ä¾‹å¦‚2011å¹´ç™¼è¡¨æ–¼Lancetçš„é€™ç¯‡RCTè­‰å¯¦denosumabç›¸è¼ƒæ–¼zolendronic acidå¯é¡¯è‘—é™ä½SRE(skeletal-related events)ã€‚[Lancet. 2011 Mar 5;377(9768):813-22]",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/020/explain_figures/ALSYMPCA.jpg",
      "/qabank/020/explain_figures/Lu_177_PSMA_therapy.jpg",
      "/qabank/020/explain_figures/Ra223decay.png",
      "/qabank/020/explain_figures/VISION_tiral.jpg"
    ]
  },
  {
    "id": 21,
    "question": "æ™šæœŸå­å®®å…§è†œç™Œçš„å…ç–«æ²»ç™‚ï¼Œä¸‹åˆ—ä½•è€…æ˜¯éŒ¯èª¤çš„ï¼Ÿ",
    "options": [
      "æ ¹æ“š KEYNOTE-028ã€KEYNOTE-158ï¼Œpembrolizumab å–®ç¨ä½¿ç”¨åœ¨ deficient MMR /   microsatellite instability-highï¼ˆMSI-Hï¼‰è…«ç˜¤æ¯”è¼ƒæœ‰æ•ˆæœï¼Œproficient MMR / microsatellite  stableï¼ˆMSSï¼‰è…«æ¯”è¼ƒæ²’æœ‰æ•ˆæœã€‚",
      "æ ¹æ“š GARNETï¼Œdostarlimab å–®ç¨ä½¿ç”¨åœ¨ deficient MMR / microsatellite instability-highï¼ˆMSI-Hï¼‰  è…«ç˜¤æœ‰æ•ˆæœï¼Œåœ¨ proficient MMR / microsatellite stableï¼ˆMSSï¼‰è…«ç˜¤æ²’æœ‰æ•ˆæœã€‚",
      "æ ¹æ“š KEYNOTE-146ï¼Œpembrolizumab åŠ ä¸Š lenvatinib åˆä½µä½¿ç”¨åœ¨ deficient MMR / microsatellite   instability-highï¼ˆMSI-Hï¼‰è…«ç˜¤å®¢è§€åæ‡‰ç‡æ˜¯ 63.6%ï¼Œåœ¨ proficient MMR / microsatellite stable  ï¼ˆMSSï¼‰è…«ç˜¤å®¢è§€åæ‡‰ç‡æ˜¯ 36.2%ã€‚",
      "æ ¹æ“š KEYNOTE-775ï¼Œpembrolizumab åŠ ä¸Š lenvatinib åˆä½µä½¿ç”¨ç›¸è¼ƒæ–¼ doxorubicin æˆ– paclitaxel  åœ¨ proficient MMR / microsatellite stableï¼ˆMSSï¼‰è…«ç˜¤çš„ç¬¬äºŒç·šæ²»ç™‚æœ‰è¼ƒé•·çš„ä¸­ä½æ•¸ç„¡æƒ¡åŒ–å­˜  æ´»æœŸï¼ˆ6.6 å€‹æœˆ vs. 3.8 å€‹æœˆï¼Œå±éšªæ¯”ï¼š0.60ï¼‰åŠä¸­ä½æ•¸ç¸½å­˜æ´»æœŸï¼ˆ17.4 å€‹æœˆ vs. 12.0 å€‹æœˆï¼Œ  å±éšªæ¯”ï¼š0.68ï¼‰ã€‚",
      "ä»¥ä¸Šåªæœ‰ 3 å€‹æ˜¯æ­£ç¢ºçš„ã€‚"
    ],
    "correctAnswer": 1,
    "explanation": "(A)KN028æ”¶å…¥24ä½PD-L1 positive(CPS>=1)çš„endometrial cancerç—…äººï¼Œå…¶ä¸­19ä½æœ‰åˆ†æMSI status: 1ä½MSI-H, 18ä½non-MSI high, ORRç‚º13%ï¼›KN158å‰‡æ”¶å…¥68ä½MSI-Hçš„endometrial cancerç—…äººï¼ŒORRç‚º48.5%ã€‚é›–ç„¶ç‚ºcross trial comparison, ä¸éä¾æ“šé€™å…©å€‹è©¦é©—çµæœåšå‡ºé¸é …çš„æ¨è«–æ‡‰ç®—åˆç†ã€‚\r\n\r\n(B)é¸é …éŒ¯èª¤ã€‚GARNET trialä¸­ï¼ŒdMMR/MSI-Hçµ„åˆ¥ORRç‚º43.5%ï¼›pMMR/MSSçµ„ORRç‚º14.1%ï¼Œæœ‰3å€‹ç—…äººé”åˆ°CRåŠ19å€‹PRã€‚é¸é …â€ proficient MMR / microsatellite stableï¼ˆMSSï¼‰è…«ç˜¤æ²’æœ‰æ•ˆæœã€‚â€éŒ¯èª¤ã€‚\r\n\r\n(C)(D)é¸é …æ­£ç¢ºã€‚\r\nå› æ­¤ç­”æ¡ˆç‚ºB",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 22,
    "question": "æ™šæœŸå­å®®å…§è†œç™Œçš„ç¬¬ä¸€ç·šå…ç–«æ²»ç™‚ï¼Œä¸‹åˆ—ä½•è€…æ˜¯éŒ¯èª¤çš„ï¼Ÿ",
    "options": [
      "æ ¹æ“š RUBYï¼Œdostarlimab åŠ ä¸Š paclitaxel / carboplatin åˆä½µä½¿ç”¨ç›¸è¼ƒæ–¼ paclitaxel / carbiplatin  ä½¿ç”¨æœ‰è¼ƒé•·çš„ 5 å¹´ç„¡æƒ¡åŒ–å­˜æ´»ç‡ï¼ˆ36.1% vs. 18.1%ï¼Œå±éšªæ¯”ï¼š0.64ï¼‰åŠ 5 å¹´ç¸½å­˜æ´»ç‡ï¼ˆ71.3%   vs. 56.0%ï¼Œå±éšªæ¯”ï¼š0.64ï¼‰ã€‚",
      "æ ¹æ“š NRG_GY018ï¼Œpembrolizumab åŠ ä¸Š paclitaxel / carboplatin åˆä½µä½¿ç”¨ç›¸è¼ƒæ–¼ paclitaxel /   carbiplatin ä½¿ç”¨åœ¨ mismatch repair-proficient (pMMR)çš„ç—…æ‚£æ—ç¾¤ï¼Œæœ‰è¼ƒé•·çš„ä¸­ä½æ•¸ç„¡æƒ¡åŒ–å­˜  æ´»æœŸï¼ˆ13.1 å€‹æœˆ vs. 8.7 å€‹æœˆï¼Œå±éšªæ¯”ï¼š0.54ï¼‰ã€‚",
      "æ ¹æ“š AtTEndï¼Œatezolizumab åŠ ä¸Š paclitaxel / carboplatin åˆä½µä½¿ç”¨ç›¸è¼ƒæ–¼ paclitaxel / carbiplatin  ä½¿ç”¨ï¼Œæœ‰è¼ƒé•·çš„ä¸­ä½æ•¸ç„¡æƒ¡åŒ–å­˜æ´»æœŸï¼ˆ10.1 å€‹æœˆ vs. 8.9 å€‹æœˆï¼Œå±éšªæ¯”ï¼š0.74ï¼‰ã€‚",
      "æ ¹æ“š DUO-Eï¼Œdurvalumab åŠ ä¸Š paclitaxel / carboplatin åˆä½µä½¿ç”¨ç›¸è¼ƒæ–¼ paclitaxel / carbiplatin  ä½¿ç”¨ï¼Œæœ‰è¼ƒé•·çš„ä¸­ä½æ•¸ç„¡æƒ¡åŒ–å­˜æ´»æœŸï¼ˆå±éšªæ¯”ï¼š0.71ï¼‰ã€‚",
      "ä»¥ä¸Šåªæœ‰ 3 å€‹æ˜¯æ­£ç¢ºçš„ã€‚"
    ],
    "correctAnswer": 0,
    "explanation": "(A)RUBY trial part 1å°šæœªreport 5å¹´follow-up data; é¸é …å¼•ç”¨çš„æ˜¯2023å¹´3æœˆç™¼è¡¨çš„ç¬¬ä¸€æ¬¡interim analysisçµæœï¼š2å¹´PFS HR=0.64, 2å¹´OS HR=0.64ï¼Œè€Œé5å¹´ã€‚2024å¹´8æœˆç™¼è¡¨çš„second interim analysis, 2å¹´ PFSç‚º36.1%(dostarlimab), 18.1% (paclitaxel / carbiplatin), HR 0.64ï¼›2å¹´OSå‰‡ç‚º70.1%(dostarlimab), 54.3% (paclitaxel / carbiplatin), HR 0.69ã€‚å› æ­¤Aé¸é …éŒ¯èª¤ã€‚\r\n(B)(C)(D)é¸é …æ­£ç¢ºã€‚",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 23,
    "question": "é—œæ–¼å­å®®é ¸ç™Œï¼Œä¸‹åˆ—ä½•è€…æ˜¯éŒ¯èª¤çš„ï¼Ÿ",
    "options": [
      "å±€éƒ¨æ™šæœŸå­å®®é ¸ç™Œçš„æ‚£è€…çš„ 5 å¹´ç¸½å­˜æ´»ç‡ç´„ 60%ï¼Œå­å®®é ¸ç™Œåˆä½µé ç«¯è½‰ç§»çš„æ‚£è€…çš„ 5 å¹´ç¸½å­˜æ´»ç‡ç´„ 19%ã€‚",
      "æ ¹æ“š CALLAï¼Œdurvalumab åŠ ä¸ŠåŒæ­¥åŒ–å­¸æ”¾å°„æ²»ç™‚ç›¸è¼ƒæ–¼ placebo åŠ ä¸ŠåŒæ­¥åŒ–å­¸æ”¾å°„æ²»ç™‚  ä½¿ç”¨åœ¨å±€éƒ¨æ™šæœŸå­å®®é ¸ç™Œæœ‰è¼ƒé•·çš„ç„¡æƒ¡åŒ–å­˜æ´»ç‡ï¼ˆå±éšªæ¯”ï¼š0.84ï¼‰ã€‚",
      "æ ¹æ“š ENGOT-cx11 / GOG-3047 / KEYNOTE-A18ï¼Œpembrolizumab åŠ ä¸ŠåŒæ­¥åŒ–å­¸æ”¾å°„æ²»ç™‚  ç›¸è¼ƒæ–¼ placebo åŠ ä¸ŠåŒæ­¥åŒ–å­¸æ”¾å°„æ²»ç™‚ä½¿ç”¨ï¼Œåœ¨å±€éƒ¨æ™šæœŸå­å®®é ¸ç™Œæœ‰è¼ƒé•·çš„ç„¡æƒ¡åŒ–å­˜æ´» ç‡ï¼ˆå±éšªæ¯”ï¼š0.70ï¼‰ã€‚",
      "æ ¹æ“š KEYNOTE-158ï¼Œpembrolizumab ä½¿ç”¨åœ¨æŒçºŒã€å¾©ç™¼ã€è½‰ç§»çš„å­å®®é ¸ç™Œçš„å®¢è§€åæ‡‰ç‡æ˜¯ 14.3%ï¼Œpembrolizumab ä½¿ç”¨åœ¨æŒçºŒã€å¾©ç™¼ã€è½‰ç§» PD-L1 é™½æ€§çš„å­å®®é ¸ç™Œçš„å®¢è§€åæ‡‰ç‡æ˜¯ 17%ã€‚",
      "æ ¹æ“š KEYNOTE-826ï¼Œpembrolizumab åŠ ä¸Šå«é‰‘é¡åŒ–å­¸æ²»ç™‚ï¼ˆÂ± bevacizumabï¼‰åˆä½µä½¿ç”¨ç›¸è¼ƒ  æ–¼ placebo åŠ ä¸Šå«é‰‘é¡åŒ–å­¸æ²»ç™‚ï¼ˆÂ± bevacizumabï¼‰ä½¿ç”¨åœ¨æŒçºŒã€å¾©ç™¼ã€è½‰ç§»çš„å­å®®é ¸ç™Œï¼Œ  æœ‰è¼ƒé•·çš„ 24 å€‹æœˆç¸½å­˜æ´»ç‡ï¼šæ‰€æœ‰å—è©¦è€…ï¼ˆ50.4% vs. 40.4%ï¼‰ã€PD-L1 CPS >æˆ–= 1ï¼ˆ53.0%  vs. 41.7%ï¼‰ã€PD-L1 CPS >æˆ–= 10ï¼ˆ54.4% vs. 44.6%ï¼‰ã€‚"
    ],
    "correctAnswer": 1,
    "explanation": "(A) Locally advanced cervical canceråŒ…å«FIGO IB3~IVA:\r\n- Confined to the cervix with a clinically visible tumor >4 cm in greatest dimension (stage IB3)\r\n- Invades beyond the uterus but not to the pelvic wall or to the lower third of vagina (stage II)\r\n- Extends to the pelvic sidewall, and/or involves the lower third of vagina, and/or causes hydronephrosis or a nonfunctioning kidney, and/or involves pelvic and/or para-aortic lymph nodes (stage III)\r\n- Invades the mucosa of the bladder or rectum, or extends beyond the true pelvis (stage IVA)\r\næ ¹æ“šUptodateæä¾›çš„è³‡æ–™Survival by FIGO stage for patients with cervical cancer: 2018 FIGO statisticsï¼ŒFIGO IB3~IVAçš„æ‚£è€…5å¹´å­˜æ´»ç‡ç´„ç‚º55%ï¼ŒIVB(æœ‰é ç«¯è½‰ç§»)çš„5å¹´å­˜æ´»ç‡ç´„14.7%ï¼Œèˆ‡é¸é …æè¿°å°šåœ¨ç›¸è¿‘ç¯„åœã€‚\r\n\r\n(B)é¸é …æè¿°çš„æ•¸å€¼æ­£ç¢ºï¼Œä¸éCALLAç‚ºä¸€å¤±æ•—çš„è‡¨åºŠè©¦é©—ï¼šPFS hazard ratio 0.84 (95% CI, 0.65-1.08; P = .17)ï¼Œpå€¼ä¸¦æœªé”æ¨™ã€‚å› æ­¤ç„¡æ³•å®£ç¨±durvalumab+CCRTä½¿ç”¨åœ¨å±€éƒ¨æ™šæœŸå­å®®é ¸ç™Œæœ‰è¼ƒé•·çš„ç„¡æƒ¡åŒ–å­˜æ´»ç‡ã€‚\r\n\r\n(C)(D)(E)é¸é …æ­£ç¢ºã€‚",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/023/explain_figures/5yearOS.jpg"
    ]
  },
  {
    "id": 24,
    "question": "é—œæ–¼è¡¨çš®åµå·¢ç™Œçš„æ¨™é¶æ²»ç™‚ï¼Œä¸‹åˆ—ä½•è€…æ˜¯éŒ¯èª¤çš„ï¼Ÿ",
    "options": [
      "ç´„ 30%çš„ high-grade è¡¨çš®åµå·¢ç™Œæœ‰ BRCA1/2 åŸºå› çªè®Šã€‚",
      "BRACA1/2 åŸºå› çªè®Šçš„è¡¨çš®åµå·¢ç™Œä½¿ç”¨ PARP æŠ‘åˆ¶åŠ‘åšç‚ºç¬¬ä¸€ç·šæ²»ç™‚çš„ç¶­æŒæ²»ç™‚ï¼Œå¯é¡¯è‘—  å»¶é•·ç„¡æƒ¡åŒ–å­˜æ´»æœŸï¼ˆä¸­ä½æ•¸å¢åŠ  2 å¹´ä»¥ä¸Šï¼Œå±éšªæ¯”ä»‹æ–¼ 0.30 å’Œ 0.40 ä¹‹é–“ï¼‰ã€ç¸½å­˜æ´»æœŸï¼ˆä¸­ä½æ•¸å¢åŠ  1.5 å¹´ä»¥ä¸Šï¼Œå±éšªæ¯”ä»‹æ–¼ 0.55 å’Œ 0.62 ä¹‹é–“ï¼‰ã€‚",
      "BRCA1/2 åŸºå› çªè®Šçš„çš„è¡¨çš®åµå·¢ç™Œç¶“éå®Œå–„æ¸›ç©æ‰‹è¡“å’Œå«é‰‘åŒ–å­¸æ²»ç™‚ï¼Œè¶…é 5 å¹´ä» disease-free ç´„æœ‰ 15-20%ã€‚BRCA1/2 åŸºå› çªè®Šçš„çš„è¡¨çš®åµå·¢ç™Œï¼Œè‹¥ç¶“å®Œå–„æ¸›ç©æ‰‹è¡“å’Œå«é‰‘åŒ–å­¸æ²»  ç™‚å¾Œï¼Œå†ä½¿ç”¨ PARP æŠ‘åˆ¶åŠ‘åšç‚ºç¬¬ä¸€ç·šæ²»ç™‚çš„ç¶­æŒæ²»ç™‚ï¼Œè¶…é 5 å¹´ä»ç„¶ disease-free ç´„ 50%ã€‚",
      "ç´„ 60%çš„è¡¨çš®åµå·¢ç™Œæ˜¯ BRCA1/2 åŸºå› é‡ç”Ÿå‹ã€genomic instability scoresï¼ˆGISï¼‰highã€‚",
      "BRACA1/2 åŸºå› é‡ç”Ÿå‹ã€genomic instability scoresï¼ˆGISï¼‰high çš„è¡¨çš®åµå·¢ç™Œä½¿ç”¨ PARP  æŠ‘åˆ¶åŠ‘åšç‚ºç¬¬ä¸€ç·šæ²»ç™‚çš„ç¶­æŒæ²»ç™‚ï¼Œå¯é¡¯è‘—å»¶é•·ç„¡æƒ¡åŒ–å­˜æ´»æœŸï¼ˆå±éšªæ¯” 0.50ï¼‰ã€ ç¸½å­˜æ´»æœŸ  ï¼ˆå±éšªæ¯” 0.70ï¼‰ã€‚"
    ],
    "correctAnswer": 3,
    "explanation": "(A)æ­£ç¢ºï¼Œ2019å¹´ä¸€ç¯‡æµè¡Œç—…å­¸ç ”ç©¶çµ±è¨ˆ74ä½High grade ovarian cancerç—…æ‚£ä¸­æœ‰25.7%æœ‰BRCA mutationã€‚\r\nGynecol Oncol Rep. 2019 Aug 13;29:102-105.\r\n\r\n(B)3å€‹PARPiç”¨æ–¼1L maintenance therapyçš„è©¦é©—:\r\nğŸš©SOLO1: Olaparib vs. placebo as 1L maintenance therapy \r\nmPFS: 56.0 months (Olaparib) vs. 13.8 months (placebo) HR: 0.33\r\nmOS: NR vs 75.2 months, HR: 0.55\r\nğŸš©PAOLA-1: Olaparib+Bevacizumab vs. Bevacizumab alone as 1L maintenance therapy\r\nBRCAm: mPFS: 60.7 months vs. 21.7 months (placebo) HR: 0.45\r\nmOS: 73.2 months vs. 53.8 months HR: 0.60\r\nğŸš©PRIMA: Niraparib vs. placebo as 1L maintenance therapy\r\nHRD+: mPFS: 21.9months vs. 10.4 months (placebo) HR: 0.43\r\nmOS 71.9 months vs. 69.8 months HR:0.95\r\nå…¶å¯¦PRIMAä¸¦æœªç¬¦åˆé¡Œå¹¹æ•˜è¿°ã€‚\r\n\r\n(C)æ­£ç¢ºã€‚SOLO1(Olaparib)å’ŒPAOLA-1(Olaparib)çš„äº”å¹´PFSï¼Œæ²»ç™‚çµ„ç´„åœ¨50%ï¼Œå°ç…§çµ„ç´„åœ¨20%å·¦å³ã€‚ä½†PRIMA(Niraparib)å‰‡æ˜¯35% vs. 16%ï¼Œå…¶å¯¦ä¸¦æœªç¬¦åˆé¸é …æ•˜è¿°ã€‚\r\n\r\n(D)éŒ¯èª¤ï¼ŒEOCç´„50%ç—…äººç‚ºHRD+ï¼Œå…¶ä¸­ä¸€åŠå’ŒBRCA mutation/pathogenic variantsç›¸é—œï¼Œå¦ä¸€åŠç‚ºGIS highã€‚GIS highä½”å…¨éƒ¨ovarian cancerç—…äººçš„25%ã€‚\r\n\r\n(E)æ­£ç¢ºï¼Œæ­¤ç¾¤ç—…äººå³ç‚ºHRD+ excluding tBRCAmã€‚é¸é …æè¿°ç‚ºPAOLA-1 trialè©¦é©—çš„çµæœï¼šPFS HR=0.47, OS HR=0.71",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/024/explain_figures/figure1.jpg",
      "/qabank/024/explain_figures/figure2.jpg"
    ]
  },
  {
    "id": 25,
    "question": "é—œæ–¼éå°ç´°èƒè‚ºç™Œçš„å»ºè­°ï¼Œä¸‹åˆ—å“ªå€‹æ•˜è¿°æ˜¯éŒ¯èª¤çš„ï¼Ÿ [ è¨»æ˜ï¼š(C)(D)(E)ä¸­æåŠä¹‹æœŸåˆŠï¼Œå‡æ ¹æ“šAJCC TNM stage system(8th ed)]",
    "options": [
      "æ ¹æ“š KEYNOTE-671 trialï¼Œæ‰‹è¡“å‰ neoadjuvant therapy ä½¿ç”¨ pembrolizumab plus platinum-doublet   chemotherapy x 4 cycles followed by surgery then adjuvant pembrolizumab ç›¸è¼ƒæ–¼ç›´æ¥ surgery   then adjuvant pembrolizumab ï¼Œå¯é¡¯è‘—å»¶é•· event-free survival(EFS)",
      "æ ¹æ“šCheckMate 816 trialï¼Œæ‰‹è¡“å‰neoadjuvant therapyä½¿ç”¨nivolumab åŠ ä¸Š platinum-doublet   chemotherapy x 3 cyclesç›¸è¼ƒæ–¼neoadjuvant chemotherapyï¼Œå¯é¡¯è‘—å»¶é•·event-free survival(EFS)ã€‚",
      "æ ¹æ“šADAURA trialï¼Œå°æ–¼completely resected stage IBâ€“IIIA or stage IIIB (T3, N2) NSCLC   and positive for EGFR (exon 19 deletion, exon 21 L858R) mutationsï¼Œè¡“å¾Œå¯è€ƒæ…®ä½¿ç”¨adjuvant   osimertinib for 3 yearsã€‚",
      "æ ¹æ“šKEYNOTE-091 trialï¼Œå°æ–¼completely resected stage IIBâ€“IIIA, stage IIIB (T3, N2), or   high-risk stage IIA NSCLC and negative for EGFR exon 19 deletion or exon 21 L858R   mutations or ALK rearrangementsï¼Œä¸ç®¡PD-L1è¡¨ç¾å¦‚ä½•ï¼Œè¡“å¾Œå¯è€ƒæ…®ä½¿ç”¨adjuvant   pembrolizumab for up to 1 yearã€‚",
      "æ ¹æ“šIMpower010 trialï¼Œå°æ–¼completely resected stage IIBâ€“IIIA, stage IIIB (T3, N2), or  high-risk stage IIA NSCLC with PD-L1 â‰¥1% and negative for EGFR exon 19 deletion or   exon 21 L858R mutations or ALK rearrangementsï¼Œè¡“å¾Œå¯è€ƒæ…®ä½¿ç”¨adjuvant atezolizumab  for up to 1 yearã€‚"
    ],
    "correctAnswer": 0,
    "explanation": "(A) éŒ¯èª¤, KEYNOTE-671 trial ç ”ç©¶æ¯”è¼ƒ neoadjuvant pembrolizumab + platinum-doublet chemotherapy (4 cycles) followed by surgery and adjuvant pembrolizumab vs. surgery followed by adjuvant pembrolizumabã€‚\r\nå¯¦éš›çš„æ¯”è¼ƒçµ„åˆ¥æ‡‰è©²æ˜¯ï¼š\r\nè©•ä¼° neoadjuvant pembrolizumab + chemotherapy vs. chemotherapy alone  â†’ surgery â†’ adjuvant pembrolizumab\r\nä¸»è¦çµæœï¼š\r\nNeoadjuvant pembrolizumab + chemotherapy çµ„ç›¸è¼ƒæ–¼ç´”åŒ–ç™‚çµ„é¡¯è‘—å»¶é•· EFSã€‚\r\nä½†è©¦é©—å°ç…§çµ„ä¸¦éã€Œç›´æ¥æ‰‹è¡“å¾Œ adjuvant pembrolizumabã€ï¼Œæ‰€ä»¥è©²æ•˜è¿°éŒ¯èª¤ã€‚\r\n(B) æ­£ç¢º\r\nCheckMate 816 trial è­‰å¯¦ neoadjuvant nivolumab + platinum-doublet chemotherapy (3 cycles) ç›¸è¼ƒæ–¼å–®ç´” neoadjuvant chemotherapy é¡¯è‘—å»¶é•· EFSã€‚\r\n(C) æ­£ç¢º\r\nADAURA trial ç ”ç©¶é¡¯ç¤º å°æ–¼å®Œå…¨åˆ‡é™¤ (completely resected) çš„ IB-IIIA æˆ– stage IIIB (T3, N2) EGFR çªè®Š (exon 19 deletion, exon 21 L858R) é™½æ€§ NSCLCï¼Œè¡“å¾Œä½¿ç”¨ adjuvant osimertinib 3 å¹´å¯é¡¯è‘—æ”¹å–„ç„¡ç—…å­˜æ´»æœŸ (DFS)ã€‚\r\n(D) æ­£ç¢º\r\nKEYNOTE-091 trial ç ”ç©¶é¡¯ç¤º å®Œå…¨åˆ‡é™¤çš„ IIB-IIIAã€IIIB (T3, N2) æˆ– high-risk IIA æœŸ NSCLCï¼ŒEGFR å’Œ ALK é™°æ€§ï¼Œä¸è«– PD-L1 è¡¨ç¾å¦‚ä½•ï¼Œè¡“å¾Œä½¿ç”¨ adjuvant pembrolizumab å¯é•·é” 1 å¹´ã€‚\r\n(E) æ­£ç¢º\r\nIMpower010 trial ç ”ç©¶é¡¯ç¤º PD-L1 â‰¥1% ä¸” EGFR/ALK é™°æ€§çš„ NSCLC (stage IIBâ€“IIIA, stage IIIB T3N2, or high-risk IIA)ï¼Œè¡“å¾Œä½¿ç”¨ adjuvant atezolizumab å¯é•·é” 1 å¹´ã€‚\r\n\r\n1. KEYNOTE-671 Trial: (Perioperative Pembrolizumab in Resectable NSCLC)\r\nç›®çš„ï¼šè©•ä¼° perioperative pembrolizumab + Ch/T vs. neoadjuvant Ch/T åœ¨resectable NSCLC (stage II, IIIA, IIIB T3N2) ä¸­çš„ç™‚æ•ˆã€‚\r\nå°è±¡ï¼šå¯æ‰‹è¡“åˆ‡é™¤çš„ II, IIIA, IIIB (T3N2) NSCLC\r\næ²»ç™‚çµ„åˆ¥ï¼š\r\nè©¦é©—çµ„ï¼š\r\nNeoadjuvantï¼špembrolizumab (200 mg) + platinum-doublet chemotherapy (Q3W x 4 cycles) > Surgery > Adjuvant pembrolizumab (200 mg Q3W x 13 cycles)\r\nå°ç…§çµ„ï¼š\r\nNeoadjuvantï¼šplacebo + platinum-doublet chemotherapy (Q3Wx 4 cycles) > Surgery > Adjuvant placebo \r\nPrimary endpointï¼š\r\nEvent-Free Survival (EFS)\r\nOverall Survival (OS)\r\nä¸»è¦çµæœ\r\nEFSï¼šé¡¯è‘—å»¶é•· EFS (HR = 0.58, 95% CI: 0.46â€“0.72, p<0.001)ã€‚\r\nOSï¼š é¡¯è‘—å»¶é•· OS (HR = 0.72, 95% CI: 0.56â€“0.93, p = 0.004)ã€‚\r\npCR: é¡¯è‘—æé«˜ (18.1% vs. 4.0%)ã€‚\r\nMPR (major pathologic response): é¡¯è‘—æé«˜ (30.2% vs. 11.0%)ã€‚\r\n\r\n2. CheckMate 816 Trial (Neoadjuvant Nivolumab in Resectable NSCLC)\r\nç›®çš„ï¼šè©•ä¼° neoadjuvant nivolumab + åŒ–ç™‚ vs. neoadjuvant åŒ–ç™‚ åœ¨ resectable stage IB-IIIA NSCLCã€‚\r\nå°è±¡ï¼šå¯æ‰‹è¡“åˆ‡é™¤çš„ stage IB (â‰¥4 cm), II, IIIA NSCLC\r\næ²»ç™‚çµ„åˆ¥ï¼š\r\nè©¦é©—çµ„ï¼š\r\nNeoadjuvantï¼šnivolumab (360 mg) + platinum-doublet chemotherapy (Q3Wï¼Œå…± 3 cycles)\r\nSurgery\r\nå°ç…§çµ„ï¼š\r\nNeoadjuvantï¼šplatinum-doublet chemotherapy (Q3Wï¼Œå…± 3 cycles)\r\nSurgery\r\nPrimary endpointï¼š\r\nEvent-Free Survival (EFS)\r\nPathologic Complete Response (pCR)\r\nä¸»è¦çµæœ\r\nEFSï¼š EFS é¡¯è‘—æé«˜ (HR = 0.63, p = 0.005)ã€‚\r\npCRï¼š pCR é¡¯è‘—æé«˜ (24.0% vs. 2.2%)ã€‚\r\nR0 resection ï¼šé¡¯è‘—æé«˜ (83.2% vs. 75.4%)ã€‚\r\nOS (æ—©æœŸåˆ†æ)ï¼šæœ‰å»¶é•·è¶¨å‹¢ (HR = 0.57, 95% CI: 0.38â€“0.87)ã€‚\r\nè‡¨åºŠæ„ç¾©\r\nç¢ºç«‹ neoadjuvant nivolumab + åŒ–ç™‚ä½œç‚ºå¯åˆ‡é™¤ NSCLC çš„æ²»ç™‚é¸é …ã€‚\r\né¡¯è‘—æ”¹å–„ pCR å’Œ EFSï¼Œæé«˜ R0 åˆ‡é™¤ç‡ã€‚\r\n\r\n3. ADAURA Trial (Adjuvant Osimertinib in EGFR+ NSCLC)\r\nç›®çš„ï¼šè©•ä¼° adjuvant osimertinib åœ¨ EGFR çªè®Šé™½æ€§ (exon 19 deletion, exon 21 L858R) NSCLC ä¸­çš„ç™‚æ•ˆã€‚\r\nå°è±¡ï¼šcompletely resected stage IB-IIIA or stage IIIB (T3N2) EGFR+ NSCLC\r\næ²»ç™‚çµ„åˆ¥ï¼š\r\nè©¦é©—çµ„ï¼š\r\nAdjuvantï¼šosimertinib (80 mg/day, æŒçºŒ 3 å¹´)\r\nå°ç…§çµ„ï¼š\r\nPlacebo\r\nPrimary endpointï¼š\r\nDisease-Free Survival (DFS)\r\nOverall Survival (OS) (æ¬¡è¦çµ‚é»)\r\nä¸»è¦çµæœ\r\nDFS (II-IIIA)ï¼šosimertinib é¡¯è‘—å»¶é•· DFS (HR = 0.17, 95% CI: 0.12â€“0.23, p<0.001)ã€‚\r\nDFS (å…¨é«” IB-IIIA)ï¼šHR = 0.20, 95% CI: 0.15â€“0.27, p<0.001ã€‚\r\nOSï¼šæ›´æ–°åˆ†æ osimertinib é¡¯è‘—å»¶é•· OS (HR = 0.49, p<0.001)ã€‚\r\nè‡¨åºŠæ„ç¾©\r\nç¢ºç«‹ adjuvant osimertinib ç‚º EGFR+ NSCLC çš„æ¨™æº–è¡“å¾Œæ²»ç™‚ã€‚\r\n\r\n4.KEYNOTE-091 Trial (Adjuvant Pembrolizumab in Resectable NSCLC)\r\nç ”ç©¶è¨­è¨ˆ\r\nç›®çš„ï¼šè©•ä¼° adjuvant pembrolizumab åœ¨ EGFR/ALK é™°æ€§ NSCLC çš„ç™‚æ•ˆã€‚\r\nå°è±¡ï¼šcompletely resected stage IIB-IIIA or IIIB (T3N2) or high-risk stage IIA NSCLC\r\næ²»ç™‚çµ„åˆ¥ï¼š\r\nè©¦é©—çµ„ï¼š\r\nAdjuvantï¼špembrolizumab (200 mg Q3Wï¼Œæœ€å¤š 1 å¹´)\r\nå°ç…§çµ„ï¼š\r\nPlacebo\r\nPrimary endpointï¼š\r\nDFS\r\nä¸»è¦çµæœ\r\nDFSï¼špembrolizumab é¡¯è‘—å»¶é•· DFS (HR = 0.76, p = 0.0014)ã€‚\r\nè‡¨åºŠæ„ç¾©\r\nç¢ºç«‹ adjuvant pembrolizumab ç‚º EGFR/ALK é™°æ€§ NSCLC çš„æ¨™æº–è¡“å¾Œæ²»ç™‚ã€‚\r\n\r\n5.IMpower010 Trial (Adjuvant Atezolizumab in Resectable NSCLC)\r\nç ”ç©¶è¨­è¨ˆ\r\nç›®çš„ï¼šè©•ä¼° adjuvant atezolizumab åœ¨ PD-L1 â‰¥1% ä¸” EGFR/ALK é™°æ€§ NSCLC çš„ç™‚æ•ˆã€‚\r\nä¸»è¦çµæœï¼š\r\nDFS (PD-L1 â‰¥1%)ï¼šHR = 0.66, 95% CI: 0.50â€“0.88, p = 0.0039ã€‚\r\nDFS (å…¨é«” stage II-IIIA)ï¼šHR = 0.79, 95% CI: 0.64â€“0.96, p = 0.020ã€‚\r\nè‡¨åºŠæ„ç¾©\r\nç¢ºç«‹ adjuvant atezolizumab ä½œç‚º PD-L1 â‰¥1% NSCLC çš„æ¨™æº–è¡“å¾Œæ²»ç™‚ã€‚",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 26,
    "question": "é—œæ–¼ ERBB2 (HER2) Mutations éå°ç´°èƒè‚ºç™Œçš„å»ºè­°ï¼Œä¸‹åˆ—å“ªå€‹æ•˜è¿°æ˜¯éŒ¯èª¤çš„ï¼Ÿ",
    "options": [
      "ERBB2 (HER2) Mutationsç™¼ç”Ÿåœ¨å¤§ç´„ 3% of patients with advanced nonsquamouséå°ç´°èƒ  è‚ºç™Œï¼Œéå°ç´°èƒè‚ºç™Œå¤§éƒ¨åˆ†çš„ERBB2 (HER2) Mutationså¯ä»¥åƒä¹³ç™Œä¸€æ¨£ä½¿ç”¨  immunohistochemistryè©•ä¼°ï¼Œè¼ƒä¸éœ€è¦ç”¨åˆ°NGSã€‚",
      "éå°ç´°èƒè‚ºç™Œçš„ERBB2 (HER2) Mutationsè¼ƒå¸¸ç™¼ç”Ÿåœ¨å¥³æ€§åŠä¸å¸è¸è€…ã€‚",
      "éå°ç´°èƒè‚ºç™Œçš„ ERBB2 (HER2) Mutations è¼ƒå¸¸ç™¼ç”Ÿçš„æ˜¯ insertion/duplication events in   exon 20ã€‚",
      "è³‡æ–™é¡¯ç¤º ERBB2 mutations çš„éå°ç´°èƒè‚ºç™Œç—…äººå¯èƒ½ respond to first-line immunotherapy   regimensã€‚",
      "æ ¹æ“š DESTINY-Lung01 trialï¼ŒmetastaticHER2-mutant éå°ç´°èƒè‚ºç™Œç—…æ‚£ refractory to standard treatment å¾Œï¼Œä½¿ç”¨ trastuzumab deruxtecan ä»æœ‰ 55% objective response rate åŠ 92% disease   control rateï¼Œmedian progression-free survival 8.2 monthsã€‚"
    ],
    "correctAnswer": 0,
    "explanation": "(A) éŒ¯èª¤ï¼ŒERBB2 (HER2) mutations åœ¨ éå°ç´°èƒè‚ºç™Œ (NSCLC) ä¸­ç™¼ç”Ÿæ–¼ 3% çš„ NSCLC ç—…æ‚£ã€‚\r\nä½†èˆ‡ä¹³ç™Œä¸åŒï¼ŒHER2 mutations ä¸»è¦é€é NGS (Next-Generation Sequencing) æª¢æ¸¬ï¼Œè€Œé IHC (Immunohistochemistry) è©•ä¼°ã€‚\r\nå› ç‚ºåœ¨ NSCLC ä¸­ï¼ŒHER2 mutations èˆ‡ HER2 overexpression ä¸ä¸€å®šä¸€è‡´ï¼ŒNGS æª¢æ¸¬æ›´ç‚ºæº–ç¢ºï¼Œä¸»å› æ˜¯IHCæˆ–FISHåƒ…åœ¨ HER2 amplification æ™‚å¯èƒ½æœ‰ç”¨ï¼Œä½†å°æ–¼è‚ºç™Œå¸¸è¦‹çš„æ˜¯HER2 mutationsï¼ŒIHC ä¸¦éä¸»è¦æª¢æ¸¬æ–¹æ³•ã€‚ä»¥DESTINY-Lung01 Trialçš„Biomarker analysis ä¸­æ”¶éŒ„çš„ç—…äººæ˜¯ä»¥ NGS æª¢é©—åˆ°HER2 mutation/amplification çš„ç—…æ‚£ï¼Œå…¶ä¸­HER2 mutation exon 20 insertions å°±å äº†86%\r\n(B) æ­£ç¢ºï¼ŒHER2 mutations åœ¨éå°ç´°èƒè‚ºç™Œä¸­è¼ƒå¸¸è¦‹æ–¼å¥³æ€§åŠä¸å¸è¸è€…ï¼Œèˆ‡ EGFR çªè®Š çš„æ—ç¾¤ç›¸ä¼¼ã€‚\r\n(C) æ­£ç¢ºï¼ŒHER2 mutations åœ¨ NSCLC æœ€å¸¸è¦‹æ–¼ exon 20 insertion/duplication eventsï¼Œç´„ä½” 90% çš„ HER2 mutations (DESTINY-Lung01 Trial æ˜¯86%)\r\n(D) æ­£ç¢ºï¼Œé›–ç„¶HER2 mutations çš„ NSCLC ç—…äººå°å…ç–«æ²»ç™‚åæ‡‰æœ‰é™ï¼Œç‰¹åˆ¥æ˜¯å–®ç¨ä½¿ç”¨å› HER2 mutant NSCLC å¤šæ•¸ PD-L1 è¡¨é”ä¸é«˜ï¼ŒTMB ä¹Ÿè¼ƒä½ï¼Œä½†æ ¹æ“šmeta-analysisï¼ŒHER2 mutations å°åŒ–ç™‚ + å…ç–«æ²»ç™‚åˆä½µä»æœ‰æœ‰ä¸€å®šåæ‡‰ Zhang J, Han W, Guo J, Zhang C, Cao L, Peng L, Han X, Wang Z. Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis. J Cancer Res Clin Oncol. 2024 Jan 27;150(2):42. doi: 10.1007/s00432-023-05509-0\r\n(E) DESTINY-Lung01 Trialï¼šç ”ç©¶ HER2-mutant NSCLC ç—…äººï¼Œåœ¨æ¨™æº–æ²»ç™‚å¤±æ•—å¾Œï¼Œä½¿ç”¨ trastuzumab deruxtecanã€‚\r\nORR (Objective Response Rate)ï¼š55%\r\nDCR (Disease Control Rate)ï¼š92%\r\nmPFS (Median Progression-Free Survival)ï¼š8.2 å€‹æœˆ\r\nmOS (Median Overall Survival)ï¼š17.8 å€‹æœˆ\r\nè­‰å¯¦ T-DXd å° HER2-mutant NSCLC æœ‰é«˜åæ‡‰ç‡",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 27,
    "question": "é—œæ–¼æ²»ç™‚ EGFR-mutated çš„è‚ºç™Œæ‚£è€…ï¼Œä¸‹åˆ—æ•˜è¿°ä½•è€…éŒ¯èª¤ï¼Ÿ",
    "options": [
      "Exon 19 del ç›¸è¼ƒæ–¼ Exon 21 L858R mutation çš„ç—…æ‚£ï¼Œåœ¨æ¥å— EGFR tyrosine kinase inhibitor  (TKI)å¾Œæœ‰æ›´é•·çš„ Progression free survival (PFS)åŠ Overall survival (OS)ã€‚",
      "æ ¹æ“š FLAURA2 trialï¼Œ å°æ–¼ EGFR-mutated advanced NSCLCï¼ŒOsimertinib plus chemotherapy  ç›¸è¼ƒæ–¼ Osimertinib monotherapyï¼Œprogression-free survival æœ‰é¡¯è‘—å»¶é•·ã€‚",
      "æ ¹æ“š FLAURA trialï¼Œç¬¬ä¸€ç·šä½¿ç”¨ Osimertinib ç›¸è¼ƒæ–¼ 1st generation TKI ä¸åƒ… PFS æœ‰é¡¯è‘—å·®ç•°ï¼Œåœ¨ updated analysis ä¸­ OS ä¹Ÿæœ‰é¡¯è‘—çš„å»¶é•·ã€‚",
      "å°æ–¼ä½¿ç”¨ EGFR target therapy ä¸­ progression çš„ç—…äººï¼ŒMET amplification & ERBB2 amplification  æ˜¯å…¶ä¸­æœ‰å¯èƒ½çš„æ©Ÿè½‰ï¼Œè‹¥èƒ½ test å‰‡è¼ƒä½³",
      "å°æ–¼ä½¿ç”¨ EGFR target therapy ä¸­ progression çš„ç—…äººï¼Œå¯åš liquid biopsy for NGS testing å–ä»£  å° progressing lesion åš tissue biopsyï¼Œå›  histology transformation such as small cell transformation   å¹¾ä¹ä¸æœƒç™¼ç”Ÿã€‚"
    ],
    "correctAnswer": 4,
    "explanation": "(A) æ­£ç¢ºï¼ŒExon 19 deletion (del19) ç›¸è¼ƒæ–¼ Exon 21 L858R mutationï¼Œä½¿ç”¨ EGFR TKI å¾Œçš„ PFS å’Œ OS è¼ƒé•·ã€‚\r\nFLAURA trial çš„äºçµ„åˆ†æé¡¯ç¤ºï¼Œdel19 æ‚£è€…çš„ PFS å’Œ OS å„ªæ–¼ L858R çªè®Šæ‚£è€…ã€‚\r\n(B) æ­£ç¢ºï¼ŒFLAURA2 trial ç ”ç©¶æ¯”è¼ƒäº† osimertinib  vs. osimertinib + åŒ–ç™‚ (pemetrexed + platinum) åœ¨ EGFR çªè®Šæ™šæœŸ NSCLC æ‚£è€…ä¸­çš„æ•ˆæœã€‚\r\nä¸»è¦çµæœï¼š\r\nPFS é¡¯è‘—å»¶é•·ï¼ˆHR = 0.62, 95% CI: 0.49â€“0.79, p<0.001ï¼‰ã€‚\r\nORR (Objective Response Rate) ä¹Ÿè¼ƒé«˜ã€‚\r\n(C) æ­£ç¢ºï¼ŒFLAURA trial ç ”ç©¶ osimertinib vs. ç¬¬ä¸€ä»£ EGFR TKI (gefitinib, erlotinib) ä½œç‚º EGFR çªè®Š NSCLC çš„ä¸€ç·šæ²»ç™‚ã€‚\r\nä¸»è¦çµæœï¼š\r\nPFSï¼šosimertinib é¡¯è‘—å„ªæ–¼ ç¬¬ä¸€ä»£ TKI (18.9 vs. 10.2 å€‹æœˆ)ã€‚\r\nOS (updated analysis)ï¼šosimertinib é¡¯è‘—å»¶é•· OS (38.6 vs. 31.8 å€‹æœˆ, HR = 0.80, p=0.046)ã€‚\r\n(D) æ­£ç¢ºï¼ŒEGFR target therapy é€²å±•å¾Œï¼ŒMET amplification åŠ ERBB2 amplification æ˜¯å¸¸è¦‹çš„æŠ—è—¥æ€§æ©Ÿè½‰ã€‚\r\nReference: Coleman N, Hong L, Zhang J, Heymach J, Hong D, Le X. Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer. ESMO Open. 2021 Dec;6(6):100319. doi: 10.1016/j.esmoop.2021.100319. Epub 2021 Nov 24. \r\nå…¶ä»–æŠ—è—¥æ€§æ©Ÿè½‰åŒ…æ‹¬ï¼š\r\nEGFR C797S çªè®Š (Osimertinib æŠ—è—¥æ€§)\r\nHistologic transformation (å¦‚å°ç´°èƒè½‰åŒ–)\r\nå…¶ä»– bypass pathway activation (å¦‚ RAS/PI3K pathway activation)ã€‚\r\n\r\n(E) éŒ¯èª¤\r\nliquid biopsyå¯ç”¨æ–¼åµæ¸¬æŠ—è—¥æ€§çªè®Š (å¦‚ EGFR T790M, MET amplification)ï¼Œä½†ä¸èƒ½å®Œå…¨å–ä»£çµ„ç¹”åˆ‡ç‰‡ (tissue biopsy)ï¼Œå› ç‚ºï¼š\r\nHistologic transformation (å¦‚å°ç´°èƒè½‰åŒ–, squamous transformation) å¯èƒ½ç™¼ç”Ÿï¼Œliquid biopsyç„¡æ³•æª¢æ¸¬é€™äº›è®ŠåŒ–ã€‚\r\nåœ¨éƒ¨åˆ† EGFR TKI é€²å±•æ‚£è€… (~5-10%)ï¼Œæœƒç™¼ç”Ÿsmall cell transformationï¼Œé€™éœ€è¦é€éçµ„ç¹”åˆ‡ç‰‡æ‰èƒ½ä¾†ç¢ºè¨ºã€‚\r\nå¦‚æœåƒ…ä¾è³´ liquid biopsyï¼Œå¯èƒ½æœƒéŒ¯å¤± histologic transformation å°è‡´çš„æ²»ç™‚ç­–ç•¥æ”¹è®Š",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 28,
    "question": "ä¸€ä½ 64 æ­²ç”·æ€§ç¶“ç”±é›»è…¦æ–·å±¤å°å¼•åˆ‡ç‰‡è¨ºæ–·ç‚ºè‚ºé±—ç‹€ä¸Šçš®ç™Œ(lung squamous cell carcinoma)ï¼Œ  å…¨èº«æ€§æª¢æŸ¥ç™¼ç¾æœ‰å¤šè™•é›™å´è‚ºå°è‚ºã€è‚è‡Ÿè½‰ç§»ï¼ŒåŸºå› æª¢æ¸¬ Roche cobas EGFR mutation test   v2 kit: mutation not detectedï¼ŒALK immunohistochemistry: negativeï¼ŒPD-L1: 80%ï¼Œä¸‹åˆ—æ²»ç™‚  ä½•è€…ä¸¦é NCCN guideline å»ºè­°?",
    "options": [
      "Carboplatin + paclitaxel + atezolizumab",
      "Pembrolizumab alone",
      "Atezolizumab alone",
      "Carboplatin + paclitaxel + pembrolizumab",
      "Nivolumab + ipilimumab + paclitaxel + carboplatin"
    ],
    "correctAnswer": 2,
    "explanation": "(A) Carboplatin + paclitaxel + atezolizumab âœ… (å¯è¡Œï¼Œä½†éé¦–é¸)\r\n\r\nIMpower131 trial é¡¯ç¤ºï¼Œå°æ–¼ PD-L1 é«˜è¡¨ç¾ (â‰¥50%) çš„ è‚ºé±—ç‹€ç´°èƒç™Œæ‚£è€…ï¼Œä½¿ç”¨ Carboplatin + nab-paclitaxel + atezolizumab å¯å»¶é•· PFSï¼Œä½†OSæ²’æœ‰é¡¯è‘—ã€‚\r\nå› æ­¤NCCN guidelines å»ºè­° Atezolizumab åˆä½µåŒ–ç™‚ä½œç‚ºå¯é¸æ–¹æ¡ˆä½† éä¸»è¦é¦–é¸æ–¹æ¡ˆã€‚\r\n(B) Pembrolizumab alone âœ… (å¯è¡Œ)\r\n\r\nKEYNOTE-024 & KEYNOTE-042 trials é¡¯ç¤ºï¼š\r\nPD-L1 â‰¥50% å¯å–®ç¨ä½¿ç”¨ pembrolizumabï¼Œä¸”ç›¸è¼ƒæ–¼åŒ–ç™‚ï¼Œèƒ½é¡¯è‘—æ”¹å–„ PFS å’Œ OSã€‚\r\n\r\n(C) Atezolizumab alone âŒ (é NCCN æŒ‡å—å»ºè­°)\r\nIMpower110 trial é¡¯ç¤º Atezolizumab Alone é›–åœ¨ PD-L1 â‰¥50% NSCLCæœ‰é¡¯è‘—ç™‚æ•ˆï¼Œä½†åŸºæ–¼IMpower110 trialåœ¨OS subgroup analysisä¸¦æ²’æœ‰é”åˆ°é¡¯è‘—ï¼Œä¸”PD-L1 é«˜è¡¨é” (â‰¥50%) çš„é±—ç‹€ NSCLC subgroupæ•¸æ“šæœªå–®ç¨å ±å‘Š OSï¼Œå¦å¤–IMpower131åŒ–ç™‚åŠ ä¸Šå…ç–«çš„æ•ˆæœéƒ½å·®å¼·äººæ„ï¼Œå–®ç¨åªç”¨Atezolizumabä»¤äººä¸å¤ªæ”¾å¿ƒï¼Œæœ€çµ‚NCCNå»ºè­°å–®ç¨å…ç–«æ²»ç™‚åƒ…æ¨è–¦Pembrolizumab\r\n\r\n(D) Carboplatin + paclitaxel + pembrolizumab âœ… (æ¨™æº–æ²»ç™‚)\r\n\r\nKEYNOTE-407 trial ç¢ºç«‹äº† Carboplatin + paclitaxel + pembrolizumab ç‚º PD-L1 é«˜è¡¨é” (â‰¥50%) é±—ç‹€è‚ºç™Œçš„æ¨™æº–ä¸€ç·šæ²»ç™‚ã€‚\r\n(E) Nivolumab + ipilimumab + paclitaxel + carboplatin âœ… (å¯è¡Œ)\r\nCheckMate 9LA trial é¡¯ç¤ºï¼Œnivolumab + ipilimumab  + 2 cycles åŒ–ç™‚ å¯é¡¯è‘—æ”¹å–„ OSã€‚\r\n\r\n1. IMpower131 Trial (Carboplatin + nab-Paclitaxel + Atezolizumab in Squamous NSCLC)\r\nç ”ç©¶è¨­è¨ˆ\r\nç›®çš„ï¼šè©•ä¼° Carboplatin + nab-Paclitaxel + Atezolizumab ç›¸è¼ƒæ–¼ Carboplatin + nab-Paclitaxel (åŒ–ç™‚å°ç…§çµ„) åœ¨ è½‰ç§»æ€§é±—ç‹€éå°ç´°èƒè‚ºç™Œ (LUSC, stage IV) çš„ç™‚æ•ˆã€‚\r\nå°è±¡ï¼šæœªæ¥å—éç³»çµ±æ€§æ²»ç™‚çš„è½‰ç§»æ€§é±—ç‹€ NSCLC (Stage IV LUSC)\r\næ²»ç™‚çµ„åˆ¥ï¼š\r\nè©¦é©—çµ„ï¼š\r\nAtezolizumab + Carboplatin + nab-Paclitaxel\r\nå°ç…§çµ„ï¼š\r\nCarboplatin + nab-Paclitaxel (åŒ–ç™‚)\r\nä¸»è¦çµ‚é»ï¼š\r\nProgression-Free Survival (PFS)\r\nOverall Survival (OS)\r\nä¸»è¦çµæœ\r\nPFS (PD-L1 â‰¥50%)ï¼š\r\nAtezolizumab + åŒ–ç™‚é¡¯è‘—å»¶é•· PFS (6.3 vs. 5.6 å€‹æœˆ, HR = 0.71, p = 0.0001)ã€‚\r\nOS (å…¨é«”å—è©¦è€…)ï¼š\r\næœªé”çµ±è¨ˆé¡¯è‘—å·®ç•° (HR = 0.88, p = 0.14)ã€‚\r\nè‡¨åºŠæ„ç¾©\r\nIMpower131 é¡¯ç¤º Atezolizumab + åŒ–ç™‚å¯æ”¹å–„ PFSï¼Œä½†å° OS çš„å½±éŸ¿æœ‰é™ã€‚\r\n\r\n2. KEYNOTE-024 & KEYNOTE-042 Trials (Pembrolizumab  Monotherapy  in  High PD-L1 NSCLC)\r\nç ”ç©¶è¨­è¨ˆ\r\nç›®çš„ï¼šè©•ä¼° Pembrolizumab  alone  vs. æ¨™æº–åŒ–ç™‚ åœ¨ PD-L1 é«˜è¡¨é” (â‰¥50%) çš„ NSCLC ä¹‹é–“çš„ç™‚æ•ˆæ¯”è¼ƒã€‚\r\nå°è±¡ï¼šPD-L1 TPS â‰¥50% (KEYNOTE-024) æˆ– PD-L1 TPS â‰¥1% (KEYNOTE-042) çš„è½‰ç§»æ€§ NSCLC\r\næ²»ç™‚çµ„åˆ¥ï¼š\r\nè©¦é©—çµ„ï¼š\r\nPembrolizumab å–®è—¥\r\nå°ç…§çµ„ï¼š\r\né‰‘é¡åŒ–ç™‚ (Carboplatin æˆ– Cisplatin + Pemetrexed æˆ– Paclitaxel)\r\nä¸»è¦çµ‚é»ï¼š\r\nOverall Survival (OS)\r\nProgression-Free Survival (PFS)\r\nä¸»è¦çµæœ\r\nKEYNOTE-024 (PD-L1 â‰¥50%)ï¼š\r\nOSï¼šPembrolizumab é¡¯è‘—å»¶é•· OS (26.3 vs. 14.2 å€‹æœˆ, HR = 0.62, p < 0.0001)ã€‚\r\nPFSï¼šPembrolizumab é¡¯è‘—å„ªæ–¼åŒ–ç™‚ (10.3 vs. 6.0 å€‹æœˆ, HR = 0.50, p < 0.001)ã€‚\r\nKEYNOTE-042 (PD-L1 â‰¥1%)ï¼š\r\nOS (PD-L1 â‰¥50%)ï¼šHR = 0.69, p < 0.0001ã€‚\r\nä½† PD-L1 1-49% æ‚£è€…çš„ OS æ”¹å–„ä¸å¦‚é«˜è¡¨é”çµ„ã€‚\r\nè‡¨åºŠæ„ç¾©\r\nPembrolizumab aloneæ²»ç™‚å¯ä½œç‚º PD-L1 â‰¥50% è½‰ç§»æ€§ NSCLC çš„ä¸€ç·šæ¨™æº–æ²»ç™‚ã€‚\r\n\r\n3. IMpower110 Trial (Atezolizumab  Monotherapy in  High  PD-L1 NSCLC)\r\nç ”ç©¶è¨­è¨ˆ\r\nç›®çš„ï¼šè©•ä¼° Atezolizumab å–®è—¥ vs. åŒ–ç™‚ åœ¨ PD-L1 é«˜è¡¨é” NSCLC çš„ç™‚æ•ˆã€‚\r\nå°è±¡ï¼šPD-L1 TPS â‰¥50% çš„è½‰ç§»æ€§éå°ç´°èƒè‚ºç™Œ (NSCLC)\r\næ²»ç™‚çµ„åˆ¥ï¼š\r\nè©¦é©—çµ„ï¼š\r\nAtezolizumab  alone\r\nå°ç…§çµ„ï¼š\r\né‰‘é¡åŒ–ç™‚\r\nä¸»è¦çµ‚é»ï¼š\r\nOverall Survival (OS)\r\nä¸»è¦çµæœ\r\nOS (PD-L1 â‰¥50%)ï¼š\r\nAtezolizumab é¡¯è‘—å»¶é•· OS (20.2 vs. 13.1 å€‹æœˆ, HR = 0.59, p = 0.0106)ã€‚\r\nè‡¨åºŠæ„ç¾©\r\nIMpower110 æ”¯æŒ Atezolizumab å–®è—¥ä½œç‚º PD-L1 â‰¥50% éé±—ç‹€ NSCLC (Adenocarcinoma) çš„ä¸€ç·šé¸æ“‡ã€‚\r\n\r\n\r\n4. KEYNOTE-407 Trial (Carboplatin + Paclitaxel + Pembrolizumab in  Squamous NSCLC)\r\nç ”ç©¶è¨­è¨ˆ\r\nç›®çš„ï¼šè©•ä¼° Carboplatin + Paclitaxel + Pembrolizumab vs. åŒ–ç™‚ åœ¨ è½‰ç§»æ€§è‚ºé±—ç‹€ç´°èƒç™Œ (LUSC, stage IV) çš„ç™‚æ•ˆã€‚\r\nå°è±¡ï¼šè½‰ç§»æ€§ LUSC\r\næ²»ç™‚çµ„åˆ¥ï¼š\r\nè©¦é©—çµ„ï¼š\r\nCarboplatin + Paclitaxel + Pembrolizumab\r\nå°ç…§çµ„ï¼š\r\nCarboplatin + Paclitaxel (åŒ–ç™‚)\r\nä¸»è¦çµ‚é»ï¼š\r\nOverall Survival (OS)\r\nProgression-Free Survival (PFS)\r\nä¸»è¦çµæœ\r\nOSï¼š\r\nPembrolizumab + åŒ–ç™‚çµ„ OS é¡¯è‘—å»¶é•· (15.9 vs. 11.3 å€‹æœˆ, HR = 0.64, p < 0.0001)ã€‚\r\nPFSï¼š\r\nPembrolizumab + åŒ–ç™‚çµ„ PFS äº¦é¡¯è‘—å»¶é•· (6.4 vs. 4.8 å€‹æœˆ, HR = 0.56, p < 0.0001)ã€‚\r\nè‡¨åºŠæ„ç¾©\r\nKEYNOTE-407 ç¢ºç«‹äº† Pembrolizumab + åŒ–ç™‚ç‚º PD-L1 é«˜è¡¨é” LUSC çš„æ¨™æº–æ²»ç™‚ã€‚\r\n\r\n5.CheckMate 9LA Trial (Nivolumab + Ipilimumab + Chemotherapy in NSCLC)\r\nç›®çš„ï¼šè©•ä¼° Nivolumab + Ipilimumab + çŸ­ç¨‹åŒ–ç™‚ vs. æ¨™æº–åŒ–ç™‚ åœ¨ æ™šæœŸ NSCLC (åŒ…æ‹¬ LUSC) çš„ç™‚æ•ˆã€‚\r\nç ”ç©¶é¡å‹ï¼šPhase 3, Randomized, Open-label\r\nä¸»è¦çµæœï¼š\r\nOSï¼šNivolumab + Ipilimumab + åŒ–ç™‚ é¡¯è‘—å»¶é•· OS (15.6 vs. 10.9 å€‹æœˆ, HR = 0.66, p < 0.0001)ã€‚\r\nè‡¨åºŠæ„ç¾©\r\nCheckMate 9LA æ”¯æŒ Nivolumab + Ipilimumab + åŒ–ç™‚ä½œç‚º NSCLC çš„ä¸€ç·šæ²»ç™‚ã€‚",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 29,
    "question": "é—œæ–¼è‚ºç™Œæ¨™é¶è—¥ç‰©åŠåŸºå› çªè®Šé…å°ï¼Œä¸‹åˆ—æ•˜è¿°ä½•è€…éŒ¯èª¤ï¼Ÿ",
    "options": [
      "MET exon 14 skipping â€“ selpercatinib, pralsetinib",
      "ROS1 rearrangement â€“ crizotinib, entrectinib",
      "EGFR exon 20 insertion mutation - amivantamab",
      "NTRK1/2/3 gene Fusion â€“ larotrectinib, entrectinib",
      "KRAS G12C mutation â€“sotorasib, adagrasib"
    ],
    "correctAnswer": 0,
    "explanation": "æ ¹æ“šNCCN Non-small Cell Lung Cancer, Version 3.2025 â€” January 14, 2025\r\nå…¶ä¸­Aé¸é …ä¸­selpercatinib, pralsetinibç‚ºå£æœçµ¦äºˆçš„highly selective RET inhibitorsã€‚Pivotal trial ïƒ  LIBRETTO-001 (Selpercatinib) ä»¥åŠ ARROW trial (pralsetinib)ã€‚å› æ­¤ï¼Œæ­¤å…©è€…è—¥ç‰©ä¸ç”¨æ–¼MET exon 14 skippingçš„mutation",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/029/explain_figures/Fig 1.jpg"
    ]
  },
  {
    "id": 30,
    "question": "ä¸€ä½ 62 æ­²ç”·æ€§,å¥åº·æª¢æŸ¥æ„å¤–ç™¼ç¾èƒ¸éƒ¨è…«å¡Š,è€Œç¶“é›»è…¦æ–·å±¤åŠæ”¯æ°£ç®¡é¡è¨ºæ–·ç‚ºå³å´è‚ºéƒ¨è‚ºè…ºç™Œ,æœ‰æƒ¡æ€§è‚‹è†œç©æ°´,åŸºå› æª¢æ¸¬ Roche cobas EGFR mutation test v2 kit: mutation not detected,ALK immunohistochemistry: negative,PD-L1: 10%,ECOG PS ç‚º 1ã€‚é‡å°ä¸Šè¿°ç—…æ‚£,ä¸‹åˆ—æ•˜è¿°ä½•è€…éŒ¯èª¤?",
    "options": [
      "å¯æ¥å— atezolizumab + bevacizumab + carboplatin + paclitaxel åšç‚ºç¬¬ä¸€ç·šæ²»ç™‚ã€‚",
      "æ­¤ç—…æ‚£å¯é¸æ“‡ pembrolizumab + cisplatin + pemetrexed åšç‚ºç¬¬ä¸€ç·šæ²»ç™‚ã€‚",
      "è‹¥ç—…æ‚£ç¬¬ä¸€ç·šå·²æ¥å—é platinum-doublet chemotherapy ç–¾ç—…ä»é€²å±•,å¯è€ƒæ…®ä½¿ç”¨pembrolizumab æˆ– nivolumab æˆ– atezolizumab æˆ– durvalumab åšç‚ºäºŒç·šæ²»ç™‚ã€‚",
      "è‹¥ç—…æ‚£ç¬¬ä¸€ç·šå·²æ¥å—é pembrolizumab + cisplatin + pembrolizumab ç–¾ç—…ä»é€²å±•,å¯è€ƒæ…®ä½¿ç”¨ ramucirumab/docetaxel åšç‚ºäºŒç·šæ²»ç™‚ã€‚",
      "è‹¥ç—…æ‚£åœ¨æ¥å—é 4-6 å€‹ç™‚ç¨‹çš„åŒ–å­¸æ²»ç™‚åŠ ä¸Šå…ç–«æ²»ç™‚,ä¸”ç–¾ç—…æ•´é«”ç„¡æƒ¡åŒ–çš„æƒ…å½¢ä¸‹,å¯è€ƒæ…®å–®ç¨ä½¿ç”¨å…ç–«æ²»ç™‚åšç‚º maintenance therapyã€‚"
    ],
    "correctAnswer": 2,
    "explanation": "æ ¹æ“šNCCN Non-small Cell Lung Cancer, Version 3.2025 â€” January 14, 2025\r\n\r\né¦–å…ˆï¼šé¡Œå¹¹é—œéµè©ã€Œ å³å´è‚ºéƒ¨è‚ºè…ºç™Œ,æœ‰æƒ¡æ€§è‚‹è†œç©æ°´ã€ïƒ  å› æ­¤è‡³å°‘M1aèµ·è·³, æ ¹æ“šAJCC 8ç‰ˆstagingç‚ºStage IVA\r\n\r\nå†è€…ï¼šåŸºå› æª¢æ¸¬çµæœæ²’æœ‰EGFR mutation/ ALK rearrangementï¼Œåƒ…æœ‰PD-L1: 10%\r\n\r\næ²»ç™‚ ïƒ  å¯ä»¥ä½¿ç”¨å…ç–«åŠ ä¸ŠåŒ–ç™‚\r\n\r\n(A) æ­£ç¢ºã€‚æ ¹æ“šIMpower150 (N Engl J Med 2018;378:2288-2301) ïƒ   atezolizumab + bevacizumab + carboplatin + paclitaxel (ABCP) æ˜¯è½‰ç§»æ€§EGFR/ALK é™°æ€§çš„æ™šæœŸéé±—ç‹€ NSCLC ä¸€ç·šæ²»ç™‚é¸æ“‡ã€‚ èˆ‡ BCPï¼ˆbevacizumab + carboplatin + paclitaxelï¼‰ç›¸æ¯”ï¼ŒABCP çµ„çš„ PFS/OSçš†æœ‰é¡¯è‘—æå‡ã€‚\r\n\r\n(B) æ­£ç¢ºã€‚ä¾æ“š KEYNOTE-189 (N Engl J Med 2018;378:2078-2092) ïƒ pembrolizumab + platinum-based chemotherapyï¼ˆcisplatin/ carboplatin + pemetrexedï¼‰ç‚ºè½‰ç§»æ€§ EGFR/ALK é™°æ€§ã€PD-L1 any expression nonsquamous NSCLC ä¹‹ä¸€ç·šæ²»ç™‚ï¼›ç›¸è¼ƒæ–¼å–®ç´”åŒ–ç™‚ï¼ŒPembrolizumab+C/T é¡¯è‘—æå‡ OS/ PFSï¼Œä¸” PD-L1 â‰¥1% çš†æœ‰ç™‚æ•ˆï¼ŒPD-L1 â‰¥50% æ•ˆæœæ›´æ˜é¡¯ã€‚\r\n\r\n(C) éŒ¯èª¤ã€‚Durvalumab ä¸é©ç”¨æ–¼äºŒç·šæ²»ç™‚\r\n*Nivolumabï¼ˆCheckMate 017/057; J Clin Oncol. 2021 Mar 1;39(7):723-733.ï¼‰\r\n*Atezolizumabï¼ˆOAKï¼›Lancet. 2017 Jan 21;389(10066):255-265.ï¼‰\r\n*Pembrolizumabï¼ˆKEYNOTE-010ï¼›Lancet. 2016 Apr 9;387(10027):1540-1550.ï¼‰\r\n\r\n(D) æ­£ç¢ºã€‚æ ¹æ“š REVEL trialï¼ˆLancet. 2014 Aug 23;384(9944):665-73.ï¼‰ï¼Œramucirumab + docetaxel åœ¨æ¥å—é platinum-based chemotherapy å¤±æ•—çš„è½‰ç§»æ€§NSCLC å¯æå‡ OS/ PFSï¼Œç‚ºäºŒç·šæ¨™æº–æ²»ç™‚é¸æ“‡ä¹‹ä¸€\r\n\r\n(E) æ ¹æ“šè‡¨åºŠè©¦é©—è¨­è¨ˆKEYNOTE-189(Pembrolizumab), IMpower150(Atezolizumab),CheckMate 9LA (Nivolumab/ipilimumab) å¯è€ƒæ…®å–®ç¨ä½¿ç”¨å…ç–«æ²»ç™‚åšç‚º maintenance therapy",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 31,
    "question": "ç½¹æ‚£æƒ¡æ€§è…«ç˜¤çš„ç—…æ‚£å› ç‚º cerebral metastases with/without intracranial hemorrhageã€leptomeningeal metastasesã€dural sinus thrombosis due to cancer-associated hypercoagulability æˆ– CNS infection in immunocompromised hosts ç­‰åŸå› ,å¯èƒ½å¼•ç™¼ã€Œincreased intracranial pressure (IICP)ã€çš„æ€¥ç—‡ã€‚ä»¥ä¸‹ç‚ºæœ‰é—œ IICP è—¥ç‰©æ²»ç™‚åŠè™•ç½®çš„æ•˜è¿°,æ­£ç¢ºçš„æ˜¯:",
    "options": [
      "Intracranial hemorrhage æ‰€å¼•èµ·çš„è…¦æ°´è…«æ‡‰æŠ•äºˆå¤§åŠ‘é‡ systemic corticosteroids(ç›¸ç•¶æ–¼ 100 mg/day dexamethasone)ã€‚",
      "Mannitol ç‚º hyperosmolar agent,å¯é™ä½ ICP,å¸¸ç”¨çš„åŠ‘é‡ç‚º 7.5~ 10g/kgã€æ¯ 4-6 å°æ™‚æŠ•äºˆä¸€æ¬¡ã€‚",
      "æ°£ç®¡æ’ç®¡æ–½ä»¥ mechanical hyperventilation å¯æœ‰æ•ˆåœ°é™ä½ ICP,è©²è™•ç½®æ‡‰å°‡ç—…æ‚£çš„ PaCO2ä¸‹é™è‡³ 12~15mmHg,æ‰èƒ½ç²è‡´æœ€ä½³çš„æ²»ç™‚æ•ˆæœã€‚",
      "Obstructive hydrocephalus æ‡‰è€ƒæ…®ç¥ç¶“å¤–ç§‘æ‰‹è¡“è™•ç½®(å¦‚ external ventriculostomy æˆ–ventriculoperitoneal shunting);ä½†,normal pressure hydrocephalus (NPH)ä¸æ‡‰è©²è€ƒæ…®å¤–ç§‘æ²»ç™‚ã€‚",
      "è‹¥ç—…æ‚£æ‡·ç–‘ç½¹æ‚£ CNS lymphomaã€ä¸”å°šæœªç²å¾—çµ„ç¹”å­¸è¨ºæ–·æ™‚,æ‡‰é¿å…ä½¿ç”¨ systemic corticosteroidsã€‚"
    ],
    "correctAnswer": 4,
    "explanation": "(A) éŒ¯èª¤ã€‚é¡å›ºé†‡ä¸»è¦å° vasogenic edemaï¼ˆå¦‚è…«ç˜¤å¼•èµ·çš„è…¦æ°´è…«ï¼‰ æœ‰æ•ˆï¼Œä½†å°å‡ºè¡€æ€§è…¦æ°´è…«ç„¡æ•ˆï¼Œç”šè‡³å¯èƒ½å¢åŠ æ„ŸæŸ“ã€èƒƒæ½°ç˜åŠé«˜è¡€ç³–é¢¨éšªã€‚\r\n\r\n(B) éŒ¯èª¤ã€‚NCCN Guidelines åŠç¥ç¶“é‡ç—‡å­¸æŒ‡å—ï¼šå»ºè­°ä½¿ç”¨è¼ƒä½åŠ‘é‡ï¼ˆ0.25-1 g/kgï¼‰ï¼Œä¸¦ç›£æ¸¬ è¡€æ¼¿æ»²é€å£“ï¼ˆç¶­æŒ â‰¤320 mOsm/Lï¼‰ï¼Œé¿å…éåº¦ä½¿ç”¨å°è‡´åå½ˆæ€§é¡±å…§å£“å‡é«˜ã€‚\r\n\r\n(C) éŒ¯èª¤ã€‚æ€¥æ€§ IICP å±æ€¥è™•ç†æ™‚ï¼Œå¯çŸ­æš«é™ä½ PaCOâ‚‚ è‡³ 30-35 mmHgï¼ˆä½†é¿å…é•·æœŸç¶­æŒï¼‰ï¼›éåº¦æ›æ°£ï¼ˆPaCOâ‚‚ <25 mmHgï¼‰æœƒé€ æˆè…¦è¡€æµçŒæ³¨ä¸è¶³ï¼Œå°è‡´ç¼ºè¡€æ€§è…¦æå‚·ã€‚\r\n\r\n(D) éŒ¯èª¤ã€‚VP shuntingï¼ˆè…¦å®¤è…¹è…”åˆ†æµè¡“ï¼‰æ˜¯ NPH çš„æ¨™æº–æ²»ç™‚é¸æ“‡ä¹‹ä¸€ï¼Œå¯æ”¹å–„å…¸å‹ç—‡ç‹€ï¼ˆæ­¥æ…‹ä¸ç©©ã€å°¿å¤±ç¦ã€èªçŸ¥åŠŸèƒ½ä¸‹é™ï¼‰ã€‚\r\n\r\n(E) æ­£ç¢ºã€‚åœ¨ CNS lymphoma è¨ºæ–·æœªç¢ºç«‹å‰ï¼Œé¿å…ä½¿ç”¨corticosteroidsï¼Œå› ç‚º é¡å›ºé†‡æœƒé€ æˆè…«ç˜¤ç´°èƒé€€ç¸®ï¼Œå¯èƒ½å½±éŸ¿ ç—…ç†çµ„ç¹”å­¸è¨ºæ–·ï¼Œå°è‡´ç„¡æ³•ç²å¾—ç¢ºåˆ‡çš„çµ„ç¹”å­¸è­‰æ“š (NCCN Guidelines åŠå¤šç¯‡ç ”ç©¶ï¼Œé¡å›ºé†‡å¯èƒ½ä½¿è…«ç˜¤ç¸®å°ç”šè‡³æš«æ™‚æ¶ˆå¤±ï¼Œå½±éŸ¿è…«ç˜¤çš„çµ„ç¹”åˆ‡ç‰‡è¨ºæ–·)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 32,
    "question": "ä¸‹åˆ—é—œæ–¼ chronic myeloid leukemia (CML)çš„æ•˜è¿°ä½•è€…éŒ¯èª¤?",
    "options": [
      "Ponatinib å¯ç”¨æ–¼æ²»ç™‚å…·æœ‰ T315I mutation ä¹‹ CML",
      "æ–¼ chronic phase æ™‚ç¬¬ä¸€ç·šæ²»ç™‚,dasatinib èˆ‡ imatinib æ²»ç™‚æ•ˆæœ OS (overall survival) ä¸¦ç„¡æ˜é¡¯å·®åˆ¥ã€‚",
      "æ–¼ chronic phase æ™‚ç¬¬ä¸€ç·šæ²»ç™‚,imatinib æ¯”èµ· nilotinib é›–æ²»ç™‚æ•ˆæœ OS (overall survival)ä¸¦ç„¡æ˜é¡¯å·®åˆ¥,ä½† imatinib æœ‰è¼ƒå¿«çš„ treatment responseã€‚",
      "Asciminib çµåˆæ–¼ the myristoyl site of the BCR-ABL protein,å¯ç”¨æ–¼ä¹‹å‰å·²æ¥å—éå…©ç¨®æˆ–ä»¥ä¸Šä¹‹ tyrosine kinase inhibitors (TKIs)æ²»ç™‚çš„ CML ç—…æ‚£ã€‚",
      "ä½¿ç”¨ dasatinib æ–¼ç¬¬ä¸€ç·šæ²»ç™‚ chronic phase CML (typical e13a2 or e14a2 BCR-ABL1transcripts),æ•ˆæœé”åˆ° deep molecular responseå¤§æ–¼ 3 å¹´ä¸”ä½¿ç”¨æ™‚é–“å¤§æ–¼ 5 å¹´,å¯ä»¥è€ƒæ…®åœè—¥è§€å¯Ÿ BCR-ABL è¡¨ç¾é‡ã€‚"
    ],
    "correctAnswer": 2,
    "explanation": "(A) æ­£ç¢ºã€‚æ ¹æ“šPACE trial (Blood. 2018 Jul 26;132(4):393-404.)ã€‚å…¶ä¸­T315I mutation å° imatinibã€dasatinibã€nilotinibã€bosutinib ç­‰ ç¬¬ä¸€ã€äºŒä»£ TKIs å…·æœ‰æŠ—è—¥æ€§ï¼Œä½† Ponatinib å¯å…‹æœ T315I çªè®Šã€‚ \r\n\r\n(B) æ­£ç¢ºã€‚æ ¹æ“š DASISION trialï¼ˆN Engl J Med 2010;362:2260-2270ï¼‰ã€‚Dasatinib ç›¸è¼ƒæ–¼ Imatinibïƒ é”åˆ° MMR åŠ CCyR çš„é€Ÿç‡è¼ƒå¿«ï¼›é•·æœŸ OS ä¸¦æœªé¡¯ç¤ºé¡¯è‘—å·®ç•°ã€‚\r\n\r\n(C) éŒ¯èª¤ã€‚æ ¹æ“šENESTnd trialï¼ˆN Engl J Med 2010;362:2251-2259ï¼‰ã€‚è©¦é©—é¡¯ç¤ºNilotinib 300 mg BID åœ¨ 12 å€‹æœˆæ™‚é”åˆ° MMRï¼ˆMajor Molecular Responseï¼‰/ DMRï¼ˆDeep Molecular Responseï¼‰çš„æ¯”ç‡é«˜æ–¼ Imatinib 400 mg QD; CCyRï¼ˆComplete Cytogenetic Responseï¼‰ ä¹Ÿæ¯” imatinib ä¾†å¾—å¿«; é•·æœŸ OS ä¸¦æœªé¡¯ç¤ºå‡ºé¡¯è‘—å·®ç•°ã€‚\r\n\r\n(D) æ­£ç¢ºã€‚æ ¹æ“šASCEMBL trial ï¼ˆBlood (2021) 138 (21): 2031â€“2041.ï¼‰\r\n\r\n(E) æ­£ç¢ºã€‚æ ¹æ“š EURO-SKI  trialï¼ˆJ Clin Oncol. 2024 Jun 1;42(16):1875-1880.ï¼‰åŠDADI  trialï¼ˆLancet Haematol. 2020 Mar;7(3):e218-e225.ï¼‰ \r\nïƒ  Dasatinib å¯ä½œç‚º TKI åœè—¥ï¼ˆtreatment-free remission, TFRï¼‰ç­–ç•¥çš„ä¸€éƒ¨åˆ†ã€‚\r\n*Treatment-free remission (TFR )çš„æ¢ä»¶ï¼š\r\n- æŒçºŒ DMRï¼ˆMR4.0 æˆ– MR4.5ï¼‰â‰¥ 3 å¹´\r\n- TKI æ²»ç™‚æ™‚é–“ â‰¥ 5 å¹´\r\n\r\n*å¦å€‹ç ”ç©¶DASFREE trialï¼ˆBr J Haematol. 2023 Sep;202(5):942-952.ï¼‰ä¹Ÿæ”¯æŒ dasatinib åœè—¥å¯è¡Œï¼Œä½†é ˆå¯†åˆ‡ç›£æ¸¬ BCR-ABL1 è¡¨ç¾é‡ã€‚",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/032/explain_figures/Fig 1.jpg"
    ]
  },
  {
    "id": 33,
    "question": "ä¸‹åˆ—é—œæ–¼ Hodgkin lymphoma çš„æ•˜è¿°ä½•è€…éŒ¯èª¤?",
    "options": [
      "Early-stage Hodgkin lymphoma çš„é¢¨éšªå› å­åŒ…å«: bulky diseaseã€ESR åŠä¾µçŠ¯çš„æ·‹å·´å€åŸŸã€‚",
      "Interim PET/CT scan çš„è©•ä¼°çµæœå¯ç”¨ä»¥æ±ºå®šå¾ŒçºŒæ²»ç™‚ã€‚",
      "é«˜å¾©ç™¼é¢¨éšªçš„ Hodgkin lymphomaï¼Œæ–¼è‡ªé«”å¹¹ç´°èƒç§»æ¤å¾Œï¼Œæ¥å— anti-CD30 antibody-drug   conjugate (ADC)â€“brentuximab vedotin çš„éå›ºæ²»ç™‚å¯æ”¹å–„ PFSã€‚",
      "æ ¹æ“š ECHELON-1 çš„çµæœ: åœ¨ stage III/IV Hodgkin lymphoma çš„ç¬¬ä¸€ç·šæ²»ç™‚ä¸­ï¼Œbrentuximab   vedotin åˆä½µåŒ–ç™‚ç›¸è¼ƒæ–¼å‚³çµ±çš„åŒ–ç™‚ ABVDï¼Œæœ‰è¼ƒé•·çš„ PFS åŠ OSï¼Œä¸”è¼ƒå°‘çš„ febrile   neutropeniaã€‚",
      "relapse/refractory Hodgkin lymphoma æ¥å— PD-1 inhibitorï¼Œè‹¥æ¥å—ç•°é«”å¹¹ç´°èƒç§»æ¤ï¼Œå¯èƒ½æœ‰è¼ƒé«˜é¢¨éšªç”¢ç”Ÿ graft versus host disease (GVHD)ã€‚"
    ],
    "correctAnswer": 3,
    "explanation": "éŒ¯èª¤çš„é¸é …æ˜¯ (D)ï¼Œå› ç‚º ECHELON-1 ç ”ç©¶é¡¯ç¤º brentuximab vedotin + AVD ç¢ºå¯¦æœ‰è¼ƒé•·çš„ PFSï¼Œä½†æ²’æœ‰é¡¯è‘—æ”¹å–„ OSï¼Œä¸” febrile neutropenia åè€Œè¼ƒé«˜ã€‚\r\n(A)Early-stage Hodgkin lymphoma (HL) çš„é¢¨éšªå› å­åŒ…æ‹¬ bulky diseaseï¼ˆé€šå¸¸æŒ‡ç¸±è†ˆè…«å¡Šç›´å¾‘ â‰¥10 cmï¼‰ã€ESRï¼ˆerythrocyte sedimentation rateï¼Œç´…è¡€çƒæ²‰é™é€Ÿç‡ï¼‰å‡é«˜ï¼Œä»¥åŠå—ä¾µçŠ¯çš„æ·‹å·´å€åŸŸæ•¸ç›®ï¼ˆé€šå¸¸ >3 å€‹æ·‹å·´çµå€åŸŸä»£è¡¨è¼ƒé«˜é¢¨éšªï¼‰ã€‚\r\n(B)Interim PET/CT scanï¼ˆé€šå¸¸åœ¨ 2-3 å€‹ç™‚ç¨‹å¾Œé€²è¡Œï¼‰å¯ç”¨æ–¼è©•ä¼°æ²»ç™‚åæ‡‰ï¼Œæ ¹æ“š Deauville score ä¾†æ±ºå®šæ˜¯å¦éœ€è¦èª¿æ•´å¾ŒçºŒæ²»ç™‚ã€‚ä¾‹å¦‚ï¼Œè‹¥ PET/CT é¡¯ç¤ºè‰¯å¥½åæ‡‰ï¼ˆDeauville 1-3ï¼‰ï¼Œå¯èƒ½å¯æ¸›å°‘æ²»ç™‚å¼·åº¦ï¼›è‹¥åæ‡‰ä¸ä½³ï¼ˆDeauville 4-5ï¼‰ï¼Œå¯èƒ½éœ€è¦å‡ç´šæ²»ç™‚ç­–ç•¥ã€‚\r\n(C)é«˜å¾©ç™¼é¢¨éšªçš„ Hodgkin lymphomaï¼ˆä¾‹å¦‚åˆå§‹ç–¾ç—…å»£æ³›ã€åˆæ²»å¾Œå¿«é€Ÿå¾©ç™¼æˆ–å°æ²»ç™‚åæ‡‰ä¸ä½³ï¼‰ï¼Œåœ¨æ¥å—**è‡ªé«”å¹¹ç´°èƒç§»æ¤ï¼ˆASCTï¼‰**å¾Œï¼Œè‹¥å†æ¥å— anti-CD30 antibody-drug conjugate (ADC) - brentuximab vedotin ä½œç‚ºéå›ºæ²»ç™‚ï¼Œå¯é¡¯è‘—æ”¹å–„ ç„¡é€²å±•ç”Ÿå­˜æœŸï¼ˆPFSï¼‰ã€‚é€™é»å·²ç¶“åœ¨ AETHERA trial ä¸­å¾—åˆ°è­‰å¯¦ã€‚\r\n(E)åœ¨ relapse/refractory Hodgkin lymphomaï¼ˆå¾©ç™¼/é›£æ²»æ€§ HLï¼‰ä¸­ï¼ŒPD-1 inhibitorsï¼ˆå¦‚ nivolumabã€pembrolizumabï¼‰ æ˜¯æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ã€‚ç„¶è€Œï¼Œè‹¥æ‚£è€…å¾ŒçºŒæ¥å— ç•°é«”å¹¹ç´°èƒç§»æ¤ï¼ˆallo-HSCTï¼‰ï¼Œå‰‡å¯èƒ½å¢åŠ ç§»æ¤ç‰©æŠ—å®¿ä¸»ç—…ï¼ˆGVHDï¼‰çš„é¢¨éšªï¼Œå› ç‚º PD-1 æŠ‘åˆ¶å¯èƒ½å¢å¼· T ç´°èƒæ´»æ€§ï¼Œé€²è€Œèª˜ç™¼æ›´åš´é‡çš„å…ç–«åæ‡‰ã€‚é€™ä¸€é»åœ¨è‡¨åºŠä¸Šå·²è¢«è§€å¯Ÿåˆ°ï¼Œå› æ­¤é¸é …æ˜¯æ­£ç¢ºçš„ã€‚",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 34,
    "question": "å°ç£å·²é€šé Chimeric antigen receptor T cell (CAR-T)çš„å¥ä¿é©æ‡‰ç—‡ï¼Œä¸‹åˆ—é—œæ–¼ CAR-T æ‡‰ç”¨æ–¼diffuse large B-cell lymphoma (DLBCL)çš„æ•˜è¿°ï¼Œä½•è€…éŒ¯èª¤?",
    "options": [
      "Tisagenlecleucel (tisa-cel) æ˜¯ä¸€ç¨® é‡å° CD19 çš„ CAR-Tã€‚",
      "æ›¾æ¥å— bendamustine æ²»ç™‚ CAR-T ç´°èƒæ²»ç™‚æ•ˆæœå’Œå­˜æ´»è¼ƒå·®ã€‚",
      "Cytokine release syndrome (CRS)ç‚º CAR-T å¸¸è¦‹çš„å‰¯ä½œç”¨ï¼Œæ‰€æœ‰ç™¼ç”Ÿ CRS çš„ç—…äººéƒ½å¿…é ˆé€²è¡Œè¡€æ¶²åŸ¹é¤Šã€å°¿æ¶²åŸ¹é¤Šã€èƒ¸éƒ¨ X å…‰ç­‰æª¢æŸ¥ï¼Œç”¨ä»¥æ’é™¤æ„ŸæŸ“çš„å¯èƒ½æ€§ã€‚",
      "ç•¶å‡ºç¾ grade 2ä»¥ä¸ŠCRSæ™‚æ‡‰çµ¦äºˆtocilizumab æ²»ç™‚ã€‚",
      "ç•¶ç—…äººæ¥å— CAR-T å¾Œå‡ºç¾æ„è­˜æ··äº‚ã€ç™²ç™‡ç™¼ä½œæˆ–èªè¨€éšœç¤™ç­‰ç¥ç¶“å­¸è¡¨ç¾ï¼Œæ‡‰è©•ä¼°æ˜¯å¦ç‚ºimmune effector cell-associated neurotoxicity syndrome (ICANS)ï¼Œä¸¦æ‡‰å…ˆçµ¦äºˆ tocilizumab æ²»ç™‚ã€‚"
    ],
    "correctAnswer": 4,
    "explanation": "éŒ¯èª¤çš„é¸é …æ˜¯ (E)ï¼Œå› ç‚º ICANS çš„é¦–é¸æ²»ç™‚æ˜¯é¡å›ºé†‡ï¼ˆå¦‚ dexamethasoneï¼‰ï¼Œè€Œé tocilizumabã€‚\r\n(A)ä¸»è¦é©ç”¨æ–¼ å¾©ç™¼/é›£æ²»æ€§ï¼ˆR/Rï¼‰å¤§Bç´°èƒæ·‹å·´ç˜¤ï¼ˆDLBCLï¼‰ã€‚CD19 æ˜¯ B ç´°èƒè¡¨é¢çš„æ¨™èªŒï¼Œè¨±å¤š CAR-T ç´°èƒæ²»ç™‚ï¼ˆå¦‚ tisa-celã€axi-celã€liso-celï¼‰éƒ½æ˜¯é‡å° CD19 è¨­è¨ˆçš„ï¼Œä»¥é¸æ“‡æ€§æ”»æ“Š B ç´°èƒæƒ¡æ€§è…«ç˜¤\r\n(B)Bendamustine æ˜¯ä¸€ç¨®çƒ·åŒ–åŠ‘é¡çš„åŒ–ç™‚è—¥ç‰©ï¼ŒæœƒæŠ‘åˆ¶ T ç´°èƒçš„åŠŸèƒ½èˆ‡æ•¸é‡ï¼Œå½±éŸ¿ CAR-T ç´°èƒçš„æ“´å¢èˆ‡æŒä¹…æ€§ï¼Œé€²è€Œé™ä½æ²»ç™‚æ•ˆæœã€‚æ¥å— bendamustine ä½œç‚ºbridging therapy çš„æ‚£è€…ï¼Œå…¶ CAR-T ç´°èƒå¢æ®–è¼ƒå·®ï¼Œæ²»ç™‚åæ‡‰è¼ƒä½ï¼ŒPFS å’Œ OS çš†è¼ƒçŸ­ã€‚\r\n(C)ç´°èƒæ¿€ç´ é‡‹æ”¾ç—‡å€™ç¾¤ï¼ˆCRS, Cytokine Release Syndromeï¼‰ æ˜¯ CAR-T ç™‚æ³•çš„æœ€å¸¸è¦‹å‰¯ä½œç”¨ï¼Œé€šå¸¸ç™¼ç”Ÿåœ¨æ²»ç™‚å¾Œå¹¾å¤©å…§ï¼Œåš´é‡æ™‚å¯å°è‡´é«˜ç‡’ã€ä½è¡€å£“ã€ä½æ°§ã€å™¨å®˜è¡°ç«­ã€‚ç”±æ–¼ CRS èˆ‡æ„ŸæŸ“ç—‡ç‹€é¡ä¼¼ï¼Œæ‰€æœ‰ç™¼ç”Ÿ CRS çš„æ‚£è€…æ‡‰é€²è¡Œæ„ŸæŸ“è©•ä¼°ï¼ŒåŒ…æ‹¬ è¡€æ¶²åŸ¹é¤Šã€å°¿æ¶²åŸ¹é¤Šã€èƒ¸éƒ¨ X å…‰ ç­‰ï¼Œä»¥æ’é™¤æ„ŸæŸ“å°è‡´çš„æ•—è¡€ç—‡æˆ–è‚ºç‚ã€‚\r\n(D)Tocilizumab æ˜¯ä¸€ç¨® IL-6 receptor antagonistï¼Œå¯æ¸›è¼• CAR-T ç´°èƒå¼•èµ·çš„éåº¦å…ç–«åæ‡‰ï¼Œç‰¹åˆ¥é©ç”¨æ–¼ ä¸­é‡åº¦ CRSï¼ˆGrade 2â€“4ï¼‰ã€‚è‹¥æ‚£è€…åˆä½µä½è¡€å£“ã€ä½æ°§ï¼Œæ‡‰åŠæ—©çµ¦äºˆ tocilizumabã€‚è‹¥ç—‡ç‹€æ›´åš´é‡ï¼ˆå¦‚ Grade 3-4ï¼‰ï¼Œå¯èƒ½éœ€è¦åˆä½µé¡å›ºé†‡æ²»ç™‚ã€‚",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 35,
    "question": "ä¸‹åˆ—é—œæ–¼ multiple myeloma (MM)æ²»ç™‚çš„æ•˜è¿°ï¼Œä½•è€…éŒ¯èª¤?",
    "options": [
      "æ¥å—è‡ªé«”å¹¹ç´°èƒç§»æ¤å¾Œï¼ŒéŠœæ¥ lenalidomide ç¶­æŒæ²»ç™‚å¯å»¶é•· PFSã€‚",
      "Carfilzomib ç‚ºç¬¬äºŒä»£çš„ proteasome inhibitorï¼Œå¯ç”¨ä»¥æ²»ç™‚ relapse/refractory MMï¼Œç›¸è¼ƒæ–¼  ç¬¬ä¸€ä»£ çš„ bortezomib è¼ƒå°‘å‡ºç¾å¿ƒè¡°ç«­æˆ–å¿ƒå¾‹ä¸æ•´ç­‰å‰¯ä½œç”¨ã€‚",
      "Daratumumab ç‚º anti-CD38 å–®æ ªæŠ—é«”ï¼Œä½¿ç”¨å‰æ‡‰å»ºç«‹ç—…äººå®Œæ•´çš„è¡€å‹å ±å‘Šã€‚",
      "Elotuzumab ç‚º anti- SLAMF7 å–®æ ªæŠ—é«”ï¼Œå¯èˆ‡ pomalidomide åŠ dexamethasone åˆä½µä½¿ç”¨æ–¼  æ²»ç™‚ lenalidomide-refractory MMã€‚",
      "Ide-cel ç‚ºé‡å° BCMA çš„ CAR-Tï¼Œæ–¼ relapse/refractory MM ç›¸è¼ƒæ–¼å‚³çµ±æ²»ç™‚æœ‰è¼ƒé•·çš„ PFSã€‚"
    ],
    "correctAnswer": 1,
    "explanation": "éŒ¯èª¤çš„é¸é …æ˜¯ (B)ï¼Œå› ç‚º Carfilzomib çš„å¿ƒè¡€ç®¡å‰¯ä½œç”¨ï¼ˆå¦‚å¿ƒè¡°ç«­ã€å¿ƒå¾‹ä¸æ•´ï¼‰æ¯” bortezomib æ›´å¸¸è¦‹ï¼Œè€Œä¸æ˜¯è¼ƒå°‘ã€‚\r\nå…¶é¤˜é¸é …å‡ç¬¦åˆè‡¨åºŠç ”ç©¶çµæœèˆ‡ç¾è¡Œæ²»ç™‚æŒ‡å¼•ã€‚Carfilzomib æ˜¯ç¬¬äºŒä»£ proteasome inhibitorï¼ˆPIï¼‰ï¼Œå¯ç”¨æ–¼æ²»ç™‚å¾©ç™¼/é›£æ²»æ€§å¤šç™¼æ€§éª¨é«“ç˜¤ï¼ˆR/R MMï¼‰ã€‚èˆ‡ç¬¬ä¸€ä»£ bortezomib ç›¸æ¯”ï¼Œcarfilzomib ç¢ºå¯¦æœ‰è¼ƒä½çš„å‘¨é‚Šç¥ç¶“ç—…è®Šï¼ˆperipheral neuropathyï¼‰é¢¨éšªï¼Œé€™æ˜¯ bortezomib å¸¸è¦‹çš„å‰¯ä½œç”¨ã€‚ä½† carfilzomib åè€Œè¼ƒå®¹æ˜“å°è‡´å¿ƒè¡€ç®¡å‰¯ä½œç”¨ï¼Œå¦‚é«˜è¡€å£“ã€å¿ƒå¾‹ä¸æ•´åŠå¿ƒè¡°ç«­ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œcarfilzomib ç›¸é—œçš„ é«˜è¡€å£“ï¼ˆ~12-15%ï¼‰ã€å¿ƒè¡°ç«­ï¼ˆ~4-7%ï¼‰èˆ‡å¿ƒå¾‹ä¸æ•´ï¼ˆ~3-5%ï¼‰çš„é¢¨éšªè¼ƒ bortezomib æ›´é«˜ã€‚å› æ­¤ï¼Œèªªã€Œcarfilzomib å¿ƒè‡Ÿå‰¯ä½œç”¨è¼ƒå°‘ã€æ˜¯éŒ¯èª¤çš„ã€‚\r\n(A)Lenalidomide ç¶­æŒæ²»ç™‚å¯å»¶é•· PFSã€‚è‡ªé«”å¹¹ç´°èƒç§»æ¤ï¼ˆASCTï¼‰ æ˜¯å¹´è¼•ä¸”é«”èƒ½ç‹€æ³è‰¯å¥½çš„å¤šç™¼æ€§éª¨é«“ç˜¤ï¼ˆMMï¼‰æ‚£è€…çš„æ¨™æº–æ²»ç™‚æ–¹å¼ä¹‹ä¸€ã€‚ç ”ç©¶ï¼ˆå¦‚ CALGB 100104 å’Œ IFM 2005-02ï¼‰é¡¯ç¤ºï¼Œç§»æ¤å¾Œä½¿ç”¨ lenalidomide ä½œç‚ºç¶­æŒæ²»ç™‚ï¼Œå¯é¡¯è‘—å»¶é•·ç„¡é€²å±•ç”Ÿå­˜æœŸ(PFSï¼‰ï¼Œç”šè‡³æ”¹å–„æ•´é«”å­˜æ´»ï¼ˆOSï¼‰ã€‚\r\nç„¶è€Œï¼Œlenalidomide ç¶­æŒæ²»ç™‚å¯èƒ½å¢åŠ æ¬¡ç™¼æ€§æƒ¡æ€§è…«ç˜¤ï¼ˆsecondary malignancyï¼‰çš„é¢¨éšªï¼Œå› æ­¤éœ€æ¬Šè¡¡é¢¨éšªèˆ‡æ•ˆç›Šã€‚\r\n(C)Daratumumab ç‚ºæŠ— CD38 å–®æ ªæŠ—é«”ï¼Œä½¿ç”¨å‰æ‡‰å»ºç«‹ç—…äººçš„å®Œæ•´è¡€å‹å ±å‘Šã€‚Daratumumab æ˜¯ä¸€ç¨® anti-CD38 å–®æ ªæŠ—é«”ï¼Œä½œç”¨æ–¼ MM ç´°èƒä¸Šçš„ CD38 åˆ†å­ï¼Œèƒ½é€éæŠ—é«”ä¾è³´æ€§ç´°èƒæ¯’æ€§ï¼ˆADCCï¼‰å’Œè£œé«”ä¾è³´æ€§ç´°èƒæ¯’æ€§ï¼ˆCDCï¼‰ä¾†ç ´å£è…«ç˜¤ç´°èƒã€‚ç”±æ–¼ Daratumumab æœƒèˆ‡ç´…è¡€çƒä¸Šçš„ CD38 äº¤å‰åæ‡‰ï¼Œå¯èƒ½å¹²æ“¾è¡€å‹æª¢æ¸¬ï¼ˆå¦‚ Indirect Coombs testï¼‰ï¼Œå½±éŸ¿è¼¸è¡€åŒ¹é…ï¼Œä½¿ç”¨å‰éœ€å»ºç«‹å®Œæ•´çš„è¡€å‹æª”æ¡ˆã€‚æ­¤å¤–ï¼ŒDaratumumab å¯èƒ½å¼•èµ·è¼¸æ¶²ç›¸é—œåæ‡‰ï¼ˆinfusion-related reactions, IRRï¼‰ï¼Œå› æ­¤éœ€é é˜²æ€§çµ¦è—¥ï¼ˆå¦‚é¡å›ºé†‡ã€æŠ—çµ„ç¹”èƒºã€ä¹™é†¯åŠèƒ±æ°¨é…¸ç­‰ï¼‰ã€‚\r\n(D)Elotuzumab ç‚º anti-SLAMF7 å–®æ ªæŠ—é«”ï¼Œå¯èˆ‡ pomalidomide åŠ dexamethasone åˆä½µç”¨æ–¼ lenalidomide-refractory MMã€‚ Elotuzumab é‡å° SLAMF7ï¼ˆSignaling Lymphocytic Activation Molecule Family member 7ï¼‰ï¼Œå¯å¢å¼· NK ç´°èƒå° MM ç´°èƒçš„æ¯’æ®ºä½œç”¨ã€‚åœ¨ lenalidomide-refractory MM ä¸­ï¼Œelotuzumab å¯èˆ‡ pomalidomideï¼ˆç¬¬äºŒä»£ IMiDï¼‰åŠ dexamethasone ä½µç”¨ï¼Œæ­¤çµ„åˆå·²ç²æ‰¹ç”¨æ–¼æ²»ç™‚ R/R MMï¼ˆELOQUENT-3 ç ”ç©¶ï¼‰ã€‚\r\n(E)Ide-cel ç‚ºé‡å° BCMA çš„ CAR-Tï¼Œæ–¼ relapse/refractory MM ç›¸è¼ƒæ–¼å‚³çµ±æ²»ç™‚æœ‰è¼ƒé•·çš„ PFSã€‚BCMAï¼ˆB-cell maturation antigenï¼‰ æ˜¯ MM ç´°èƒç‰¹ç•°æ€§æ¨™è¨˜ï¼ŒCAR-T ç´°èƒç™‚æ³•å¦‚ idecabtagene vicleucelï¼ˆIde-cel, Abecmaï¼‰ å¯é‡å° BCMA ä¾†æ¸…é™¤ MM ç´°èƒã€‚KarMMa ç ”ç©¶é¡¯ç¤ºï¼Œå°æ–¼å¤šç·šæ²»ç™‚å¤±æ•—çš„ R/R MMï¼Œide-cel å¯é¡¯è‘—å»¶é•· PFSï¼Œç›¸è¼ƒæ–¼æ¨™æº–æ²»ç™‚æœ‰æ›´é«˜çš„ç·©è§£ç‡ã€‚å¦ä¸€æ¬¾é‡å° BCMA çš„ CAR-T ç™‚æ³• cilta-celï¼ˆciltacabtagene autoleucel, Carvyktiï¼‰ äº¦é¡¯ç¤ºé¡ä¼¼æ•ˆæœï¼Œç”šè‡³ PFS æ›´é•·ã€‚",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 36,
    "question": "ä»¥ä¸‹é—œæ–¼ Diffuse large B-cell lymphoma (DLBCL)é—œæ–¼ germinal center B-cell (GCB) and activated B-cell (ABC) type ä¹‹æ•˜è¿°ï¼Œä½•è€…éŒ¯èª¤ ?",
    "options": [
      "CD10 and BCL6 æ¯”è¼ƒå®¹æ˜“åœ¨GCB typeè¡¨ç¾ã€‚",
      "interferon response factor 4/MUM1 æ¯”è¼ƒå®¹æ˜“åœ¨ ABC type è¡¨ç¾ã€‚",
      "GCB type æ¯”ä¾‹è¼ƒé«˜ã€‚",
      "DLBCL è¡¨ç¾ç‚º CD10-, BCL6+, MUM1+ä¾æ“š Hans algorithm ç‚º GCB typeã€‚",
      "DLBCL with double expression å¤§å¤šç‚º ABC typeã€‚"
    ],
    "correctAnswer": 3,
    "explanation": "éŒ¯èª¤çš„é¸é …æ˜¯ (D)ï¼Œå› ç‚º CD10-, BCL6+, MUM1+ ä¾æ“š Hans algorithm æ‡‰æ­¸é¡ç‚º ABC typeï¼Œè€Œé GCB typeã€‚\r\nHans algorithm æ˜¯æœ€å¸¸ç”¨çš„ DLBCL äºå‹åˆ†é¡æ–¹æ³•ï¼Œä¸»è¦ä¾æ“š CD10ã€BCL6 å’Œ MUM1ï¼ˆIRF4ï¼‰è¡¨ç¾ä¾†å€åˆ† GCB æˆ– ABC typeï¼š\r\nCD10+ â†’ GCB type\r\nCD10-ï¼ŒBCL6+ï¼ŒMUM1- â†’ GCB type\r\nCD10-ï¼ŒBCL6+ï¼ŒMUM1+ â†’ ABC typeï¼ˆéŒ¯èª¤é¸é …çš„æ¢ä»¶ï¼‰\r\nCD10-ï¼ŒBCL6-ï¼ŒMUM1+ â†’ ABC type\r\nå› æ­¤ï¼ŒCD10-, BCL6+, MUM1+ ç‚º ABC typeï¼Œè€Œé GCB typeï¼Œé€™æ˜¯æ­¤é¸é …éŒ¯èª¤ä¹‹è™•ã€‚\r\n(A)CD10 å’Œ BCL6 æ¯”è¼ƒå®¹æ˜“åœ¨ GCB type è¡¨ç¾ã€‚Diffuse large B-cell lymphoma (DLBCL) æ ¹æ“šåŸºå› è¡¨ç¾å¯åˆ†ç‚º germinal center B-cell-like (GCB) å‹ å’Œ activated B-cell-like (ABC) å‹ã€‚CD10 å’Œ BCL6 æ˜¯ ç”Ÿç™¼ä¸­å¿ƒï¼ˆgerminal center, GCï¼‰ç›¸é—œæ¨™èªŒï¼Œå› æ­¤ GCB type å¸¸è¡¨ç¾ CD10 å’Œ BCL6ã€‚\r\n(B)Interferon response factor 4 (IRF4)/MUM1 æ¯”è¼ƒå®¹æ˜“åœ¨ ABC type è¡¨ç¾ã€‚MUM1ï¼ˆIRF4ï¼‰æ˜¯ plasma cell differentiation markerï¼Œèˆ‡æ´»åŒ– B ç´°èƒç›¸é—œï¼Œä¸»è¦è¡¨ç¾åœ¨ ABC type DLBCLã€‚GCB type ä¸€èˆ¬ä¸æœƒè¡¨ç¾ MUM1ï¼Œæˆ–è€…è¡¨ç¾é‡è¼ƒä½ã€‚\r\n(C)GCB type æ¯”ä¾‹è¼ƒé«˜ã€‚DLBCL ç´„ 50â€“60% å±¬æ–¼ GCB typeï¼Œè€Œ ABC type ç´„ä½” 30â€“40%ã€‚GCB type é å¾Œè¼ƒä½³ï¼Œè€Œ ABC type é å¾Œè¼ƒå·®ï¼Œå°æ¨™æº– R-CHOP æ²»ç™‚åæ‡‰è¼ƒå·®ã€‚\r\n(E)DLBCL with double expressionï¼ˆå³ Myc å’Œ BCL2 é«˜è¡¨ç¾çš„ \"double expressor lymphoma\"ï¼‰å¤§å¤šç‚º ABC typeã€‚\"Double expressor\" lymphoma æŒ‡çš„æ˜¯ Myc+ å’Œ BCL2+ï¼ˆIHC æª¢æ¸¬ï¼‰ï¼Œé€™é¡ DLBCL é€šå¸¸é å¾Œè¼ƒå·®ã€‚ç ”ç©¶é¡¯ç¤º \"double expressor\" lymphoma ä¸»è¦å±¬æ–¼ ABC typeï¼Œå› ç‚º ABC type DLBCL æ›´å¸¸ä¼´éš¨ BCL2 éåº¦è¡¨ç¾ï¼Œè€Œ GCB type å‰‡è¼ƒå°‘è¦‹ã€‚",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 37,
    "question": "é—œæ–¼ primary central nervous system lymphoma (PCNSL)çš„æè¿°ï¼Œä»¥ä¸‹ä½•è€…éŒ¯èª¤ï¼Ÿ",
    "options": [
      "PCNSL è¢«æ­¸é¡åœ¨ non-Hodgkin lympoma å…§ï¼Œç™¼ç”Ÿç‡ç´„ä½” NHL 1%,å¥½ç™¼å¹´é½¡ä¸­ä½æ•¸ç´„ 65 æ­²ã€‚",
      "PCNSL ç´„ 90%ç‚º diffuse large B cell lymphomas, å…¶é¤˜åŒ…å« T-cell, Burkitt, lymphoblastic  åŠ poor characterized low-grade lymphomasã€‚",
      "é‡å° PCNSLï¼ŒHD-MTX based chemotherapy +/- whole brain radiotherapy(WBRT)æ˜¯è­‰å¯¦æœ‰æ•ˆ  çš„æ²»ç™‚æ–¹å¼ã€‚",
      "å¤§éƒ¨åˆ†çš„ç—…æ‚£æ¥å— HD-MTX based therapy å¾Œï¼Œå¾©ç™¼æ©Ÿæœƒæ¥µä½ã€‚",
      "PCNSL æœ€å¸¸è¦‹çš„é•·æœŸä½µç™¼ç—‡ç‚ºå»¶é²æ€§ç¥ç¶“æ¯’æ€§ï¼Œå…¶ä¸­å¹´ç´€>60 æ­²æˆ–æ¥å—é WBRT çš„  ç—…æ‚£ç™¼ç”Ÿæ©Ÿç‡è¼ƒé«˜ã€‚"
    ],
    "correctAnswer": 3,
    "explanation": "Despite recent therapeutic progress and improved survival for many patients with primary central nervous system lymphoma (PCNSL), up to 50% of patients will experience refractory or relapsed disease following first-line treatment with high dose methotrexate (HD-MTX) based regimens. The majority of such events occur within 2 years.\r\n\r\nref: Ambady P, Doolittle ND, Fox CP. Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice. Ann Lymphoma. 2021;5:23. doi:10.21037/aol-21-20",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 38,
    "question": "55 æ­²å¥³æ€§åˆè¨ºæ–·èƒƒè…ºç™Œç¬¬å››æœŸï¼Œåˆä½µè‚åŠè…¹è…”è½‰ç§»ï¼ŒECOG PS 0ï¼Œç—…ç†çµ„ç¹”å…ç–«æŸ“è‰²æª¢æŸ¥  çµæœç‚º HER2: 3+ã€PD-L1 CPS=1ã€pMMRï¼Œä¸‹åˆ—ä½•ç¨®é…æ–¹ç‚ºæ­¤ç—…æ‚£ä¹‹ç¬¬ä¸€ç·šæ²»ç™‚é¦–é¸?",
    "options": [
      "Fluoropyrimidine, cisplatin and trastuzumab",
      "Fluoropyrimidine, oxaliplatin and trastuzumab",
      "Fluoropyrimidine, oxaliplatin, trastuzumab, and nivolumab",
      "Nivolumab and ipilimumab",
      "Fluoropyrimidine, oxaliplatin, trastuzumab, and pembrolizumab"
    ],
    "correctAnswer": 4,
    "explanation": "KEYNOTE-811 è©¦é©—é¡¯ç¤ºï¼Œåœ¨ HER2 é™½æ€§æ™šæœŸèƒƒç™Œæ‚£è€…ä¸­ï¼Œpembrolizumab + trastuzumab + åŒ–ç™‚ï¼ˆå¦‚ 5-FU + oxaliplatinï¼‰ èƒ½é¡¯è‘—æé«˜ORRï¼Œå¢åŠ PFSï¼Œå› æ­¤æˆç‚º FDA æ‰¹å‡†çš„æ¨™æº–ä¸€ç·šæ²»ç™‚æ–¹æ¡ˆã€‚(å°è£œå……ï¼šCheckMate-649é›–ç„¶é¡¯ç¤º nivolumab + åŒ–ç™‚å¯ä»¥æé«˜èƒƒç™Œæ‚£è€…çš„å­˜æ´»ç‡ä½†æ˜¯é¸æ“‡çš„æ˜¯HER2 é™°æ€§æ‚£è€…ï¼Œå› æ­¤nivolumab + trastuzumab çš„çµ„åˆä»ç¼ºä¹æ˜ç¢ºçš„å¤§å‹ III æœŸè‡¨åºŠè©¦é©—æ”¯æŒã€‚)å› æ­¤ï¼Œæ ¹æ“šç›®å‰çš„è‡¨åºŠè©¦é©—æ•¸æ“šï¼ŒKEYNOTE-811 è©¦é©—æä¾›äº†æœ€å¼·çš„è­‰æ“šæ”¯æŒ pembrolizumab + trastuzumab ä½œç‚º HER2 é™½æ€§èƒƒç™Œä¸€ç·šæ²»ç™‚çš„ä¸€éƒ¨åˆ†ï¼Œé€™ä½¿å¾—é¸é … (E) æ›´ç¬¦åˆç›®å‰çš„æ¨™æº–æ²»ç™‚å»ºè­°ã€‚",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 39,
    "question": "ä¸‹åˆ—æœ‰é—œ Peptide Receptor Radionucide Therapy (PRRT) çš„æ•˜è¿°, ä½•è€…æœ‰èª¤?",
    "options": [
      "è©•ä¼°ç—…äººæ˜¯å¦é©åˆæ¥å— PRRT, æœ€é‡è¦æ˜¯è¦çœ‹è…«ç˜¤ SSTR çš„è¡¨ç¾ã€‚",
      "SSTR çš„è¡¨ç¾ä¸»è¦æ˜¯ç”± SSTR-PET/CT or SSTR-PET/MRI ä¾†è©•ä¼°, Krenning score â‰¥1 å³å¯è€ƒæ…®  æ¥å— PRRTã€‚",
      "PRRT çš„é•·æœŸå‰¯ä½œç”¨è¦å°å¿ƒè¡€æ¶²ç–¾ç—…,å¦‚éª¨é«“å¢ç”Ÿä¸è‰¯æ€§ç–¾ç—…æˆ–ç™½è¡€ç—…ã€‚",
      "NETTER1 çµæœé¡¯ç¤º PRRT åœ¨ SSTR é™½æ€§çš„ midgut NET, æ¯”é«˜åŠ‘é‡ octreotide æ›´èƒ½å¢åŠ  ORR  åŠå»¶é•· PFSã€‚",
      "NETTER2 çµæœé¡¯ç¤º PRRT åœ¨ SSTR é™½æ€§çš„ G2 or G3 GEP NET, æ¯”é«˜åŠ‘é‡ octreotide æ›´èƒ½å¢åŠ   ORR åŠå»¶é•· PFSã€‚"
    ],
    "correctAnswer": 1,
    "explanation": "Krenning è©•åˆ†ç”¨æ–¼è©•ä¼°ç¥ç¶“å…§åˆ†æ³Œè…«ç˜¤å°ç”Ÿé•·æŠ‘ç´ å—é«”çš„æ”å–ç¨‹åº¦ã€‚ é€šå¸¸ï¼Œç•¶ Krenning è©•åˆ†å¤§æ–¼ 2 æ™‚ï¼Œè¡¨ç¤ºè…«ç˜¤æœ‰æ˜é¡¯çš„ SSTR è¡¨ç¾ï¼Œèƒ½æœ‰æ•ˆå¸æ”¶æ”¾å°„æ€§åŒä½ç´ ï¼Œæ‰è€ƒæ…®é€²è¡Œ PRRT æ²»ç™‚ã€‚ å› æ­¤ï¼Œé¸é … (B) ä¸­æåˆ°çš„ Krenning è©•åˆ† â‰¥1 å³å¯è€ƒæ…®æ¥å— PRRT æ˜¯ä¸æ­£ç¢ºçš„ã€‚",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 40,
    "question": "é—œæ–¼å±€éƒ¨æ™šæœŸé£Ÿé“ç™Œçš„ chemoradiotherapy (CRT)æ²»ç™‚ï¼Œä¸‹åˆ—æè¿°ä½•è€…ä¸æ­£ç¢º?",
    "options": [
      "ä½¿ç”¨é…æ–¹æ‡‰å„ªå…ˆè€ƒæ…®carboplatin plus paclitaxel regimen (CROSS trial) æˆ–æ˜¯ fluorouracil plus  cisplatin (CALGB 9781 trial)ã€‚",
      "CROSS and CALGB 9781 trial å…©çµ„çš„å°ç…§çµ„éƒ½æ˜¯æ‰‹è¡“åˆ‡é™¤ï¼Œå› æ­¤ç›®å‰ä»ç„¡ carboplatin plus  paclitaxel vs fluoruracil plus cisplatin å…©ç¨® regimens çš„ head to head ç›´æ¥æ¯”è¼ƒã€‚",
      "CROSS trial å› æ”¶æ¡ˆé‡ä¸è¶³è€Œææ—©çµæŸï¼Œå› ç™‚æ•ˆä¸æˆç†Ÿï¼Œå°ç£å¥ä¿å±€ä¸é¡˜çµ¦ä»˜ carboplatin plus paclitaxel åœ¨é£Ÿé“ç™Œæ‚£è€…ä½¿ç”¨ã€‚",
      "CRTå¾Œæ¥å—æ‰‹è¡“åˆ‡é™¤ï¼Œè‹¥ç—…ç†å ±å‘Šå‘ˆç¾ residual tumorï¼Œå¯ä»¥è€ƒæ…®ä½¿ç”¨ nivolumab  ä¸€å¹´ä¾†å¢åŠ  disease-free survivalã€‚",
      "CRTå¾Œæ¥å—æ‰‹è¡“åˆ‡é™¤ï¼Œè‹¥ç—…ç†å ±å‘Šå‘ˆç¾ complete pathology responseï¼Œå¾ŒçºŒä¸ç”¨æ¥å—  adjuvant treatmentã€‚"
    ],
    "correctAnswer": 2,
    "explanation": "CROSS è©¦é©—æ˜¯ä¸€é …å¤§å‹éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œè©•ä¼°äº† carboplatin åŠ  paclitaxel çš„æ–°è¼”åŠ©åŒ–ç™‚è¯åˆæ”¾ç™‚åœ¨é£Ÿé“ç™Œæ²»ç™‚ä¸­çš„æ•ˆæœã€‚ è©²è©¦é©—çµæœé¡¯ç¤ºï¼Œè©²æ²»ç™‚æ–¹æ¡ˆå¯æé«˜æ‚£è€…çš„ç¸½ç”Ÿå­˜ç‡ã€‚ å› æ­¤ï¼Œé¸é … (C) ä¸­é—œæ–¼ CROSS è©¦é©—å› æ”¶æ¡ˆé‡ä¸è¶³è€Œææ—©çµæŸï¼Œä¸”ç™‚æ•ˆä¸æˆç†Ÿçš„æè¿°æ˜¯ä¸æ­£ç¢ºçš„ã€‚",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 41,
    "question": "70æ­²å¥³æ€§ç—…æ‚£ï¼Œç½¹æ‚£èƒƒç™Œå››æœŸåˆä½µè‚è½‰ç§»ï¼ŒMSSã€HER2 3+ã€CPS 1ï¼Œç¬¬ä¸€ç·šæ¥å—herceptin + pembrozilumab + capecitabine + oxalipatin æ²»ç™‚3å€‹æœˆå¾Œï¼Œè…«ç˜¤åæ‡‰PRï¼Œä½†3å€‹æœˆå¾Œå†åº¦è©•ä¼°é¡¯ç¤ºprogressive disease with enlarged liver metastasesï¼Œä¸‹åˆ—ä½•è€…æ²»ç™‚æ–¹å¼è¼ƒä¸è€ƒæ…®?",
    "options": [
      "è€ƒæ…®é‡æ–°åˆ‡ç‰‡é‡æ–°æª¢æ¸¬HER2ï¼Œè‹¥HER2 æŒçºŒoverexpressionï¼Œè€ƒæ…® Fam-trastuzumab deruxtecanä½œç‚ºäºŒç·šæ²»ç™‚",
      "å¯ä»¥è€ƒæ…®ä½¿ç”¨ ramucirumab plus paclitaxel",
      "å¯ä»¥è€ƒæ…®å–®ç¨ä½¿ç”¨ docetaxel",
      "å¯ä»¥è€ƒæ…®å–®ç¨ä½¿ç”¨ ramucirumab",
      "å¯ä»¥è€ƒæ…®å–®ç¨ä½¿ç”¨ trifluridine-tipiracil"
    ],
    "correctAnswer": 4,
    "explanation": "(A) æ­£ç¢ºã€‚æ ¹æ“šDESTINY-Gastric02 ï¼Œåœ¨æ¥å—étrastuzumab-containing regimenå¾Œprogressionçš„HER2+ advanced gastric or GEJ cancerï¼Œè‹¥é‡æ–°åˆ‡ç‰‡ä»æ˜¯HER2+ï¼Œç”¨TDXdæ²»ç™‚æœ‰é¡¯è‘—ç™‚æ•ˆï¼ŒORR 38%ï¼ŒPFS 5.5 months\r\n(B) æ­£ç¢ºã€‚ æ ¹æ“šRAINBOWï¼Œèƒƒç™ŒäºŒç·šæ²»ç™‚ramucirumab + paclitaxel vs. placebo + paclitaxelï¼ŒOS 9.6 vs. 7.4 months (HR=0.807, p=0.0169)ï¼Œramucirumab + paclitaxel æ˜¯äºŒç·šæ²»ç™‚çš„æ¨™æº–é¸æ“‡\r\n(C) æ­£ç¢ºã€‚æ ¹æ“šCOUGAR-02ï¼Œdocetaxel monotherapyå¯ä½œç‚ºäºŒç·šæ²»ç™‚é¸é …ï¼Œå°¤å…¶æ˜¯Ramuä¸é©åˆçš„ç—…äºº(ESMO guideline, gastric cancer) \r\n(D) æ­£ç¢ºã€‚ æ ¹æ“šREGARDï¼Œramucirumab monotherapyå¯ä½œç‚ºäºŒç·šæ²»ç™‚é¸é …ï¼Œå°¤å…¶æ˜¯ä¸é©åˆåŒ–ç™‚çš„ç—…äºº\r\n(E) éŒ¯èª¤ã€‚æ ¹æ“šTAGSï¼Œtrifluridine-tipiracilæ˜¯ä¸‰ç·šæˆ–å¾ŒçºŒæ²»ç™‚çš„é¸é …\r\n=> Ans. (E)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/041/explain_figures/Figure_41.jpg"
    ]
  },
  {
    "id": 42,
    "question": "Which one is not the recommendation for molecular therapeutic targets testing in unresectable or metastatic biliary tract cancers?",
    "options": [
      "NTRK gene fusion",
      "BRAF V600E mutation",
      "IDH1 mutation",
      "KRAS G12D mutation",
      "FGFR2 fusion or rearrangement"
    ],
    "correctAnswer": 3,
    "explanation": "(A) å¯ç”¨NTRK inhibitor (e.g. repotrectinib [TRIDENT-1], larotrectinib [HONG et al], entrectinib [DOEBELE et al])\r\n(B) å¯ç”¨dabrafenib + trametinib [ROAR trial]\r\n(C)å¯ç”¨ivosidenib [ClarIDHy]\r\n(D) éŒ¯èª¤ã€‚KRAS inhibitor not in current guideline\r\n(E) å¯ç”¨FGFR inhibitor (pemigatinib [FIGHT-202], futibatinib [FOENIX])\r\n=> Ans. (D)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/042/explain_figures/Figure_42.jpg"
    ]
  },
  {
    "id": 43,
    "question": "Which description about the treatment for advanced hepatocellular carcinoma is wrong?",
    "options": [
      "According to IMbrave150 trial results, patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival than sorafenib.",
      "According to HIMALAYA study results, the median overall survival was 16.43 months with STRIDE regimen (tremelimumab 300 mg one dose plus durvalumab), 16.56 month with durvalumab, and 13.77 months with sorafenib. The overall survival hazard ratio for STRIDE versus sorafenib was 0.78. Overall survival with durvalumab monotherapy was non inferior to sorafenib (hazard ratio, 0.86).",
      "According to 9DW trial results, nivolumab plus ipilimumab demonstrated statistically significant OS benefit vs lenvatinib or sorafenib in patient with previously untreated unresectable hepatocellular carcinoma, as well as higher ORR and durable responses.",
      "According to LEAP-002 study results, the addition of pembrolizumab to lenvatinib as first-line therapy for advanced hepatocellular carcinoma has shown statistically significant OS benefit.",
      "In the phase III IMbrave 050 trial, patients with HCC at high risk of recurrence after resection or local ablation who received adjuvant atezolizumab plus bevacizumab had significantly improved recurrence-free survival compared with those who had active surveillance."
    ],
    "correctAnswer": 3,
    "explanation": "(A) æ­£ç¢ºã€‚æ ¹æ“šIMbrave150ï¼Œåœ¨unresectable HCCä¸€ç·šæ²»ç™‚ï¼Œatezolizumab + bevacizumab vs. sorafenibï¼ŒORR 30% vs. 11%ï¼ŒPFS 6.8 vs. 4.3 monthsï¼ŒOS 19.2 vs. 13.4 months\r\n(B) æ­£ç¢ºã€‚æ ¹æ“šHIMALAYAï¼Œæ­¤é¸é …æ•˜è¿°å…§å®¹æ­£ç¢º\r\n(C) æ­£ç¢ºã€‚æ ¹æ“šCheckMate 9DWï¼Œ åœ¨unresectable HCCä¸€ç·šæ²»ç™‚ï¼ŒNivo + Ipi vs. Lenvatinib/Sorafenibï¼ŒOS 23.7 vs. 20.6 months (HR 0.79, p=0.0180)ï¼ŒORR 36% vs. 13% (p<0.0001)ï¼ŒDOR 30.4 vs. 12.9 months\r\n(D) éŒ¯èª¤ã€‚æ ¹æ“šLEAP-002ï¼Œåœ¨unresectable HCCä¸€ç·šæ²»ç™‚ï¼Œlenvatinib + pembrolizumab vs. lenvatinib + placeboï¼ŒOS 21.2 vs. 19 months (HR 0.84, p = 0.0227)ï¼ŒOSæœªé”åˆ°çµ±è¨ˆä¸Šçš„é¡¯è‘—å·®ç•°\r\n(E) æ­£ç¢ºã€‚æ ¹æ“šIMbrave050ï¼ŒHCC post resection/ablationçš„é«˜å¾©ç™¼é¢¨éšªç—…äººï¼Œadjuvant atezolizumab + bevacizumab vs. active surveillanceï¼Œåœ¨interim analysis (Oct 21, 2022)ï¼ŒRFS (recurrence-free survival)çš„HR 0.72 (p=0Â·012) [é™„è¨»: å¾Œä¾†2024å¹´å¹´ä¸­ESMO Congress 2024 update [A. Yopp, LBA39]çµæœé¡¯ç¤ºinitial RFS benefit was not sustainedï¼Œå› æ­¤ç›®å‰æœ€æ–°æ•¸æ“šæ˜¯ä¸æ”¯æŒçµ¦adjuvant Atezo/Bev (ESMO guideline: hepatocellular carcinoma 2025)\r\n=> Ans. (D)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 44,
    "question": "Which of the following statements about the advanced pancreatic cancer treatment is wrong?",
    "options": [
      "Patients who have response or stable disease after 4â€“6 months of chemotherapy may undergo maintenance therapy with olaparib for germline BRCA1/2 mutations.",
      "For metastatic pancreatic adenocarcinoma patients after prior gemcitabine-based therapy failure, the sequent treatment could be 5-FU + leucovorin + liposomal irinotecan.",
      "Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS G12V mutation.",
      "According to the NAPOLI 3 study in first line treatment of metastatic pancreatic cancer, the median overall survival was 11.1 months with NALIRIFOX versus 9.2 months with nab-paclitaxelâ€“gemcitabine (hazard ratio 0.83)",
      "Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects."
    ],
    "correctAnswer": 2,
    "explanation": "(A) æ­£ç¢ºã€‚â€‹æ ¹æ“šPOLO studyï¼Œå°æ–¼æœ‰germline BRCA1/2 mutationä¸”åœ¨æ¥å—1-line platinum-based therapyå¾Œç–¾ç—…æ²’æœ‰progressionçš„è½‰ç§»æ€§èƒ°è‡Ÿç™Œç—…äººï¼ŒOlaparib (PARP inhibitor) maintenance vs. placeboï¼ŒPFS 7.4 vs. 3.8 months (HR 0.53, p=0.004)ï¼Œå³Olaparib maintenanceå¯å»¶é•·PFS\r\n(B) æ­£ç¢ºã€‚â€‹æ ¹æ“šNAPOLI-1ï¼Œå°æ–¼æ¥å—gemcitabine-based therapyæ²»ç™‚å¤±æ•—å¾Œçš„è½‰ç§»æ€§èƒ°è‡Ÿç™Œç—…äººï¼Œå¯ç”¨5-FU + Leucovorin + liposomal irinotecanä½œç‚ºäºŒç·šæ²»ç™‚ï¼Œå¯å»¶é•·survival (OS 6.1 vs 4.2 months [HR=0.67, p=0.012])\r\n(C) éŒ¯èª¤ã€‚â€‹Sotorasibæ˜¯é‡å°KRAS G12C mutationï¼Œä½†KRAS G12V mutationå°Sotorasibä¸¦ä¸æ•æ„Ÿ\r\n(D) æ­£ç¢ºã€‚â€‹æ ¹æ“šNAPOLI-3ï¼Œåœ¨è½‰ç§»æ€§èƒ°è‡Ÿç™Œçš„ä¸€ç·šæ²»ç™‚ä¸­ï¼ŒNALIRIFOX (liposomal irinotecan + oxaliplatin + leucovorin + fluorouracil)çš„median OS 11.1 monthsï¼Œè€ŒNab-Paclitaxel + Gemcitabineçš„median OS 9.2 monthsï¼Œhazard ratioç‚º0.83 (p=0.036)\r\n(E) æ­£ç¢ºã€‚â€‹åœ¨PRODIGE 24/CCTG PA.6è©¦é©—ä¸­ï¼Œåœ¨resected pancreatic ductal adenocarcinoma (R0 or R1)ç—…äººï¼Œadjuvant mFOLFIRINOX vs. adjuvant Gemcitabineï¼ŒDFS (disease-free survival) 21.6 vs. 12.8m (HR 0.58, p<0.001)ï¼ŒOS 54.4 vs. 35.0 months (HR 0.64, p=0.003)ï¼ŒGrade 3-4 adverese events: 75.9% vs. 52.9%ï¼Œå³mFOLFIRINOXçš„survivalæ¯”è¼ƒå¥½ä½†æ¯’æ€§è¼ƒé«˜\r\n=> Ans. C",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 45,
    "question": "é—œæ–¼ mismatch repair-deficient (dMMR/MSI-H)å¤§è…¸ç™Œçš„æ•˜è¿°ï¼Œä¸‹åˆ—ä½•è€…éŒ¯èª¤ï¼Ÿ",
    "options": [
      "BRAF-mutation çš„å¤§è…¸ç™Œç—…æ‚£ç›¸è¼ƒæ–¼ BRAF-wild type çš„å¤§è…¸ç™Œç—…æ‚£æ›´å®¹æ˜“æª¢é©—å‡º MMR deficiencyã€‚",
      "dMMR/MSI-H å¸¸è¦‹æ–¼å³å´å¤§è…¸ç™Œï¼Œåœ¨æ—©æœŸå¤§è…¸ç™Œè‹¥æœ‰ dMMR/MSI-H ç‚ºè‰¯å¥½çš„é å¾Œå› å­ã€‚",
      "ç´„ 15%å¤§è…¸ç™Œç—…æ‚£ç‚º dMMR/MSI-Hï¼Œå…¶ä¸­ sporadic dMMR å¤šç‚º MLH1 promoter methylationï¼Œ è€Œ germline dMMR å¤šç‚º MLH1, MSH2 mutationã€‚",
      "æ ¹æ“š KEYNOTE-177ï¼Œpembrolizumab ç›¸è¼ƒæ–¼ chemotherapyï¼Œå¯é¡¯è‘—å»¶é•· PFS è‡³ 16 å€‹æœˆã€‚",
      "åœ¨ dMMR/MSI-H çš„å¤§è…¸ç™Œç—…æ‚£æ¥å—å…ç–«æ²»ç™‚æ™‚ï¼ŒPD-L1 é«˜è¡¨ç¾çš„ç—…æ‚£ï¼Œå…¶æ²»ç™‚åæ‡‰ç‡åŠå­˜æ´»ç‡ç›¸è¼ƒæ–¼ PD-L1 ä½è¡¨ç¾çš„ç—…æ‚£æœ‰æ˜é¡¯çš„å·®ç•°ã€‚"
    ],
    "correctAnswer": 4,
    "explanation": "(A) å°ã€‚ The presence of BRAF V600E mutation or MLH1 promoter methylation is consistent with sporadic cancer. Number of sporadic cancer >>> Lynch syndrome (ref. Colon Cancer NCCN V1 2025, COL-B)\r\n\r\n\r\n(B) å°ã€‚Features associated with MMR-defective tumorsâ€¦ 87% were located within the proximal colon, 61% showed an expanding growth pattern, 54% were poorly differentiated, 85% had any degree of mucinous differentiation, and 89% lacked dirty necrosisã€‚æ‰€ä»¥â€dMMR/MSI-H å¸¸è¦‹æ–¼å³å´å¤§è…¸ç™Œï¼Œå…¶ç—…ç†ç‰¹å¾µç‚º poor differentiationâ€ é€™å¥è©±æ˜¯å°çš„ (ref. Am J Clin Pathol 2008;129:238-244)\n\nThe favorable impact of dMMR on outcomes seems to be more limited in stage III colon cancer and may vary with primary tumor location. æ‰€ä»¥dMMR/MSI-Hç‹€æ…‹å°æ–¼æ—©æœŸå¤§è…¸ç™Œ (Stage II) ä¾†èªªæ˜¯è¼ƒå¥½çš„é å¾Œå› å­ã€‚(ref. Colon Cancer NCCN V1 2025, MS-20)\r\n\r\n\r\n(C) å°ã€‚\"dMMR/MSI phenotype can be acquired in sporadic CRC (75%) or constitutivelyâ€¦ germline mutation (25%). Sporadic [dMMR mostly due to] loss of expression of MLH1 caused by hypermethylation of the MLH1 gene promoter.â€ \n\nâ€œMost of the germline mutations in Lynch Syndrome occur in MLH1 or MSH2 genes (90%).â€\r\n(Ref: Evrard C. et al, Cancers (Basel). 2019;11(10):1567)\n\n\r\n(D) å°ã€‚ \r\nPembrolizumab vs ChT in MSI mCRC (ref N Engl J Med 2020;383:2207-2218)\r\nğŸ‘‰mPFS 8.2 vs 16.5 mo (HR 0.6)\r\nğŸ‘‰DoR 10.6 vs 75.4 mo\r\nğŸ‘‰mOS 36.7 vs 77.5 (HR 0.73), 5yr OS 54 vs 44%\n\n\r\n(E) éŒ¯ã€‚\nğŸ‘‰KEYNOTE-177 trialï¼ˆpembrolizumab vs. Chemotherapyï¼‰é¡¯ç¤ºï¼ŒPD-L1 è¡¨ç¾èˆ‡ PFS æˆ– ORR ç„¡é¡¯è‘—ç›¸é—œã€‚(ref. N Engl J Med 2020;383(23):2207-2218) \n\nğŸ‘‰CheckMate-142 è©¦é©—ï¼ˆnivolumab Â± ipilimumab åœ¨ dMMR/MSI-H mCRC çš„ç ”ç©¶ï¼‰ä¹Ÿé¡¯ç¤ºï¼ŒPD-L1 è¡¨ç¾èˆ‡ ORR æˆ– PFS ä¸¦ç„¡é¡¯è‘—é—œè¯ã€‚(ref. Lancet Oncol 2017;18(9):1182-1191.)\r\n\r\nğŸ‘‰It is important to note that there is currently no role for PD-L1 testing in CRC, outside a clinical trial, and that PD-L1 testing is not recommended. (ref. Colon Cancer NCCN V1 2025, MS-50)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/045/explain_figures/ÏƒÂ£Ã»Ï„Ã«Ã§ 1.png",
      "/qabank/045/explain_figures/ÏƒÂ£Ã»Ï„Ã«Ã§ 2.png",
      "/qabank/045/explain_figures/ÏƒÂ£Ã»Ï„Ã«Ã§ 3.png"
    ]
  },
  {
    "id": 46,
    "question": "ä¸€ä½ 48 æ­²çš„ç”·æ€§ï¼Œå› è²§è¡€ç™¼ç¾å‡çµè…¸æƒ¡æ€§è…«ç˜¤ï¼Œèƒ¸è…¹éƒ¨é›»è…¦æ–·å±¤ç™¼ç¾å¤šé¡†è‚è‡Ÿè½‰ç§»ï¼Œç¶“åˆ‡ç‰‡ç—…ç†çµ„ç¹”æª¢æ¸¬ç‚º pMMRã€BRAFV600Eã€RASwt ä¹‹å¤§è…¸ç™Œï¼ŒECOG PS ç‚º 0ã€‚ä¸‹åˆ—é—œæ–¼æ­¤ç—…æ‚£ æ²»ç™‚çš„é¸æ“‡ï¼Œä½•è€…éŒ¯èª¤ï¼Ÿ",
    "options": [
      "ç—…æ‚£ä¸å¯é¸æ“‡ dabrafenib + trametinib åšç‚º BRAFV600Eçš„å¯¦é«”è…«ç˜¤çš„æ²»ç™‚ã€‚",
      "æ­¤ç—…æ‚£å¯ä½¿ç”¨ FOLFIRI + bevacizumab åšç‚ºè½‰ç§»ç¬¬ä¸€ç·šæ²»ç™‚ã€‚",
      "æ­¤ç—…æ‚£åœ¨ä¸€ç·šæ²»ç™‚ç„¡æ•ˆå¾Œï¼Œå¯æ ¹æ“š BEACON studyï¼Œé¸æ“‡ encorafenib + binimetinib æ²»ç™‚ã€‚",
      "è‹¥ç—…æ‚£ä¹‹è‚è½‰ç§»åœ¨æ¥å—åŒ–å­¸æ²»ç™‚æœ‰æ•ˆç¸®å°ï¼Œå¯è€ƒæ…®è«‹å¤–ç§‘é†«å¸«å°‡è‚è‡Ÿè…«ç˜¤åŠåŸç™¼è…«ç˜¤ åŒæ™‚åˆ‡é™¤ã€‚",
      "è‹¥æ­¤ç—…æ‚£ä¹‹ BRAF ä¸ç‚º V600E mutationï¼Œå¯è€ƒæ…®ä½¿ç”¨ anti-EGFR çš„æ²»ç™‚ã€‚"
    ],
    "correctAnswer": 2,
    "explanation": "(A) å°ã€‚\r\nFailed: Dabrafenib in combination with trametinib is not indicated for patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition.é€™å€‹çµ„åˆåœ¨melanoma, glioma, NSCLC, thyroid, solid tumor basket trial(NCI-MATCH trial, BELIEVE trial, ROAR trial; ORR 80%) \n(ref. J Clin Oncol. 2015 Dec 1;33(34):4023-31)\r\n\n\n\r\n(B) å°ã€‚\nBRAF V600Eé æœŸå°åŒ–ç™‚æ•ˆæœæœƒæ¯”è¼ƒå·®ï¼Œæ‰€ä»¥é«”åŠ›å¯è¡Œçš„è©±FOLFOXIRIæœƒæ¯”Doubletå¥½ï¼Œä¾æ“šBEACON trial, BRAF V600E TKIç›®å‰äºŒç·šæ‰æœ‰è§’è‰²ï¼Œä½†ç›®å‰FDAå·²ç¶“accelerated approval encorafenib+ cetuximab + mFOLFOX6åœ¨ä¸€ç·šä½¿ç”¨ã€‚åœ¨ä¸€ç·šæ²»ç™‚æ™‚ï¼ŒCetuximab è·Ÿ Panitumumab é€™é¡anti-EGFRè—¥ç‰©ä¾ç›®å‰ç ”ç©¶æ¯”è¼ƒåå‘ä¸é©åˆä½¿ç”¨(ref. NCCN V1.2025, MS-48)\n\n\r\n(C) éŒ¯ã€‚\nBEACON studyæ˜¯BRAF V600E äºŒç·šæ²»ç™‚ï¼Œçµè«–æ˜¯:\n1.EC(Encorafenib+Cetuximab or Panitumumab)+/- Binimetinibæ¯”FOLFIRI+Cetuximabå¥½;\n2. EC+Bå¯èƒ½æ²’æœ‰æ¯”ECå¥½åˆ°å“ª(æ²’æœ‰çµ±è¨ˆpower) ä¸”severe AEè¼ƒå¤š(58% vs 50%); å¾Œä¾†æœ‰ANCHOR phase 2 studyæ˜¯æŒ‘æˆ°BRAF V600E ä¸€ç·šæ²»ç™‚ï¼Œç”¨EC+Binimetinibçœ‹èµ·ä¾†ORRä¸éŒ¯ï¼Œç¾åœ¨è¦ç­‰Breakwater phase 3çœ‹ä¸€ç·šEC+chemotherapyæŒ‘æˆ°æœ‰æ²’æœ‰æˆåŠŸï¼Œç›®å‰åˆæ­¥çµæœORR was 61% (95% CI: 52%, 70%) in the encorafenib+ cetuximab, + mFOLFOX6 arm and 40% (95% CI: 31%, 49%) in the control arm. Median DoR was 13.9 months (95% CI: 8.5, not estimable) and 11.1 months (95% CI: 6.7, 12.7) in the respective armsï¼ŒFDA å·²åœ¨2024/12 accelerated approval.\r\n(ref. Scott Kopetz. et al. N Engl J Med 2019;381:1632-1643, BEACON trial)\n\r\n \r\n(D) å°ã€‚ \r\nStudies of selected patients undergoing surgery to remove colorectal liver metastases have shown that cure is possible in this population and should be the goal for a substantial number of these patients.\r\nâ€¢  å¯åˆ‡é™¤ï¼ˆResectableï¼‰è‚è½‰ç§» â†’ ç›´æ¥è€ƒæ…®æ‰‹è¡“ +/- è¼”åŠ©æ²»ç™‚\r\nâ€¢  æ½›åœ¨å¯åˆ‡é™¤ï¼ˆPotentially resectableï¼‰è‚è½‰ç§» â†’ å…ˆæ¥å—è½‰åŒ–æ€§åŒ–ç™‚ï¼ˆconversion therapyï¼‰ï¼Œè‹¥è…«ç˜¤ç¸®å°åˆ°å¯åˆ‡é™¤æ¨™æº–ï¼Œå‰‡è€ƒæ…®æ‰‹è¡“\r\nâ€¢  ä¸å¯åˆ‡é™¤ï¼ˆUnresectableï¼‰è‚è½‰ç§» â†’ ä»¥**å…¨èº«æ€§æ²»ç™‚ï¼ˆåŒ–ç™‚ã€æ¨™é¶ã€å…ç–«æ²»ç™‚**ç‚ºä¸»\n(ref. NCCN V1.2025, MS-29, 37-43, ESMO guideline)\r\n\n\r\n(E) å°ã€‚ \r\nBRAF é V600E çªè®Šï¼ˆNon-V600E BRAF mutationsï¼‰\r\nBRAF é V600E çªè®Šï¼ˆå¦‚ BRAF D594G, G469A ç­‰ï¼‰èˆ‡ BRAF V600E åœ¨åˆ†å­æ©Ÿåˆ¶ä¸Šä¸åŒï¼š\r\n.Class 2 çªè®Šï¼ˆå¦‚ K601E, L597Vï¼‰ï¼šå¢å¼· ERK è¨Šè™Ÿå‚³å°ï¼Œå° anti-EGFR å¯èƒ½åæ‡‰ä¸ä½³ï¼Œä½†ç›®å‰è­‰æ“šæœ‰é™ã€‚\r\n.Class 3 çªè®Šï¼ˆå¦‚ D594G, G469Aï¼‰ï¼šå±¬æ–¼ã€Œkinase-deadã€çªè®Šï¼Œæœƒä¾è³´ EGFR æ´»åŒ–ï¼Œå› æ­¤å° anti-EGFR å¯èƒ½æœ‰æ•ˆã€‚\n\r\nç ”ç©¶é¡¯ç¤ºï¼šBRAF é V600E çªè®Šæ‚£è€…å¯èƒ½å° anti-EGFR å–®ç¨æˆ–åˆä½µæ²»ç™‚æœ‰åæ‡‰ï¼Œå°¤å…¶æ˜¯ã€ŒClass 3 çªè®Šã€ã€‚å› æ­¤ï¼Œè‹¥æ‚£è€…BRAF é V600E çªè®Šï¼Œå‰‡å¯è€ƒæ…®ä½¿ç”¨ anti-EGFR æ²»ç™‚ã€‚\n(ref. NEJM, 381(17), 1632-1643, Cancer Cell, 33(1), 125-136.e3, NCCN V1.2025, MS-48 49)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/046/explain_figures/ÏƒÂ£Ã»Ï„Ã«Ã§ 1.png",
      "/qabank/046/explain_figures/ÏƒÂ£Ã»Ï„Ã«Ã§ 2.png",
      "/qabank/046/explain_figures/ÏƒÂ£Ã»Ï„Ã«Ã§ 3.png",
      "/qabank/046/explain_figures/ÏƒÂ£Ã»Ï„Ã«Ã§ 4.png",
      "/qabank/046/explain_figures/ÏƒÂ£Ã»Ï„Ã«Ã§ 5.png",
      "/qabank/046/explain_figures/ÏƒÂ£Ã»Ï„Ã«Ã§ 6.png",
      "/qabank/046/explain_figures/ÏƒÂ£Ã»Ï„Ã«Ã§ 7.png",
      "/qabank/046/explain_figures/ÏƒÂ£Ã»Ï„Ã«Ã§ 8.png",
      "/qabank/046/explain_figures/ÏƒÂ£Ã»Ï„Ã«Ã§ 9.png"
    ]
  },
  {
    "id": 47,
    "question": "é—œæ–¼å¤§è…¸ç™Œçš„æ‰‹è¡“å¾Œè¼”åŠ©æ€§åŒ–å­¸æ²»ç™‚(adjuvant chemotherapy)ï¼Œä¸‹åˆ—æ•˜è¿°ä½•è€…æ­£ç¢ºï¼Ÿ",
    "options": [
      "åœ¨ 70 æ­²ä»¥ä¸Šï¼Œç¬¬äºŒæœŸä¸”ç„¡ high risk factors çš„å¤§è…¸ç™Œç—…æ‚£ï¼Œä½¿ç”¨ 5-FU/LV åŠ ä¸Š Oxaliplatin ä¸¦å¯é¡¯è‘—æå‡ Overall survivalã€‚",
      "æ ¹æ“š MOSAIC trialï¼Œç¬¬ä¸‰æœŸå¤§è…¸ç™Œç—…æ‚£åœ¨è¡“å¾Œæ¥å—å…­å€‹æœˆçš„ oxaliplatin + 5-FU/LV ç›¸è¼ƒ æ–¼å–®ç”¨ 5-FU/LV æœ‰ç„¡æ³•é¡¯è‘—å»¶é•· disease free survival(DFS)ã€‚",
      "æ ¹æ“š IDEA collaborationï¼Œhigh-risk stage III çš„å¤§è…¸ç™Œç—…æ‚£ä½¿ç”¨ä¸‰å€‹æœˆ FOLFOXçš„DFSä¸åŠ£æ–¼(non-inferior)ä½¿ç”¨å…­å€‹æœˆçš„FOLFOXã€‚",
      "æ‰¿ä¸Šï¼Œlow-risk stage III çš„å¤§è…¸ç™Œç—…æ‚£ä½¿ç”¨ä¸‰å€‹æœˆçš„ CAPOXï¼Œå…¶ DFS ä¸åŠ£æ–¼ä½¿ç”¨å…­å€‹æœˆçš„CAPOXã€‚",
      "Poorly differentiation ä¸¦æœ‰ mismatch repair deficiency çš„ stage II å¤§è…¸ç™Œç—…æ‚£å¯å–®ç¨ä½¿ç”¨ 5-FU/LV ä½œç‚ºè¼”åŠ©æ€§åŒ–å­¸æ²»ç™‚ã€‚"
    ],
    "correctAnswer": 3,
    "explanation": "(A) éŒ¯ã€‚\r\nPatients with low-risk stage II disease that is MSS or pMMR can be observed without adjuvant therapy or considered for capecitabine or 5-FU/LV. Based on results of the MOSAIC trial, and the possible long-term sequelae of oxaliplatin-based chemotherapy, the Panel does not consider FOLFOX (infusional 5-FU, LV, oxaliplatin) to be an appropriate adjuvant therapy option for patients with stage II disease without high-risk features. \r\n\nHigh risk for systemic recurrence: \u000b- T4 tumors (stage IIB/IIC); poorly differentiated/undifferentiated histology; lymphovascular invasion; PNI; tumor budding; bowel obstruction; lesions with localized perforation or close, indeterminate, or positive margins; or inadequately sampled nodes.\r\n(ref. Colon Cancer NCCN V1 2025 MS-17)\n\n\r\n(B) éŒ¯ã€‚\nMOSAIC trialï¼Œç¬¬ä¸‰æœŸå¤§è…¸ç™Œç—…æ‚£åœ¨è¡“å¾Œæ¥å—å…­å€‹æœˆçš„ oxaliplatin + 5FU/LV ç›¸è¼ƒæ–¼å–®ç”¨ 5FU/LV æœ‰æ›´é•·çš„ Disease free survival(DFS)ï¼Œä½† overall survivalä¸¦æ²’æœ‰é¡¯è‘—å·®ç•° (HR=0.90, 95% CI 0.71-1.13)ã€‚\r\n\nä½†2009å¹´JCOç™¼è¡¨äº†8å¹´çš„è¿½è¹¤çµæœï¼Œä¸¦æŠŠstage IIå’Œstage IIIåˆ†é–‹ä¾†çœ‹ï¼Œåœ¨stage IIçš„OSæ²’æœ‰å·®åˆ¥ï¼›ä½†æ˜¯stage IIIä¸­å…©çµ„OSå°±æœ‰é¡¯è‘—å·®ç•° (FL+oxaliplatin vs FL, HR:0.80 (0.65-0.97), p=0.023)\r\n\nå¦‚ä¸‹åœ–ï¼šFig.2 Overall survival by treatment arm and by stage\r\n(ref: J Clin Oncol. 2009 Jul 1;27(19):3109-16.)\r\n\n\r\n(C)éŒ¯ \næ ¹æ“š IDEA collaborationï¼Œ ä¸‰å€‹æœˆ FOLFOX çš„DFSåŠ£æ–¼(inferior) ä½¿ç”¨å…­å€‹æœˆçš„ FOLFOXã€‚è‡¨åºŠå¯¦é©—çµæœç´°é …ï¼š\r\nåœ¨åˆ†æäº†è¶…é12,800åstage III colon canceræ‚£è€…å’Œ3,263ä¾‹ç–¾ç—…å¾©ç™¼æˆ–æ­»äº¡äº‹ä»¶çš„æ•¸æ“šå¾Œï¼Œç ”ç©¶ç™¼ç¾3å€‹æœˆçš„adjuvant chemotherapyåœ¨æ•´é«”äººç¾¤ä¸­ä¸¦ééåŠ£æ•ˆæ–¼6å€‹æœˆ(hazard ratio, 1.07; 95% confidence interval [CI], 1.00 to 1.15)ã€‚\n\r\nç„¶è€Œï¼Œåœ¨ä¸€é …æ¢ç´¢æ€§åˆ†æä¸­ï¼Œç™¼ç¾å°æ–¼CAPOXï¼Œè¼ƒçŸ­çš„ç™‚ç¨‹åœ¨Stage III Colon Canceræ˜¯éåŠ£æ•ˆçš„(hazard ratio, 0.95; 95% CI, 0.85 to 1.06)ï¼Œä½†å°æ–¼FOLFOXå‰‡ä¸æ˜¯(hazard ratio, 1.16; 95% CI, 1.06 to 1.26)ã€‚\n\r\nåŸå‰‡ä¸Šï¼Œadjuvant chemotherapyåœ¨ä½é¢¨éšªå¤§è…¸ç™Œç—‡æ‚£è€…ï¼ˆT1ã€T2æˆ–T3å’ŒN1ï¼‰ä¸­ï¼Œ3å€‹æœˆçš„æ²»ç™‚æ˜¯éåŠ£æ•ˆæ–¼6å€‹æœˆã€‚ç›¸åï¼Œåœ¨é«˜é¢¨éšªå¤§è…¸ç™Œç—‡æ‚£è€…ï¼ˆT4ã€N2æˆ–å…©è€…å…¼æœ‰ï¼‰ä¸­ï¼Œ6å€‹æœˆçš„ç™‚ç¨‹å„ªæ–¼3å€‹æœˆã€‚\n\r\nçµè«–ï¼š\r\né€™é …ç ”ç©¶è¡¨æ˜ï¼Œå°æ–¼ç¬¬ä¸‰æœŸå¤§è…¸ç™Œæ‚£è€…ï¼Œ3å€‹æœˆçš„æ²»ç™‚èˆ‡æ¨™æº–çš„6å€‹æœˆç›¸æ¯”ï¼Œåœ¨æ•´é«”ä¸Šä¸¦ééåŠ£æ•ˆã€‚ç„¶è€Œï¼Œå°æ–¼æ¥å—CAPOXæ²»ç™‚çš„æ‚£è€…ï¼Œ3å€‹æœˆçš„æ²»ç™‚èˆ‡6å€‹æœˆä¸€æ¨£æœ‰æ•ˆï¼Œç‰¹åˆ¥æ˜¯åœ¨ä½é¢¨éšªäºçµ„ä¸­ã€‚\n(ref. N Engl J Med 2018;378:1177-88)\n\n\r\n(D )å°\nè§£é‡‹åŒä¸Šä¸€é¸é … (ref. N Engl J Med 2018;378:1177-88)\n\n\r\n(E) éŒ¯ã€‚\r\ndMMR or MSI-H tumor status may be a predictive marker of decreased benefit and possibly a detrimental impact from adjuvant therapy with a fluoropyrimidine alone in patients with stage II disease. \n\nA retrospective study involving long-term follow-up of patients with stage II and III disease evaluated according to MSI tumor status showed that those characterized as MSI-L or MSS had improved outcomes with 5-FU adjuvant therapy. However, patients with tumors characterized as MSI-H did not show a statistically significant benefit from 5-FU after surgery, instead exhibiting a lower 5-year survival rate than those undergoing surgery alone. Similarly, results from another retrospective study of pooled data from adjuvant trials by Sargent et al. showed that in tumors characterized as dMMR, adjuvant 5-FU chemotherapy seemed to be detrimental in patients with stage II disease, but not in those with stage III disease\n(ref. Colon cancer NCCN V1 2025 MS-20)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/047/explain_figures/ÏƒÂ£Ã»Ï„Ã«Ã§ 1.png",
      "/qabank/047/explain_figures/ÏƒÂ£Ã»Ï„Ã«Ã§ 2.png"
    ]
  },
  {
    "id": 48,
    "question": "é—œæ–¼ small bowel adenocarcinomaï¼Œä¸‹åˆ—æ•˜è¿°ä½•è€…éŒ¯èª¤ï¼Ÿ",
    "options": [
      "å°è…¸ç™Œç›¸è¼ƒæ–¼å¤§è…¸ç™Œï¼Œç—…æ‚£è¨ºæ–·æ™‚çš„å¹´é½¡è¼ƒè¼•ï¼Œè¨ºæ–·çš„æœŸåˆ¥è¼ƒæ™šæœŸï¼Œå…¶ä¸­æœ€å¸¸è¦‹çš„è½‰ç§»éƒ¨ä½æ˜¯è‚è‡ŸåŠè…¹è†œè½‰ç§»ã€‚",
      "è‹¥ç—…æ‚£ç‚º RASwtè½‰ç§»æ€§å°è…¸ç™Œï¼Œä½¿ç”¨ cetuximab æˆ–æ˜¯ panitumumab åŠ ä¸ŠåŒ–å­¸æ²»ç™‚åšç‚º ç¬¬ä¸€ç·šæ²»ç™‚ä¸¦æ²’æœ‰æ˜é¡¯çš„æ²»ç™‚æ•ˆæœã€‚",
      "ç¬¬ä¸€ç·šåŒ–å­¸æ²»ç™‚å¯ä½¿ç”¨ FOLFOXï¼Œè€Œå¾Œç·šæ²»ç™‚å¯ä½¿ç”¨ FOLFIRI æˆ–æ˜¯ Taxane-based chemotherapyã€‚",
      "ç•¶åŒ–å­¸æ²»ç™‚çš†å¤±æ•—æ™‚ï¼Œ2024 å¹´ NCCN æ²»ç™‚æŒ‡å¼•ä¸å»ºè­°æ ¹æ“šå¤§è…¸ç™Œå¾Œç·šæ²»ç™‚æ–¹å¼ï¼Œå³ä½¿ç”¨ regorafenib æˆ–æ˜¯ trifluridine-tipiracilã€‚",
      "å°è…¸ç™Œ HER2 é™½æ€§åŠ dMMR/MSI-H, PD-L1 é«˜è¡¨ç¾åŠ TMB-H çš„æ©Ÿç‡è¼ƒå¤§è…¸ç™Œä½ã€‚"
    ],
    "correctAnswer": 4,
    "explanation": "**Answers in Small Bowel Adenocarcinoma NCCN Guideline**\n\r\n[A]å°ã€‚**ç­”æ¡ˆå¯«åœ¨V2 2025 MS-4ã€‚å°è…¸ç™Œçš„è¨ºæ–·å¹´é½¡å¤§ç´„æ˜¯66æ­²ï¼Œå€¼å¾—æ³¨æ„çš„æ˜¯ç™¼ç”Ÿç‡åœ¨è¿‘å¹´æ˜¯ä¸Šå‡çš„ï¼Œèˆ‡å¤§è…¸ç™Œç›¸åã€‚30-40%å°è…¸ç™Œæ˜¯adenocarcinomaï¼Œå…¶é¤˜çš„æ˜¯GIST, lymphoma, neuroendocrine tumorã€‚ç–¾ç—…è¡¨ç¾ç‚ºè…¸é˜»å¡è·Ÿè…¹ç—›ï¼Œæ‰€ä»¥ç™¼ç¾æ˜¯é€šå¸¸æ˜¯æ™šæœŸã€‚å±éšªå› å­è·Ÿå¤§è…¸ç™Œä¸€æ¨£(inflammatory bowel disease, lynch syndromeç­‰ç­‰)ã€‚(ref. NCCN 2.2025, MS-2)\r\nPatients with SBA tend to be younger at diagnosis and often present with a higher stage and grade compared to those with CRC.40 SBA often presents with a local complication of the tumor, most often gastric outlet obstruction in the case of a duodenal SBA or cramping abdominal pain in the case of a jejunal or ileal SBA.36,41,42 Occult gastrointestinal bleeding is another common presentation for SBA, occurring in approximately one-quarter to one-third of cases. (ref. NCCN V2.2025, MS-4)\r\nApproximately 32% of patients diagnosed with SBA have stage IV (distant metastatic) disease.40 The most common sites for metastatic spread include the peritoneal cavity and liver, consistent with other gastrointestinal malignancies.(ref. NCCN V2.2025, MS-10). \n\n\r\n[B] å° \r\nA 2017 retrospective analysis reported that the efficacy of cetuximabcontaining chemotherapy for RAS wild-type SBA was inconclusive.124 Subsequently, a phase II trial published in 2018 showed that panitumumab has no clinically meaningful activity in RAS wild-type SBA125; therefore, cetuximab or panitumumab should not be used for treatment of SBA.(ref. NCCN V2.2025, MS-12) \n\n\r\n[C,D]å°ã€‚\r\nè¦æ³¨æ„bevacizumabå¯ä»¥è€ƒæ…®åŠ ä¸Šå»ä½¿ç”¨ï¼Œæ˜¯å› ç‚ºè¢«è­‰å¯¦åœ¨å°è…¸ç™Œæ˜¯å®‰å…¨çš„ï¼Œä½†æ•ˆæœåˆ°åº•å¥½ä¸å¥½ä¸çŸ¥é“ã€‚ä¸‹åˆ—è™•æ–¹å¹¾ä¹éƒ½æ˜¯å¾å¤§è…¸ç™Œtrialæ’ˆå‡ºå°è…¸ç™Œæ‚£è€…è¡ä¼¸å‡ºä¾†çš„ï¼Œé‚£ç¬¬ä¸€ç·šæ²»ç™‚ä¹Ÿå¹¾ä¹æ˜¯FOLFOX baseã€‚å¦å¤–åœ¨BRAFV600E å°±è·Ÿå¤§è…¸ç™Œä¸åŒï¼Œæ˜¯åŸºæ–¼dabrafenib/trametinib basket ROAR studyå»ºè­°ï¼Œä¸æ˜¯BEACON\r\n \n(ref. NCCN V2.2025, MS-12-17)\n\n\r\n[E] éŒ¯**ç­”æ¡ˆå¾NCCNå¯ä»¥ç›´æ¥æ‰¾åˆ°\r\nImportantly, human epidermal growth factor receptor 2 (HER2) alterations, MSI-H/dMMR, programmed death-ligand 1 (PD-L1) expression, and tumor mutational burden-high (TMB-H) are enhanced in SBA compared to CRC and may reveal greater importance of targeted or immunotherapeutic treatments compared to current CRC treatment algorithms. One study showed higher rates of PD-L1 positivity in SBA associated with Crohnâ€™s or celiac disease, compared with sporadic SBA. (ref. NCCN V2.2025, MS-11,12)\n\r\n(ä¸‹åœ–JAMA Oncol 2017;3:1546-1553)ï¼Œè€å¯¦èªªPD-L1æœ‰æ²’æœ‰æ¯”è¼ƒé«˜è¡¨ç¾å°±æ²’æœ‰å¾ˆå¥½è­‰æ“šã€‚å¦å¤–ï¼ŒMSI-H/dMMRåœ¨ç¬¬äºŒæœŸå°è…¸ç™Œæ˜¯å€‹prognostic factorï¼Œé€™äº›ç—…äººé å¾Œè¼ƒå¥½ï¼Œä½†æ˜¯ä¸æ˜¯å€‹è—¥ç‰©çš„predictive markeré‚„ä¸æ˜ç¢º(QUASAR study, CALGB 9581 and 89803 trials)ï¼Œæ‰€ä»¥èƒ½ä¸èƒ½ç”¨é€™å€‹æ±ºå®šè¦ä¸è¦æ¥å—adjuvant therapyé‚„ä¸æ˜ç¢ºã€‚",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/048/explain_figures/ÏƒÂ£Ã»Ï„Ã«Ã§ 1.png",
      "/qabank/048/explain_figures/ÏƒÂ£Ã»Ï„Ã«Ã§ 2.png",
      "/qabank/048/explain_figures/ÏƒÂ£Ã»Ï„Ã«Ã§ 3.png"
    ]
  },
  {
    "id": 49,
    "question": "ASPEN (American Society for Parenteral and Enteral Nutrition) has guidelines for â€œNutritional Support Therapy During Anticancer Treatmentâ€. Which of the followings statement about the guidelines is incorrect?",
    "options": [
      "Nutrition support should not be used routinely in patients undergoing head and neck, abdominal, or pelvic irradiation.",
      "Nutrition support therapy should not be used routinely as an adjunct to chemotherapy.",
      "Nutrition support therapy is beneficial in cancer patients if administered for 7-14 days preoperatively.",
      "Omega-3 fatty acid supplementation may help stabilize weight in cancer patients on oral diets experiencing progressively, unintentional weight loss.",
      "Omega-3 fatty acid supplementation may help stabilize weight in cancer patients on oral diets experiencing progressively, unintentional weight loss."
    ],
    "correctAnswer": 2,
    "explanation": "The ASPEN Clinical Guidelines developed a section for cancer patients aiming to \"examine the literature and develop guidelines only for NST\" (nutritional support therapy) \"in adult cancer patients.\" \n\nQuestion 49 is derived from guideline recommendations seen in Table 2 at the bottom of this page.\n\n(A) Nutrition support should not be used routinely in patients undergoing head and neck, abdominal, or pelvic irradiation.\n--> Correct; Table 2, Point 5\n\n(B) Nutrition support therapy should not be used routinely as an adjunct to chemotherapy.\n--> Correct; Table 2, Point 4 \n\n**(C) Nutrition support therapy is beneficial in cancer patients if administered for 7-14 days preoperatively.\n--> Incorrect; the above statement needs to be qualified, see Table 2, Point 3\nPre-OP NST may benefit \"moderately or severely malnourished\" cancer patients, but we must weigh the pros and cons, lest we delay surgery itself. \n\n(D) Patients should not use therapeutic diets to treat cancer.\n--> Correct; Table 2, Point 9 \n\n(E) Omega-3 fatty acid supplementation may help stabilize weight in cancer patients on oral diets experiencing progressively, unintentional weight loss.\n--> Correct; Table 2, Point 8\n\n\nTable 2. Nutrition Support Therapy During Anticancer Treatment\n--------------------------\nGuideline Recommendations\n--------------------------\n\n1. Patients with cancer are nutritionally-at-risk and should undergo nutrition screening to identify those who require formal nutrition assessment with development of a nutrition care plan. Grade D\n\n2. Nutrition support therapy should not be used routinely in patients undergoing major cancer operations. Grade A\n\n3. Perioperative nutrition support therapy may be beneficial in moderately or severely malnourished patients if administered for 7-14 days preoperatively, but the potential benefits of nutrition support must be weighed against the potential risks of the nutrition support therapy itself and of delaying the operation. Grade A\n\n4. Nutrition support therapy should not be used routinely as an adjunct to chemotherapy. Grade B\n\n5. Nutrition support therapy should not be used routinely in patients undergoing head and neck, abdominal, or pelvic irradiation. Grade B\n\n6. Nutrition support therapy is appropriate in patients receiving active anticancer treatment who are malnourished and who are anticipated to be unable to ingest and/or absorb adequate nutrients for a prolonged period of time(see Guideline 6 Rationale for discussion of â€œprolonged period of timeâ€). Grade B\n\n7. The palliative use of nutrition support therapy in terminally ill cancer patients is rarely indicated. Grade B\n\n8. Ï‰-3 Fatty acid supplementation may help stabilize weight in cancer patients on oral diets experiencing progressive, unintentional weight loss. Grade B\n\n9. Patients should not use therapeutic diets to treat cancer. Grade E\n\n10. Immune-enhancing enteral formulas containing mixtures of arginine, nucleic acids, and essential fatty acids maybe beneficial in malnourished patients undergoing major cancer operations. Grade A\n\nReference: August DA, et al. JPEN J Parenter Enteral Nutr. 2009 Sep-Oct;33(5):472-500.",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 50,
    "question": "ä¸‹åˆ—é—œæ–¼ä¸‹è‚¢æ·‹å·´æ°´è…«(lymphedema)çš„æ•˜è¿°,ä½•è€…éŒ¯èª¤?",
    "options": [
      "å¸¸è¦‹æœ‰ä¸‹è‚¢æ·‹å·´æ°´è…«çš„ç™Œç—‡ä¸»è¦æ˜¯æ³Œå°¿é“ç™Œã€å©¦ç™ŒåŠé»‘è‰²ç´ ç™Œ,ç´„æœ‰ 20%æ­¤é¡ç™Œç—‡ç—…äººæœ‰ä¸‹è‚¢æ·‹å·´æ°´è…«å•é¡Œã€‚",
      "Chronic venous insufficiency ä¹Ÿæœƒå°è‡´ä¸‹è‚¢æ·‹å·´æ°´è…«ã€‚",
      "è‚¥èƒ–ç‚ºä¸‹è‚¢æ·‹å·´æ°´è…«çš„å±éšªå› å­ã€‚",
      "Complete decongestive therapy (CDT)å¯ä»¥ä½¿ä¸‹è‚¢æ·‹å·´æ°´è…«çš„é«”ç©ä¸‹é™ 31-73%,ä¸¦ä¸”æ•ˆæœæŒçºŒä¹…ã€‚",
      "æ‰‹è¡“æ–¹å¼å¦‚ lymphovenous anastomosis æˆ– vascularized lymph node transfer,å¯ä»¥ä½¿ä¸‹è‚¢æ·‹å·´æ°´è…«çš„é«”ç©ä¸‹é™ 42-59%ã€‚"
    ],
    "correctAnswer": 3,
    "explanation": "The following responses/statements are sourced from \"Up to Date\" articles discussing peripheral lymphedema. \n\n(A) å¸¸è¦‹æœ‰ä¸‹è‚¢æ·‹å·´æ°´è…«çš„ç™Œç—‡ä¸»è¦æ˜¯æ³Œå°¿é“ç™Œã€å©¦ç™ŒåŠé»‘è‰²ç´ ç™Œ,ç´„æœ‰ 20%æ­¤é¡ç™Œç—‡ç—…äººæœ‰ä¸‹è‚¢æ·‹å·´æ°´è…«å•é¡Œã€‚\n--> Correct; numbers vary widely by study! (Ref 1)\n\nâ€œoverall incidence of lymphedema was 15.5% and varied by malignancy (P < .001): melanoma, 16% (upper extremity,5%; lower extremity, 28%); gynecologic, 20%; genitourinary, 10%; head/neck, 4%; and sarcoma, 30%. Increasedlymphedema risk was also noted for patients undergoing pelvic dissections (22%) and radiation therapy (31%).\" \n\n(B) Chronic venous insufficiency ä¹Ÿæœƒå°è‡´ä¸‹è‚¢æ·‹å·´æ°´è…«ã€‚\n--> Correct; Table 1 from Ref 2 \n\t\n**Primary lymphedema\n-Congenital\n-Precox (adolescence) \n-Tarda (adulthood)\n\n**Secondary lymphedema \n-Cancer and cancer treatment\n-Lymph node dissection\n-Lymph node irradiation\n-Obesity\n-Chronic venous insufficiency\n-Infection/chronic inflammation (eg, recurrent cellulitis filariasis)\n\n(C) è‚¥èƒ–ç‚ºä¸‹è‚¢æ·‹å·´æ°´è…«çš„å±éšªå› å­ã€‚\n--> Correct; See answer (B)\n\n(D) Complete decongestive therapy (CDT) å¯ä»¥ä½¿ä¸‹è‚¢æ·‹å·´æ°´è…«çš„é«”ç©ä¸‹é™ 31-73%,ä¸¦ä¸”æ•ˆæœæŒçºŒä¹…ã€‚\n--> Incorrect; Volume reduction by 31-73% is correct, but effects may not last forever. (Ref 2)\n\nUpper extremity lymphedema: CDT may reduce limb volume by 28-70%. \nQuality of life and functional indicators are also significantly improved.\n\nLower extremity lymphedema: CDT may reduce limb volume by 31-73%. There are fewer studies for this. \n\n\"Patient compliance with treatment is important for achieving and maintaining a successful outcome...\n[but] can be difficult... As such, lymphedema can progress despite conservative treatment measures.\"\n\n(E) æ‰‹è¡“æ–¹å¼å¦‚ lymphovenous anastomosis æˆ– vascularized lymph node transfer,å¯ä»¥ä½¿ä¸‹è‚¢æ·‹å·´æ°´è…«çš„é«”ç©ä¸‹é™ 42-59%ã€‚\n--> Correct; However, volume reduction varies widely by study (Ref 3)\n\nReferences: \n1. Cormier JN, et al. Cancer. 2010 Nov 15;116(22):5138-49\n2. Mehrara B, et al. Management of peripheral lymphedema. In: UptoDate, Connor RF (Ed), Wolters Kluwer. (Accessed on March 3, 2025.)\n3. Mehrara B, et al. Surgical treatment of primary and secondary lymphedema. In: UptoDate, Connor RF (Ed), Wolters Kluwer. (Accessed on March 3, 2025.)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/050/explain_figures/Screenshot 2025-03-03 at 1.19.48 PM.png"
    ]
  },
  {
    "id": 51,
    "question": "Which is not the complication of erythropoiesis stimulating agents used?",
    "options": [
      "Thrombocytopenia",
      "Hypertension",
      "Seizure",
      "Thromboembolism",
      "Pure red cell aplasia"
    ],
    "correctAnswer": 0,
    "explanation": "Contraindications:\n-Uncontrolled hypertension\n-Pure red cell aplasia (PRCA)\n-Severe allergic reactions\n-Hypersensitivity to non-human mammal-derived products\n-Neonates, permpartum mothers, breastfeeding mothers (if containing benzyl alcohol --> gasping syndrome)\n\nWarning and Precautions:\n-Thromboembolic events\n-Pure red cell aplasia \n-Seizures\n-Allergic reactions\n-Severe cutaneous adverse drug reactions\n-Potential for abuse\n-Dialysis monitoring \n\n(A) Thrombocytopenia\n--> Incorrect; however, this is still seen in some multi center studies...  \n\n(B) Hypertension\n--> Correct \n\n(C) Seizure\n--> Correct \n\n(D) Thromboembolism\n--> Correct \n\n(E) Pure red cell aplasia\n--> Correct \n\n\nReference: \n1. Schoener B, Borger J. Erythropoietin Stimulating Agents. [Updated 2024 Jul 14]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536997/",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 52,
    "question": "åˆä½µåŒ–å­¸æ²»ç™‚èˆ‡æ”¾å°„ç·šæ²»ç™‚,æ˜¯ç›®å‰ä¾·é™æ€§å°ç´°èƒå‹è‚ºç™Œçš„æ¨™æº–æ²»ç™‚ã€‚é—œæ–¼ç›®å‰å·²ç™¼è¡¨çš„å…©å€‹é‡è¦ç¬¬ä¸‰æœŸéš¨æ©Ÿæ€§è‡¨åºŠè©¦é©—(CONVERT è©¦é©—å’Œ CALGB30610 è©¦é©—)ä¹‹åŒ–å­¸è—¥ç‰©ã€æ”¾å°„æ²»ç™‚åŠ‘é‡å’Œè‡¨åºŠé å¾Œæè¿°,ä¸‹åˆ°ä½•è€…éŒ¯èª¤?",
    "options": [
      "CONVERT è©¦é©—,å…¶ä½¿ç”¨çš„åŒ–å­¸è—¥ç‰©æ˜¯ cisplatin å’Œ etoposideã€‚",
      "CONVERT è©¦é©—,è­‰å¯¦æ¯å¤©ä¸€æ¬¡æ”¾å°„æ²»ç™‚(ç¸½åŠ‘é‡ 66 Gy),èˆ‡æ¯å¤©å…©æ¬¡æ”¾å°„æ²»ç™‚(ç¸½åŠ‘é‡45 Gy),å…¶æ•´é«”å­˜æ´»ç‡å…©çµ„ç›¸åŒã€‚",
      "CALGB30610 è©¦é©—,è­‰å¯¦æ¯å¤©ä¸€æ¬¡æ”¾å°„æ²»ç™‚(ç¸½åŠ‘é‡ 70 Gy),æ¯”æ¯å¤©å…©æ¬¡æ”¾å°„æ²»ç™‚(ç¸½åŠ‘é‡45 Gy),æé«˜æ›´å¥½çš„æ•´é«”å­˜æ´»ç‡ã€‚",
      "ä¸Šè¿°å…©ç¨®è‡¨åºŠè©¦é©—,æ”¾å°„æ²»ç™‚å»ºè­°åœ¨åŒ–å­¸æ²»ç™‚çš„ç¬¬ä¸€å€‹æˆ–ç¬¬äºŒå€‹ cycle é–‹å§‹çµ¦äºˆã€‚",
      "CALGB30610 å¤§éƒ¨åˆ†è™•æ–¹æ˜¯ cisplatin å’Œ etoposide,éƒ¨åˆ†è™•æ–¹æ˜¯ carboplatin å’Œ etoposideã€‚"
    ],
    "correctAnswer": 2,
    "explanation": "This question asks us to compare two Phase III trials on CCRT for limited-stage small cell lung cancer and answer if \"twice daily RT better is than once daily RT in CCRT for limited stage SCC patients.\"\n\nSee below for summary of both trials. \n\n--------------------------------------------------\n\n(A) CONVERT è©¦é©—,å…¶ä½¿ç”¨çš„åŒ–å­¸è—¥ç‰©æ˜¯ cisplatin å’Œ etoposideã€‚\n--> Correct; cisplatin + etoposide for 4-6 cycles every 3 weeks \nFor CALGB 30610: 4 cycles platinum + etoposide \n\n(B) CONVERT è©¦é©—,è­‰å¯¦æ¯å¤©ä¸€æ¬¡æ”¾å°„æ²»ç™‚(ç¸½åŠ‘é‡ 66 Gy),èˆ‡æ¯å¤©å…©æ¬¡æ”¾å°„æ²»ç™‚(ç¸½åŠ‘é‡ 45 Gy),å…¶æ•´é«”å­˜æ´»ç‡å…©çµ„ç›¸åŒã€‚\n--> Correct \ntwice daily OS = 30 months; once daily OS = 25 months\nHazard ratio of death = 1.18 (95% CI 0.95-1.45); p=0.14\n2-year OS = 56% vs 51% \n\n**(C) CALGB30610 è©¦é©—,è­‰å¯¦æ¯å¤©ä¸€æ¬¡æ”¾å°„æ²»ç™‚(ç¸½åŠ‘é‡ 70 Gy),æ¯”æ¯å¤©å…©æ¬¡æ”¾å°„æ²»ç™‚(ç¸½åŠ‘é‡ 45 Gy),æé«˜æ›´å¥½çš„æ•´é«”å­˜æ´»ç‡ã€‚\n--> Incorrect\nTwice daily OS = 28.5 months; once daily OS = 30.1\nHazard ratio of death = 0.94 (95% CI 0.76-1.17); p=0.594 \n\n(D) ä¸Šè¿°å…©ç¨®è‡¨åºŠè©¦é©—,æ”¾å°„æ²»ç™‚å»ºè­°åœ¨åŒ–å­¸æ²»ç™‚çš„ç¬¬ä¸€å€‹æˆ–ç¬¬äºŒå€‹ cycle é–‹å§‹çµ¦äºˆã€‚\n--> Correct\nCONVERT trial: begin at D22 after beginning Cisplatin + etoposide\nCALGB 30610: starting with either 1st or 2nd chemotherapy cycle \n\n(E) CALGB30610 å¤§éƒ¨åˆ†è™•æ–¹æ˜¯ cisplatin å’Œ etoposide,éƒ¨åˆ†è™•æ–¹æ˜¯ carboplatin å’Œ etoposideã€‚\n--> Correct \nCisplatin: total 81.3%, 45 Gy 80.5%, 70 Gy 82.2%\nCarboplatin: total 18.7%, 45 Gy 19.5%, 70 Gy 17.8% \n\n--------------------------------------------------\n\n[CONVERT Trial] * chemo: Cisplatin + Etoposide q3w \n\nQuestion: is twice daily RT better than once daily RT in CCRT for limited stage SCC patients? \n\nP: limited-stage SCC patients\nI: Twice daily RT (45 Gy / 30 bid of 1.5 Gy)\nC: Once daily RT (66 Gy / 33 Fx of 2 Gy)\nO: primary outcome is OS (superiority study) \n\nResults: no difference in OS (30 vs 25 months)\n\n--------------------------------------------------\n\n[CALGB 30610 (Alliance) / RTOG 0538] * initially only Cisplatin + Etoposide --> amendment to include carbo in 2015 \nRT begins at 1st or 2nd chemotherapy cycle \n\nQuestion: is twice daily RT better than once daily RT in CCRT for limited stage SCC patients? \n\nP: limited stage SCC patients \nI: Twice daily RT (45 Gy)\n   Concomitant boost RT (61.2 Gy) --> this arm is discontinued due to toxicity \nC: Once daily RT (70 Gy)\nO: primary outcome is OS in ITT \n\nResults: no difference in OS (28.5 vs 30.1 months) \n\nReference:\n1. Faivre-Finn C, et al. Lancet Oncol. 2017 Aug;18(8):1116-1125\n2. Bogart J, et al. J Clin Oncol. 2023 May 1;41(13):2394-2402",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 53,
    "question": "ç¬¬ä¸‰æœŸéš¨æ©Ÿæ€§è‡¨åºŠè©¦é©—å·²ç¶“è­‰å¯¦ä½åˆ†æ¬¡å…¨ä¹³æˆ¿æ”¾å°„ç·šæ²»ç™‚ (hypofractionated radiotherapy) èˆ‡å‚³çµ±å¼åˆ†å¼å…¨ä¹³æˆ¿æ”¾å°„ç·šæ²»ç™‚ï¼Œåœ¨æ—©æœŸä¹³ç™Œä¹‹è‡¨åºŠé å¾Œå’Œå‰¯ä½œç”¨ç›¸ä¼¼ã€‚ æ ¹æ“š 2018 å¹´ç¾åœ‹æ”¾å°„è…«ç˜¤å­¸æœƒæ¨™æº–å»ºè­°ï¼Œæœ‰é—œä¹³ç™Œä¿ç•™æ‰‹è¡“å¾Œä¹‹ä½åˆ†æ¬¡å…¨ä¹³æˆ¿æ”¾å°„ç·šæ²»ç™‚ä¹‹é©æ‡‰ç—‡ï¼Œä¸‹åˆ—æ•˜è¿°ä½•è€…æ­£ç¢ºï¼Ÿ",
    "options": [
      "å¹´é½¡è¦å¤§æ–¼ 50 æ­²æ‰è€ƒæ…®ã€‚",
      "ä¹‹å‰æ¥å—è¡“å¾ŒåŒ–å­¸æ²»ç™‚å‰‡ä¸é©åˆã€‚",
      "ä¸éœ€è¦ç…§å°„å±€éƒ¨æ·‹å·´å€åŸŸæ‰è€ƒæ…®ã€‚",
      "ä¸é ˆæ³¨æ„ä¹³æˆ¿çµ„ç¹”çš„æ”¾å°„è…«ç˜¤åŠ‘é‡ã€‚",
      "ä¸å»ºè­°ä½¿ç”¨åœ¨ HER2 é™½æ€§ç—…äººã€‚"
    ],
    "correctAnswer": 2,
    "explanation": "(A) å¹´é½¡è¦å¤§æ–¼50æ­²æ‰è€ƒæ…®ã€‚\u000b=>æ ¹æ“šASTROæŒ‡å—ï¼Œå¹´é½¡ä¸å†æ˜¯ä½åˆ†æ¬¡å…¨ä¹³æˆ¿æ”¾å°„æ²»ç™‚çš„é‡è¦é™åˆ¶æ¢ä»¶ï¼Œå› æ­¤ä¸éœ€ä¸€å®šå¤§æ–¼50æ­²æ‰è€ƒæ…®ä½¿ç”¨ã€‚\r\n(B) ä¹‹å‰æ¥å—è¡“å¾ŒåŒ–å­¸æ²»ç™‚å‰‡ä¸é©åˆã€‚\u000b=>å…ˆå‰æ¥å—éè¡“å¾ŒåŒ–å­¸æ²»ç™‚ä¸¦éä½åˆ†æ¬¡æ²»ç™‚çš„ç¦å¿Œæ¢ä»¶ã€‚\r\n(C) ä¸éœ€è¦ç…§å°„å±€éƒ¨æ·‹å·´å€åŸŸæ‰è€ƒæ…®ã€‚\u000b=>æ ¹æ“šASTROå»ºè­°ï¼Œç•¶æ²»ç™‚å€åŸŸåƒ…ç‚ºä¹³æˆ¿è€Œéå€åŸŸæ·‹å·´çµï¼ˆregional lymph nodesï¼‰æ™‚ï¼Œä½åˆ†æ¬¡æ‰è¢«å»ºè­°ä½¿ç”¨ã€‚å¦‚æœéœ€è¦åŒæ™‚æ²»ç™‚å€åŸŸæ·‹å·´çµï¼Œé€šå¸¸ä¸ä½¿ç”¨ä½åˆ†æ¬¡**æœƒä½¿ç”¨50Gy/25fxçš„å‚³çµ±åˆ†æ¬¡ä¾†ç…§å°„**ã€‚å› æ­¤æ­¤é¸é …æ­£ç¢ºã€‚\r\n(D) ä¸é ˆæ³¨æ„ä¹³æˆ¿çµ„ç¹”çš„æ”¾å°„è…«ç˜¤åŠ‘é‡ã€‚\u000b=>æ”¾å°„è…«ç˜¤åŠ‘é‡çš„åˆ†ä½ˆï¼ˆdose homogeneityï¼‰ä»é ˆä»”ç´°æ³¨æ„ï¼Œä»¥é¿å…éé‡ç…§å°„ä¹³æˆ¿çµ„ç¹”ã€‚\r\n(E) ä¸å»ºè­°ä½¿ç”¨åœ¨HER2é™½æ€§ç—…äººã€‚\u000b=>HER2é™½æ€§ä¸¦éä½åˆ†æ¬¡æ²»ç™‚çš„ç¦å¿Œè­‰ã€‚",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/053/explain_figures/figure 1.png"
    ]
  },
  {
    "id": 54,
    "question": "é—œæ–¼ explanatory è‡¨åºŠè©¦é©—ã€pragmatic è‡¨åºŠè©¦é©—çš„æ¯”è¼ƒï¼Œä¸‹åˆ—ä½•è€…æ˜¯éŒ¯èª¤çš„ï¼Ÿ",
    "options": [
      "explanatory:æ—¥å¸¸é†«ç™‚å·¥ä½œ \r\npragmatic:è³‡æºè±å¯Œï¼Œç†æƒ³å ´æ™¯",
      "explanatory:é«˜é¸æ“‡æ€§ç—…äººæ—ç¾¤ï¼Œæœ‰åš´æ ¼çš„ç´å…¥ã€æ’é™¤æ¢ä»¶ \r\npragmatic:æœ‰èˆˆè¶£çš„è‡¨åºŠé©æ‡‰ç—‡ï¼Œæ¥µå°‘çš„ç´å…¥ã€æ’é™¤æ¢ä»¶",
      "explanatory:å¼·çš„é †å¾æ€§åš´æ ¼åŸ·è¡Œ \r\npragmatic:æœ‰å½ˆæ€§ï¼Œå…è¨±ä¿®æ”¹",
      "explanatory:é€šå¸¸æ˜¯ä»£ç†çš„æ»¿è¶³é»ï¼ˆä¾‹å¦‚ï¼šå®¢è§€åæ‡‰ç‡ã€ç„¡æƒ¡åŒ–å­˜æ´»æ™‚é–“ï¼‰ \r\npragmatic:è·Ÿå—è©¦è€…ã€ç¤¾å€ã€é†«ç™‚ç…§é¡§æä¾›è€…ç›´æ¥ç›¸é—œï¼ˆä¾‹å¦‚ï¼šå®¢è§€åæ‡‰ç‡ã€ç¸½å­˜æ´»æ™‚é–“ï¼‰",
      "explanatory:é–“æ¥ \r\npragmatic:ç›´æ¥"
    ],
    "correctAnswer": 0,
    "explanation": "é¡Œæº:INT J TUBERC LUNG DIS 15(7):862â€“870, Table 2 æ”¹å¯«\r\nå°±ç®—ä¸çŸ¥é“ä»€éº¼æ˜¯Explanatory Trial & Pragmatic Trialï¼Œçœ‹å®Œæ¯å€‹é¸é …å°±çŸ¥é“Aè·Ÿå…¶ä»–å¹¾å€‹é¸é …éƒ½ç›¸åäº†\r\n\r\n1967 å¹´ï¼ŒSchwartz è·Ÿ Lellouch æè¿°äº†å…©ç¨®éš¨æ©Ÿåˆ†æ´¾è©¦é©—çš„æ¨¡å¼ï¼Œpragmatic æˆ–explanatory\r\nexplanatoryï¼Œè§£é‡‹å‹çš„éš¨æ©Ÿè©¦é©—ï¼Œç›®çš„æ˜¯æ¢è¨ä¸€å€‹ä»‹å…¥å¸¶ä¾†çš„å½±éŸ¿ï¼Œå…¶å®ƒè®Šæ•¸å¿…é ˆç›¡é‡åš´æ ¼æ§åˆ¶\r\npragmatic trial å‹™å¯¦ç ”ç©¶ï¼Œä»æ˜¯éš¨æ©Ÿåˆ†æ´¾è©¦é©—ï¼Œä½†å„˜é‡é™ä½ä»‹å…¥ï¼Œæ¨¡æ“¬ç¾å¯¦ç‹€æ³ã€‚Pragmatic æˆ–è¨±æœ‰äº›æŠ½è±¡ï¼Œä½†æŠŠé€™å€‹å­—æ”¹æˆ practice å°±å¥½æ‡‚å¤šäº†ï¼Œpractice trialï¼Œæ¢è¨å¯¦éš›æ‡‰ç”¨çš„ç ”ç©¶ï¼›å› ç‚ºè¨±å¤šç ”ç©¶çš„ç•¶ä¸‹ç’°å¢ƒï¼Œåœ¨å¯¦éš›æƒ…æ³å¾ˆé›£é‡ç¾ï¼Œæ¯”å¦‚èªªæœ‰äººç›¯è‘—ä½ åƒè—¥ï¼Œè¦å¾‹çš„æŠ½è¡€è¿½è¹¤ç­‰",
    "questionFigures": [
      "/qabank/054/question_figures/figure 1.png"
    ],
    "explainFigures": []
  },
  {
    "id": 55,
    "question": "Schrag D, et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med 389:322-34, 2023 æ˜¯ä¸€å€‹æ¯”è¼ƒ neoadjuvant chemotherapy å’Œ neoadjuvant chemoradiotherapy çš„ non-inferiority randomized controlled trialã€‚é—œæ–¼ non-inferiority randomized controlled trialsï¼Œä¸‹åˆ—æ•˜è¿°ä½•è€…æ˜¯éŒ¯èª¤çš„ï¼Ÿ",
    "options": [
      "åœ¨ noninferiority trialsï¼Œç ”ç©¶è€…æƒ³è¦è­‰æ˜æ–°çš„æ²»ç™‚ä¸åŠ£æ–¼æ¨™æº–æ²»ç™‚ã€‚",
      "ä¸åŠ£æ–¼æ¨™æº–æ²»ç™‚çš„æ–°çš„æ²»ç™‚é€šå¸¸æ˜¯æ¯’æ€§è¼ƒå°æˆ–è¼ƒç‚ºæ–¹ä¾¿ã€‚",
      "æ¨£æœ¬æ•¸çš„è€ƒé‡è·Ÿ superiority trials ä¸€èˆ¬è€Œè¨€æ˜¯é¡ä¼¼çš„ã€‚",
      "æ¨£æœ¬æ•¸çš„è€ƒé‡è·Ÿ superiority trials çš„ä¸€å€‹é‡è¦ä¾‹å¤–æ˜¯ targeted treatment effect åœ¨ non-inferiority trials é€šå¸¸æ¯”è¼ƒå°ï¼Œå°è‡´ non-inferiority trials çš„æ¨£æœ¬æ•¸è¼ƒå¤§ã€‚",
      "åœ¨ noninferiority trialsï¼Œintention-to-treat çš„åŸå‰‡ä¹Ÿè¦åš´æ ¼éµå®ˆã€‚"
    ],
    "correctAnswer": 2,
    "explanation": "é¡Œæº:é€™é¡Œæ˜¯è€ƒå¤é¡Œ112-63\r\né€šå¸¸éåŠ£æ€§è©¦é©—çš„ç›®æ¨™æ•ˆæ‡‰è¼ƒå°ï¼Œå› æ­¤éœ€è¦æ›´å¤§çš„æ¨£æœ¬é‡ä¾†é”åˆ°çµ±è¨ˆçš„é¡¯è‘—æ€§ã€‚\r\nAlthough noninferiority trials typically have smaller sample sizes than active-controlled superiority trials, they can have considerably larger sample sizes than placebo-controlled trials. This is because the equivalence margin is often smaller than the treatment difference for which a placebo-controlled trial is powered. In addition, the sample size of a noninferiority trial is very sensitive to the assumed effect of the new treatment relative to the active control; the sample size can be considerably larger if the two treatments are assumed to be slightly more effective than the active control. \r\n\r\nREF: Snapinn SM. Curr Control Trials Cardiovasc Med. 2000;1(1):19-21",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 56,
    "question": "é—œæ–¼ç™Œç—‡è‡¨åºŠè©¦é©—æ»¿è¶³é»ï¼ˆendpointï¼‰ï¼Œä¸‹åˆ—ä½•è€…æ˜¯éŒ¯èª¤çš„ï¼Ÿ",
    "options": [
      "ä»¥ overall survival ç‚ºä¸»è¦æ»¿è¶³é»ï¼Œå¦‚æœå°ç…§çµ„æ•ˆæœå¾ˆå¥½ï¼Œæœƒå°è‡´è©¦é©—è¦æ¨¡å¾ˆå¤§ã€è¿½è¹¤æ™‚é–“å¾ˆé•·ã€‚",
      "ä»¥ overall survival ç‚ºä¸»è¦æ»¿è¶³é»ï¼Œå¦‚æœå¯¦é©—çµ„ã€å°ç…§çµ„ä¸èƒ½ crossoverï¼Œæœƒçœ‹ä¸å‡º 2 çµ„overall survival çš„å·®åˆ¥ã€‚",
      "ä»¥ overall survival ç‚ºä¸»è¦æ»¿è¶³é»ï¼Œå¦‚æœæœ‰ competing mortalityï¼ˆä¾‹å¦‚ï¼šè¼”åŠ©æ€§åŒ–å­¸æ²»ç™‚ç”¨æ–¼å¹´ç´€å¤§ç—…æ‚£çš„è‡¨åºŠè©¦é©—ï¼‰ï¼Œæœƒç¨€é‡‹å¯¦é©—çµ„çš„æ²»ç™‚æ•ˆæœï¼Œå¯ä»¥è€ƒæ…®å¾åˆ†æ overallsurvivalã€æ”¹æˆåˆ†æ disease-specific survivalã€‚",
      "ä»¥ progression-free survival ç‚ºä¸»è¦æ»¿è¶³é»ï¼Œå¦‚æœè©¦é©—æ˜¯ unblindedï¼Œä¸€å€‹å¯èƒ½çš„ bias æ˜¯assessment time biasã€‚",
      "ä»¥ progression-free survival ç‚ºä¸»è¦æ»¿è¶³é»ï¼Œå¦‚æœè©¦é©—æ˜¯ unblindedï¼Œå¯ä»¥è€ƒæ…® blinded independent central reviewã€‚"
    ],
    "correctAnswer": 1,
    "explanation": "é¡Œæº:112-65\r\nå³ä½¿å¯¦é©—çµ„å’Œå°ç…§çµ„æ²’æœ‰ crossoverï¼ˆå³æ‚£è€…ä¸æœƒå¾ä¸€çµ„è½‰åˆ°å¦ä¸€çµ„ï¼‰ï¼Œä»ç„¶å¯ä»¥è§€å¯Ÿåˆ° overall survival çš„å·®åˆ¥ã€‚Crossover å¯èƒ½æœƒå½±éŸ¿çµæœçš„è§£è®€ï¼Œä½†ä¸æ˜¯å”¯ä¸€çš„ç„¡æ³•æ¯”è¼ƒæ•´é«”ç”Ÿå­˜ç‡çš„å› ç´ ã€‚",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 57,
    "question": "ä¸‹åˆ—åŒ–ç™‚æˆ–æ¨™é¶è—¥ç‰©å¯èƒ½é€ æˆinterstitial lung disease (ILD) or pneumonitisï¼Œä½•è€…ç‚º**é**ï¼Ÿ",
    "options": [
      "Trastuzumab deruxtecan",
      "Pembrolizumab",
      "Abemaciclib",
      "Trastuzumab emtansine (TDM1)",
      "Bleomycin"
    ],
    "correctAnswer": 3,
    "explanation": "57.  ä¸‹åˆ—åŒ–ç™‚æˆ–æ¨™é¶è—¥ç‰©å¯èƒ½é€ æˆinterstitial lung disease (ILD) or pneumonitisï¼Œä½•è€…ç‚º**é**ï¼Ÿ \r\n        (A) Trastuzumab deruxtecan  \r\n        (B) Pembrolizumab  \r\n        (C) Abemaciclib \r\n        (D) Trastuzumab emtansine (TDM1) \r\n        (E) Bleomycin \r\n\r\nè§£ç­”: D\r\n\r\nèªªæ˜:\r\n(A) Trastuzumab deruxtecan é€ æˆ Interstitial lung disease ç‚º 13.6%\r\n(B) Pembrolizumab é€ æˆ  Pneumonitis ç‚º 5.8%\r\n(C) Abemaciclib é€ æˆ Pneumonitis ç‚º 2.7%, placebo ç‚º 1.3%\r\n(D) Trastuzumab emtansine (TDM1) ç„¡ lung fibrosis æ¯’æ€§, å…¶ä»–åš´é‡å‰¯ä½œç”¨ç‚ºliver toxicity, decrease LVEF \r\n(E) Bleomycin æ˜¯é•·æœŸå·²çŸ¥çš„lung fibrosiså±éšªå› å­,ç™¼ç”Ÿç‡æ¥è¿‘10%\r\n\r\n\r\nåƒè€ƒ:\r\n(A) Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer\r\n    https://www.nejm.org/doi/full/10.1056/NEJMoa1914510\r\n\r\n(B) Pembrolizumab versus Chemotherapy for PD-L1â€“Positive Nonâ€“Small-Cell Lung Cancer\r\n    https://www.nejm.org/doi/full/10.1056/NEJMoa1606774\r\n\r\n(C) Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2âˆ’, Node-Positive, High-Risk, Early Breast Cancer (monarchE)\r\n    https://ascopubs.org/doi/10.1200/JCO.20.02514?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed\r\n\r\n(D) Overview and Management of Drug-Induced Interstitial Lung Disease With Novel Treatments in HER2+ Breast Cancer, Lung Cancers, and Gastrointestinal Cancers\r\n    https://www.onclive.com/view/overview-and-management-of-drug-induced-interstitial-lung-disease-with-novel-treatments-in-her2\r\n\r\n(E) Bleomycin-Induced Lung Injury\r\n    https://onlinelibrary.wiley.com/doi/full/10.1155/2013/480608",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 58,
    "question": "å¥ä¿ç½²åœ¨2024å¹´7æœˆå·²ç¶“é–‹æ”¾NGSæª¢æ¸¬ï¼Œé‡å°è‚ºç™Œï¼Œä¸‹åˆ—ä½•è€…**é**ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) evidence tier I markeråŠå…¶å°æ‡‰è—¥ç‰©(ready for routine use)ï¼Ÿ",
    "options": [
      "BRAF V600E: Dabrafenib plus trametinib",
      "MET exon 14 skipping mutation: Capmatinib",
      "gPALB2 mutation: Talazoparib",
      "ALK translocation: Crizotinib",
      "EGFR exon 20 insertion mutation: Amivantamab"
    ],
    "correctAnswer": 2,
    "explanation": "58.  å¥ä¿ç½²åœ¨2024å¹´7æœˆå·²ç¶“é–‹æ”¾NGSæª¢æ¸¬ï¼Œé‡å°è‚ºç™Œï¼Œä¸‹åˆ—ä½•è€…**é**ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) evidence tier I markeråŠå…¶å°æ‡‰è—¥ç‰©(ready for routine use)ï¼Ÿ \r\n        (A) BRAF V600E: Dabrafenib plus trametinib \r\n        (B) MET exon 14 skipping mutation: Capmatinib \r\n        (C) gPALB2 mutation: Talazoparib \r\n        (D) ALK translocation: Crizotinib \r\n        (E) EGFR exon 20 insertion mutation: Amivantamab\r\n\r\nè§£ç­”: C\r\n\r\nè©³è§£:\r\n(A) BRAF V600E: Dabrafenib plus trametinib : Capmatinib ESCAT ç‚º IB ç´š (2023 ESMO NSCLC)\r\n(B) MET exon 14 skipping mutation: Capmatinib ESCAT ç‚º IB ç´š (2023 ESMO NSCLC)\r\n(C) gPALB2 mutation: Talazoparib ä¸åœ¨2023 ESMO NSCLCåå–®ä¸Š,åœ¨ 2020 ESCATç‚º IIIA ç´š\r\n(D) ALK translocation: Crizotinib ESCAT ç‚º IB ç´š (2023 ESMO NSCLC)\r\n(E) EGFR exon 20 insertion mutation: Amivantamab ESCAT ç‚º IB ç´š (2023 ESMO NSCLC)\r\n\r\nåƒè€ƒ:\r\nRecommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group\r\nhttps://www.annalsofoncology.org/article/S0923-7534(20)39971-3/fulltext\r\n\r\nOncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\r\nhttps://www.annalsofoncology.org/article/S0923-7534(22)04781-0/fulltext",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/058/explain_figures/Image 1.jpg",
      "/qabank/058/explain_figures/Image 2.jpg"
    ]
  },
  {
    "id": 59,
    "question": "æœ‰é—œPoly (ADP-ribose) polymerase (PARP) inhibitoræ²»ç™‚ç›¸é—œæ•˜è¿°åŠè‡¨åºŠè©¦é©—ï¼Œä¸‹åˆ—æ•˜è¿°ä½•è€…**éŒ¯èª¤**ï¼Ÿ",
    "options": [
      "Phase III OlympiA trial è­‰å¯¦ adjuvant olaparib åœ¨high risk gBRCA mutation (TNBC or Luminal BCæ‰‹è¡“å¾Œ) æœ‰EFSåŠOS befefit.",
      "Four different PARP inhibitors (olaparib, rucaparib, niraparib, and talazoparib) have now received regulatory approval in the United States for the treatment of ovarian cancer, breast, prostate, and pancreatic cancers with BRCA1 or BRCA2 mutations and in some cases other defects in DNA repair by homologous recombination.",
      "The FDA has approved rucaparib and olaparib for men with metastatic castration-resistant prostate cancer (mCRPC) who have certain genetic mutations based on the EMBRACA trials.",
      "PARP æŠ‘åˆ¶ IC50: olaparib > rucaparib > talazoparib.",
      "In NOVA trial, niraparib has demonstrated survival benefit in platinum-sensitive, recurrent ovarian cancer, regardless of the presence or absence of gBRCA mutations or homologous recombination deficiency (HRD) status."
    ],
    "correctAnswer": 2,
    "explanation": "æœ‰é—œPoly (ADP-ribose) polymerase (PARP) inhibitoræ²»ç™‚ç›¸é—œæ•˜è¿°åŠè‡¨åºŠè©¦é©—ï¼Œä¸‹åˆ—æ•˜è¿°ä½•è€…**éŒ¯èª¤**ï¼Ÿ \r\n(A) Phase III OlympiA trial è­‰å¯¦ adjuvant olaparib åœ¨high risk gBRCA mutation (TNBC or Luminal BCæ‰‹è¡“å¾Œ) æœ‰EFSåŠOS befefit. \r\n(B) Four different PARP inhibitors (olaparib, rucaparib, niraparib, and talazoparib) have now received regulatory approval in the United States for the treatment of ovarian cancer, breast, prostate, and pancreatic cancers with BRCA1 or BRCA2 mutations and in some cases other defects in DNA repair by homologous recombination. \r\n(C) The FDA has approved rucaparib and olaparib for men with metastatic castration-resistant prostate cancer (mCRPC) who have certain genetic mutations based on the EMBRACA trials. \r\n(D) PARP æŠ‘åˆ¶ IC50: olaparib > rucaparib > talazoparib.    \r\n(E) in NOVA trial, niraparib has demonstrated survival benefit in platinum-sensitive, recurrent ovarian cancer, regardless of the presence or absence of gBRCA mutations or homologous recombination deficiency (HRD) status. \r\n\r\nè§£ç­”: C\r\n\r\nè©³è§£:\r\n\r\n(A) [Image 1]\r\nTNBC or Luminal BCæ‰‹è¡“å¾Œ, adjuvant olaparib 3y DFS ç‚º 85.9 vs. 77.1%, HR 0.58, p<0.001; OS ç‚º 92.0% vs. 88.3%, HR 0.68, p=0.02\r\n\r\n(B)\r\nolaparib was approved for ovarian, breast, pancreatic and prostate cancer\r\nrucaparib was approved for ovarian and prostate cancer\r\nniraparib was approved for ovarian cancer\r\ntalazoparib was approved for breast and prostate cancer\r\n\r\n(C) EMBRACA trial ç ”ç©¶å°è±¡ç‚º Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation\r\n\r\n(D)\r\nOlaparib IC 50 = 68.5 uM\r\nrucaparib IC 50 = 53.7 uM\r\nTalazoparib IC 50 =  8.40 uM\r\n\r\n(E) [Image 2]\r\ngBRCA cohort, mPFS 21.0m vs. 5.5m, HR 0.27, p<0.001\r\nnon-gBRCA cohort, mPFS 9.3m vs. 3.9m, HR 0.45, p<0.001\r\n\r\n\r\nåƒè€ƒ:\r\nAdjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer\r\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa2105215\r\n\r\nFDA aprroved for olaparib, rucaparib, niraparib, and talazoparib\r\nhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf\r\nhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s011lbl.pdf\r\nhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf\r\nhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217439s000lbl.pdf\r\n\r\nTalazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation\r\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa1802905\r\n\r\nolaparib, rucaparib, talazoparib IC50\r\nhttps://www.cancerrxgene.org/compound/Olaparib/1017/overview/ic50\r\nhttps://www.cancerrxgene.org/compound/Rucaparib/1175/overview/ic50\r\nhttps://www.cancerrxgene.org/compound/Talazoparib/1259/overview/ic50?screening_set=GDSC1\r\n\r\nNiraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer\r\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa1611310",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/059/explain_figures/Image 1.jpg",
      "/qabank/059/explain_figures/Image 2.jpg"
    ]
  },
  {
    "id": 60,
    "question": "Reprogramming energy metabolism is one of the hallmakers of cancer, one of the following descriptions is **incorrect**?",
    "options": [
      "Otto Warburg first observed an anomalous characteristic of cancer cell energy metabolism that cancer cells could use glycolysis without using oxygen.",
      "The reprogramming includes upregulation of glucose transporters, notably GLUT1.",
      "The reprogramming is associated with activated oncogenes (e.g., RAS, MYC) and mutant tumor suppressors (e.g., TP53)",
      "Glycolysis allows the diversion of glycolytic intermediates into various biosynthesis of nucleosides and amino acids.",
      "Other than Warburgâ€™s effect, cancer cells still could use mitochondrial oxidative phosphorylation to generate fuel (ADP)."
    ],
    "correctAnswer": 4,
    "explanation": "Reprogramming energy metabolism is one of the hallmakers of cancer, one of the following descriptions is incorrect ?  \r\n(A) Otto Warburg first observed an anomalous characteristic of cancer cell energy metabolism that cancer cells could use glycolysis without using oxygen. \r\n(B) The reprogramming includes upregulation of glucose transporters, notably GLUT1. \r\n(C) The reprogramming is associated with activated oncogenes (e.g., RAS, MYC) and mutant tumor suppressors (e.g., TP53)  \r\n(D) Glycolysis allows the diversion of glycolytic intermediates into various biosynthesis of nucleosides and amino acids. \r\n(E) Other than Warburgâ€™s effect, cancer cells still could use mitochondrial oxidative phosphorylation to generate fuel (ADP).\r\n\r\nè§£ç­”: E\r\n\r\nè©³è§£: è€ƒçš„æ˜¯æ–‡ç« çš„åŸæ–‡\r\n\r\n(A)\r\nOtto Warburg first observed an anomalous characteristic of cancer cell energy metabolism (Warburg, 1930, 1956a, 1956b): even in the presence of oxygen, cancer cells can reprogram their glucose metabolism, and thus their energy production, by limiting their energy metabolism largely to glycolysis, leading to a state that has been termed â€˜â€˜aerobic glycolysis.â€™â€™\r\n\r\n(B)\r\nThey do so in part by upregulating glucose transporters, notably GLUT1, which substantially increases glucose import into the cytoplasm\r\n\r\n(C)\r\nGlycolytic fueling has been shown to be associated with activated oncogenes (e.g., RAS, MYC) and mutant tumor suppressors (e.g., TP53) \r\n\r\n(D)\r\nincreased glycolysis allows the diversion of glycolytic intermediates into various biosynthetic pathways, including those generating nucleosides and amino acids;\r\n\r\n(E)\r\nOne subpopulation consists of glucose-dependent (â€˜â€˜Warburg-effectâ€™â€™) cells that secrete lactate, whereas cells of the second subpopulation preferentially import and utilize the lactate produced by their neighbors as their main energy source, employing part of the citric acid cycle to do so.\r\n\r\nåƒè€ƒ:\r\nHallmarks of Cancer: The Next Generation\r\nhttps://www.cell.com/fulltext/S0092-8674(11)00127-9",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 61,
    "question": "The current standard genetic testing for identifying HER2 amplification is by",
    "options": [
      "Real-time polymerase chain reaction",
      "Sanger sequencing",
      "Next-generation sequencing",
      "Fluoresce in situ hybridization",
      "Genomic microarray"
    ],
    "correctAnswer": 3,
    "explanation": "æ ¹æ“šguidelineï¼Œç¾è¡ŒHER2æª¢é©—æ˜¯ä½¿ç”¨Fluoresce in situ hybridizationã€‚\r\nReference:\r\nHuman Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society\r\nof Clinical Oncology/College of American Pathologists Clinical Practice Guideline\r\nFocused Update. J Clin Oncol 2018;36:2105-2122.\r\n\r\næ ¡ç¨¿:é€™å€‹èˆ‡ç¾è¡ŒHER2é™½æ€§èªå®šæœ‰é—œï¼Œæ‡¶å¾—çœ‹PaperåŸæ–‡å¯å¿«é€Ÿæƒéä»¥ä¸‹åŠ æ·±å°è±¡\r\n\r\nHER2çš„æª¢é©—æ–¹å¼\r\nç›®å‰ä»¥å…ç–«åŒ–å­¸æŸ“è‰²æ³•ï¼ˆImmunohistochemitry IHCï¼‰åŠè¢å…‰åŸä½é›œäº¤æ³•ï¼ˆFluorescence in situ hybridization FISHï¼‰ç‚ºä¸»ã€‚å…ç–«åŒ–å­¸æŸ“è‰²æ³•çš„æª¢æ¸¬ï¼Œç”±ç—…ç†é†«å¸«æ ¹æ“šç´°èƒè†œä¸Šä¹‹HER2ç¬¬äºŒå‹äººé¡ä¸Šçš®ç´°èƒç”Ÿé•·å› å­æ¥å—å™¨æŸ“è‰²å¼·å¼±åŠå…¶ä½”ä¹³ç™Œç´°èƒæ¯”ä¾‹ï¼Œçµæœä»¥0ã€1ï¼‹ã€2ï¼‹ã€3ï¼‹å‘ˆç¾ï¼ŒHER2åŸºå› ä½æ–¼äººé¡ç¬¬17å°æŸ“è‰²é«”ä¸Šï¼Œç´„å››åˆ†ä¹‹ä¸€çš„ä¹³ç™Œè…«ç˜¤ç´°èƒæœƒæœ‰å¾ˆå¤šHER2åŸºå› çš„é‡è¤‡ç‰‡æ®µï¼Œé€™äº›éåº¦çš„HER2åŸºå› å°±æœƒè£½é€ å‡ºæ›´å¤šçš„ç´°èƒè†œä¸ŠHER2æ¥å—å™¨ï¼Œè¢å…‰åŸä½é›œäº¤æ³•çš„æª¢æ¸¬çš„åŸç†å°±æ˜¯åˆ©ç”¨ä¸åŒè¢å…‰å»åµæ¸¬HER2åŸºå› ä»¥åŠç¬¬17å°æŸ“è‰²é«”ä¸­å¿ƒç²’åŠHER2åŸºå› çš„é‡è¤‡ç‰‡æ®µï¼Œç®—å‡ºHER2åŸºå› ç›¸å°ç¬¬17å°æŸ“è‰²é«”ä¸­å¿ƒç²’è¢å…‰æŸ“è‰²ä¹‹æ¯”ç‡ï¼Œä»¥æ‹·è²å€æ•¸(copy number)ä¾†å‘ˆç¾ã€‚ç›®å‰ä»¥å…ç–«åŒ–å­¸æŸ“è‰²æ³•3+æˆ–è¢å…‰åŸä½é›œäº¤æ³•çš„æª¢é©—é™½æ€§(æ‹·è²å€æ•¸2.0æˆ–2.2ä»¥ä¸Š)æ‰èƒ½è¢«ç¢ºå®šç‚ºHER2é™½æ€§ã€‚HER2å…ç–«åŒ–å­¸æŸ“è‰²æ³•2+çš„ä¹³ç™Œï¼Œä»¥è¢å…‰åŸä½é›œäº¤æ³•å†ç¢ºèªï¼Œç´„æœ‰20%~40%çš„ä¹³ç™Œçš„æª¢é©—çµæœæœƒæ˜¯é™½æ€§ã€‚å…©ç¨®æª¢é©—æ–¹å¼ä¸­ï¼Œè¢å…‰åŸä½é›œäº¤æ³•ï¼ˆFISHï¼‰ç‚ºé‡åŒ–çš„æª¢é©—æ–¹å¼ï¼Œè¼ƒç„¡å½é™½æ€§åŠå½é™°æ€§çš„å•é¡Œï¼›ç¼ºé»æ˜¯åƒ¹æ ¼è¼ƒé«˜ã€‚å°æ–¼HER2å…ç–«åŒ–å­¸æŸ“è‰²æ³•2+çš„ä¹³ç™Œï¼Œç›®å‰è‡ºç£å¥ä¿å±€çµ¦ä»˜è¢å…‰åŸä½é›œäº¤æª¢é©—ã€‚\r\n\r\nå‡ºè™•:https://www.canceraway.org.tw/page.php?IDno=1131",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 62,
    "question": "Which of the following descriptions of cell death is INCORRECT?",
    "options": [
      "Apoptosis is a type of cell death in which a dying cell contracts into an almost-invisible corpse that is soon consumed by its neighbors, and it is non-immunogenic.",
      "Necroptosis is a type of cell death in which necrotic cells become bloated and explode, releasing their contents into the local tissue microenvironment, and it is immunogenic.",
      "Ferroptosis is a type of cell death caused by excessive production of reactive oxygen species (ROS) and insufficient capability to eliminate ROS.",
      "Pyroptosis is a type of cell death in which formation of pores causes cell membrane rupture and release of cytokines as well as damage-associated molecular pattern (DAMP) molecules out of the cell, and it is immunogenic.",
      "Apoptosis does not release proinflammatory signals into the surrounding tissue microenvironment, whereas necroptosis and pyroptosis release proinflammatory molecules out of the cell."
    ],
    "correctAnswer": 0,
    "explanation": "(A)(B)(E)é¸é …çš„æ•˜è¿°å‡ºè‡ªHallmarks of cancer: the next generationï¼Œä½†Apoptosisä¸¦éçš†æ˜¯non-immunogenicï¼Œæ•…é¸(A)é¸é …ä¸æ­£ç¢ºã€‚\r\nReference\r\nHanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013\r\n\r\n\r\næ ¡ç¨¿:æœ¬é¡Œæœ‰çˆ­è­°ï¼Œç‚ºè€ƒå¤ï¼Œå¯è¦‹112è€ƒå¤è©³è§£çµ±æ•´çš„120é¡Œæ›´å®Œæ•´\r\n112å¹´è©³è§£ï¼Œ1234å°æ‡‰ABDEå››å€‹é¸é …çš†æ­£ç¢ºï¼Œä½†Apoptosis is less immunogenic than necroptosis or pyroptosisä¸¦éå®Œå…¨æ²’æœ‰ï¼ŒåŸæœ¬Aé¸é …å°±æœ‰çˆ­è­°ã€‚\r\n113å¹´å¤šäº†Cé¸é …ï¼Œé‚è¼¯ä¸Šæ‡‰è©²Cç‚ºéŒ¯èª¤é¸é …ï¼Œä½†å°æ‡‰PAPERæ•˜è¿°ï¼Œä¸¦æœªæ‰¾åˆ°Cé¸é …æœ‰ç”šéº¼æ˜é¡¯éŒ¯èª¤\r\nFerroptosis is a new type of cell death that was discovered in recent years and is usually accompanied by a large amount of iron accumulation and lipid peroxidation during the cell death process; the occurrence of ferroptosis is iron-dependent. Ferroptosis-inducing factors can directly or indirectly affect glutathione peroxidase through different pathways, resulting in a decrease in antioxidant capacity and accumulation of lipid reactive oxygen species (ROS) in cells, ultimately leading to oxidative cell death.\r\nå‡ºè™•:Cell Death & Disease volume 11, Article number: 88 (2020)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 63,
    "question": "Which of the following statements about cancer pain control are (is) correct? \r\n(1) For an opioid-naÃ¯ve patient suffering from moderate pain, start with short-acting opioid every 3-4 hours, like morphine 7.5 mg, hydromorphone 2 mg or oxycondone immediate release 2 mg orally. \r\n(2) For an opioid-tolerant patient suffering from moderate pain, increase the long-acting opioid dose of 30-100%. \r\n(3) Use fentanyl patch on in patients tolerant to opioid therapy. \r\n(4) Short-acting opioid (50% of the 24-hour total of long-acting opioid) can be used as a rescue dose.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1) ç›¸åŒæ•˜è¿°å¯è¦‹æ–¼DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, 12th Editionï¼Œç¬¬1798é ï¼Œè—¥ç‰©æ›ç®—å¯ä»¥ä¾æ“šç¬¬1796é ï¼ŒTable 98.5ã€‚é›–ç„¶Oxycodoneçš„åŠ‘é‡æ›ç®—æœ‰é»å¥‡æ€ªã€‚\r\n(2) æ•˜è¿°éŒ¯èª¤ï¼Œæ ¹æ“šNCCN Guidelines Version 3.2024-Adult Cancer Painçš„PAIN-4é‚£ä¸€é ï¼Œæ˜¯å»ºè­°Titrate short-acting opioid (may require dose increase of 30%â€“100%)\r\n(3) ç„¡æ˜é¡¯éŒ¯èª¤ã€‚\r\n(4) éŒ¯èª¤ï¼Œrescue opioidsåŠ‘é‡æ‡‰ç‚º5%åˆ°15%çš„24å°æ™‚ç¸½åŠ‘é‡ï¼Œç¬¬1798é ï¼ŒBreakthrough pain is best managed with the use of a rescue medication, which is a short-acting opioid given on an as-needed basis in addition to the baseline regimen for patients on a fixed opioid schedule. In general, the dose required for rescue opioids is 5% to 15% of the total (or â€œbasalâ€) daily requirement of opioid in 24 hours.\r\n\r\nReference:\r\nDeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, 12th Edition\r\n\r\næ ¡ç¨¿:ç„¡ä¿®æ­£",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 64,
    "question": "ä»¥ä¸‹é—œæ–¼ç¬¬ä¸€ç·š recurrent and metastatic head and neck squamous cell carcinoma æ²»ç™‚æ•˜è¿°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰?\r\n(1) å¦‚æœç—…äºº PD-L1 CPS â‰¥20, pembrolizumab monotherapy ç‚ºä¸€å¯ä»¥è€ƒæ…®çš„æ²»ç™‚é¸é …ã€‚ \r\n(2) å¦‚æœç—…äºº PD-L1 CPS < 1, pembrolizumab monotherapy ç‚ºä¸€å¯ä»¥è€ƒæ…®çš„æ²»ç™‚é¸é …ã€‚ \r\n(3) å¦‚æœç—…äºº PD-L1 CPS ä»‹æ–¼ 1-19, pembrolizumab monotherapy ç‚ºä¸€å¯ä»¥è€ƒæ…®çš„æ²»ç™‚é¸é …ã€‚ \r\n(4) Pembrolizumab plus platinum/5FU æ‡‰åƒ…è€ƒæ…®åœ¨ PD-L1 CPS â‰¥ 1 çš„æ—ç¾¤ä½¿ç”¨ã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "æ ¹æ“šNCCN Guidelines Version 1.2025-Head and Neck Cancersï¼Œåœ¨SYST-A 2 OF 5é‚£é ï¼Œfirst line preferred regimensæœ‰ Pembrolizumab/platinum å’Œ Pembrolizumabï¼Œä½†å–®ç”¨Pembrolizumabéœ€è¦è…«ç˜¤è¡¨ç¾PD-L1 with CPS â‰¥1ã€‚æ‰€ä»¥æ•˜è¿°(2)ã€(4)éŒ¯èª¤ã€‚\r\n\r\n\r\næ ¡ç¨¿: ç„¡ä¿®æ­£",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 65,
    "question": "ä»¥ä¸‹é—œæ–¼locally advanced head and neck squamous cell carcinoma (HNSCC) CCRT çš„æ•˜è¿°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰?\r\n\r\n(1) æ ¹æ“š EORTC 22931 ä»¥åŠ RTOG 9501 å°æ–¼high risk group çš„å®šç¾©ï¼Œå…¶é‡ç–Šéƒ¨åˆ†åŒ…å«ï¼šresection margin involvementã€ extranodal extension positiveã€ infiltrative tumor frontsã€perineural invasionã€lymphovascular invasionã€‚\r\n(2) å°æ–¼ç„¡æ³•æ¥å—platinum æ²»ç™‚çš„æ‚£è€…ï¼ŒCCRT æ™‚çµ¦äºˆavelumab plus cetuximab ç›¸å°æ–¼ cetuximab alone ä¸¦ç„¡è­‰æ“šé¡¯ç¤ºè¼ƒä½³ä¹‹é å¾Œã€‚\r\n(3) In CCRT of HNSCCï¼Œweekly cisplatin 30mg/m2 per week is non-inferior to standard cisplatin 100mg/ m2 every three weeksã€‚\r\n(4) In CCRT of HNSCCï¼Œweekly cisplatin 40mg/m2 per week is non-inferior to standard cisplatin 100mg/ m2 every three weeksã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 2,
    "explanation": "(1) æ ¹æ“š EORTC 22931 ä»¥åŠ RTOG 9501 å°æ–¼high risk group çš„å®šç¾©ï¼Œå…¶é‡ç–Šéƒ¨åˆ†åŒ…å«ï¼š\r\nresection margin involvementã€ extranodal extension positiveã€ infiltrative tumor frontsã€perineural invasionã€lymphovascular invasionã€‚\r\n\r\néŒ¯èª¤ï¼Œè«‹è¦‹figure 1ï¼Œåƒ…ä¸‹åˆ—ä¸‰æ¢é‡ç–Š\r\nâ€¢ SCC of oral cavity, oropharynx, larynx, hypopharynx\r\nâ€¢ Surgical margins microscopic involved\r\nâ€¢ Extracapsular extension in positive LN\r\nå‡ºè™•:International Journal of Head and Neck Surgery, May-August 2010;1(2):93-96çš„æ•´ç†è¡¨æ ¼\r\n\r\n(2) å°æ–¼ç„¡æ³•æ¥å—platinum æ²»ç™‚çš„æ‚£è€…ï¼ŒCCRT æ™‚çµ¦äºˆavelumab plus cetuximab ç›¸å°æ–¼ cetuximab alone ä¸¦ç„¡è­‰æ“šé¡¯ç¤ºè¼ƒä½³ä¹‹é å¾Œã€‚\r\n\r\nçµè«–ï¼šæ­£ç¢º\r\n\r\næ­¤é¸é …ç‚ºREACH studyçš„çµè«–ï¼Œæ•´ç†å¦‚ä¸‹:\r\nâ€¢ open-labelã€éš¨æ©Ÿåˆ†æ´¾çš„ç¬¬ä¸‰æœŸè©¦é©—ã€‚\r\nâ€¢ æ”¶éŒ„å£è…”ã€å£å’½ã€ä¸‹å’½åŠå–‰éƒ¨ä¹‹å±€éƒ¨ä¾µçŠ¯æ€§é ­é ¸é±—ç‹€ç´°èƒç™Œä¹‹æ‚£è€…ã€‚\r\nâ€¢ ä»¥ 1:1 éš¨æ©Ÿåˆ†é…è‡³ä»¥ä¸‹å„çµ„ï¼š\r\nç¬¬ä¸€çµ„ Fit for high dose cisplatin:\r\nâœ“ Arm A: æ”¾ç™‚ 70 Gy/33 Fractionï¼ŒåŒ–ç™‚ç‚ºé †é‰‘ 100 mg/m2 Q3W for 3 cycles\r\nâœ“ Arm B: æ”¾ç™‚ 70 Gy/33 Fractionï¼Œåˆä½µ Avelumab 10 mg/kg Q2W ä»¥åŠ Cetuximab QWï¼Œæ”¾ç™‚çµæŸå¾Œç¶­æŒ Avelumab 10 mg/kg ä¸€å¹´ã€‚\r\nâ–ª Non-fit for high dose cisplatin:\r\nâœ“ Arm C: æ”¾ç™‚ 70 Gy/33 Fractionï¼Œåˆä½µ Avelumab 10 mg/kg Q2W ä»¥åŠ Cetuximab QWï¼Œæ”¾ç™‚çµæŸå¾Œç¶­æŒ Avelumab 10 mg/kg ä¸€å¹´ã€‚\r\nâœ“ Arm D: æ”¾ç™‚ 70 Gy/33 Fractionï¼ŒåŒæ­¥çµ¦äºˆ Cetuximab QWã€‚\r\nâ€¢ Primary endpoint: PFS ç™‚æ•ˆ\r\nâ€¢ åœ¨ cisplatin-fit çµ„åˆ¥ï¼Œinterim analysis é¡¯ç¤ºå¯¦é©—çµ„ä¹‹ä¸€å¹´ PFS ç‚º 64%ï¼Œå°ç…§çµ„ç‚º 73%ï¼ŒHR=1.27 (95% CI: 0.83-1.93)ï¼Œæ­¤çµ„åˆ¥å› ç„¡ç™‚æ•ˆæ€§ (futility) è€Œä¸­æ­¢ã€‚\r\nâ€¢ åœ¨ cisplatin-unfit çµ„åˆ¥ï¼Œå¯¦é©—çµ„ä¹‹å…©å¹´ç„¡æƒ¡åŒ–å­˜æ´»ç‡ç‚º 44%ï¼Œå°ç…§çµ„ç‚º 31%, HR=0.85, p=0.15ã€‚æ­¤å¤–ï¼Œå¯¦é©—çµ„ä¹‹å…©å¹´å­˜æ´»ç‡ç‚º 58%ï¼Œå°ç…§çµ„ç‚º54% (HR=1.08, p=0.69)ã€‚\r\n\r\nåœ¨å±€éƒ¨ä¾µçŠ¯æ€§é ­é ¸ç™Œçš„ç—…äººæ—ç¾¤ï¼Œä½¿ç”¨åŒæ­¥æ”¾ç™‚åˆä½µ Avelumab/Cetuximab ç›¸æ¯”å‚³çµ±åŒæ­¥æ”¾åŒ–ç™‚åˆä½µcisplatinä¸¦ç„¡æ³•æ”¹å–„PFSã€‚ä½¿ç”¨åŒæ­¥æ”¾ç™‚åˆä½µAvelumab/Cetuximab ç›¸æ¯”åŒæ­¥æ”¾ç™‚åˆä½µ Cetuximab å‰‡æœ‰æ”¹å–„ PFS çš„è¶¨å‹¢ï¼Œä½†æœªèƒ½é”åˆ°é¡¯è‘—ã€‚\r\n\r\nå‡ºè™•:å°ç£é ­é ¸ç™Œå…ç–«è—¥ç‰©æ²»ç™‚æŒ‡å¼•\r\n\r\næ­¤å¤–NCCN guidelineä¹ŸæœªæåŠåˆä½µavelumab plus cetuximabä¹‹æ²»ç™‚æ–¹å¼ï¼Œavelumabçš„è…³è‰²åƒ…æœ‰axitinibå¯è€ƒæ…®åˆä½µavelumabç”¨æ–¼æ²»ç™‚salivary gland tumors.\r\nUse of certain tyrosine kinase inhibitors such as axitinib (with or without avelumab) and sorafenib have been evaluated in nonrandomized phase II trials734-736 and are recommended by the panel as category 2B options for patients with unresectable, metastatic, or recurrent salivary gland tumors (useful in certain circumstances).\r\nå‡ºè™•:NCCN Guidelines Version 2.2025 Head and Neck Cancers(MS-58)\r\n\r\n\r\n(3) In CCRT of HNSCCï¼Œweekly cisplatin 30mg/m2 per week is non-inferior to standard cisplatin 100mg/ m2 every three weeksã€‚\r\næ¨™æº–åŠ‘é‡ cisplatin (100 mg/mÂ² æ¯ä¸‰é€±) æ˜¯ HNSCC CCRT çš„åŸºçŸ³ã€‚ç„¶è€Œï¼Œæ¯é€±ä½åŠ‘é‡ cisplatinï¼ˆå¦‚ 30-40 mg/mÂ²ï¼‰çš„éåŠ£æ•ˆæ€§ä¸€ç›´æ˜¯æœ‰çˆ­è­°çš„è©±é¡Œã€‚ä¸€äº›ç ”ç©¶ï¼ˆå¦‚å°åº¦ Tata Memorial Hospital çš„è©¦é©—ï¼‰é¡¯ç¤ºæ¯é€± 30 mg/mÂ² çš„ cisplatin åœ¨å±€éƒ¨æ™šæœŸ HNSCC ä¸­å¯èƒ½ç™‚æ•ˆä¸è¶³ï¼Œç‰¹åˆ¥æ˜¯åœ¨é ç«¯æ§åˆ¶å’Œç¸½ç”Ÿå­˜ç‡ä¸Šèˆ‡æ¨™æº–åŠ‘é‡ç›¸æ¯”æœ‰å·®è·ã€‚å› æ­¤ï¼Œç›®å‰å¤šæ•¸è­‰æ“šä¸æ”¯æŒ 30 mg/mÂ² æ¯é€±åŠ‘é‡èˆ‡æ¨™æº–åŠ‘é‡å…·æœ‰éåŠ£æ•ˆæ€§ã€‚\r\n\r\nçµè«–ï¼šéŒ¯èª¤\r\nNoronha V, Patil V, Menon N, et al. Long-Term Update of a Phase 3 Randomized Study Comparing Once-a-Week Versus Once-Every-3-Weeks Cisplatin Along With Radiation in Head and Neck Cancer. International Journal of Radiation Oncology*Biology*Physics. 2025;121(1):128-136. doi:https://doi.org/10.1016/j.ijrobp.2024.07.2315\r\n\r\n(4) In CCRT of HNSCCï¼Œweekly cisplatin 40mg/m2 per week is non-inferior to standard\r\ncisplatin 100mg/ m2 every three weeksã€‚\r\n\r\nçµè«–ï¼šæ­£ç¢º\r\n\r\nIn this multi-institutional open-label phase II/III trial, patients with postoperative high-risk LA-SCCHN were randomly assigned to receive either chemoradiotherapy with 3-weekly cisplatin (100 mg/m2) or with weekly cisplatin (40 mg/m2) to confirm the noninferiority of weekly cisplatin. \r\nChemoradiotherapy with weekly cisplatin is noninferior to 3-weekly cisplatin for patients with postoperative high-risk LA-SCCHN.\r\nå‡ºè™•:J Clin Oncol. 2022 Mar 1;40(18):1980â€“1990\r\n\r\nç¶œä¸Šè¿°ï¼Œæ­£è§£æ‡‰ç‚º(C) (2),(4)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/065/explain_figures/figure1.jpg"
    ]
  },
  {
    "id": 66,
    "question": "é—œæ–¼ locally advanced nasopharyngeal carcinoma çš„æ²»ç™‚ï¼Œä¸‹åˆ—æ•˜è¿°ä¸­æ­£ç¢ºçš„æœ‰?\r\n(1) T3-T4N0 NPC with high-risk features å¯è€ƒæ…®induction chemotherapy followed by CCRTã€‚\r\n(2) Adjuvant chemotherapy å¯è€ƒæ…® cisplatin/5-FU for 6 cyclesã€‚\r\n(3) Adjuvant chemotherapy å¯è€ƒæ…® metronomic capecitabine for up to 1 yearã€‚\r\n(4) CCRT å¾Œçš„ EBV copy number å°æ–¼ recurrence é æ¸¬åŠ›ä¸ä½³ã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1) T3-T4N0 NPC with high-risk features å¯è€ƒæ…®induction chemotherapy followed by CCRTã€‚\r\nçµè«–ï¼šæ­£ç¢º\r\n\r\nå°æ–¼ T3-T4N0 çš„å±€éƒ¨æ™šæœŸé¼»å’½ç™Œï¼Œå°¤å…¶æ˜¯ä¼´éš¨é«˜é¢¨éšªç‰¹å¾µï¼ˆå¦‚è…«ç˜¤é«”ç©å¤§ã€ä¾µè¥²æ€§æˆ– EBV DNA é«˜æ°´å¹³ï¼‰ï¼Œèª˜å°åŒ–ç™‚ (induction chemotherapy) å¾Œæ¥ CCRT å·²æˆç‚ºä¸€ç¨®å¸¸è¦‹ç­–ç•¥ã€‚è«¸å¤šè‡¨åºŠè©¦é©—ï¼ˆå¦‚ NPC-0501 ï¼‰ä»¥åŠ NCCN æ”¯æŒåœ¨é«˜é¢¨éšªå±€éƒ¨æ™šæœŸ NPC ä¸­ä½¿ç”¨ Induction Chemotherapyï¼ˆå¦‚ gemcitabine/cisplatin æˆ– TPF æ–¹æ¡ˆï¼‰ä»¥ç¸®å°è…«ç˜¤ä¸¦æ”¹å–„é ç«¯æ§åˆ¶ç‡ã€‚å› æ­¤ï¼Œé€™é …æ•˜è¿°ç¬¦åˆç•¶å‰æ²»ç™‚å…±è­˜ã€‚\r\n\r\nT3N0M0 NPC : å»ºè­°Concurrent systemic therapy/RT\r\nâ€¢ Consider induction or adjuvant chemotherapy if high-risk features\r\nT4N0-3M0 NPC:Induction chemotherapy followed by systemic therapy/RT\r\nå‡ºè™•:NCCN Guidelines Version 2.2025 Cancer of the Nasopharynx(NASO-2)\r\n\r\nAnne, Roger, Ng W, et al. NPCâ€0501 trial on the value of changing chemoradiotherapy sequence, replacing 5â€fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. Cancer. 2020;126(16):3674-3688. doi:https://doi.org/10.1002/cncr.32972\r\n\r\n(2) Adjuvant chemotherapy å¯è€ƒæ…® cisplatin/5-FU for 6 cyclesã€‚\r\n\r\nçµè«–ï¼šéŒ¯èª¤\r\n\r\nRegimenæ­£ç¢ºä½†cycleséŒ¯èª¤ã€‚å¦å¤–ç¾ä»£è­‰æ“šé¡¯ç¤ºï¼Œå–®ç´” CCRT å·²è¶³å¤ æ²»ç™‚å¤§å¤šæ•¸å±€éƒ¨æ™šæœŸ NPCï¼Œä¸”é¡å¤–çš„è¼”åŠ© cisplatin/5-FUï¼ˆç‰¹åˆ¥æ˜¯é•·é” 6 å€‹ cycles ï¼‰ä¸¦æœªé¡¯è‘—æ”¹å–„ç¸½ç”Ÿå­˜ç‡æˆ–ç„¡ç—…ç”Ÿå­˜ç‡ï¼Œä¸”æ¯’æ€§è¼ƒé«˜ï¼Œå› æ­¤ï¼Œç•¶å‰æŒ‡å—ï¼ˆå¦‚ NCCN 2025ï¼‰ä¸æ¨è–¦å¸¸è¦ä½¿ç”¨å¦‚æ­¤é•·æœŸçš„è¼”åŠ©åŒ–ç™‚ï¼Œæ›´å¤šå‚¾å‘ induction chemotherapyã€‚\r\n\r\nPreferred Regimens\r\nâ€¢ Cisplatin + RT followed by cisplatin/5-FU\r\nå‡ºè™•:NCCN Guidelines Version 2.2025 Cancer of the Nasopharynx postradiotherapy, chemotherapy with cisplatin 80 mg/m2 on day 1 and fluorouracil 1,000 mg/m2/d on days 1 to 4 was administered every 4 weeks for â€˜threeâ€™ courses.\r\nå‡ºè™•:J Clin Oncol 1998;16:1310-1317. J Natl Cancer Inst 2005;97:536-539\r\n\r\n(3) Adjuvant chemotherapy å¯è€ƒæ…® metronomic capecitabine for up to 1 yearã€‚\r\nçµè«–ï¼šæ­£ç¢º\r\nå¯è€ƒæ…®oral metronomic capecitabine (650 mg/m2 BSA twice daily for 1 year)ï¼Œå…¶ Failure-free survival at 3 years was significantly higher in the metronomic capecitabine group (85Â·3%) than in the standard therapy group (75Â·7%), with a HR of 0Â·50. \r\n\r\nMetronomic capecitabineï¼ˆä½åŠ‘é‡ã€é•·ç™‚ç¨‹çš„å£æœ capecitabineï¼‰ä½œç‚ºè¼”åŠ©æ²»ç™‚åœ¨ NPC ä¸­çš„æ‡‰ç”¨è¿‘å¹´ä¾†å—åˆ°é—œæ³¨ã€‚ä¸€é …é—œéµç ”ç©¶ Lancet Oncology 2021 é¡¯ç¤ºï¼Œåœ¨ CCRT å¾Œä½¿ç”¨ metronomic capecitabine é•·é” 1 å¹´å¯é¡¯è‘—é™ä½å¾©ç™¼é¢¨éšªä¸¦æ”¹å–„ç„¡ç—…ç”Ÿå­˜ç‡ï¼Œç‰¹åˆ¥é©ç”¨æ–¼é«˜å¾©ç™¼é¢¨éšªæ‚£è€…ï¼ˆå¦‚ EBV DNA æŒçºŒé™½æ€§è€…ï¼‰ã€‚æ­¤ç­–ç•¥å› è€å—æ€§è¼ƒå¥½ä¸”ç™‚æ•ˆé¡¯è‘—ã€‚\r\n\r\nå‡ºè™•:112è€ƒå¤è©³è§£72é¡Œï¼ŒLancet. 2021 Jul 24;398(10297):303-313\r\n\r\n(4) CCRT å¾Œçš„ EBV copy number å°æ–¼ recurrence é æ¸¬åŠ›ä¸ä½³ã€‚\r\n\r\nçµè«–ï¼šéŒ¯èª¤\r\n\r\nLevels of plasma EBV DNA have been shown to be independently prognostic at baseline and following definitive chemoradiation. After induction chemotherapy, and after radiation, plasma EBV DNA levels are used in some centers as a means of outcome prognostication and residual disease monitoring. \r\n\r\nå‡ºè™•:NCCN Guidelines Version 2.2025 Cancer of the Nasopharynx(MS-37)\r\n\r\nç¶œä¸Šè¿°ï¼Œæ­£è§£æ‡‰ç‚º(B) (1),(3)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 67,
    "question": "æœ‰é—œä¸‰é™°æ€§æ—©æœŸä¹³ç™Œï¼Œç›®å‰æ¨™æº–çš„è¼”åŠ©æ€§æ²»ç™‚ç­–ç•¥çš„æ•˜è¿°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰:\r\n\r\n(1) è‹¥ç—…äººä¸¦æ²’æœ‰å¹´é½¡æˆ–å¥åº·çš„ç–‘æ…®ï¼Œè‡³å°‘æ‡‰è©²çµ¦äºˆathracycline/cyclophosphamideï¼ŒçºŒæ¥ taxane çš„è¼”åŠ©æ€§(æˆ–æ–°è¼”åŠ©æ€§)åŒ–å­¸æ²»ç™‚ï¼Œä»¥æ¸›å°‘å¾©ç™¼åŠæ­»äº¡ç‡ã€‚\r\n(2) å¯ä»¥è€ƒæ…®å…ˆåšæ–°è¼”åŠ©æ€§(neoadjuvant)åŒ–å­¸æ²»ç™‚ï¼Œå†æ‰‹è¡“ã€‚å¦‚æœè¡“å¾Œç—…ç†æª¢æŸ¥æ²’æœ‰é”æˆpCRï¼Œå¯ä»¥å†è¿½åŠ 6å€‹æœˆçš„capecitabineã€‚é€™æ¨£çš„æ²»ç™‚æ–¹å¼å¯ä»¥å¢åŠ å­˜æ´»ç‡ã€‚\r\n(3) å¯ä»¥è€ƒæ…®ä½¿ç”¨å…ç–«æ²»ç™‚åˆä½µåŒ–å­¸æ²»ç™‚ä½œç‚ºæ–°è¼”åŠ©æ€§(neoadjuvant)æ²»ç™‚ã€‚ç›¸è¼ƒæ–¼å‚³çµ±çš„è¼”åŠ©æ€§åŒ–å­¸æ²»ç™‚ï¼Œé€™ç¨®æ–¹æ³•å¯ä»¥é¡¯è‘—æé«˜pCR rateä»¥åŠevent free survivalã€‚\r\n(4) è‹¥æ²’æœ‰germline BRCA1/2 mutationï¼Œä½†ç—…äººè…«ç˜¤æª¢é«”é©—å‡ºæœ‰BRCA 1/2 somatic mutationï¼Œæ‡‰è©²åœ¨åŒ–ç™‚çµæŸä¹‹å¾Œè¿½åŠ ä¸€å¹´çš„å£æœPARP æŠ‘åˆ¶åŠ‘ã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "æœ‰é—œä¸‰é™°æ€§æ—©æœŸä¹³ç™Œï¼Œç›®å‰æ¨™æº–çš„è¼”åŠ©æ€§æ²»ç™‚ç­–ç•¥çš„æ•˜è¿°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰:\r\n\r\n(1) è‹¥ç—…äººä¸¦æ²’æœ‰å¹´é½¡æˆ–å¥åº·çš„ç–‘æ…®ï¼Œè‡³å°‘æ‡‰è©²çµ¦äºˆathracycline/cyclophosphamideï¼ŒçºŒæ¥ taxane çš„è¼”åŠ©æ€§(æˆ–æ–°è¼”åŠ©æ€§)åŒ–å­¸æ²»ç™‚ï¼Œä»¥æ¸›å°‘å¾©ç™¼åŠæ­»äº¡ç‡ã€‚\r\n\r\nçµè«–ï¼šæ­£ç¢º\r\n\r\nä¾NCCN guideline, pT1N0ä¸é ˆæ¥å—adjuvant therapy\r\nå‡ºè™•:NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-10)\r\nä½†å°TNBCè€Œè¨€ï¼Œæ¥å—Preoperative Systemic Therapyæœƒæœ‰Known Benefits \r\nå‡ºè™•:NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-L 1 OF 2)\r\n\r\n(2) å¯ä»¥è€ƒæ…®å…ˆåš neoadjuvant å†æ‰‹è¡“ã€‚å¦‚æœè¡“å¾Œç—…ç†æª¢æŸ¥æ²’æœ‰é”æˆpCRï¼Œå¯ä»¥å†è¿½åŠ 6å€‹æœˆçš„capecitabineã€‚é€™æ¨£çš„æ²»ç™‚æ–¹å¼å¯ä»¥å¢åŠ å­˜æ´»ç‡ã€‚\r\n\r\nçµè«–ï¼šæ­£ç¢º\r\n\r\nå¯å†è¿½åŠ Adjuvant capecitabine (every 3 weeks for six or eight cycles)\r\nAfter standard neoadjuvant chemotherapy containing anthracycline, taxane, or both, the addition of adjuvant capecitabine therapy was safe and effective in prolonging disease-free survival and overall survival among patients with HER2-negative breast cancer who had residual invasive disease on pathological testing. \r\n\r\nCREATE-X è©¦é©—é¡¯ç¤ºï¼Œè‹¥æ–°è¼”åŠ©æ€§åŒ–ç™‚å¾Œæœªé”ç—…ç†å®Œå…¨ç·©è§£ (pathologic complete response, pCR)ï¼Œè¿½åŠ  6-8 å‘¨æœŸçš„ capecitabineï¼ˆé€šå¸¸ç‚º 6 å€‹æœˆï¼‰å¯é¡¯è‘—æ”¹å–„ç„¡ç—…ç”Ÿå­˜ç‡ (DFS) å’Œç¸½ç”Ÿå­˜ç‡ (OS)ï¼Œç‰¹åˆ¥æ˜¯åœ¨ TNBC æ‚£è€…ä¸­ã€‚\r\n\r\nå‡ºè™•:NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-16)ã€N Engl J Med 2017;376:2147-2159\r\n\r\n(3) å¯ä»¥è€ƒæ…®ä½¿ç”¨å…ç–«æ²»ç™‚åˆä½µåŒ–å­¸æ²»ç™‚ä½œç‚ºæ–°è¼”åŠ©æ€§(neoadjuvant)æ²»ç™‚ã€‚ç›¸è¼ƒæ–¼å‚³çµ±çš„è¼”åŠ©æ€§åŒ–å­¸æ²»ç™‚ï¼Œé€™ç¨®æ–¹æ³•å¯ä»¥é¡¯è‘—æé«˜pCR rateä»¥åŠevent free survivalã€‚\r\n\r\nçµè«–ï¼šæ­£ç¢º\r\n\r\nStage IIâ€“III Preoperative followed by adjuvant:\r\nâ€¢ Preoperative pembrolizumab + carboplatin + paclitaxel, followed by preoperative pembrolizumab + cyclophosphamide + doxorubicin or epirubicin, followed by adjuvant pembrolizumab (category 1) \r\n\r\nKEYNOTE-522 è©¦é©—è­‰å¯¦ï¼Œå°æ–¼æ—©æœŸ TNBCï¼Œpembrolizumab è¯åˆåŒ–ç™‚ï¼ˆåŒ…æ‹¬ taxaneã€carboplatin å’Œ anthracyclineï¼‰å¯é¡¯è‘—æé«˜ pCR ç‡ï¼ˆç´„ 65% vs. 51%ï¼‰ä¸¦æ”¹å–„ç„¡äº‹ä»¶ç”Ÿå­˜ç‡ (event-free survival, EFS)ã€‚é€™ä¸€ç­–ç•¥å·²æˆç‚ºé«˜é¢¨éšª TNBC æ‚£è€…çš„æ¨™æº–é¸æ“‡\r\n\r\nå‡ºè™•:NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-M 3 OF 10)\r\n\r\n(4) è‹¥æ²’æœ‰germline BRCA1/2 mutationï¼Œä½†ç—…äººè…«ç˜¤æª¢é«”é©—å‡ºæœ‰BRCA 1/2 somatic mutationï¼Œæ‡‰è©²åœ¨åŒ–ç™‚çµæŸä¹‹å¾Œè¿½åŠ ä¸€å¹´çš„å£æœPARP æŠ‘åˆ¶åŠ‘ã€‚\r\n\r\nçµè«–ï¼šéŒ¯èª¤\r\n\r\nPARP æŠ‘åˆ¶åŠ‘ï¼ˆå¦‚ olaparibï¼‰åœ¨ TNBC ä¸­çš„æ‡‰ç”¨ä¸»è¦åŸºæ–¼ OlympiA è©¦é©—ï¼Œè©²è©¦é©—é¡¯ç¤ºï¼Œå°æ–¼æ”œå¸¶ germline BRCA1/2 çªè®Š çš„æ—©æœŸ TNBC æ‚£è€…ï¼ŒåŒ–ç™‚å¾Œè¿½åŠ  1 å¹´ olaparib å¯é¡¯è‘—æ”¹å–„ DFS å’Œ OSã€‚ç„¶è€Œï¼Œç›®å‰è­‰æ“šå°šæœªæ”¯æŒå°‡ PARP æŠ‘åˆ¶åŠ‘å¸¸è¦ç”¨æ–¼åƒ…æœ‰ somatic BRCA1/2 çªè®Šï¼ˆé«”ç´°èƒçªè®Šï¼‰è€Œç„¡ germline çªè®Šçš„æ‚£è€…ã€‚é›–ç„¶ somatic BRCA çªè®Šå¯èƒ½æç¤º PARP æŠ‘åˆ¶åŠ‘çš„æ½›åœ¨ç™‚æ•ˆï¼Œä½†ç¼ºä¹å¤§å‹éš¨æ©Ÿè©¦é©—æ”¯æŒå…¶æ¨™æº–æ‡‰ç”¨ã€‚\r\n\r\nä¾NCCN guideline, æœªæåŠsomatic mutation Adjuvant olaparib for 1 year if germline BRCA1/2 mutation (category 1), \r\nå‡ºè™•:NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-10)\r\n\r\nä½†å°æ–¼è½‰ç§»æ€§ä¹³ç™Œï¼Œæœ‰Somatic BRCA1/2 mutationsï¼Œå‰‡å»ºè­°å¯ä½¿ç”¨olaparib(category 2B)\r\nå‡ºè™•:NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-Q 8 OF 15)\r\n\r\nç¶œä¸Šè¿°ï¼Œæ­£è§£æ‡‰ç‚º(A) (1),(2),(3)ï¼Œä½†(1)(3)çš„æ–‡å­—æ•˜è¿°ä¼¼ä¹é‚„æ˜¯æœ‰é» bug",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 68,
    "question": "æœ‰é—œé›Œæ¿€ç´ å—é«”(Estrogen Receptor)é™½æ€§HER2é™°æ€§æ—©æœŸä¹³ç™Œæ‚£è€…ï¼Œç›®å‰æ¨™æº–çš„è¼”åŠ©æ€§æ²»ç™‚å»ºè­°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰:\r\n\r\n(1) é™¤éæœ‰ç‰¹æ®Šç¦å¿Œç—‡ï¼Œå¦å‰‡æ¯ä¸€å€‹ç—…äººåœ¨è¡“å¾Œéƒ½å»ºè­°çµ¦äºˆè¼”åŠ©æ€§å…§åˆ†æ³Œæ²»ç™‚5è‡³10å¹´ã€‚\r\n(2) ç ”ç©¶é¡¯ç¤ºå°æ–¼é«˜å¾©ç™¼é¢¨éšªçš„æ‚£è€…è¼”åŠ©æ€§å…§åˆ†æ³Œæ²»ç™‚åˆä½µ2-3 å¹´çš„CDK4/6æŠ‘åˆ¶åŠ‘ (å¦‚abemaciclib or ribociclib)æœƒé¡¯è‘—æ¸›å°‘è½‰ç§»å¾©ç™¼ç‡ã€‚\r\n(3) åœç¶“å‰å©¦å¥³ï¼Œç›¸è¼ƒæ–¼å–®ç¨ä½¿ç”¨å‚³çµ±è¼”åŠ©æ€§è·çˆ¾è’™æ²»ç™‚ï¼Œåˆä½µä½¿ç”¨åµå·¢æŠ‘åˆ¶çš„è—¥ç‰© (LHRH agonist)æœƒé¡¯è‘—æ¸›å°‘è½‰ç§»å¾©ç™¼ç‡ã€‚\r\n(4) å»ºè­°å…ˆåšæ–°è¼”åŠ©æ€§åŒ–å­¸æ²»ç™‚ä¾†å¢åŠ ç—…ç†å®Œå…¨ç·©è§£ç‡ (pCR rate)ã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "æœ‰é—œé›Œæ¿€ç´ å—é«”(Estrogen Receptor)é™½æ€§HER2é™°æ€§æ—©æœŸä¹³ç™Œæ‚£è€…ï¼Œç›®å‰æ¨™æº–çš„è¼”åŠ©æ€§æ²»ç™‚\r\nå»ºè­°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰:\r\n\r\n(1) é™¤éæœ‰ç‰¹æ®Šç¦å¿Œç—‡ï¼Œå¦å‰‡æ¯ä¸€å€‹ç—…äººåœ¨è¡“å¾Œéƒ½å»ºè­°çµ¦äºˆè¼”åŠ©æ€§å…§åˆ†æ³Œæ²»ç™‚5è‡³10å¹´ã€‚\r\n\r\nçµè«–ï¼šæ­£ç¢º\r\n\r\nå°æ–¼ ER+ HER2- æ—©æœŸä¹³ç™Œæ‚£è€…ï¼Œè¼”åŠ©æ€§å…§åˆ†æ³Œæ²»ç™‚ï¼ˆå¦‚ tamoxifen æˆ–èŠ³é¦™é…¶æŠ‘åˆ¶åŠ‘ [AI]ï¼‰æ˜¯æ¨™æº–æ²»ç™‚ï¼Œæ—¨åœ¨é™ä½å¾©ç™¼é¢¨éšªã€‚æ ¹æ“šæ‚£è€…åœç¶“ç‹€æ…‹å’Œå¾©ç™¼é¢¨éšªï¼Œæ²»ç™‚é€šå¸¸æŒçºŒ 5 å¹´ï¼ˆä½é¢¨éšªï¼‰è‡³ 10 å¹´ï¼ˆé«˜é¢¨éšªï¼‰ï¼Œé€™ä¸€é»å·²è¢« ATLAS å’Œ aTTom ç­‰è©¦é©—è­‰å¯¦ã€‚å› æ­¤ï¼Œé™¤éæœ‰æ˜ç¢ºç¦å¿Œç—‡ï¼ˆå¦‚åš´é‡è‚ç—…æˆ–è¡€æ “å²ï¼‰ï¼Œæ‰€æœ‰æ‚£è€…å‡æ‡‰æ¥å—æ­¤æ²»ç™‚\r\n\r\nè«‹ç›´æ¥åƒè€ƒNCCN Guideline,ä¸è«–PREMENOPAUSAL OR POSTMENOPAUSALè¡“å¾Œéƒ½å»ºè­°çµ¦äºˆè¼”åŠ©æ€§å…§åˆ†æ³Œæ²»ç™‚\r\nå‡ºè™•:\r\n- NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-6.7.8åŠBINV-K 2 OF 3ã€2 OF 3)\r\n- Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet. 2012;381(9869):805-816. doi:https://doi.org/10.1016/s0140-6736(12)61963-1\r\n- Gray RG, Rea D, Handley K, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. Journal of Clinical Oncology. 2013;31(18_suppl):5-5. doi:https://doi.org/10.1200/jco.2013.31.18_suppl.5\r\n\r\n(2) ç ”ç©¶é¡¯ç¤ºå°æ–¼é«˜å¾©ç™¼é¢¨éšªçš„æ‚£è€…è¼”åŠ©æ€§å…§åˆ†æ³Œæ²»ç™‚åˆä½µ2-3 å¹´çš„CDK4/6æŠ‘åˆ¶åŠ‘ (å¦‚abemaciclib or ribociclib)æœƒé¡¯è‘—æ¸›å°‘è½‰ç§»å¾©ç™¼ç‡ã€‚\r\n\r\nçµï¼šæ­£ç¢º\r\n\r\nIn patients with HR-positive/HER2-negative breast cancer, \r\n1) for those with high-risk breast cancer (ie, those with â‰¥4 positive lymph nodes (confirmed preoperatively and/or at surgery), or 1â€“3 positive lymph nodes with either grade 3 disease or tumor sizeâ‰¥5 cm (on pre-operative imaging and/or at surgery), 2 years of adjuvant abemaciclibcan be considered in combination with endocrine therapy (category 1, preferred). [VTE risk should be considered when combining abemaciclib with tamoxifen.] \r\n2) For those with any lymph node involvement (excluding microscopic nodal involvement),or if no nodal involvement either tumor size >5 cm, or if tumor size 2â€“5 cm, either\r\nGrade 2 (and high genomic risk or Ki-67 â‰¥20%), or Grade 3, 3 years of ribociclib with aromatase inhibitor may be considered (Category 1, preferred). \r\nNotably adjuvant CDK4/6 inhibitors have been studied in patients at high risk who mostly received adjuvant/neoadjuvant chemotherapy; there are limited data in those who did not receive chemotherapy. \r\n\r\nå‡ºè™•:NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-K 2 OF 3)\r\n\r\n(3) åœç¶“å‰å©¦å¥³ï¼Œç›¸è¼ƒæ–¼å–®ç¨ä½¿ç”¨å‚³çµ±è¼”åŠ©æ€§è·çˆ¾è’™æ²»ç™‚ï¼Œåˆä½µä½¿ç”¨åµå·¢æŠ‘åˆ¶çš„è—¥ç‰© (LHRH\r\nagonist)æœƒé¡¯è‘—æ¸›å°‘è½‰ç§»å¾©ç™¼ç‡ã€‚\r\n\r\næ­£ç¢º\r\nA balanced discussion of the risks and benefits associated with ovarian suppression therapy is critical, including the potential side effects of premature menopause. Aromatase inhibitor or tamoxifen for 5 years plus ovarian suppression should be considered, based on SOFT and TEXT clinical trial outcomes, for premenopausal patients at higher risk of recurrence (ie, young age, high-grade tumor, lymph node involvement).\r\n\r\nå°æ–¼åœç¶“å‰ ER+ ä¹³ç™Œæ‚£è€…ï¼ŒSOFT å’Œ TEXT è©¦é©—è­‰å¯¦ï¼Œå–®ç¨ä½¿ç”¨ tamoxifen ç›¸æ¯”ï¼Œè¯åˆLHRH agnoist (å¦‚ goserelin) åŠ  tamoxifen æˆ–èŠ³é¦™é…¶æŠ‘åˆ¶åŠ‘ï¼ˆå¦‚ exemestaneï¼‰å¯é€²ä¸€æ­¥é™ä½å¾©ç™¼é¢¨éšªï¼Œç‰¹åˆ¥æ˜¯åœ¨é«˜é¢¨éšªäººç¾¤ï¼ˆå¦‚å¹´è¼•æ‚£è€…æˆ–æ·‹å·´çµé™½æ€§ï¼‰ã€‚é€™ç¨®ç­–ç•¥é¡¯è‘—æ¸›å°‘é ç«¯è½‰ç§»å¾©ç™¼ç‡\r\n\r\nå‡ºè™•:NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-K 2 OF 3)\r\n\r\n(4) å»ºè­°å…ˆåšæ–°è¼”åŠ©æ€§åŒ–å­¸æ²»ç™‚ä¾†å¢åŠ ç—…ç†å®Œå…¨ç·©è§£ç‡ (pCR rate)ã€‚\r\n\r\néŒ¯èª¤\r\n\r\nåƒè€ƒNCCN Guideline, TNBC or HER2-positive breast canceræœƒæ¯”è¼ƒæœ‰Known Benefits\r\n\r\nKnown Benefits of Preoperative Systemic Therapy\r\nâ€¢ Facilitates breast conservation\r\nâ€¢ Can render inoperable tumors operable\r\nâ€¢ Treatment response provides important prognostic information at an individual patient level, particularly in patients with TNBC or HER2-positive breast cancer\r\nâ€¢ Identifies patients with residual disease at higher risk for relapse to allow for the addition of supplemental adjuvant regimens, particularly\r\nin patients with TNBC or HER2-positive breast cancer. \r\n\r\næ–°è¼”åŠ©æ€§åŒ–ç™‚é€šå¸¸ç”¨æ–¼ä¸‰é™°æ€§ä¹³ç™Œ (TNBC) æˆ– HER2+ ä¹³ç™Œï¼Œä»¥ç¸®å°è…«ç˜¤ä¸¦æé«˜ pCR ç‡ã€‚ç„¶è€Œï¼Œå°æ–¼ ER+ HER2- æ—©æœŸä¹³ç™Œï¼ŒpCR ç‡é€šå¸¸è¼ƒä½ï¼ˆå› å…¶å°åŒ–ç™‚æ•æ„Ÿæ€§ä¸å¦‚å…¶ä»–äºå‹ï¼‰ï¼Œä¸”æ–°è¼”åŠ©æ€§å…§åˆ†æ³Œæ²»ç™‚ï¼ˆå¦‚ AIï¼‰æ›´å¸¸è¢«è€ƒæ…®ç”¨æ–¼åœç¶“å¾Œæ‚£è€…ä»¥è©•ä¼°è…«ç˜¤åæ‡‰ã€‚æ–°è¼”åŠ©æ€§åŒ–ç™‚åœ¨ ER+ HER2- ä¸­çš„æ‡‰ç”¨ä¸»è¦é™æ–¼ç‰¹å®šæƒ…æ³ï¼ˆå¦‚è…«ç˜¤éå¤§ç„¡æ³•æ‰‹è¡“ï¼‰ï¼Œä½†ä¸¦éæ¨™æº–å»ºè­°ï¼Œä¹Ÿéä¸»è¦ç›®æ¨™ç‚ºæé«˜ pCRã€‚å› æ­¤ï¼Œæ­¤æ•˜è¿°ä¸ç¬¦åˆç•¶å‰æ¨™æº–ã€‚\r\n\r\nå‡ºè™•:NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-L 1 OF 2)\r\n\r\nç¶œä¸Šè¿°ï¼Œæ­£è§£æ‡‰ç‚º(A) (1),(2),(3)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 69,
    "question": "é—œæ–¼ BRCA1/2 mutationï¼Œä»¥ä¸‹æ•˜è¿°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰?\n(1) å…·æœ‰ germline mutation çš„å¥³æ€§ï¼Œæœ‰é¡¯è‘—è¼ƒé«˜ç½¹æ‚£ä¹³ç™ŒåŠåµå·¢ç™Œé¢¨éšªã€‚\n(2) é é˜²æ€§åµå·¢åˆ‡é™¤ï¼Œå¯ä»¥æ¸›å°‘ç½¹æ‚£ä¹³ç™Œçš„æ©Ÿç‡ã€‚\n(3) è½‰ç§»æ€§ä¹³ç™Œï¼Œä½¿ç”¨ PARP æŠ‘åˆ¶åŠ‘ï¼Œé™¤äº†æœ‰è¼ƒä½³çš„ç„¡ç–¾ç—…æƒ¡åŒ–å­˜æ´»æœŸä¹‹å¤–ï¼Œå…¶æ•´é«”å­˜æ´»æœŸ(overall survival)ä¹Ÿé¡¯è‘—é«˜æ–¼å–®ä¸€åŒ–å­¸æ²»ç™‚ï¼Œæ‡‰å„ªå…ˆä½¿ç”¨ã€‚\n(4) åŒ–ç™‚è—¥å“ä¸­ï¼Œé‰‘é‡‘é¡(platinum)æ•ˆæœç›¸å°è¼ƒä½³ã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "å·åƒæ­¥è§£æ³•ï¼š(1), (4) å¿…é¸ï¼Œé¸(E)\n\n(1) âœ“ æ­£ç¢ºã€‚BRCA1/2èƒšç´°èƒç³»çªè®Šç¢ºå¯¦æœƒé¡¯è‘—å¢åŠ å¥³æ€§ç½¹æ‚£ä¹³ç™Œå’Œåµå·¢ç™Œçš„é¢¨éšªã€‚BRCA1çªè®Šè€…ä¸€ç”Ÿä¸­ç½¹æ‚£ä¹³ç™Œçš„é¢¨éšªç´„ç‚º65-80%ï¼Œåµå·¢ç™Œé¢¨éšªç´„ç‚º39-44%ï¼›BRCA2çªè®Šè€…ä¹³ç™Œé¢¨éšªç´„ç‚º45-69%ï¼Œåµå·¢ç™Œé¢¨éšªç´„ç‚º11-17%ã€‚\n\nKurian AW, Gong GD, John EM, et al. Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: Findings From the Breast Cancer Family Registry - PMC. Journal of Clinical Oncology. 29(34). doi:10.1200/JCO.2010.34.4440\n  \n(2) âœ“ æ­£ç¢ºã€‚2002 NEJMç™¼è¡¨ï¼šé é˜²æ€§åµå·¢åˆ‡é™¤è¡“(prophylactic oophorectomy)ä¸åƒ…å¯é™ä½åµå·¢ç™Œé¢¨éšªï¼Œç ”ç©¶ä¹Ÿé¡¯ç¤ºå®ƒå¯æ¸›å°‘BRCAçªè®Šå¸¶å› è€…ä¹³ç™Œé¢¨éšªç´„50%ï¼Œä¸»è¦æ˜¯é€šéé™ä½é›Œæ¿€ç´ æ°´å¹³çš„æ©Ÿåˆ¶ã€‚\n\nRebbeck TR. Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations. The New England Journal of Medicine. May 23, 2002. Accessed March 6, 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa012158\n\n(3) âœ“ æ­£ç¢ºï¼ŒPARPæŠ‘åˆ¶åŠ‘åœ¨BRCAçªè®Šçš„è½‰ç§»æ€§ä¹³ç™Œæ‚£è€…ä¸­æé«˜äº†ç„¡ç–¾ç—…æƒ¡åŒ–å­˜æ´»æœŸ(PFS)ï¼Œç•¶å¹´å°šæœªè­‰å¯¦å®ƒå€‘åœ¨æ•´é«”å­˜æ´»æœŸ(OS)æ–¹é¢æœ‰é¡¯è‘—å„ªå‹¢ï¼Œä½†è¿‘æœŸ OlympiAD åœ¨2024ç™¼è¡¨ä¸­ï¼Œåœ¨ç·šä½¿ç”¨æœ‰OS benifitï¼Œæ•…æ­£ç¢ºã€‚\n\nRobson ME, Im SA, Senkus E, et al. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physicianâ€™s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. European Journal of Cancer. 2023;184:39-47. doi:10.1016/j.ejca.2023.01.031\n  \nRobson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523-533.\n\nLitton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med.\n2018;379(8):753-763.\n\n*é—œæ–¼PARPæŠ‘åˆ¶åŠ‘æ˜¯å¦å…·æœ‰OS benefitä»å…·çˆ­è­°æ€§ã€‚åœ¨2023å¹´ç™¼è¡¨çš„OlympiAD extended follow-up for OSåˆ†æä¸­ï¼Œåƒ…æœ‰æ¥å—olaparibä½œç‚ºç¬¬ä¸€ç·šæ²»ç™‚çš„subgroupé¡¯ç¤ºå‡ºç›¸æ¯” chemotherapy æœ‰OS benefit (also not powered for OS in this study)ã€‚åœ¨æ•´é«”æ—ç¾¤ä¸­ï¼Œolaparibç›¸è¼ƒæ–¼TPC ä¸¦æœªé¡¯ç¤ºçµ±è¨ˆä¸Šé¡¯è‘—çš„æ•´é«”å­˜æ´»å„ªå‹¢ã€‚\næ­¤å¤–ï¼Œåœ¨EMBRACA study ä¸­ï¼Œä½¿ç”¨talazoparibç›¸è¼ƒæ–¼åŒ–ç™‚ä¹Ÿæœªé¡¯è‘—æ”¹å–„overall survivalã€‚\nç„¶è€Œï¼Œé‘‘æ–¼é¸é …çš„é™åˆ¶ï¼Œæˆ‘å€‘åªèƒ½é¸æ“‡ Eï¼ˆ1ã€2ã€3ã€4 çš†æ­£ç¢º)ä½œç‚ºæœ€é©åˆçš„ç­”æ¡ˆã€‚\n\n(4) âœ“ æ­£ç¢ºã€‚BRCAçªè®Šçš„è…«ç˜¤å­˜åœ¨DNAä¿®å¾©ç¼ºé™·ï¼Œå°å¼•èµ·DNAæå‚·çš„è—¥ç‰©ç‰¹åˆ¥æ•æ„Ÿã€‚Cells with BRCA1 pathogenic variant are more sensitive to platinum-based chemotherapeutic agents, which disrupt the DNA structureã€‚\n\n3.Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D. The effect of loss of BRCA1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol. 2003;22:1169â€“1173.\n\n4.Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003;88:1285â€“1291. doi: 10.1038/sj.bjc.6600859IF: 6.4 Q1 .",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/069/explain_figures/fig1.png",
      "/qabank/069/explain_figures/fig2.png"
    ]
  },
  {
    "id": 70,
    "question": "é—œæ–¼è½‰ç§»æ€§ä¹³ç™Œçš„ biomarker åŠå…¶ç›¸å°æ‡‰çš„è—¥ç‰©ï¼Œä»¥ä¸‹ biomarker ä¸­ï¼Œä¸å¿…æª¢é©—é™½æ€§å³å¯ ä½¿ç”¨è©²è—¥ç‰©æ²»ç™‚çš„æœ‰?\n(1) PIK3CA mutation: PI3K æŠ‘åˆ¶åŠ‘ (å¦‚ alpelisib)\n(2) PI3K/akt/mTOR alteration: mTOR inhibitor (å¦‚ everolimus)\n(3) HER2 overexpression (IHC 3+ or FISH positive): trastuzumab, TDM1\n(4) Trop 2 protein expression: anti-Trop2 antibody-drug conjugate (å¦‚ sacituzumab govitecan)",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 2,
    "explanation": "(2)(4)\n\n1. PIK3CA mutation: Alpelisib â†’ éœ€è¦ PIK3CA çªè®Šé™½æ€§æ‰èƒ½ä½¿ç”¨\n2. PI3K/AKT/mTOR alteration: Everolimus â†’ è¦ HR+/HER2- ï¼Œä½† Everolimus ä¸éœ€è¦ç‰¹å®š PI3K/AKT/mTOR æ”¹è®Šçš„æª¢æ¸¬\nï¼ˆä½†å¦‚æœä»Šå¤©æ˜¯ Capivasertibâ€“fulvestrantï¼Œå‰‡è¦é©—åˆ° PIK3CA/AKT1/PTEN-alterations æ‰å¯ä»¥ç”¨ï¼‰\n3. HER2 overexpression: Trastuzumab, TDM1 â†’ éœ€è¦ HER2 IHC 3+ æˆ– FISH é™½æ€§ ï¼ˆç§’æ®ºï¼‰\n4. Sacituzumab govitecan (Trodelvy) å±¬æ–¼æŠ— Trop-2 ADCï¼Œä½†ç›®å‰åœ¨æ²»ç™‚è½‰ç§»æ€§ä¸‰é™°æ€§ä¹³ç™Œ (mTNBC) åŠ HR+/HER2- ä¹³ç™Œæ™‚ï¼Œä¸¦ä¸éœ€è¦ Trop-2 é™½æ€§æª¢æ¸¬çµæœ æ‰èƒ½ä½¿ç”¨ã€‚è‡¨åºŠè©¦é©—é¡¯ç¤ºï¼Œå¤§å¤šæ•¸ä¹³ç™Œæ‚£è€…éƒ½æœ‰ Trop-2 è¡¨ç¾ï¼Œå› æ­¤è©²è—¥ç‰©å¯é©ç”¨æ–¼å»£æ³›æ—ç¾¤ã€‚\n\nRef:\n1. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine. 2021;384(16):1529-1541. doi:10.1056/nejmoa2028485\n\n2. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptorâ€“positive advanced breast cancer. N Engl J Med. 2012;366(6):520-529. doi:10.1056/NEJMoa1109653\n\n3. Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in Hormone Receptorâ€“Positive Advanced Breast Cancer. New England Journal of Medicine. 2023;388(22):2058-2070. doi:10.1056/nejmoa2214131\n\n4. Corti C. Systemic Therapy in Breast Cancer. American Society of Clinical Oncology Educational Book. Published online July 1, 2024.",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/070/explain_figures/fig1.png"
    ]
  },
  {
    "id": 71,
    "question": "æœ‰é—œ HER2 é™½æ€§(HER2 overexpression)è½‰ç§»æ€§ä¹³ç™Œï¼Œä»¥ä¸‹æ•˜è¿°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰ï¼Ÿ\n(1) ç›®å‰ç¬¬ä¸€ç·šæ²»ç™‚å»ºè­°çš„æ˜¯ trastuzumab+pertuzumab åˆä½µç´«æ‰é†‡ã€‚\n(2) ç¬¬äºŒç·šçš„æ²»ç™‚ï¼Œç ”ç©¶é¡¯ç¤ºï¼Œæ–°ä¸€ä»£çš„ antibody-drug conjugate TDXd (trastuzumab deruxtecan)ï¼Œæ•ˆæœé¡¯è‘—çš„å„ªæ–¼ TDM1 (trastuzuamb emtansine)ã€‚\n(3) Trastuzumab+pertuzumab åˆä½µç´«æ‰é†‡æ²»ç™‚å¾Œï¼Œç”¢ç”ŸæŠ—è—¥æ€§ï¼Œç–¾ç—…æƒ¡åŒ–é€²å±•æ™‚ï¼Œæ›´æ›æˆä¸‹ä¸€ç·šçš„åŒ–ç™‚è—¥ç‰©æ™‚ï¼Œç¹¼çºŒæŒçºŒä½¿ç”¨ tratuzumab è¢«è­‰å¯¦ä»ç„¶æœƒåŠ å¼·ä¸‹ä¸€ç·šåŒ–ç™‚çš„ç™‚æ•ˆã€‚\n(4) å£æœ anti-HER2 æ¨™é¶è—¥ç‰© lapatinib åˆä½µ capecitabineï¼Œæ˜¯å¸¸ç”¨çš„ç¬¬ä¸‰ï¼Œå››ç·šè—¥ç‰©ï¼Œä½†æ˜¯å°æ–¼è…¦è½‰ç§»çš„æ‚£è€…ä¸å»ºè­°ä½¿ç”¨ã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "(1) ç›®å‰ç¬¬ä¸€ç·šæ²»ç™‚å»ºè­°çš„æ˜¯ trastuzumab+pertuzumab åˆä½µç´«æ‰é†‡ã€‚\nâœ“ æ­£ç¢ºã€‚æ ¹æ“šè‡¨åºŠå¯¦è¸æŒ‡å—ï¼ŒHER2 é™½æ€§è½‰ç§»æ€§ä¹³ç™Œçš„ç¬¬ä¸€ç·šæ²»ç™‚ç¢ºå¯¦å»ºè­°ä½¿ç”¨ trastuzumab+pertuzumab åŠ ä¸Šç´«æ‰é†‡æˆ– docetaxel çš„åŒ–ç™‚çµ„åˆã€‚CLEOPATRA ç ”ç©¶è­‰å¯¦é€™ç¨®çµ„åˆå¯æ˜é¡¯æ”¹å–„ç¸½ç”Ÿå­˜æœŸã€‚\n\n(2) ç¬¬äºŒç·šçš„æ²»ç™‚ï¼Œç ”ç©¶é¡¯ç¤ºï¼Œæ–°ä¸€ä»£çš„ antibody-drug conjugate TDXd (trastuzumab deruxtecan)ï¼Œæ•ˆæœé¡¯è‘—çš„å„ªæ–¼ TDM1 (trastuzuamb emtansine)ã€‚\nâœ“ æ­£ç¢ºã€‚DESTINY-Breast03 ç ”ç©¶é¡¯ç¤ºï¼Œåœ¨ä¹‹å‰æ¥å—é trastuzumab å’Œç´«æ‰é†‡æ²»ç™‚çš„æ‚£è€…ä¸­ï¼ŒT-DXd ç¢ºå¯¦é¡¯è‘—å„ªæ–¼ T-DM1ï¼ŒPFSå’ŒORRå‡æœ‰é¡¯è‘—æ”¹å–„ã€‚\n\n(3) Trastuzumab+pertuzumab åˆä½µç´«æ‰é†‡æ²»ç™‚å¾Œï¼Œç”¢ç”ŸæŠ—è—¥æ€§ï¼Œç–¾ç—…æƒ¡åŒ–é€²å±•æ™‚ï¼Œæ›´æ›æˆä¸‹ä¸€ç·šçš„åŒ–ç™‚è—¥ç‰©æ™‚ï¼Œç¹¼çºŒæŒçºŒä½¿ç”¨ tratuzumab è¢«è­‰å¯¦ä»ç„¶æœƒåŠ å¼·ä¸‹ä¸€ç·šåŒ–ç™‚çš„ç™‚æ•ˆã€‚\nâœ“ æ­£ç¢ºã€‚å¤šé …ç ”ç©¶åŒ…æ‹¬ GBG26 åŠ CEREBEL ç ”ç©¶é¡¯ç¤ºï¼Œå³ä½¿ç–¾ç—…åœ¨ trastuzumab æ²»ç™‚æœŸé–“é€²å±•ï¼Œç¹¼çºŒä½¿ç”¨ trastuzumab ä¸¦è½‰æ›åŒ–ç™‚è—¥ç‰©ä»å¯æä¾›è‡¨åºŠæ•ˆç›Šï¼Œæ”¯æŒä¿æŒ HER2 é˜»æ–·çš„ç­–ç•¥ã€‚\n\n(4) å£æœ anti-HER2 æ¨™é¶è—¥ç‰© lapatinib åˆä½µ capecitabineï¼Œæ˜¯å¸¸ç”¨çš„ç¬¬ä¸‰ï¼Œå››ç·šè—¥ç‰©ï¼Œä½†æ˜¯å°æ–¼è…¦è½‰ç§»çš„æ‚£è€…ä¸å»ºè­°ä½¿ç”¨ã€‚\nâœ— ä¸æ­£ç¢ºã€‚å¯¦éš›ä¸Šï¼Œlapatinib æ˜¯å°åˆ†å­æŠ‘åˆ¶åŠ‘ï¼Œå¯ç©¿éè¡€è…¦å±éšœï¼Œèˆ‡ capecitabine çµ„åˆåœ¨ HER2 é™½æ€§ä¹³ç™Œè…¦è½‰ç§»æ‚£è€…ä¸­å·²é¡¯ç¤ºå‡ºè‡¨åºŠæ´»æ€§ï¼Œå› æ­¤å¸¸è¢«è€ƒæ…®ç”¨æ–¼æ­¤é¡æ‚£è€…ï¼Œè€Œéä¸å»ºè­°ä½¿ç”¨ã€‚\n\n\n\n1.Swain SM. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. The New England Journal of Medicine. February 19, 2015. Accessed March 6, 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa1413513\n\n\n\n2. CortÃ©s J, Kim SB, Chung WP, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. New England Journal of Medicine. 2022;386(12):1143-1154. doi:10.1056/nejmoa2115022\n\n\n3.Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. European Journal of Cancer. 47(15):2273-2281. doi:10.1016/j.ejca.2011.06.021\n\n4.Pivot X. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer. Journal of Clinical Oncology. Published online May 10, 2015.\n\n5. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. The Lancet Oncology. 14(1):64-71. doi:10.1016/S1470-2045(12)70432-1",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 72,
    "question": "æœ‰é—œä¾µçŠ¯æ€§ä¹³ç™Œæ‰‹è¡“å¾Œçš„è¼”åŠ©æ€§æ”¾å°„æ²»ç™‚ï¼Œä»¥ä¸‹æ•˜è¿°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰ï¼Ÿ\n(1) è‹¥æ˜¯ä¹³æˆ¿ä¿ç•™æ‰‹è¡“ä¹‹å¾Œï¼Œå»ºè­°æ‡‰è©²å¯¦æ–½ã€‚\n(2) è‹¥æ˜¯è…‹ä¸‹æ·‹å·´çµå››é¡†é™½æ€§ï¼Œå»ºè­°æ‡‰è©²å¯¦æ–½ã€‚\n(3) è‹¥æ˜¯ç—…äººæœ‰æ¥å—é©ç•¶çš„å…¨èº«æ€§è¼”åŠ©æ€§æ²»ç™‚(systemic adjuvant therapy)ï¼Œè‡¨åºŠä¸Šç†å­¸æª¢æŸ¥æœªç™¼ç¾æœ‰æ·‹å·´çµè…«å¤§ï¼Œè…‹ä¸‹å‰å“¨æ·‹å·´çµå–æ¨£åªæœ‰ä¸€é¡†é™½æ€§ï¼Œæ”¾å°„æ²»ç™‚å¯ä»¥å–ä»£è…‹ä¸‹æ·‹å·´çµå»“æ¸…è¡“ã€‚\n(4) è‹¥æœ‰å…¶ä»–é«˜é¢¨éšªå› å­å­˜åœ¨ï¼Œè…‹ä¸‹æ·‹å·´çµåªæœ‰ 1 é¡†é™½æ€§ï¼Œä¹Ÿå»ºè­°å¯¦æ–½ã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "(1) æ­£ç¢ºã€‚ä¹³æˆ¿ä¿ç•™æ‰‹è¡“å¾Œå»ºè­°å¯¦æ–½è¼”åŠ©æ€§æ”¾å°„æ²»ç™‚ï¼Œé€™æ˜¯æ¨™æº–æ²»ç™‚æµç¨‹ï¼Œå¯é¡¯è‘—é™ä½å±€éƒ¨å¾©ç™¼é¢¨éšªã€‚ NCCN: Those who have a positive lymph node have a high risk of recurrence. Therefore, after BCS WBRT is strongly recommended with or without boost to tumor bed for node-positive disease\n\n(2) æ­£ç¢ºã€‚ç•¶è…‹ä¸‹æ·‹å·´çµæœ‰ 4 é¡†æˆ–æ›´å¤šå‘ˆé™½æ€§æ™‚ï¼Œç¢ºå¯¦å»ºè­°é€²è¡Œè¼”åŠ©æ€§æ”¾å°„æ²»ç™‚ï¼Œå› ç‚ºé€™è¡¨ç¤ºç–¾ç—…å·²æœ‰æ·‹å·´çµè½‰ç§»ä¸”é¢¨éšªè¼ƒé«˜ã€‚\n\n(3) æ­£ç¢ºã€‚æ ¹æ“š ACOSOG Z0011 è‡¨åºŠè©¦é©—çµæœï¼Œè‹¥ç—…äººç¬¦åˆä»¥ä¸‹æ¢ä»¶ï¼šæ¥å—é©ç•¶çš„å…¨èº«æ€§è¼”åŠ©æ²»ç™‚ã€è‡¨åºŠæª¢æŸ¥æœªç™¼ç¾æ·‹å·´çµè…«å¤§ã€å‰å“¨æ·‹å·´çµæ´»æª¢åƒ…æœ‰ 1-2 é¡†é™½æ€§ï¼Œå‰‡æ”¾å°„æ²»ç™‚ç¢ºå¯¦å¯ä»¥å–ä»£å®Œæ•´çš„è…‹ä¸‹æ·‹å·´çµå»“æ¸…è¡“ï¼Œä¸”ä¸æœƒå½±éŸ¿ç”Ÿå­˜ç‡ã€‚\n\n(4) æ­£ç¢ºã€‚å³ä½¿è…‹ä¸‹æ·‹å·´çµåƒ…æœ‰ 1 é¡†é™½æ€§ï¼Œè‹¥å­˜åœ¨å…¶ä»–é«˜é¢¨éšªå› ç´ ï¼ˆå¦‚è…«ç˜¤å¤§å°å¤§æ–¼ 5 å…¬åˆ†ã€åˆ†åŒ–ç¨‹åº¦å·®ã€å¹´é½¡å°æ–¼ 40 æ­²ã€æ·‹å·´è¡€ç®¡ä¾µçŠ¯ç­‰ï¼‰ï¼Œä¹Ÿå»ºè­°å¯¦æ–½è¼”åŠ©æ€§æ”¾å°„æ²»ç™‚ä»¥é™ä½å¾©ç™¼é¢¨éšªã€‚ NCCN: In the case of cT3N0, high-risk features for considering PMRT include, but are not limited to, young age and/or LVI.\n\nå› æ­¤ï¼Œé€™å››å€‹æ•˜è¿°éƒ½æ˜¯æ­£ç¢ºçš„ã€‚\n\n1.Giuliano MAE. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive. JAMA. 2017;318(10):918-926. doi:10.1001/jama.2017.11470",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 73,
    "question": "é—œæ–¼ breast cancer çš„ supportive careï¼Œä»¥ä¸‹æ•˜è¿°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰?\n(1) Denosumab æ²»ç™‚ä¹³ç™Œéª¨è½‰ç§»æ‡‰æ³¨æ„ osteonecrosis of jaw å¯èƒ½ã€‚\n(2) D-CARE study ä¸­ï¼Œæ—©æœŸé«˜é¢¨éšªä¹³ç™Œä½¿ç”¨ adjuvant denosumab é¡¯ç¤ºå¯æ¸›å°‘éª¨éª¼è½‰ç§»ã€‚\n(3) PG2 é»ƒè€†å¤šé†£é«”å¯ä½¿ç”¨æ–¼ä¹³ç™Œæ²»ç™‚ä¸­ç™Œå› æ€§ç–²æ†Šã€‚\n(4) Megestrol åƒ…èƒ½ç”¨æ–¼ cancer cachexiaï¼Œå° ER+ MBC ä¸¦ç„¡æ²»ç™‚æ•ˆæœã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1) å°ã€‚Bisphosphonateså’Œ Denosumab çš†èˆ‡ç´„ 2% çš„osteonecrosis of the jawç™¼ç”Ÿç‡ç›¸é—œã€‚ç†æƒ³æƒ…æ³ä¸‹ï¼Œé†«å¸«æ‡‰é¿å…åœ¨æ‚£è€…é€²è¡Œæˆ–å‰›å®Œæˆä»»ä½•æ¶‰åŠéª¨éª¼æ“ä½œçš„ä¾µå…¥æ€§ç‰™ç§‘æ‰‹è¡“ï¼ˆå¦‚æ‹”ç‰™æˆ–æ¤ç‰™ï¼‰å‰å¾Œä½¿ç”¨é€™äº›è—¥ç‰©ã€‚\n\n(2) éŒ¯ã€‚åœ¨ D-CARE phase III  RCTè©¦é©—ä¸­ï¼Œ4509 åå…·æœ‰é«˜é¢¨éšªæ—©æœŸä¹³ç™Œçš„premenopausalå’Œpostmenopausalå¥³æ€§è¢«éš¨æ©Ÿåˆ†é…æ¥å—Denosumab 120 mg çš®ä¸‹æ³¨å°„ï¼Œæ¯ 3 è‡³ 4 é€±ä¸€æ¬¡ï¼ŒæŒçºŒ 6 å€‹æœˆï¼Œéš¨å¾Œæ¯ 12 é€±ä¸€æ¬¡ï¼Œæœ€å¤š 5 å¹´ï¼Œæˆ–æ¥å—placeboï¼Œä¸¦èˆ‡standard neoadjuvant/adjuvant treatmentè¯åˆä½¿ç”¨ã€‚çµæœé¡¯ç¤ºï¼Œæ¥å—Denosumabæ²»ç™‚çš„æ‚£è€…èˆ‡æ¥å—placeboçš„æ‚£è€…ç›¸æ¯”ï¼Œåœ¨bone metastasis-free survivalæ–¹é¢æ²’æœ‰é¡¯è‘—å·®ç•°ã€‚\n\nReference: Coleman R, Finkelstein DM, Barrios C, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2020;21:60-72. doi:10.1016/S1470-2045(19)30687-4. PMID: 31806543. \n\n(3) å°ã€‚PG2 é»ƒè€†å¤šé†£é«” (Astragalus Polysaccharide PG2) å·²ç²å°ç£æ‰¹å‡†ç”¨æ–¼æ²»ç™‚æ™šæœŸç™Œç—‡æ‚£è€…çš„ç™Œå› æ€§ç–²æ†Šï¼ˆCRFï¼‰ã€‚ åœ¨ä¸€å€‹å°ç£ç™¼è¡¨çš„phase II , double-blind, placebo-controlled RCTè©¦é©—ä¸­ï¼Œæ­£åœ¨æ¥å—adjuvant chemotherapyçš„ stage II or III ä¹³ç™Œæ‚£è€…è¢«éš¨æ©Ÿåˆ†é…è‡³ PG2 500mg æˆ–placeboçµ„ï¼Œä¸¦æ–¼ ç¬¬ 1ã€3ã€8 å¤©ï¼Œæ¯ 21 å¤©é€²è¡Œçµ¦è—¥ã€‚ ç ”ç©¶çµæœé¡¯ç¤ºï¼ŒPG2 çµåˆadjuvant chemotherapyå¯é¡¯è‘—æ”¹å–„chemotherapy-related fatigue scoreï¼Œä¸¦æé«˜æ‚£è€…å®Œæˆadjuvant chemotherapyçš„complianceã€‚\n\nReference: Shen WC, Chen SC, Wang CH, Hung CM, Peng MT, Liu CT, Chang YS, Kuo WL, Chou HH, Yeh KY, Wu TH, Wu CF, Chang PH, Huang YM, Yu CC, Lee CH, Rau KM. Astragalus polysaccharides improve adjuvant chemotherapy-induced fatigue for patients with early breast cancer. Sci Rep. 2024 Oct 28;14(1):25690. doi: 10.1038/s41598-024-76627-z. PMID: 39465324; PMCID: PMC11514294.\n\n(4) éŒ¯ã€‚Megesterol acetate is listed on the NCCN guidelines as one of the subsequent-line therapy options for the treatment of hormone receptor-positive recurrent unresectable or stage IV breast cancer. è©³è¦‹ Figure 1",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/073/explain_figures/Figure 4.png"
    ]
  },
  {
    "id": 74,
    "question": "Based on the latest NCCN guidelines, which of the following statements regarding the descriptions of sarcoma are (is) correct?\n(1) For well-differentiated liposarcoma (with no evidence of de-differentiation) over the extremity,\nsurgical resection with oncologically appropriate margins is adequate for treatment.\n(2) Pleomorphic rhabdomyosarcoma is recommended to be treated like high-grade undifferentiated\npleomorphic sarcoma.\n(3) Immunotherapy could be considered as subsequent lines of therapy for advanced/metastatic\ndisease of cutaneous angiosarcoma.\n(4) Dermatofibrosarcoma protuberans (DFSP) with fibrosarcomatous transformation could be\nconsidered treated with chemotherapy used in soft tissue sarcoma if failed imatinib.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "(1) å°ã€‚Well-differentiated liposarcoma (WDLS) is a low-grade soft tissue sarcoma that arises from adipocytes. Unlike its more aggressive counterpart, de-differentiated liposarcoma (DDLS), WDLS is characterized by local recurrence but lacks metastatic potential. Since WDLS has minimal metastatic risk, adequate surgical resection with oncologic margins is considered definitive treatment. Chemotherapy is ineffective in treating WDLS due to the tumorâ€™s low mitotic activity. è©³è¦‹ Figure 1\n\n(2) å°ã€‚The incidence of pleomorphic rhabdomyosarcoma (PRMS) increases with age and the overall prognosis in adults is poor. PRMS is usually excluded from rhabdomyosarcoma (RMS) and soft tissue sarcoma randomized clinical trials. PRMS is treated similarly to high-grade undifferentiated pleomorphic sarcoma (UPS) because of their shared histopathological features, aggressive clinical behavior, and poor response to standard rhabdomyosarcoma (RMS) treatments (such as the â€œVACâ€ regimen). PRMS is treated using the high-grade soft tissue sarcoma approach, primarily with surgery, radiation, and anthracycline-based chemotherapy. è©³è¦‹ Figure 2\n\n(3) å°ã€‚Pembrolizumab is approved by U.S. FDA for unresectable or metastatic TMB-H (â‰¥10 mut/Mb) tumors that have progressed following prior treatment and who have no satisfactory alternative options. NCCN guidelines currently list pembrolizumab as a subsequent-line treatment option for patients with certain subtypes of advanced or metastatic soft tissue sarcoma, including myxofibrosarcoma, undifferentiated pleomorphic sarcoma (UPS), cutaneous angiosarcoma, and undifferentiated sarcomas. Cutaneous angiosarcomas often exhibit high TMB, and recently, the combination of ipilimumab and nivolumab showed a response rate of 25% in angiosarcoma with three of five patients with cutaneous angiosarcomas of the scalp and face achieving partial response. è©³è¦‹ Figure 3A, 3B\n\n(4) å°ã€‚Dermatofibrosarcoma protuberans (DFSP) is a rare, slow-growing soft tissue sarcoma, but fibrosarcomatous transformation (FS-DFSP) is an aggressive variant with increased metastatic potential and a higher recurrence rate. For unrsectable metastatic or locally advanced FS-DFSP, imatinib is the frontline systemic therapy of choice. For imatinib-resistant FS-DFSP, chemotherapy is considered, such as anthracycline- or gemcitabine-based regimen. è©³è¦‹ Figure 4",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/074/explain_figures/Figure 1.png",
      "/qabank/074/explain_figures/Figure 2.png",
      "/qabank/074/explain_figures/Figure 3A.png",
      "/qabank/074/explain_figures/Figure 3B.png",
      "/qabank/074/explain_figures/Figure 4.png"
    ]
  },
  {
    "id": 75,
    "question": "Which of the following statements regarding the treatment of soft tissue sarcoma (STS) are (is) correct?\n(1) In comparison with dacarbazine, eribulin has shown superior activity as a second line\ntherapy for leiomyosarcoma.\n(2) Trabectedin has shown better efficacy than dacarbazine in both leiomyosarcoma and\nliposarcoma.\n(3) Pazopanib has been approved as standard late line therapy for liposarcoma.\n(4) Current recommended treatments for alveolar soft part sarcoma (ASPS) included sunitinib,\npazopanib, pembrolizumab, pembrolizumab in combination with axitinib, and atezolizumab.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 2,
    "explanation": "(1) éŒ¯ã€‚A phase 3, randomized, open-label trial showed that eribulin improved OS compared to dacarbazine in patients with previously treated locally advanced or metastatic leiomyosarcoma or liposarcoma. A planned subgroup analysis by sarcoma subtype found a statistically significant improvement in both PFS and OS for liposarcoma patients treated with eribulin versus dacarbazine, with a 1.2-month increase in median PFS and a 7-month increase in OS favoring eribulin. However, no survival benefit was observed for leiomyosarcoma. Notably, dacarbazine is likely more active in leiomyosarcoma than in liposarcoma, so the lack of difference in the leiomyosarcoma group suggests similar efficacy between the two drugs rather than eribulin being ineffective. Based on these findings, the NCCN recognizes eribulin as a standard treatment option for advanced soft tissue sarcomas, not just liposarcoma, regardless of histology. è©³è¦‹ Figure 1\n\nReference: SchÃ¶ffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0IF: 98.4Â Q1Â . Epub 2016 Feb 10. PMID: 26874885.\n\n(2) å°ã€‚Trabectedin is a cytotoxic agent approved by the US FDA for patients with unresectable or metastatic leiomyosarcoma or liposarcoma who have previously received anthracycline-based chemotherapy. In a randomized, open-label, international phase 3 study, trabectedin reduced the risk of sarcoma progression or death by 45% compared to dacarbazine (P < .001). However, overall survival (OS) was not significantly different between the two treatments. Trabectedin is administered as a 24-hour intravenous infusion. The median PFS was 4.2 months with trabectedin, compared to 1.5 months with dacarbazine. Objective response rates remained below 10% and were similar in both treatment groups. Safety monitoring is crucial, as trabectedin was associated with a 1.2% incidence of rhabdomyolysis and a 2.1% incidence of treatment-related death, complications that were not observed in the dacarbazine group. Due to this risk, weekly CPK monitoring, along with standard laboratory tests, is recommended for patients receiving trabectedin. è©³è¦‹ Figure 2A, 2B, 2C\n\nReference: Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016 Mar 10;34(8):786-93. doi: 10.1200/JCO.2015.62.4734. Epub 2015 Sep 14. PMID: 26371143; PMCID: PMC5070559.\n\n(3) éŒ¯ã€‚Pazopanib is FDA-approved for the treatment of advanced soft tissue sarcomas (STS), excluding liposarcoma, after prior chemotherapy. According to NCCN guidelines, it is recommended as a subsequent-line treatment for non-liposarcoma STS, but not for liposarcoma due to limited efficacy. The Phase 3 PALETTE trial showed that pazopanib significantly improved PFS in advanced STS, but had minimal to no benefit in liposarcoma patients. As a result, pazopanib is not considered a standard late-line treatment for liposarcoma and is not included in its FDA-approved indications. Instead, eribulin and trabectedin are the preferred treatments for advanced liposarcoma after prior therapy. è©³è¦‹ Figure 3\n\nReference: van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, SchÃ¶ffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19;379(9829):1879-86. doi: 10.1016/S0140-6736(12)60651-5. Epub 2012 May 16. PMID: 22595799.\n\n(4 å°ã€‚Alveolar Soft Part Sarcoma (ASPS) is a rare, slow-growing, but highly metastatic soft tissue sarcoma that frequently affects young adults. For a list of recommended systemic therapy for metastatic or unresectable ASPS by the NCCN. è©³è¦‹ Figure 4",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/075/explain_figures/Figure 1.png",
      "/qabank/075/explain_figures/Figure 2A.png",
      "/qabank/075/explain_figures/Figure 2B.png",
      "/qabank/075/explain_figures/Figure 2C.png",
      "/qabank/075/explain_figures/Figure 3.png",
      "/qabank/075/explain_figures/Figure 4.png"
    ]
  },
  {
    "id": 76,
    "question": "Which of the following statements regarding RELATIVITY-047, a study of relatlimab plus nivolumab versus nivolumab alone in patients with advanced melanoma, are (is) correct?\n(1) The hazard ratio of progression-free survival (PFS) favored nivolumab and relatlimab.\n(2) The hazard ratio of overall survival (OS) only marginally favored nivolumab and relatlimab.\n(3) Nivolumab and relatlimab has higher chance of grade 3 or 4 treatment-related adverse\nevents (TRAEs) than nivolumab alone.\n(4) The benefit observed in patients treated with nivolumab plus relatlimab versus nivolumab\nalone was largely consistent across key patient subgroups, including those with BRAF mutations.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "(1) å°ã€‚Checkpoint inhibitors targeting CTLA-4 and PD-1 have transformed the treatment of advanced melanoma, but new combinations are needed to improve efficacy while balancing toxicity. LAG-3, a negative regulator of T-cell activity, is upregulated in melanoma and other tumor types, making it a promising therapeutic target.\nThe RELATIVITY-047 study, a phase 2/3 randomized, double-blind trial, evaluated a novel immune checkpoint combination: relatlimab (a LAG-3â€“blocking antibody) and nivolumab. Treatment-naive patients were randomized 1:1 to receive either: fixed-dose relatlimab (160 mg) + nivolumab (480 mg) every 4 weeks, or nivolumab monotherapy (480 mg every 4 weeks). At a median follow-up of 13.2 months, the combination significantly prolonged median PFS compared to nivolumab alone (10.1 vs. 4.6 months; HR 0.75; 95% CI, 0.62-0.92; P = .006). Updated data also showed a higher overall response rate (ORR) in the combination arm (43.1% [95% CI, 37.9-48.4]) compared to nivolumab alone (32.6% [95% CI, 27.8-37.7]). This study provided the first phase 3 evidence supporting the clinical benefit of dual LAG-3 and PD-1 pathway inhibition. Based on these results, the FDA approved the fixed-dose relatlimab-nivolumab combination in March 2022 for patients with previously untreated unresectable or metastatic melanoma.\n\nReference: Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo GutiÃ©rrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970. PMID: 34986285; PMCID: PMC9844513.\n\n(2) å°ã€‚With an updated median follow-up of 33.8 months, RELATIVITY-047 showed:\n* Median PFS: 10.2 months (nivolumab + relatlimab) vs. 4.6 months (nivolumab alone) (HR: 0.79 [95% CI, 0.66 to 0.95]).\n* Median OS: 51.0 months vs. 34.1 months (HR: 0.80 [95% CI, 0.66 to 0.99]).\n* Objective Response Rate (ORR): 43.7% vs. 33.7%, favoring the combination.\n\nMost subgroups showed a consistent benefit with the combination, and no new or unexpected safety concerns were reported. At 3 years of follow-up, the survival benefit remained sustained, with the upper bound of the OS hazard ratio now < 1, reinforcing the long-term efficacy and manageable safety profile of nivolumab plus relatlimab.\nLong-term overall survival data from Relativity-047 are still awaited.\n\nReference: Tawbi HA, Hodi FS, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Castillo GutiÃ©rrez E, Rutkowski P, Gogas H, Lao CD, Janoski De Menezes J, Dalle S, Arance AM, Grob JJ, Ratto B, Rodriguez S, Mazzei A, Dolfi S, Long GV. Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047. J Clin Oncol. 2024 Dec 13:JCO2401124. doi: 10.1200/JCO.24.01124. Epub ahead of print. PMID: 39671533.\n\n(3) å°ã€‚Grade 3 or 4 treatment-related adverse events occurred in 18.9% of the patients in the relatlimabâ€“nivolumab group and in 9.7% in the nivolumab group. The most common grade 3 or 4 treatment-related adverse events in the relatlimabâ€“nivolumab group included increased levels of lipase (in 1.7% of the patients), alanine aminotransferase (in 1.4%), and aspartate aminotransferase (in 1.4%), as well as fatigue (in 1.1%).\n\n(4) å°ã€‚In prespecified exploratory analyses, progression-free survival also favored relatlimab-nivolumab over nivolumab across key subgroups. The benefit of treatment with relatlimab-nivolumab was observed regardless of patientsâ€™ BRAF mutation status. In the subgroup of patients with BRAF mutations, the median PFS was 10.1 months (95% CI, 4.6 to 23.1) in the relatlimabâ€“nivolumab group and 4.6 months (95% CI, 3.0 to 6.5) in the nivolumab group (hazard ratio for progression or death, 0.74 [95% CI, 0.54 to 1.03]); in the subgroup of patients with wild-type BRAF, the median PFS was 10.1 months (95% CI, 5.9 to 17.0) with relatlimab-nivolumab and 4.6 months (95% CI, 2.9 to 6.6) with nivolumab (hazard ratio, 0.76 [95% CI, 0.59 to 0.98]).",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 77,
    "question": "ä»¥ä¸‹å“ªäº›æ˜¯å±¬æ–¼é å¾Œè¼ƒå·®çš„åŸç™¼éƒ¨ä½ä¸æ˜è½‰ç§»ç™Œæ¬¡æ—ç¾¤?\r\n(1) é ¸éƒ¨æ·‹å·´çµåˆ‡ç‰‡è¨ºæ–·ç‚º p16+ squamous cell carcinoma\r\n(2) åˆ†åŒ–ä¸å¥½çš„ small neuroendocrine carcinoma\r\n(3) å¥³æ€§è…‹ä¸‹æ·‹å·´çµè¨ºæ–·ç‚º ER+ adenocarcinoma\r\n(4) ç”·æ€§è…¹è†œè…«ç˜¤åˆ‡ç‰‡è¨ºæ–·ç‚º nonpapillary adenocarcinoma",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 2,
    "explanation": "æ ¹æ“š ESMO 2022 åˆ†é¡å‡º favorable CUP\r\n\r\nè©³è¦‹ Figure åœ–ç‰‡\r\n\r\n(1) é ¸éƒ¨æ·‹å·´çµåˆ‡ç‰‡è¨ºæ–·ç‚º p16+ squamous cell carcinoma â‡” ESMO: Squamous cell carcinoma involving non-supraclavicular cervical lymph nodes \r\n(2) åˆ†åŒ–ä¸å¥½çš„ small neuroendocrine carcinoma â‡” éESMOæ‰€åˆ—èˆ‰çš„favorable CUP  \r\n(3) å¥³æ€§è…‹ä¸‹æ·‹å·´çµè¨ºæ–·ç‚º ER+ adenocarcinoma â‡” ESMO: Women with isolated axillary lymph node metastases (breast-like CUP)\r\n(4) ç”·æ€§è…¹è†œè…«ç˜¤åˆ‡ç‰‡è¨ºæ–·ç‚º nonpapillary adenocarcinoma â‡” éESMOæ‰€åˆ—èˆ‰çš„favorable CUP  \r\n\r\næ‰€ä»¥ç­”æ¡ˆæ‡‰ç‚º (2) (4) é å¾Œè¼ƒå·®, éfavorable CUP",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/077/explain_figures/77-Figure 1.jpg"
    ]
  },
  {
    "id": 78,
    "question": "Which of the following statements regarding the differential diagnosis of â€œround cell tumorâ€\r\nare (is) correct?\r\n(1) Immunohistochemistry (IHC) staining of CD45 could help to diagnose hematological\r\nmalignancy, such as lymphoma or extramedullary myeloid leukemia.\r\n(2) If melanoma is suspected, one should order IHC staining of S100.\r\n(3) If a tumor shows positive staining of synaptophysin, chromogranin and CD56, one should\r\nconsider neuroendocrine carcinoma or small cell carcinoma.\r\n(4) For a round cell tumor positively stained with NKX3.1, one should consider Ewing sarcoma.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "Figure 1, 2å¯ä»¥å¤§ç•¥çŸ¥é“å¦‚ä½•é‹ç”¨IHC stain åš å°è—åœ“tumorçš„é‘‘åˆ¥è¨ºæ–·\r\n\r\n(1)CD45 æ˜¯ç™½è¡€çƒå…±åŒçš„marker, å› æ­¤åœ¨lymphoma å’Œ leukemia ä¸Šéƒ½æœƒè¡¨ç¾, å…¶ä»–éè¡€çƒç³»åˆ—çš„ tumor ä¸æœƒè¡¨ç¾ CD45, æ‰€ä»¥å¯ä»¥ç”¨ä¾†å¹«åŠ©è¡€æ¶²ç™Œç—‡çš„è¨ºæ–·\r\n\r\n(2)æ ¹æ“šä¸Šåœ–å¯ä»¥çŸ¥é“ Melanoma æœƒè¡¨ç¾ S-100 protein, å…¶é¤˜sarcomaçš„è¡¨ç¾å‰‡æ˜¯variable, å› æ­¤è‹¥æ‡·ç–‘Melanomaå‰‡å¯ä»¥æŸ“S-100\r\n\r\n(3)synaptophysin, chromograninéƒ½æ˜¯ç¥ç¶“å…§åˆ†æ³Œç´°èƒæœƒç”¢ç”Ÿçš„protein, å› æ­¤ small cell carcinoma å’Œ neuroendocrine carcinomaéƒ½æœƒè¡¨ç¾ (é™¤æ­¤ä¹‹å¤–é‚„æœ‰neuroblastoma, pheochromocytoma), è€ŒCD 56 æœƒè¡¨ç¾åœ¨ NK/T cell å’Œ ç¥ç¶“å…§åˆ†æ³Œç´°èƒ, æ‰€ä»¥small cell carcinoma å’Œ neuroendocrine carcinomaä¹Ÿæœƒè¡¨ç¾, æ‰€ä»¥è‹¥æ˜¯IHC è‹¥synaptophysin, chromogranin, CD 56 çš† positiveå‰‡éœ€é«˜åº¦è€ƒæ…®small cell carcinoma å’Œ neuroendocrine carcinoma\r\n\r\n(4)NKX3.1 is a 234 amino acid transcription factor protein that is expressed in the prostate, æ‰€ä»¥ä¸¦éEwing sarcoma IHC çš„è¡¨ç¾è€Œæ˜¯prostate cancer \r\n            \r\n[Ewing sarcoma IHC]\r\nCD99 (strong, diffuse membranous expression in ~90 - 95%) (Am J Surg Pathol 2005;29:1025)\r\nNKX2.2 (high specificity) (Am J Surg Pathol 2012;36:993)\r\nVimentin (80 - 90%)\r\n\r\næ‰€ä»¥ç­”æ¡ˆæ‡‰ç‚º A (1),(2),(3)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/078/explain_figures/78-Figure 1.jpg",
      "/qabank/078/explain_figures/78-Figure 2.jpg"
    ]
  },
  {
    "id": 79,
    "question": "é—œæ–¼ anaplastic thyroid cancer (ATC)çš„æè¿°ä¸­,æ­£ç¢ºçš„æœ‰?\r\n(1) é å¾Œæœ€å·®çš„ç”²ç‹€è…ºç™Œ,ç´„<1%,ç™¼ç”Ÿç‡ä½,å°æ–¼ç¢˜-131 æ²»ç™‚é€šå¸¸æœ‰åæ‡‰ã€‚\r\n(2) è½‰ç§»æ€§ ATC çš„ç—…äººå¯æª¢æ¸¬æ˜¯å¦å¸¶æœ‰ BRAF-V600E åŸºå› å‹çªè®Š, å¦‚å¸¶æœ‰æ­¤åŸºå› çªè®Š,\r\nå¯ä½¿ç”¨ BRAF æŠ‘åˆ¶åŠ‘ dabrafenib åˆä½µ MEK æŠ‘åˆ¶åŠ‘ tremetinib æ²»ç™‚ã€‚\r\n(3) ç”±æ–¼ Thyroid stimulating hormone (TSH)æœƒåˆºæ¿€ç”²ç‹€è…ºæ¿¾æ³¡ä¸Šçš®ç´°èƒçš„ç”Ÿé•·,å› æ­¤ä½¿ç”¨\r\nå·¦æ—‹ç”²ç‹€è…ºç´ (levothyroxine)å£“åˆ¶ TSH,æ˜¯ ATC æ‚£è€…çš„é©åˆæ²»ç™‚æ–¹æ³•ã€‚ç„¶è€Œç›®å‰å°æ–¼\r\nTSH è©²å£“åˆ°å¤šå°‘(å¤šä½)æ²’æœ‰å…±è­˜ã€‚\r\n(4) æ¥µå°‘çš„æ©Ÿæœƒå¯èƒ½æœƒæ¸¬åˆ° NTRK gene fusion, å¦‚æœé™½æ€§å¯ä½¿ç”¨ NTRK æŠ‘åˆ¶åŠ‘æ²»ç™‚ã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 2,
    "explanation": "(1): æ ¹æ“š DeVita, anaplastic thyroid cancer rare ç™¼ç”Ÿç‡ (1% to 2% of all thyroid cancers) è€Œä¸”é å¾Œå¾ˆå·®, median OS < 6 months, ATC æ˜¯æ²’æœ‰åˆ†åŒ–çš„ç´°èƒæ‰€ä»¥ä¸æœƒåƒæ¿¾æ³¡ç´°èƒæœƒæœ‰Thyroglobulinå¢åŠ ä»¥åŠç¢˜çš„å¸æ”¶, æ‰€ä»¥ç¢˜-131 ä¸¦éæ˜¯ATCåˆé©çš„æ²»ç™‚æ–¹å¼ (2021 ATA guideline å·²ç¶“æåˆ°ç¢˜-131ä¸è¦ç”¨åœ¨ATC)\r\n\r\n(2): Harrison æåˆ° ATC ç´„ 20-40% æœ‰ BRAF-V600E mutation, æ ¹æ“š ESMO 2019 guideline æåˆ°çš„ trial (DOI: 10.1200/JCO.2017.73.6785), ä½¿ç”¨ BRAF inhibitor dabrafenib (150 mg twice daily) åŠ ä¸Š MEK inhibitor trametinib (2 mg once daily) çš„16ä½ç—…äººæœ‰å¾ˆé«˜çš„ORR (69%), æ‰€ä»¥åœ¨ May 2018, FDA approval for the treatment of locally advanced or metastatic ATC with the BRAF V600E mutation\r\n\r\n(3): ATC æ˜¯æ²’æœ‰åˆ†åŒ–çš„ç´°èƒæ‰€ä»¥ä¸æœƒæœ‰æ¿¾æ³¡ç´°èƒçš„è¡¨ç¾(ä¾‹å¦‚:Thyroglobulinè¡¨ç¾ä»¥åŠç¢˜çš„å¸æ”¶), å› æ­¤TSHç„¡æ³•å½±éŸ¿ATC, æ‰€ä»¥ä½¿ç”¨levothyroxineä¸¦éæ˜¯ATCåˆé©çš„æ²»ç™‚æ–¹å¼, DeVita å’Œå…¶ä»–æ²»ç™‚æŒ‡å¼•å®Œå…¨æ²’æåˆ°ä½¿ç”¨ thyroxine\r\n\r\n(4): ESMO, ATA éƒ½æåˆ° NTRK fusion å³ä½¿æ˜¯åœ¨ATCä¹Ÿæ˜¯éå¸¸å°‘, ä½†æ˜¯éƒ½å»ºè­°ATCè‹¥æœ‰target drugå‰‡å»ºè­°ä½¿ç”¨,å› ç‚ºåŒ–ç™‚responseå¤ªå·®\r\n\r\nATA 2019, RECOMMENDATION 23 \r\nIn NTRK or RET fusion ATC patients with stage IVC disease, we suggest initiation of a TRK inhibitor (either larotrectinib or entrectinib) or RET inhibitor (either selpercatinib or pralsetinib), preferably in a clinical trial, if available. \r\n\r\nESMO 2019\r\nExtended molecular profiling of ATCs should be strongly encouraged as it may reveal promising possibilities for targeted therapies.\r\n\r\næ‰€ä»¥ç­”æ¡ˆæ‡‰ç‚º(C) (2),(4)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 80,
    "question": "Regarding drug treatment for metastatic renal cell carcinoma patients who previously received\r\nimmune checkpoint and antiangiogenic therapies (LITESPARK-005), which of the following\r\nstatements are (is) correct?\r\n(1) Belzutifan provides better progression-free survival\r\n(2) Belzutifan provides better overall survival\r\n(3) Belzutifan provides better objective responses\r\n(4) No active targeted therapy in the control arm in this study",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "æ­¤é¡Œè€ƒçš„æ˜¯ LITESPARK-005 é€™ä¸€trial \r\n\r\nä»¥ä¸‹ç‚ºè·Ÿç­”æ¡ˆæœ‰é—œçš„result\r\n\r\nDual Primary endpoint: PFS and OS \r\nmPFS: HR:0.75, P value < 0.00001\r\nmOS: HR: 0.87, P value: 0.099 (æ²’æœ‰é”åˆ°çµ±è¨ˆå­¸ä¸Šå·®ç•°)\r\nORR: 21.9% vs 3.5%,  P value < 0.00001\r\n\r\nå…¶é¤˜trial è©³ç´°è³‡æ–™å¯çœ‹ Figure \r\n\r\næ‰€ä»¥ç­”æ¡ˆæ‡‰ç‚º (B) (1),(3)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/080/explain_figures/80-Figure 1 trial design.jpg",
      "/qabank/080/explain_figures/80-Figure 2 characteristics and mPFS.jpg",
      "/qabank/080/explain_figures/80-Figure 3 mPFS and mOS.jpg",
      "/qabank/080/explain_figures/80-Figure 4 ORR and DOR.jpg",
      "/qabank/080/explain_figures/80-Figure 5 safety.jpg"
    ]
  },
  {
    "id": 81,
    "question": "Regarding to the adjuvant treatment for locally advanced renal cell carcinoma after operation,\r\nwhich trials show positive results to improve overall survival, which of the following are (is)\r\ncorrect?\r\n(1) CheckMate 914 (Ipilimumab+Nivolumab)\r\n(2) S-TRAC (Sunitinib)\r\n(3) IMmotion010 (Atezolizumab)\r\n(4) KEYNOTE 564 (Pembrolizumab)",
    "options": [
      "(1),(2),(3)",
      "(1)(3)",
      "(2)(4)",
      "(4)",
      "(1)(2)(3)(4)"
    ],
    "correctAnswer": 3,
    "explanation": "(1)éŒ¯èª¤\r\nCheckMate 914 (Part-A), phase 3, n=816, 1:1, 2017/8-2021/3\r\nCheckMate 914 (Part-B), phase 3, n=825, 2:1:1, 2020/3-2022/3\r\n\r\n<Inclusion criteria>\r\nLocalized RCC (clear-cell or sarcomatoid component), high risk (pT2a Fuhrman Gr 3or4, pT2b-T4 Gr any, pTany Gr any N1) of relapse after OP (radical or partial nephrectomy)\r\nNo clinical/radiologic evidence of residual disease or distant metastases \r\n\r\n<Study design>\r\n[Part A] Nivolumab (240 mg) iv. q2w * 12 +  Ipilimumab (1mg/kg) iv. q6w* 4  \r\n              placebo + placebo\r\nPri. end point : Disease free survival (DFS)\r\nSec end point: OS, safety \r\n\r\n[Part B] Nivolumab (240 mg) iv. q2w * 12 + placebo\r\n              placebo + placebo\r\n              Nivolumab (240 mg) iv. q2w * 12 +  Ipilimumab (1mg/kg) iv. q6w* 4 \r\nPri end point : DFS of Nivo vs. placebo\r\nSec end points: OS of Nivo vs. placebo\r\n                       DFS & OS of Nivo + Ipi and Nivo\r\n\r\n<Results>\r\n[Part A] Nivo + Ipi vs. placebo (Median 37 mo. follow up) \r\n              mDFS: NR vs. 50.7 mo (HR: 0Â·92, 95% CI 0Â·71â€“1Â·19; p=0Â·53)\r\n              OS: **NR (The number of events required for OS interim analysis was not reached at the time of the data cutoff, only 61 events occured ) \r\n\r\n[Part B] OS was note tested (The sec end point of OS was to be tested hierarchically, i.e., only if the pri end point of DFS was significant)     \r\n              Pri end point DFS of Nivo vs. placebo was not met (HR=0.87, p = 0.4)              \r\n\r\n[Conclusion] \r\nPart A: OS was not reached (No DFS benefit for adjuvant Nivo + Ipi vs. placebo)\r\nPart B: OS was not tested (DFS of Nivo vs. placebo was not met)\r\n\r\n<Ref>\r\nPart A: Motzer J et al. (2023) The Lancet, Vol 401(10379), 821 - 832\r\nPart B: Motzer J et al. (2024) Journal of Clinical Oncology, Vol43(2), https://doi.org/10.1200/JCO.24.00773\r\n\r\n\r\n(2) éŒ¯èª¤\r\nS-TRAC, phase 3, n= 615, 1:1, 2007/9-2011/4\r\n\r\n<Inclusion criteria> \r\nNon-metastatic, High-risk (by UISS score: TNM stage III or VI) clear-cell RCC, post resection, treatment naive\r\n\r\n<Study design> \r\n - Sunitinib (50 mg/QD) vs. placebo, 4-weeks-on, 2-weeks-off schedule for 1 year or until PD/intolerance.\r\nPrimary end point: DFS(BICR) \r\nSecondary end point: investigator-assessed DFS, OS, and safety.\r\n\r\nOverall survival data were not mature at the time of data cutoff.\r\n\r\n<Results>\r\nSunitinib vs. placebo (Median 5.4 yrs follow up) \r\nmDFS: 6.8 years vs. 5.6 years (HR: 0.76;  p=0.03) (NEJM Dec.2016)\r\nmDFS benefit of adjuvant sunitinib over placebo was observed across certain high risk subgroups  (Eu Urology Jan 2018)\r\n-T3, no or undetermined nodal involvement, Fuhrman grade â‰¥2, ECOG PS â‰¥1, T4 and/or nodal involvement (HR 0.74, 95% CI: 0.55-0.99; p=0.04), \r\n-NLR(neutrophil-to-lymphocyte ratio) â‰¤3 (HR 0.72, 95% CI 0.54-0.95; p=0.02), \r\n-Fuhrman grade 3/4 (HR 0.73, 95% CI 0.55-0.98; p=0.04). \r\n\r\nOS was not reached in either arm. (HR 0.92, p=0.6) (updated cut off date: 2017/1/31) (Eu Urology Jan 2018)\r\n\r\n[Conclusion] OS was not reached \r\n\r\n<Ref>\r\nMotzer et. al.(2018) European Urology, Vol 73(1),62-68\r\nRavaud et. al.(2016) N Engl J Med, Vol 375(23),2246-2254\r\n\r\n\r\n(3)éŒ¯èª¤\r\nIMmotion010 , phase 3, n=778, 1:1, 2017/1-2019/2\r\n\r\n<Inclusion criteria>\r\nRCC (clear-cell or sarcomatoid component) ,increased risk of recurrence (T2 Gr 4, T3a Gr3/4, T3b-T4 Gr any, TxN+ Gr any or M1rendered free of disease after resection(NED)), after nephrectomy +/- metastasectomy\r\n\r\n<Study design>\r\nAtezolizumab (1200 mg Q3W, IV) vs. placebo (Q3W, IV) for 16 cycles or 1 year.\r\nPri end point: investigator-assessed DFS\r\nSec end point: OS, investigator-assessed DFS by PD-L1 score(IC)\r\n\r\n<Results>\r\nAtezolizumab vs. placebo (Median 44.7 months follow up) \r\nmDFS:  57.2 mo. vs. 49Â·5 months (HR: 0.93, p=0Â·50). \r\nmOS: immature at data cutoff\r\n\r\n[Conclusion] OS data was immature\r\n\r\n<Ref>\r\nPal, S. K et. al. Lancet (London, England)(2022), 400(10358), 1103â€“1116. \r\nhttps://clinicaltrials.gov/study/NCT03024996\r\n\r\n(4)æ­£ç¢º\r\nKEYNOTE 564, phase 3, n=994. 1:1, 2017/6-2023/9\r\n\r\n<Inclusion criteria>\r\nLocoregional RCC with clear-cell component, high risk of recurrence (pT2 Gr4 or sarcomatoid differentiationN0, pT3-T4 Gr any N0, pTany Gr any N+ or M1 NED), post partial or radical nephrectomy +/- metastasectomy\r\n\r\n<Study design>\r\npembrolizumab (200 mg Q3W, IV) vs. placebo (Q3W) for up to 17 cycles (approximately 1 year) or until recurrence/intolerance\r\nPri endpoint: investigator-assessed DFS\r\nSec endpoint: OS, safety\r\n\r\n<Results>  \r\npembrolizumab vs. placebo (Median 24.1 months follow-up) \r\n24-month DFS: 77.3% vs. 68.1% (HR: 0.68; P=0.002)\r\n\r\n(Median 57.2 months follow-up) \r\nOS: (HR: 0.62; P=0.005)\r\n(percentage of alive participants) \r\n24 mo: 96.3% vs. 93.9% \r\n36 mo: 93.9% vs. 89.5%\r\n48 mo: 91.2% vs. 86.0% \r\n(See Figure 1)\r\n\r\n[Conclusion] Adjuvant Pembrolizumab after Nephrectomy led to significant improvement in both DFS and OS for high-risk RCC.(NEJM Feb 2024)\r\n\r\n<Ref>\r\nChoueiri, T. K et.al.(2021)  NEJM 385(8), 683â€“694. https://doi.org/10.1056/NEJMoa2106391\r\nChoueiri, T. K et. al.(2024) NEJM390(15), 1359â€“1371. https://doi.org/10.1056/NEJMoa2312695",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/081/explain_figures/081 Figure 1.jpg"
    ]
  },
  {
    "id": 82,
    "question": "Which of the following statements about clinical trials in urothelial carcinoma(UC) are (is) correct:\r\n(1) Nivolumab for high-risk recurrence after surgical treatment for UC in patients with tumors expressing PD-L1 â‰¥1% (CheckMate 274)\r\n(2) Avelumab maintenance after gemcitabine-platinum treatment (JAVELIN Bladder 100, metastatic UC)\r\n(3) Pembrolizumab+ enfortumab vedotin (EV-302/KEYNOTE-A39) for first-line treatment\r\n(4) Nivolumab +gemcitabine-platinum for first-line treatment (CheckMate-901, metastatic UC)",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "æ­¤é¡Œè€ƒè‡¨åºŠè©¦é©—æ”¶æ¡ˆæ¢ä»¶\r\n\r\n(1)æ­£ç¢º\r\nCheckMate 274, phase 3, n=790, 1:1, 2016/4-2020/1\r\n\r\n<Inclusion criteria>\r\n-muscle-invasive urothelial carcinoma(MIUC), received radical surgery\r\n-high risk of recurrence (pT3/pT4a, or pN+ ; patients not eligible for/declined adjuvant cisplatin-based chemotherapy who had not received neoadjuvant cisplatin-based chemotherapy; ypT2-ypT4a or ypN+ for patients who received neoadjuvant cisplatin).\r\n\r\n\r\n<Study design>\r\nNivolumab (240mg Q2W, IV) or placebo (Q2W) for up to 1 year\r\nPrimary endpoint : DFS among all patients, DFS among patients with PDL-1â‰¥1%\r\n\r\n<Ref>\r\nBajorin et. al. NEJM 2021;384:2102-2114 \r\n\r\n\r\n(2) æ­£ç¢º\r\nJAVELIN Bladder 100, phase 3, n=700, 1:1, 2016/5-2019/6 \r\n\r\n<Inclusion criteria>\r\nunresectable locally advanced or metastatic urothelial cancer who did not have disease progression with first-line chemotherapy (4-6 cycles of gemcitabine + cisplatin/carboplatin)\r\n\r\n<Study design>\r\nMaintenance avelumab (10 mg/kg, Q2W, IV) vs. Best supportive care\r\nPrimary end points: OS\r\nSecondary end points: PFS, safety\r\n\r\n<Ref>\r\nPowles, T et. al. NEJM, 383(13), 1218â€“1230. \r\n\r\n\r\n(3) æ­£ç¢º\r\nEV-302, phase 3, n=886, 1:1, 2020/3-2023/8 \r\n\r\n<Inclusion criteria>\r\n-Previously untreated , unresectable locally advanced or metastatic urothelial carcinoma \r\n-Key exclusion : Previous PD-1 or PD-L1 inhibitor therapy or other systemic therapy (except for neoadjuvant or adjuvant chemotherapy after surgery with recurrence >12 months after the completion of therapy)\r\n\r\n<Study design>\r\n-Enfortumab vedotin (1.25 mg/kg IV, days1 & 8, 3-week cycle) + pembrolizumab (200 mg IV, day 1, 3-week cycle) (enfortumab vedotinâ€“pembrolizumab group)\r\n-Gemcitabine + cisplatin/\tcarboplatin  (chemotherapy group). \r\n\r\n<Ref> Powles T, et al. N Engl J Med 2024;390:875-888\r\n\r\n(4)æ­£ç¢º\r\nCheckMate-901, phase 3, n=608, 1:1, 2018/1-2022/9\r\n\r\n<Inclusion criteria>\r\n-Previously untreated, unresectable or metastatic urothelial carcinoma \r\n-Eligible to receive cisplatin therapy\r\n-Previous intravesical therapy was permitted if the treatment had been completed at least 4 weeks before the initiation of the trial treatment. \r\n Previous neoadjuvant therapy, RT, or adjuvant platinum-based chemotherapy was permitted with recurrence 12 months or more after the completion of therapy.\r\n\r\n<Study design>\r\n[nivolumab (360 mg) + gemcitabineâ€“cisplatin] Q3W *6 => [nivolumab (480 mg)] Q4W for a maximum of 2 years\r\n[nivolumab (360 mg) + gemcitabineâ€“cisplatin] Q3W *6 => [gemcitabineâ€“cisplatin alone] Q3W *6 cycles \r\nPrimary endpoint: PFS & OS\r\nExploratory endpoint: oRR & safety \r\n\r\n<Ref> van der Heijden MS, et al. N Engl J Med 2023;389:1778-1789",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 83,
    "question": "Nectin 4 is an important target for drug design for urothelial carcinoma. Which of the following statements are (is) correct ?\r\n(1) Nectin 4 is expressed in many cancer cells, such as urothelial carcinoma cells.\r\n(2) Nectin 4 is a membranous protein\r\n(3) Membranous Nectin-4 expression frequently decreases during metastatic spread of urothelial carcinoma\r\n(4) Cancer cells with small cell carcinoma differentiation express less.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "(1) æ­£ç¢º\r\nNectin-4ï¼ˆNectin Cell Adhesion Molecule 4ï¼‰is a cell adhesion molecule of the Nectin and Nectin-like families that is highly abundant in normal embryonic and fetal tissues and poorly expressed in healthy adult tissues. (Normal tissues including skin, salivary glands, bladder and esophagus express only low to medium levels of Nectin-4)\r\nSolid tumors that highly express Nectin-4 include bladder cancer, pancreatic cancer, triple-negative breast cancer, non-small cell lung cancer, gastric cancer, esophageal cancer, ovarian cancer, and many other cancers. (https://www.biochempeg.com/article/288.html)\r\n\r\nNectin-4 is a transmembrane protein involved in making and maintaining adherens junctions. Although it is not expressed in high levels in adult somatic cells, it is upregulated in bladder cancer \r\n(UpToDate: Molecular biology of bladder cancer)\r\n\r\n\r\n\r\n(2) æ­£ç¢º\r\nNectin-4 is a type I membrane glycoprotein that consists of an extracellular region with three Ig domains of Ig V and IgC types. (https://www.biochempeg.com/article/288.html)\r\n(See Figure.1)\r\n\r\nNectin-4 is a transmembrane protein involved in making and maintaining adherens junctions (UpToDate: Molecular biology of bladder cancer)\r\n\r\n\r\n\r\n(3) æ­£ç¢º\r\nKlÃ¼mper, N. et. al. assessed Membranous NECTIN-4 protein expression (H-score by Immunohistochemistry (IHC)) between primary tumors (PRIM) and patient-matched distant metastases (MET), they noted that membranous Nectin-4 expression significantly decreased during metastatic spread, with 39.4% of MET lacking membranous Nectin-4 expression. (Wilcoxon matched pairs P < 0.001)\r\nThe other multicenter EV-treated cohort (N=47) showed absence or weak membranous Nectin-4 expression (34.0% of the cohort) was associated with a significantly shortened PFS on EV (log-rank P < 0.001).\r\n(Clin Cancer Res (2023) 29 (8): 1496â€“1505.)\r\n\r\n\r\n\r\n\r\n(4) æ­£ç¢º\r\nImmunohistochemistry for nectin-4 was performed on 169 patients including 83 with non-muscle invasive bladder cancer and 86 patients with muscle invasive bladder cancer.\r\nOverall, 50/86 muscle invasive tumors were positive, including 15/22 (68.2%) urothelial carcinomas, 1/10 (10%) sarcomatoid carcinomas, and 0/15 (0%) small cell carcinomas...etc\r\n\r\nWhole transcriptome RNA sequencing revealed that compared to conventional urothelial carcinomas, most sarcomatoid carcinomas and all but two small cell carcinomas expressed very low levels of nectin-4 mRNA\r\n(Hoffman-Censits et. al.(2021) Appl Immunohistochem Mol Morphol. 1;29(8):619-625.)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/083/explain_figures/083 figure 1.jpg"
    ]
  },
  {
    "id": 84,
    "question": "åœ¨ ALK rearrangement éå°ç´°èƒè‚ºç™Œçš„æ²»ç™‚ä¸­,ä¸‹åˆ—é¸é …ä½•è€…æ­£ç¢º?\r\n(1) Alectinib, brigatinib, lorlatinib ç›¸è¼ƒæ–¼ crizotinib æ˜¯ä¸€ç·šæ²»ç™‚ ALK-rearranged NSCLC çš„preferred regimenã€‚\r\n(2) Immunohistochemistry ä½¿ç”¨ç‰¹å®š antibody å¯è©•ä¼° ALK è®Šç•°,è‹¥ immunohistochemistry ç‚ºé™½æ€§,ä¸éœ€å†é€²ä¸€æ­¥ä½¿ç”¨ FISH åšç¢ºèª,è‡¨åºŠä¸Šå¯ç›´æ¥ä½¿ç”¨ç›¸é—œæ¨™é¶è—¥ç‰©æ²»ç™‚ã€‚\r\n(3) ALKâ€“rearrangement éå°ç´°èƒè‚ºç™Œ è‹¥ç”¢ç”Ÿ central nervous system metastases,targettherapy ä¸­ alectinib, ceritinib æˆ– lorlatinib ç›¸è¼ƒæ–¼ crizotinib æ˜¯è¼ƒä½³çš„é¸æ“‡ã€‚\r\n(4) å‰¯ä½œç”¨è¡¨ç¾ä¸Š, é«˜è¡€è„‚è¼ƒå¸¸è¦‹æ–¼ crizotinib, diarrhea è¼ƒå¸¸è¦‹æ–¼ ceritinib, edema åŠç¥ç¶“èªçŸ¥åŠŸèƒ½ä¸‹é™å¸¸è¦‹æ–¼ lorlatinibã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "(1)æ­£ç¢º\r\n1st generation ALK TKI: Crizotinib \r\n2nd generation ALK TKI: Ceritinib, Alectinib, Brigatinib, Ensartinib \r\n3rd generation ALK TKI: Lorlatinib \r\n\r\n*2G & 3G ALK TKIs compared to Crizotinib: CROWN trial & ALEX trial & ALTA-1L (See Figure 1.)\r\n=> Alectinib, brigatinib, lorlatinib all showed prominent and superior risk reduction  of disease progression over crizotinib. \r\n(Cathleen Park, MD et.al. ASCO daily news. January 30, 2025)\r\n\r\n\r\n(2)æ­£ç¢º\r\nMultiple monoclonal antibodies have been developed for the IHC detection of the ALK fusion oncoprotein (Uptodate: ALK(+) advanced NSCLC)\r\nFDA-approved IHC can be utilized as a stand-alone test, not requiring confirmation by FISH (NCCN-NSCLC-v3.2025. P.97/285) \r\n\r\n\r\n(3) æ­£ç¢º  \r\nkeypoint: For asymptomatic and symptomatic patients, second- or third- generation ALK TKIs should be used, as data exist for each of these drugs regarding brain penetration and central nervous system efficacy\r\n(Uptodate: ALK-positive advanced NSCLC - special considerations regarding treatment - brain metastasis)\r\n\r\nAlthough ceritinib has demonstrated CNS activity, it is less CNS penetrant than alectinib, brigatinib, and lorlatinib, and cross-trial comparisons suggest a lower durability of CNS response with ceritinib\r\n(Uptodate: brain mets in NSCLC - patients with oncogenic drivers - ALK translocation - brain mets at presentation)\r\n\r\nCeritinib has been compared with platinum/pemetrexed chemotherapy in the front-line setting(Phase 3 ASCEND-4 trial) but not with crizotinib.\r\n\r\n==============ä»¥ä¸‹è£œå……=================\r\nThere was one adjusted comparison of studies : ASCEND-1 & 3 vs. PROFILE 1001, 1005, and 1007 had mentioned the better CNS efficacy of ceritinib over crizotinib in \"previosuly treated\" locally advanced or metastatic ALK+  NSCLC : ((2016) J Thorac Oncol, 11(9), 1550â€“1557.)\r\n\r\n[Total population] \r\nceritinib vs. crizotinib (n = 189 vs. n = 557)\r\n1-year OS rate: 82.6 % vs. 66.0 % ; HR: 0.59 (95% CI: 0.46â€“0.75) \r\nmPFS : 13.8 mo. vs. 8.3 mo. ; HR=0.56 (95% CI: 0.43â€“0.73)\r\n\r\n[For baseline brain metastases (excluding PROFILE 1001)] \t\r\nceritinib vs. crizotinib   (n = 189 vs. n = 432)\r\nOS  HR: 0.47 (95% CI: 0.32â€“0.71), p<0.001\t\r\nPFS HR: 0.53 (0.40â€“0.69), p<0.001\r\n==============ä»¥ä¸Šè£œå……=================\r\n\r\n(4) éŒ¯èª¤\r\n=> é«˜è¡€è„‚è¼ƒå¸¸è¦‹æ–¼ lorlatinib, å…¶ä»–æ•˜è¿°æ­£ç¢º\r\n(see figure. 2)\r\n\r\n=> Lorlatinib was designed to accumulate in the CNS, resulting in profound efficacy in the CNS and thus higher CNS toxicities, such as mood disturbances, cognitive impairment, and personality change\r\n\r\n==============ä»¥ä¸‹è£œå……=================\r\n[è£œå……-1] Crizotinib\r\nPROFILE 1014 Clinical trial, Ph 3, n=343, 2011/1-2013/7\r\n<Inclusion criteria>\r\nPreviously untreated advanced ALK-positive nonsquamous NSCLC \r\n\r\n<Study design>\r\n-oral crizotinib 250 mg twice daily \r\n-iv. chemotherapy (Pemetrexed, 500 mg / m2 plus either cisplatin (75mg/m2) or carboplatin AUC 5-6) every 3 weeks for up to six cycles. \r\n\r\n<Results>\r\nCrizotinib vs. chemo\r\n(46 months median follow up)\r\nOS: NR vs. 47.5 mo \r\n(HR: 0.76 , 95% CI: 0.548 to 1.053; two-sided P = .0978)\r\nPFS: 10.9 mo vs. 7.0 mo (HR= 0.45; 95% CI: 0.35 to 0.60; P<0.001). )\r\n=> Crizotinib was superior to standard first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive NSCLC.\r\n\r\n[è£œå……-2] Ceritinib\r\nASCEND-4 study, phase 3, n=376 (158 (42.0%)Asian), 1:1, 2013/8-2015/5\r\n<Inclusion criteria>\r\nPreviously untreated, stage IIIB or IV ALK+ non-squamous NSCLC, include brain mets. (symptematic or not)\r\n\r\n<Study design>\r\nceritinib 750 mg/day (fasted) QD PO or chemotherapy ([cisplatin 75 mg/m2 or carboplatin AUC 5â€“6 + pemetrexed 500 mg/m2] q3w => pemetrexed maintenance.\r\nPrimary end point: PFS\r\n\r\n<Results> Mar 2017. Lancet\r\nmedian duration of treatment exposure was 66Â·4 weeks\r\nmPFS: 16.6 mo vs. 8.1 mo (HR= 0.55 , 95% CI : 0.42â€“0.73]; p<0.00001). \r\nmPFS (baseline BM+): 10.7 mo.vs. 6.7 mo. (HR= 0.75 , 95% CI : 0.44â€“1.12)\r\nmPFS (baseline BM-): 26.3 mo.vs. 8.3 mo. (HR= 0.48 , 95% CI : 0.33â€“0.69)\r\n\r\n*C/T: cisplatin 75 mg/m2 or carboplatin AUC 5â€“6 + pemetrexed 500 mg/m2, q3w\r\n==============ä»¥ä¸Šè£œå……=================\r\n\r\n<Ref>\r\nShaw AT, et al. N Engl J Med. 2020.\r\nPeters S, et al. N Engl J Med. 2017. \r\nCamidge DR, et al. N Engl J Med. 2018. \r\nSolomon BJ, et al. N Engl J Med. 2014\r\nSolomon BJ, et al. (2018) J. Clin. Oncol. 36(22), 2251â€“2258. \r\nTan, D. S. et. al. (2016) J Thorac Oncol, 11(9), 1550â€“1557. \r\nRybarczyk-Kasiuchnicz A, et al. Int J Mol Sci. 2021\r\nCathleen Park, MD et. al. ASCO daily news, January 30, 2025\r\nE Thunnissen et. al. Lung Cancer. 2019 Dec:138:13-18.\r\nNCCN guideline Ver.3 2025 \r\nShaverdashvili et. al. (2022) Default Digital Object Group. \r\nSoria JC et. al. Lancet.2017 Mar 4;389(10072):917-929.",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/084/explain_figures/084 Figure 1.jpg",
      "/qabank/084/explain_figures/084 Figure 2.jpg"
    ]
  },
  {
    "id": 85,
    "question": "ä¸‹åˆ—é—œæ–¼ Malignant pleural mesothelioma çš„æ•˜è¿°ä¸­,æ­£ç¢ºçš„æœ‰?\r\n(1) æ ¹æ“š phase 3 randomized trial (MAPS),åœ¨ unresectable malignant pleural mesotheliomç—…äºº,bevacizumab åŠ ä¸Š chemotherapy ç›¸è¼ƒæ–¼ chemotherapy alone å¯é¡¯è‘—å»¶é•· overall survivalã€‚\r\n(2) ç—…ç†ä¸Š,malignant pleural mesothelioma å¸¸å‘ˆç¾ positive çš„ immunohistochemical marker ç‚º WT1, calretinin, and D2-40; thyroid transcription factor-1 (TTF-1)å¸¸ç‚º negative\r\n(3) æ ¹æ“š CheckMate 743 trial,immune checkpoint inhibitors çš„ overall survival benefit ä¸»è¦ç™¼ç”Ÿåœ¨éä¸Šçš®å‹(Non-epithelioid)çš„ç—…äººæ—ç¾¤ã€‚\r\n(4) CheckMate 743 trial é¡¯ç¤º,åœ¨ unresectable malignant pleural mesothelioma ç—…äºº,nivolumab + chemotherapy ç›¸è¼ƒæ–¼ chemotherapy å¯é¡¯è‘—å»¶é•· overall survival (OS)",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "(1)æ­£ç¢º\r\nMAPS trial: randomized, controlled, open-label, Phase 3 trial. (Lancet 2016;387:1405-1414)\r\n\r\nBackground: assess the effect on survival of bevacizumab when added to the present standard of care, cisplatin plus pemetrexed, as first-line treatment of advanced malignant pleural mesothelioma\r\n\r\nKey inclusion criteria: unresectable malignant pleural mesothelioma, chemotherapy naive, ECOG 0â€“2, no substantial cardiovascular comorbidity, not amenable to curative surgery\r\n\r\nRegimen:\r\nPCB Q3W (up to 6cycles): pemetrexed (500 mg/m2) + cisplatin (75 mg/m2) + bevacizumab (15mg/kg)\r\nPC Q3W (up to 6cycles): pemetrexed (500 mg/m2) + cisplatin (75 mg/m2) \r\n\r\nFindings\r\nMedian OS: PCB vs.PC\r\n           18.8 vs. 16.1 months\r\n           (HR: 0.77, p-value: 0.0167)\r\n\r\n\r\n(2)æ­£ç¢º\r\nUseful IHC markers include: \r\n# positive markers to confirm mesothelial differentiation, such as WT1, calretinin, and D2-40\r\n# negative markers to exclude mimics, such as polyclonal carcinoembryonic antigen (CEA), thyroid transcription factor-1 (TTF-1), and claudin-4.\r\n# One of the caveats is that no individual IHC marker is entirely sensitive and specific.\r\n# Therefore, it is recommended that a panel including at least two mesothelial markers (eg, calretinin, WT1, D2-40) and two carcinoma markers (eg, claudin-4, TTF-1, polyclonal CEA) should be used to establish the diagnosis.\r\n\r\nNCCN guideline v2.2025 â€“ Principles of pathologic review (Page 11/61) \r\n\r\n(3)æ­£ç¢ºã€‚ epithelioid & non-epithelioid çš†æœ‰OS benefitï¼Œä½†non-epithelioidçµ„HRè¼ƒä½ä¸”forest plotæ²’è·¨éä¸­ç·š (è¦‹explain_figure 1)\r\n(4)éŒ¯èª¤ã€‚æ­¤trial ç‚º Nivo + Ipi vs. chemo\r\n\r\nCheckmate-743 trial: a multicenter, randomized, open-label, phase 3\r\nLancet 2021;397:375-386\r\nAnnals of Oncology2022, Volume 33, Issue 5, 488 - 499\r\n\r\nBackground: \r\nâ€“ Approved systemic treatments for malignant pleural mesothelioma (MPM) have been limited to chemotherapy (moderate survival benefit with poor outcomes). \r\nâ€“ Nivolumab plus ipilimumab has shown clinical benefit in other tumour types, including 1L NSCLC \r\nâ€“ Hypothesis: Nivo + Ipi would improve overall survival in MPM.\r\n\r\nKey inclusion criteria: previously untreated, histologically confirmed, unresectable MPM and ECOG â‰¤1\r\n\r\nExperimental arm: Nivolumab (3 mg/kg)Q2W + Ipilimumab (1 mg/kg) Q6W for up to 2 years\r\nControl arm: platinum plus pemetrexed chemotherapy, 6 cycles\r\n\r\nFindings: \r\nNivolumab + ipilimumab to prolong OS versus chemotherapy across subgroups, including histology. Median OS of \r\nâ€“ All patients: 18.1 vs. 14.1 mo, HR 0.73\r\nâ€“ Epithelioid: 18.2 vs. 16.7 mo, HR 0.85\r\nâ€“ Non epithelioid: 18.1 vs. 8.8 mo, HR 0.48\n\n<è£œå……ï¼šæ¯”è¼ƒMAPSå’ŒCM-743>\nå€¼å¾—æ³¨æ„çš„æ˜¯MAPSä»¥åŠCM-743éƒ½æœ‰æ’é™¤CNS metastasis\nMAPSä¸­epithelioidä»¥åŠnon-epithelioidä¼¼ä¹éƒ½åå‘ä½¿ç”¨cis+alimta+bevaï¼Œä½†éƒ½æ²’æœ‰é”åˆ°çµ±è¨ˆä¸Šçš„é¡¯è‘—å·®ç•°(Epitheloid HR:0.82(0.64-1.06);non-epitheloid HR:0.64(0.40-1.02))\nè€Œåœ¨CM-743ä¸­çš„subgroup analysis, PD-L1>=1%ç›¸è¼ƒæ–¼<1%å°æ–¼ä½¿ç”¨nivo+ipiåœ¨median OSçš„å¥½è™•æ›´å¤§(>=1%, HR:0.69(0.55-0.87);<1%, HR:0.94(0.62-1.40))",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/085/explain_figures/explain_figure 1.jpg"
    ]
  },
  {
    "id": 86,
    "question": "ä¸€ä½ 56 æ­²å¥³æ€§,å¥åº·æª¢æŸ¥æ„å¤–ç™¼ç¾èƒ¸éƒ¨è…«å¡Š,é›»è…¦æ–·å±¤é¡¯ç¤º anterior mediastinum mass and suspicious lung and pleural metastases,ç¶“åˆ‡ç‰‡è¨ºæ–·ç‚º thymoma with lung and pleural metastases,ECOG PS ç‚º 1,èˆ‡ç—…äººè¨è«–å¾Œæ±ºå®šå…ˆè®“ç—…äººæ¥å—ç¬¬ä¸€ç·š systemic therapy,ä¸‹åˆ—é‚£äº›(ä½•è€…)æ˜¯æ‚¨æœƒè€ƒæ…®å¹«ç—…äººä½¿ç”¨çš„è™•æ–¹?\r\n(1) Pembrolizumab plus CAP (cisplatin + doxorubicin + cyclophosphamide IV) day 1 every 3 weeks\r\n(2) Pembrolizumab plus cisplatin + etoposide day 1 every 3 weeks\r\n(3) Pembrolizumab plus paclitaxel + carboplatin day 1 every 3 weeks\r\n(4) ADOC (doxorubicin IV day 1 + cisplatin 50 mg/m2 IV day 1 + vincristine IV day3 + cyclophosphamide IV day 4) every 3 weeks",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 3,
    "explanation": "æ ¹æ“šNCCN guideline-thymoma&thymic carcinoma v1.2025 (P.13 & 14/46), 1st line chemotherapy for thymoma å»ºè­°CAP, CAP+prednisolone, ADOC; pembrolizumab monotherapy å»ºè­°åœ¨ thymic carcinoma 2nd line ä½¿ç”¨ã€‚",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 87,
    "question": "é—œæ–¼å°ç´°èƒè‚ºç™Œçš„æ•˜è¿°ä¸­,æ­£ç¢ºçš„æœ‰?\r\n(1) åœ¨ limited-stage small cell lung cancer ç—…æ‚£æ¥å—é definitive concurrent chemoradiation å¾Œ,è‹¥ç–¾ç—…é”åˆ°ç·©è§£,å¯è€ƒæ…®åŸ·è¡Œ prophylactic cranial irradiation\r\n(2) æ ¹æ“š IMpower133 trial & CASPIAN trial,ç›®å‰ carboplatin + etoposide + atezolizumab æˆ–carboplatin/cisplatin + etoposide + durvalumab å‡è¢« NCCN guideline åˆ—ç‚º extensive-stage small cell lung cancer PD-L1â‰§1%ç—…æ‚£çš„ç¬¬ä¸€ç·šè—¥ç‰©,PD-L1<1%ç—…æ‚£å‰‡ä¸å»ºè­°ã€‚\r\n(3) Lurbinectedin, topotecan, and irinotecan å‡æ˜¯ extensive-stage small cell lung cancer æœ‰å¯èƒ½ä½¿ç”¨çš„äºŒç·šè—¥ç‰©ã€‚\r\n(4) æ ¹æ“š PACIFIC trial,limited-stage small cell lung cancer ç—…æ‚£,åœ¨æ¥å— definitive concurrent chemoradiation çµæŸå¾Œå†åŠ å…¥ Durvalumab/Tremelimumab,å¯é¡¯è‘—å»¶é•· overall survivalã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1)æ­£ç¢º\r\nNCCN guideline-SCLC - v4.2025 (P. 9,10,12/86)\r\nPrimary treatment ä¹‹å¾Œé”CR or PRçš„limited stage SCLCï¼Œå»ºè­°durvalumab (category 1)ï¼Œæˆ–è€ƒæ…®prophylactic cranial irradiation\r\n\r\n\r\n(2)éŒ¯èª¤ã€‚é€™å…©å€‹trialé¡¯ç¤º treatment outcomes å’Œ PDL-1 level ç„¡é—œ\r\nImpwer133 trial: double-blind, placebo-controlled, phase 3 \r\nN Engl J Med 2018;379:2220-2229\r\nJ Clin Oncol 39:619-630  (2021)\r\n\r\nBackground: Analyze the synergistic effect and efficacy of combining checkpoint inhibitior with chemotherapy\r\n\r\nKey inclusion criteria: treatment-naive extensive stage SCLC\r\n\r\nExperimental arm: atezolizumab + carboplatin + etoposide\r\nControl arm: placebo + carboplatin + etoposide\r\n\r\nKey findings\r\nâ€“ addition of atezolizumab to chemotherapy resulted in significantly longer OS & PFS than chemotherapy alone\r\nâ€“ No numerical difference in efficacy outcomes was observed across the PD-L1 IHC subgroups. \r\nâ€“ Overall, the data suggest that clinical benefit was observed in patients with extensive stage-SCLC treated with 1L atezolizumab plus carboplatin+etoposide, independent of bTMB(blood-based tumor mutational burden) or PD-L1 biomarker status.\r\n\r\n===================================\r\nCaspian trial:randomised, controlled, open-label, phase 3\r\nThe Lancet 2019, Volume 394, Issue 10212, 1929 - 1939\r\nESMO Open 2022, Volume 7, Issue 2, 100408\r\n\r\nBackground: Assess durvalumab, +/- tremelimumab, in combination with platinumâ€“etoposide in treatment-naive patients with extensive stage-SCLC\r\n\r\nKey inclusion criteria: treatment-naive extensive stage SCLC\r\n\r\nExperimental arm:\r\nDurvalumab+tremelimumab+platinumâ€“etoposide,Durvalumab+platinumâ€“etoposide\r\nControl arm: platinumâ€“etoposide\r\n\r\nKey findings: \r\nâ€“ 1st line durvalumab plus platinumâ€“etoposide significantly improved overall survival in patients with ES-SCLC\r\nâ€“ To date, no association has been found between outcomes with first-line immunotherapy and PD-L1 expression or tumor mutational burden in extensive stage-SCLC\r\n\r\n\r\n(3)æ­£ç¢º \r\nNCCN guideline-SCLC - v4.2025 (P. 23/86)\r\nä¸‰è€…çš†ç‚º subsequent line (ç„¡limited stage/extensive stageä¹‹åˆ†) systemic therapy å¯èƒ½ç”¨è—¥\r\n\r\n(4)éŒ¯èª¤ã€‚Pacific trial æ˜¯é‡å°NSCLCï¼›Adriatic trial æ‰æ˜¯é‡å°SCLC\r\nPacific trial: \r\n[JCO 40, 1301-1311(2022)]\r\nDurvalumab as consolidation therapy in patients with unresectable, stage III NSCLC and no disease progression after CCRT\r\n\r\nAdriatic trial:\r\n(N Engl J Med 2024;391:1313-1327)\r\nAdjuvant therapy with durvalumab, +/- tremelimumab in patients with limited-stage SCLC and no disease progression after standard platinum-based CCRT\n\n<è£œå……>\nç¸½çµä¾†èªª\n1. Advanced stage: \nCASPIAN trial: dura+/-treme + EP > EP in OS\nIMpower133: atezo + EP > EP in OS\n\n2. Limited stage (adjuvant after CCRT)\nAdriatic trial adjuvant durva+/-treme > placebo\n\nè‡³æ–¼CASPIANä»¥åŠAdriatic trialä¸­åˆ°åº•è¦ä¸è¦é™¤äº†durvaä»¥å¤–é‚„è¦å¦å¤–å†åŠ ä¸Štremelimumab (durva +treme arm)ï¼Œä»¥ç¾æœ‰dataä¾†èªªé‚„ä¸åˆ°çµ±è¨ˆåŠ›å¯ä»¥åšå‡ºå·®ç•°ï¼Œå› æ­¤study groupé‚„ä¸é¡˜æ„unblindedçµæœï¼Œå°šå¾…æ›´å¤šè³‡æ–™ã€‚å› æ­¤ç›®å‰guidelineä»ä»¥+/-tremelimumabä½œç‚ºå»ºè­°ã€‚",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 88,
    "question": "Catheter-related infections æ˜¯ç™Œç—‡ç—…æ‚£å¸¸è¦‹çš„æ„ŸæŸ“åˆä½µç—‡,åŒ…æ‹¬æœ‰ exit site infectionã€tunnel or pocket infection åŠ catheter-related bacteremia or fungemia ç­‰é¡å‹ã€‚ä»¥ä¸‹ç‚ºæœ‰é—œ catheter-related infections è¨ºæ²»çš„æ•˜è¿°ä¸­,æ­£ç¢ºçš„æœ‰:\r\n\r\n(1) Exit site åŠ pocket site æ„ŸæŸ“æ™‚çš„ç´…ã€è…«ã€ç†±ã€ç—›ç­‰ç—‡ç‹€,åœ¨æœ‰ neutropenia çš„ç—…æ‚£èº«ä¸Šå¯èƒ½è¼ƒä¸æ˜é¡¯ã€‚\r\n(2) åœ¨åˆ¤æ–·ç—…æ‚£æ˜¯å¦ç™¼ç”Ÿcatheter-related bacteremia æ™‚,ã€Œdifferential time to positivityã€æ˜¯å¸¸ç”¨çš„åˆ¤æ–·åŸå‰‡ã€‚\r\n(3) è‹¥ç—…æ‚£ç™¼ç‡’æ™‚ç”± catheter æ‰€åšçš„è¡€æ¶²åŸ¹é¤Šç™¼ç¾æœ‰gram-positive bacteria,è‹¥è©²èŒè­‰å¯¦ç‚ºCorynebacterium spp.æˆ– Staphylococcus aureus,å‰è€…è¼ƒå¯èƒ½ç‚º blood culture contaminantã€‚\r\n(4) Central line-associated blood stream infection çš„æ¨™æº–è™•ç½®æ˜¯å…¨èº«æ€§æŠ—ç”Ÿç´ æ²»ç™‚ã€åŠ ä¸Šantibiotic lock therapy ä»¥ä¿ç•™æ­¤ central line(å³â€catheter salvageâ€)",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "(1)æ­£ç¢º\r\nTypical clinical signs such as tenderness or purulent discharge at the insertion site, implicating the catheter as the source of infection, are frequently absent during neutropenia \r\n(J Clin Microbiol. 2003 Jan;41(1):118â€“123.)\r\n\r\nLocal signs are absent in almost 60% of catheter related bloodstream infection(CRBSI), particularly with older age, critical illness, immunosuppression, catheters in place one week or less, and jugular/femoral sites.\r\n(Uptodate: Intravascular non-hemodialysis catheter-related infection: Clinical manifestations and diagnosis)\r\n\r\n\r\n(2)æ­£ç¢º\r\nDifferential time to positivity (DTTP) has been used as a tool for diagnosis of CRBSI, particularly in those with cancer, but the predictive value of this approach is uncertain. \r\nDTTP is interpreted as evidence that the central line is infected if blood obtained from the peripheral vein starts growing bacteria >2 hours after blood obtained from the central line\r\n(Uptodate: Intravascular non-hemodialysis catheter-related infection: Clinical manifestations and diagnosis)\r\n\r\n\r\n(3)æ­£ç¢º\r\nIn the absence of other identifiable sources of infection, the following blood culture results may be attributed to CRBSI\r\n##  â‰¥1 blood culture bottles positive for S. aureus, enterococci, Enterobacteriaceae, Pseudomonas aeruginosa, Candida species\r\n##  â‰¥2 blood culture bottles positive for coagulase-negative staphylococci or other common commensals (eg, Corynebacterium species [not Corynebacterium diphtheriae], Cutibacterium species, Bacillus species [not Bacillus anthracis], viridans group streptococci)\r\n(Uptodate: Intravascular non-hemodialysis catheter-related infection: Clinical manifestations and diagnosis)\r\n\r\n\r\n(4)éŒ¯èª¤ã€‚ ä¸€èˆ¬ä¾†èªªï¼Œè™•ç½®åŒ…å« catheter removal + systemic antibioticsï¼Œé™¤éç§»é™¤å°ç®¡ä¸å¯è¡Œï¼Œæ‰æœƒè€ƒæ…®catheter salvage(lock therapy + systemic antibiotics) or guidewire exchange of catheter\r\ns\r\nIn general, management of CRBSI consists of catheter removal and systemic antibiotic therapy. If catheter removal is not feasible (eg, there is no alternative access site or sites are limited, the patient has a bleeding diathesis, patient declines removal, or quality of life issues take priority over the need for catheter reinsertion at another site), a decision regarding catheter salvage or guidewire exchange must be made.\r\n(Uptodate: Intravascular non-hemodialysis catheter-related infection: Treatment)\r\n\r\n\r\n**åœ–ç‰‡è£œå……: examples of definitions of catheter related infection\r\nJournal of Infection (2005) 51, 267â€“280",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/088/explain_figures/figure 88.jpg"
    ]
  },
  {
    "id": 89,
    "question": "Superior vena cava syndrome(SVCS)æ˜¯ç½¹æ‚£æƒ¡æ€§è…«ç˜¤ç—…æ‚£å¸¸è¦‹çš„æ€¥ç—‡ä¹‹ä¸€ã€‚\nä»¥ä¸‹ç‚ºæœ‰é—œ SVCS ç—…å› ã€è¨ºæ–·åŠè™•ç½®çš„æ•˜è¿°ï¼Œæ­£ç¢ºçš„æœ‰:\n(1) ç•¶ç—…äººè¡¨ç¾ SVCS å…¸å‹çš„ç—‡ç‹€ï¼Œå¦‚ venous distention of neck and chest wall, facial\nedema ç­‰ï¼Œä¸€å®šæ˜¯ä½æ–¼ç¸±éš”è…”çš„æƒ¡æ€§è…«ç˜¤å£“è¿« SVC æ‰€é€ æˆçš„ã€‚\n(2) å¼•ç™¼ SVCS å¸¸è¦‹çš„æƒ¡æ€§è…«ç˜¤ç‚º lung cancerã€lymphomaã€thymic malignancies åŠ germ\ncell tumor ç­‰ã€‚\n(3) ç¶“ CT æˆ– MRI æ¸…æ¥šåœ°é¡¯ç¤ºæœ‰ç¸±éš”è…”è…«ç˜¤å¾Œï¼Œæ‡‰ç«‹å³çµ¦äºˆæ”¾å°„ç·šæ²»ç™‚ï¼Œä»¥è¿…é€Ÿç·©è§£\nSVCS ç›¸é—œçš„ç—‡ç‹€ã€‚\n(4) SVCS çš„è™•ç†æœ‰è³´æ­£ç¢ºçš„è¨ºæ–·åŠè…«ç˜¤åˆ†æœŸ(staging)ã€‚ä½†è‹¥æ¬²è¿…é€Ÿç·©è§£ SVCSï¼Œ\npercutaneous transluminal angioplasty using balloon dilatation æˆ– insertion of expandable metal stent æ˜¯æœ‰æ•ˆçš„è™•ç½®ä¹‹ä¸€",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 2,
    "explanation": "(1)(2)\nä»»ä½•å°è‡´SVCå›æµä¸é †çš„ç—…å› éƒ½èƒ½å¼•ç™¼SVC syndromeï¼Œä¸è«–æ˜¯å› ç‚ºå¤–åœ¨è…«ç˜¤çš„å£“è¿«æˆ–æ˜¯è¡€ç®¡å…§ç”¢ç”Ÿçš„è¡€æ “éƒ½æœ‰å¯èƒ½ã€‚ä¾ç…§éå»çµ±è¨ˆï¼Œç´„è«60%-86%çš„SVC syndromeæ˜¯å› ç‚ºæƒ¡æ€§è…«ç˜¤æ‰€å¼•èµ·(Devita 12th edition)ï¼Œè€Œå…¶ä¸­æœ€å¸¸è¦‹çš„æ˜¯è‚ºç™Œ(å°¤å…¶æ˜¯Squamouså’Œsmall cell lung cancer)ã€è½‰ç§»æ€§ä¹³ç™Œã€æ·‹å·´ç™Œã€èƒ¸è…ºç˜¤ä»¥åŠå…¶ä»–å¥½ç™¼æ–¼ç¸±éš”è…”çš„è…«ç˜¤ç­‰(Azizi et al, Figure 1.)ã€‚ä½†non-neoplastic å¼•èµ·çš„SVC syndromeç™¼ç”Ÿç‡åŒæ¨£åœ¨é€æ­¥ä¸Šå‡ä¸­ï¼Œçµ•å¤§å¤šæ•¸æ˜¯å› ç‚ºå¤–ä¾†catheter(å¦‚CVC, pacemakerç­‰)å½¢æˆçš„thrombosisï¼Œæ›´å°‘æ•¸æ˜¯å› ç‚ºå¦‚Bechet diseaseã€vascular anomaliesç­‰æ˜“å¼•èµ·è¡€æ “çš„ç–¾ç—…æ‰€å°è‡´\n(3)(4)\nSVC syndromeçš„è™•ç½®æ–¹å¼å¯ä»¥åƒè€ƒåœ–äºŒ(Azizi et al, 2020. Figure 2.)\nè‹¥è‡¨åºŠç—‡ç‹€åŠå½±åƒè¨ºæ–·é«˜åº¦æ‡·ç–‘æœ‰SVC syndromeæ™‚ï¼Œé¦–è¦åˆ¤æ–·ç—…äººæ˜¯å¦å·²æœ‰life threatening symptomsã€‚è‹¥æœ‰ç«‹å³è‡´å‘½çš„å¯èƒ½(ä¾‹å¦‚å·²ç”¢ç”Ÿå‘¼å¸è¡°ç«­ã€ä¼‘å…‹ã€ç™²ç™‡ç­‰ç—‡ç‹€ï¼‰ï¼Œå»ºè­°é™¤ç©©å®šç”Ÿå‘½å¾µè±¡å¤–å¯ä»¥è€ƒæ…®é€²è¡Œintravascular stentingæˆ–æ˜¯å°‡ä»¥å½¢æˆçš„è¡€æ “é€²è¡Œthrombolysisç­‰ã€‚è‹¥æƒ…æ³è¼ƒä¸å±æ€¥ï¼Œå‰‡å»ºè­°å…ˆé€²è¡Œtissue biopsyä»¥åŠå®Œæ•´è…«ç˜¤åˆ†ç´šå¾Œï¼Œå†æ ¹æ“šç™Œåˆ¥åŠæœŸåˆ¥é€²è¡Œç›¸å°æ‡‰çš„æ²»ç™‚ï¼ˆåŒ–ç™‚ã€æ”¾ç™‚æˆ–æ‰‹è¡“ç­‰)ã€‚",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/089/explain_figures/Figure 1.png",
      "/qabank/089/explain_figures/Figure 2.png"
    ]
  },
  {
    "id": 90,
    "question": "ä»¥ä¸‹ç‚ºæœ‰é—œ malignant spinal cord compression (MSCC)çš„æ•˜è¿°ï¼Œæ­£ç¢ºçš„æœ‰:\n(1) ç™¼ç”Ÿ MSCC cancer-specific incidence rate æœ€é«˜çš„ç™Œåˆ¥æ˜¯ multiple myelomaã€‚\n(2) ç™¼ç”Ÿ MSCC æœ€å¸¸è¦‹çš„éƒ¨ä½æ˜¯èƒ¸æ¤(thoracic spine)ã€‚\n(3) ç›¸è¼ƒæ–¼ X å…‰æª¢æŸ¥ã€CT scan åŠåŒä½ç´ éª¨æƒæï¼ŒMRI æ˜¯ MSCC è¨ºæ–·è¼ƒä½³çš„å½±åƒå­¸æª¢æŸ¥\næ–¹å¼ã€‚\n(4) MSCC çš„ç—…ç†çµ„ç¹”å­¸æª¢æŸ¥ï¼Œæœ€ä¸»è¦ç™¼ç¾æ˜¯ gray matter å‡ºç¾ demyelination æˆ– necrosisã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "(1)ä»¥ä¸‹æ‘˜éŒ„è‡ªDevita: åœ¨ç™¼å±•å‡ºã€Œè½‰ç§»æ€§è„Šé«“å£“è¿«ç—‡ï¼ˆMSCCï¼‰ã€çš„æ‚£è€…ä¸­ï¼Œæœ€å¸¸è¦‹çš„ç™Œç—‡é¡å‹åŒ…æ‹¬è‚ºç™Œï¼ˆ25%ï¼‰ã€å‰åˆ—è…ºç™Œï¼ˆ16%ï¼‰ã€å¤šç™¼æ€§éª¨é«“ç˜¤ï¼ˆ11%ï¼‰å’Œä¹³è…ºç™Œï¼ˆ7%ï¼‰ã€‚åœ¨ç‰¹å®šç™Œç—‡ç™¼ç”Ÿç‡æœ€é«˜çš„ç™Œç—‡ä¸­ï¼ŒåŒ…æ‹¬å¤šç™¼æ€§éª¨é«“ç˜¤ï¼ˆ15%ï¼‰ã€æ·‹å·´ç˜¤ï¼ˆ14%ï¼‰å’Œå‰åˆ—è…ºç™Œï¼ˆ6%ï¼‰ã€‚ç¸½çµä¾†èªªï¼Œä¸€å€‹ç—…æ‚£è‹¥ç™¼ç”ŸMSCCï¼Œå‰‡æœ€é«˜æ©Ÿç‡æ˜¯å› çˆ²å¾—åˆ°è‚ºç™Œï¼Œç„¶è€Œæ‰€æœ‰ç™Œç—‡ä¸­ï¼Œmultiple myelomaæ˜¯æœ€å®¹æ˜“å½¢æˆMSCCçš„ç™Œåˆ¥ã€‚MSCCå¤§å¤šç™¼ç”Ÿåœ¨50æ­²ä»¥ä¸Šçš„æˆå¹´ç—…äººä¸­ï¼Œè€Œå…’ç«¥æ—ç¾¤ä¸­æœ€æœ‰æ©Ÿæœƒç”¢ç”ŸMSCCçš„ç™Œç—‡ç¨®é¡å‰‡æœ‰æ‰€ä¸åŒï¼Œç‚ºEwing sarcoma, neuroblastoma, primary vertebral osteosarcoma, germ cell tumors, lymphomaã€‚\n\n(2)èƒ¸æ¤æ˜¯è½‰ç§»æ€§è„Šé«“å£“è¿«ç—‡ï¼ˆMSCCï¼‰æœ€å¸¸è¦‹çš„éƒ¨ä½ï¼ˆç´„ä½”60%çš„ç—…ä¾‹ï¼Œå¯å› ç›¸è¼ƒæ–¼é ¸æ¤å’Œè…°æ¤ï¼Œèƒ¸æ¤æœ€å¤šç¯€ï¼Œå› æ­¤ç™¼ç”Ÿæ©Ÿç‡ä¹Ÿæœ€é«˜ï¼‰ã€‚\n\n(3)MRIç‚ºæœ€ä½³è¨ºæ–·MSCCçš„å·¥å…·ï¼ˆè»Ÿçµ„ç¹”è§£æåº¦ä½³ã€éä¾µå…¥æ€§ã€T2 phaseä¸‹spinal cordé¡¯å½±æ¸…æ™°ï¼‰ã€‚è‹¥ç—…æ‚£ç„¡æ³•æ¥å—MRIæª¢æŸ¥ï¼Œæœ‰å¦ä¸€æ–¹å¼æ˜¯CT myelogramï¼Œåšæ³•æ˜¯å°‡é¡¯å½±åŠ‘æ³¨å…¥CSFä¸­æ¥è‘—åšCT scanä¾†è©•ä¼°æ˜¯å¦æœ‰å£“è¿«ç”¢ç”Ÿï¼Œä½†å› ä¾µå…¥æ€§è¼ƒé«˜éå¸¸å°‘åšã€‚\n\n(4)MSCCçš„ç—…ç”Ÿç†æ©Ÿè½‰ç‚ºï¼šè…«ç˜¤å£“è¿«å°è‡´epidural venous plexuså›æµä¸é †å°è‡´spinal cordå¤–å±¤white matter edemaï¼Œè‹¥ç„¡æ³•æ¸›å£“åœ¨çµ„ç¹”ç—…ç†ä¸Šå¯ä»¥çœ‹åˆ°MSCCæœ€å…·ä»£è¡¨æ€§çš„demyelination or necrosis of white matterï¼Œè€Œgray matteræœƒç›¸å°å®Œæ•´ã€‚\n\n(1)(2)(3)çš†æ­£ç¢º",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 91,
    "question": "55 æ­²ç”·æ€§ï¼Œå› ç‚ºè½‰ç§»æ€§è…ç´°èƒç™Œ (clear cell renal cell carcinoma) æ¥å— nivolumab+ipilimumab ä¸¦ç”¨è—¥ç‰©æ²»ç™‚ã€‚åœ¨æ¥å—ç¬¬äºŒæ¬¡è—¥ç‰©æ³¨å°„å¾Œ 10 å¤©å› ç‚ºèƒ¸æ‚¶èˆ‡å‘¼å¸å›°é›£è‡³æ€¥è¨ºå°±é†«ã€‚å¿ƒé›»åœ– é¡¯ç¤º complete AV blockï¼Œç„¡æ˜é¡¯ ischemiaã€è¶…éŸ³æ³¢é¡¯ç¤ºå¾®é‡ pericardial effusionã€‚ä»¥ä¸‹æ•˜è¿°ä¸­ï¼Œ\næ­£ç¢ºçš„æœ‰?\n(1) ç›¸è¼ƒæ–¼å–®ç¨ä½¿ç”¨ anti-PD1 æˆ– anti-CTLA4 æ²»ç™‚ï¼Œä¸¦ç”¨ anti-PD1 èˆ‡ anti-CTLA4 å¯èƒ½å¢åŠ \nimmune related cardiac toxicity çš„æ©Ÿç‡ã€‚\n(2) å¯èƒ½åˆä½µå…¶ä»– immune related adverse events ä¾‹å¦‚ myositis æˆ– myasthenia gravisã€‚\n(3) Cardiac troponin å‡é«˜å¯èƒ½ä¼´éš¨åš´é‡å¿ƒè‡Ÿä¸è‰¯äº‹ä»¶ (major adverse cardiac events, MACE)\nçš„æ©Ÿç‡å‡é«˜ã€‚\n(4) å¦‚æ‡·ç–‘ immune-related cardiac toxicity æ‡‰ç›¡é€Ÿé–‹å§‹ prednisolone 1-2 mg/kg/ day æ²»ç™‚ã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "æœ¬é¡Œä¸»è¦åœ¨è€ƒimmunotherapy related toxicity\n\n(1) ä»¥nivolumab + ipilimumabç‚ºä¸»çš„combination therapyåœ¨å„è‡¨åºŠè©¦é©—ä¸­å¯ä»¥çœ‹åˆ°ï¼Œç„¡è«–æ˜¯all gradeæˆ–æ˜¯grade 3ä»¥ä¸Šçš„irAEçš„æ¯”ç‡ç›¸è¼ƒæ–¼å–®ç”¨nivolumabæˆ–ipilimumabçš„ç¢ºè¼ƒé«˜ï¼ˆå¦‚åœ–ä¸€ï¼‰ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯nivolumab 1mg/kg+ ipilimumab 3mg/kgç›¸è¼ƒæ–¼nivolumab 3mg/kg+ ipilimumab 1mg/kgçš„çµ„åˆä¾†èªªï¼Œæ¯’æ€§çš„ç¢ºä¹Ÿè¼ƒä½ã€‚\n\n(2)æ ¹æ“šé¡Œå¹¹æè¿°ï¼Œæ­¤ç—…æ‚£å·²å‡ºç¾complete AV blockä»¥åŠå‘¼å¸å›°é›£ï¼Œçš„ç¢ºå¯èƒ½å·²å‡ºç¾å¿ƒè‚Œç‚å’Œé‡ç—‡è‚Œç„¡åŠ›çš„ç—‡ç‹€ã€‚æ­¤äºŒè€…ç‚ºç›¸å°è¼ƒç‚ºç½•è¦‹çš„å‰¯ä½œç”¨ã€‚ICIå¼•èµ·çš„ç¥ç¶“æ¯’æ€§ä¸»è¦ä»¥polyneuropathyç‚ºä¸»ï¼Œç½•è¦‹æƒ…æ³æœƒå‡ºç¾è‡´å‘½æ€§å‰¯ä½œç”¨ä¾‹å¦‚Guillain-Barreå’Œmyasthenia gravisï¼Œè€ŒMyasthenia gravis è‡´æ­»ç‡é«˜é”20%, early onset (median 29â€‰days), ä¸¦å¸¸å¸¸åˆä½µmyocarditis and myositisï¼Œä¿—ç¨±ç‚ºTriple M syndromeã€‚ \n\n(3)å› æ­¤è‹¥ç—…æ‚£å‡ºç¾ç–‘ä¼¼å¿ƒè‚Œç‚ç—‡ç‹€ï¼ŒASCO guidelineå»ºè­°éœ€è¦ç«‹å³ç›£æ¸¬troponinä»¥åŠBNP, åŒæ™‚æª¢æ¸¬CPKå·²æ’é™¤myocarditisçš„å¯èƒ½ã€‚\n\n(4)æ ¹æ“šASCO guidelineï¼ˆå¦‚åœ–äºŒï¼‰ï¼Œè‹¥å‡ºç¾grade 2ä»¥ä¸Šç—‡ç‹€(abnormal cardiac biomarkersã€å‡ºç¾mild symptomsä»¥åŠnew ECG abnormalities without conduction delay)ï¼Œå‰‡é ˆç«‹å³åœæ­¢ä½¿ç”¨ICIä¸¦ä¸”çµ¦äºˆmethylprednisolone 1-2mg/kg/dã€‚è‹¥ç„¡æ•ˆå‰‡è€ƒæ…®çµ¦äºˆmethylprednisolone pulse therapy (1g/day)ï¼Œæ­é…ä½¿ç”¨MMFã€infliximabæˆ–æ˜¯ATGã€‚è‹¥å‡ºç¾è‡´å‘½æ€§ç—‡ç‹€(grade 4)å‰‡è€ƒæ…®é¡å¤–çµ¦äºˆabataceptæˆ–alemtuzumabç­‰å…ç–«æŠ‘åˆ¶åŠ‘ã€‚",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/091/explain_figures/Figure 1.png",
      "/qabank/091/explain_figures/Figure 2.png"
    ]
  },
  {
    "id": 92,
    "question": "ä½¿ç”¨ PET-CT ä¾†è©•ä¼°æ·‹å·´ç™Œæ²»ç™‚ç™‚æ•ˆçš„ 5 point scaleï¼Œæ­£ç¢ºçš„æœ‰:\n(1) Score 1: mild uptake above background\n(2) Score 2: uptake <= mediastinum\n(3) Score 3: uptake > mediastinum, but < spleen\n(4) Score 4: uptake moderately increased compared to liver",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 2,
    "explanation": "Deauville 5 points scale(D5PS)æ˜¯ç”¨ä¾†è©•ä¼°FDG-avid nodal lymphomaï¼ˆå¦‚Hogdkin lymphoma, DLBCLç­‰ï¼‰åœ¨PET scanä¸Šé¡¯å½±äº®åº¦çš„é‡è¡¨ã€‚è©³ç´°è©•åˆ†æ–¹å¼å¦‚åœ–ä¸€ï¼Œå…¶ä¸­ä¸»è¦æ˜¯ä»¥mediastinum blood poolä»¥åŠliverçš„äº®åº¦ä¾†ç•¶ä½œæ¯”è¼ƒå€¼ã€‚é™¤äº†initial stagingä»¥å¤–ï¼ŒD5PSå¯ä½œç‚ºtreatment responseçš„è©•ä¼°å·¥å…·ï¼ŒD5PS 1-3åˆ†ç‚ºmetabolic complete responseï¼Œ4-5åˆ†å‰‡å¯èƒ½ç‚ºPartial responseï¼ˆä½†FDG uptakeè¼ƒæ²»ç™‚å‰é™ä½)ã€stable diseaseï¼ˆFDG uptakeç„¡è®ŠåŒ–)ã€progressive diseaseï¼ˆFDG uptakeå¢åŠ æˆ–å‡ºç¾new lesionsï¼‰ã€‚",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/092/explain_figures/Figure 1.png"
    ]
  },
  {
    "id": 93,
    "question": "ä»¥ä¸‹å“ªäº›æƒ…æ³æœƒå¢åŠ ç½¹æ‚£ lymphoma çš„é¢¨éšªï¼Œæ­£ç¢ºçš„æœ‰ï¼Ÿ\n(1) Inherited immunodeficiency states (ChÃ©diak-Higashi syndrome, Ataxia telangiectasia)\n(2) Acquired immunodeficiency states (HIV-1 infection, Multicentric Castleman Disease)\n(3) Autoimmune and inflammatory disorders (SjÃ¶gren syndrome, Hashimoto thyroiditis)\n(4) Chemicals and drugs (phenytoin, dioxin, pesticides)",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 65252,
    "explanation": "å¦‚é™„è¡¨DeVita, Hellman and Rosenberg's Cancer 12/e (Table 67.1, p. 1372)\n\nä¸è«–æ˜¯inherited æˆ–acquired immunodeficiencyéƒ½è·Ÿå¢åŠ lymphomaç½¹æ‚£é¢¨éšªæœ‰é—œï¼Œæ¥å—å™¨å®˜ç§»æ¤çš„ç—…äººç½¹æ‚£NHLçš„æ©Ÿç‡ç´„å¢åŠ 100å€(å…¶ä¸­ç´„30%æ˜¯å¾polyclonal B-cell proliferationç™¼å±•æˆclonal B-cell malignancy)ï¼Œé™¤æ­¤ä¹‹å¤–ï¼Œä¸€ç­‰è¦ªæ‚£æœ‰NHLã€HLæˆ–CLLçš„äººä¹Ÿè§€å¯Ÿåˆ°ç½¹æ‚£NHLçš„é¢¨éšªå¢åŠ ï¼Œ9% çš„lymphomaæˆ–CLLæ‚£è€…çš„ä¸€ç­‰è¦ªæ‚£æœ‰lymphoproliferative disorder (Br J Haematol 2008;143(3):361â€“368.)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/093/explain_figures/figure1.png"
    ]
  },
  {
    "id": 94,
    "question": "55 æ­²å¥³æ€§ä¸Šè…¹ç—› 3 å€‹æœˆï¼Œè¨ºæ–·èƒƒè…ºç™Œç¬¬å››æœŸï¼Œåˆä½µè‚åŠè…¹è…”è½‰ç§»ï¼Œä¸‹åˆ—ç—…ç†çµ„ç¹”å…ç–«æŸ“è‰²æª¢æŸ¥ä¸­ï¼Œéç‚ºå¿…é ˆé …ç›®çš„æœ‰?\r\n(1) HER2/neu overexpression\r\n(2) MSI/dMMR\r\n(3) PD-L1\r\n(4) FGFR-2 amplification",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 3,
    "explanation": "é™„åœ–ESMO academy 2024ç¾è¡ŒguidelineåŠNCCN guideline\nç¾è¡Œé‡å°advanced unresectable/metastatic gastric adenocarcinomaç¬¬ä¸€ç·šæ²»ç™‚éœ€è€ƒæ…®platinum-fluoropyrimidine doublet ChTæ²»ç™‚ä¸¦æª¢æ¸¬HER2, MSI/dMMR, PD-L1ä¾†è€ƒæ…®åŠ ä¸Šæ¨™é¶æˆ–å…ç–«è—¥ç‰©ï¼Œæ¨™æº–æ²»ç™‚ä¸‹é€™ä¸‰é …ç‚ºå¿…è¦é …ç›®ã€‚å¦å¤–ä¸€ç·šæ²»ç™‚å¯èƒ½å¯è€ƒæ…®æª¢é©—CLDN18.2(SPOTLIGHT trial, GLOW trial)ã€‚\r\nNTRK gene fusionsåœ¨GI cancersé›–ç„¶å°‘è¦‹(<5%)ï¼Œç›®å‰ä¹Ÿæœ‰è—¥ç‰©(Entrectinib, larotrectinib, repotrectinib)å¯ä»¥ä½¿ç”¨ï¼Œåœ¨ä¸€ç·šæˆ–å¾Œç·šç—…äººç„¡æ³•æ¨™æº–æ²»ç™‚çš„æ‚£è€…å¯ä»¥è€ƒæ…®æª¢é©—ã€‚\r\nèƒƒç™Œä¸­FGFR-2 amplificationç´„ä½”3%â€“10% ï¼Œä½†ç›®å‰ç›¸é—œçš„FGFR-TKI(Futibatinib, AZD4547â€¦)é‚„æ²’æœ‰çœ‹åˆ°æ˜é¡¯å¥½è™•(phase II SHINE study)ã€‚\r\nğŸ’¡èƒƒç™Œä¸€ç·šIOå¥ä¿çµ¦ä»˜æ¢ä»¶ï¼š\r\n(1)èƒƒç™Œï¼ˆä¸å«èƒƒè…¸åŸºè³ªç˜¤åŠç¥ç¶“å…§åˆ†æ³Œè…«ç˜¤/ç™Œï¼‰ï¼šé™ä»¥nivolumab 120mg è¦æ ¼é‡å“é …ä½µç”¨fluoropyrimidineï¼ˆ5-FUæˆ– capecitabineï¼‰åŠoxaliplatinï¼Œç”¨æ–¼ç¬¬ä¸€ç·šæ²»ç™‚æ™šæœŸæˆ–è½‰ç§»æ€§ä¸”ä¸å…·æœ‰ HER2éåº¦è¡¨ç¾çš„èƒƒç™Œç—…äººã€‚(113/4/1ã€113/6/1)\r\n(2)CPSâ‰§5",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/094/explain_figures/figure1.png",
      "/qabank/094/explain_figures/figure2.png"
    ]
  },
  {
    "id": 95,
    "question": "é—œæ–¼å‰å°æ€§æ²»ç™‚åœ¨å±€éƒ¨æ™šæœŸèƒƒç™Œç—…æ‚£çš„è§’è‰²ï¼Œä¸‹åˆ—æè¿°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰?\r\n(1) ä½¿ç”¨é…æ–¹æ‡‰å„ªå…ˆè€ƒæ…® fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)æˆ–fluoropyrimidine and oxaliplatinã€‚\r\n(2) èƒƒç™Œçš„å‰å°æ€§ chemoradiotherapy å·²å®Œå…¨ä¸å»ºè­°ä½¿ç”¨ã€‚\r\n(3) MSI-H/dMMR ç—…æ‚£å¯ä»¥è€ƒæ…® pembrolizumab ä½œç‚ºå‰å°æ€§æ²»ç™‚ã€‚\r\n(4) FLOT åŠ ä¸Šå…ç–«è—¥ç‰©(MATTERHORN study or KEYNOTE-585)å·²è­‰å¯¦æ¯” FLOT å¯ä»¥å¢åŠ  pCR rate,disease-free survival åŠ overall survivalã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1)Landmark trial Phase III MAGIC studyè­‰æ˜æ‰‹è¡“å‰å¾ŒåŠ ä¸ŠECFä¸åƒ…ä¸å¢åŠ æ‰‹è¡“ç›¸é—œM&Mé‚„èƒ½downstagingå’Œå¢åŠ R0 resection rateï¼Œä¸¦ä¸”å¸¶ä¾† 5-year OS benefit(36% vs 23, HR 0.75, P = 0.009)ï¼Œä½†åªæœ‰42%ç—…äººæœ‰å®Œæˆè¡“å¾Œçš„ä¸‰æ¬¡ç™‚ç¨‹ï¼å¾ŒçºŒ ACCORD 07-FFCD 9703 study(åƒ…25% pure gastric cancer),æ¯”è¼ƒ perioperative CF regimenä¹Ÿæœ‰çœ‹åˆ°ç›¸ä¼¼å¥½è™• (5-year OS 38% vs 24%, HR 0.69, P = 0.02)ã€‚ACCORD 07 ç ”ç©¶çµæœé¡¯ç¤ºï¼Œä¸å«epirubicinçš„doublet chemotherapyå¯èƒ½å·²è¶³å¤ ã€‚é¡ä¼¼çš„æ•¸æ“šäº¦ä¾†è‡ª CALGB 8010195 å’Œ OE0596 è©¦é©—ï¼Œå› æ­¤ECFè¢« FOLFOXå–ä»£æˆç‚ºperioperative chemotherapyçš„é¦–é¸ã€‚\r\nå¾ŒçºŒFLOT4 phase III studyæ¯”è¼ƒ perioperative ECF/ECXå’ŒFLOTï¼ŒFLOT çš„pCRæ˜é¡¯å„ªæ–¼ ECF/ECX (16% vs 6%, P = 0.02)ï¼Œä¸” FLOT é”æˆ R0 resectionçš„æ¯”ä¾‹è¼ƒé«˜(85% vs. 78%ï¼ŒP = 0.02)ã€‚æ­¤å¤–ECF/ECX çµ„è€å—æ€§è¼ƒå·®ï¼Œæœ‰ 40% çš„æ‚£è€…å‡ºç¾è‡³å°‘ä¸€æ¬¡Severe AEï¼Œè€Œ FLOT çµ„å‰‡ç‚º 25%ã€‚FLOT æœ‰è¼ƒä½³mDFS(30 vs. 18 months; P = 0.0036), è¼ƒä½³mOS (50 vs. 35 months; HR, 0.77, P = 0.012). 3-yr OS(57% vs. 48%)ï¼Œä¸”FLOTçµ„çš„è¡“å¾Œæ²»ç™‚å®Œæˆç‡è¼ƒé«˜ (50% vs. 37%)ã€‚å› æ­¤ï¼ŒFLOT è¢«è¦–ç‚ºå±€éƒ¨æ™šæœŸèƒƒç™Œèˆ‡ EGJ è…ºç™Œåœæ‰‹è¡“æœŸæ²»ç™‚çš„æ¨™æº–ç™‚æ³•(SoC)ã€‚\r\nğŸˆFLOT é©ç”¨æ–¼patients with very good performance status, lack of comorbidities, and younger age\r\nğŸˆFOLFOX å‰‡è¼ƒé©åˆ patients with good to moderate performance status in the presence of comorbidities or older age\r\n\r\n(2)åœ¨Gastric cancer(éEGJ)é›–ç„¶å› ç‚ºè­‰æ“šä¸è¶³ï¼Œç›®å‰å¤§å¤šGuidelineæ²’æœ‰å»ºè­°(ESMO)æˆ–å·²å°‡Preoperative chemoradiationçš„å»ºè­°åˆªé™¤(NCCN)ï¼Œä½†é€™è­°é¡Œé‚„æ²’æœ‰ä¸€å€‹å®šè«–(å¾ŒçºŒé‚„æœ‰Neo-CRAG, PREACT, CRITICS-II studiesé‚„åœ¨é€²è¡Œä¸­)ï¼š\r\nå› ç‚ºCROSS studyæ’é™¤æ²’æœ‰ involving EGJçš„èƒƒç™Œç—…äººï¼Œåƒ…åœ¨å…¶ä¸­EGJ adenocarcinomaç—…äººçœ‹åˆ° neoadjuvant chemoradiotherapy æ¯”èµ·ç›´æ¥æ‰‹è¡“æœ‰OS å¥½è™•: mOS 43.2 vs. 27.1 months(HR 0.73; P = 0.038), 10-yr OS (36% vs. 26%)ï¼Œ é‡å°EGJ tumors çš„preoperative chemoradiotherapy vs. chemotherapyæ¯”è¼ƒåœ¨å¾ŒçºŒNeo-AEGIS studyä¸­ä¸¦æ²’æœ‰çœ‹åˆ°OSå¥½è™•ï¼Œtrialä¹Ÿå› æ­¤ææ—©çµ‚æ­¢ã€‚\r\nå¾ŒçºŒTOPGEAR intergroup studyç›´æ¥æ¯”è¼ƒG/GEJç—…äººæ¥å—Pre-OP CRT vs. peri-OP chemotherapyï¼Œçœ‹åˆ°Pre-OP CRT é›–ç„¶æœ‰è¼ƒé«˜ pCR rateå’Œè¼ƒå¤š tumor downstagingï¼Œä½†æ²’æœ‰survivalå’ŒPFSå¥½è™•ã€‚\r\n\r\n(3)(4)å¦‚NCCN guidelineæ›´æ–°ã€‚\r\nKEYNOTE-585 åŠ ä¸Šneoadjuvant+adjuvant pembrolizumab æœ‰è¼ƒå¥½çš„pCR(12.9 vs. 2%, p<0.00001)ï¼ŒEFSä¹Ÿæœ‰çœ‹åˆ°è¼ƒé•·çš„è¶¨å‹¢(median 44.4 vs. 25.3 mo; HR 0.81; 95% CI, 0.67-0.99; P=0.0198)ä½†æ²’æœ‰é”åˆ°é¡¯è‘—(å…¶thresholdè¨­åœ¨0.0178ï¼Œstatistical failure:Î± loss & multiplicity due to multiple interim analyses)ã€‚\r\nMATTERHORN trial é›–ç„¶åœ¨interim analysisçœ‹åˆ°FLOTå†åŠ ä¸ŠDurvalumabå¯ä»¥å¢åŠ pCR(19 vs. 7%, ORR 3.08, p<0.00001)ï¼Œæœ€è¿‘(2023-3-7)ä¹Ÿæœ‰ç™¼æ–°èç¨¿å®£ç¨±EFSé”åˆ°statistically significancyä½†æ˜¯æ­£å¼çš„EFS, OSå¥½è™•éƒ½é‚„æœªç¶“è­‰å¯¦ã€‚",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/095/explain_figures/figure1.png",
      "/qabank/095/explain_figures/figure2.png",
      "/qabank/095/explain_figures/figure3.png"
    ]
  },
  {
    "id": 96,
    "question": "é—œæ–¼èƒƒç™Œçš„è¼”åŠ©æ€§åŒ–å­¸æ²»ç™‚ï¼Œä¸‹åˆ—æè¿°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰?\r\n(1) CLASSIC trial è­‰æ˜ oxaliplatin plus capecitabine æ¯” capecitabine å–®ç¨ä½¿ç”¨æœ‰æ›´å¥½çš„ overall survival and disease-free survivalã€‚\r\n(2) ACTS-GC è­‰æ˜ä½¿ç”¨ä¸€å¹´ TS-1 æ¯”ä½¿ç”¨åŠå¹´ TS-1 æœ‰æ›´å¥½çš„ overall survival and disease-free survivalã€‚\r\n(3) JACCRO GC-07 trial è­‰æ˜èƒƒç™Œä¸‰æœŸç—…æ‚£ä½¿ç”¨ TS-1 plus paclitaxel æ¯” TS-1 å–®ç¨ä½¿ç”¨æœ‰æ›´å¥½ çš„ overall survival and disease-free survivalã€‚\r\n(4) ARTIST trial æ¬¡æ—ç¾¤åˆ†æé¡¯ç¤º node positive èƒƒç™Œç—…æ‚£è¡“å¾Œä½¿ç”¨ capecitabine plus cisplatinåŠ ä¸Š radiotherapy æ¯”ä¸åŠ  radiotherapy çš„ 3-year disease-free survival å¥½ï¼Œä½†å°æ–¼ overall survival ç„¡çµ±è¨ˆå·®ç•°ã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 3,
    "explanation": "(1)CLASSIC study: æ¥å—D2 gastrectomyçš„ç—…äººåœ¨è¡“å¾Œæ¥å—adjuvant CAPOX(6 months)æ²»ç™‚å°æ¯”surgery onlyæœ‰5y-DFSåŠ5y-OS benefitï¼Œä¸¦éæ¯”è¼ƒoxaliplatin plus capecitabine  vs. capecitabineã€‚\r\n(2)ACTS-GC study: adjuvant S-1(1 year)å°æ¯” surgery onlyæœ‰ 5-yr OS benefit(71.7 vs. 61.1%, HR  0.68, P = 0.003)ï¼Œä¸¦éæ¯”è¼ƒTS-1ç”¨åŠå¹´æˆ–ä¸€å¹´çš„æ•ˆæœã€‚\r\n(3) JACCRO GC-07 study: æ¯”è¼ƒstage III gastric cancer æ¥å—D2 gastrectomyå¾Œæ¥å—adjuvant docetaxel (18 wks) plus S-1(1 yr)å’ŒS-1(1 yr) aloneçš„æ•ˆæœï¼Œæœ‰çœ‹åˆ°3-yr RFS(68 vs. 57%, HR 0.715)å’ŒOS(78 vs. 71%, HR 0.742)ã€‚ä¸¦éåŠ ä¸Špaclitaxelã€‚\r\n(4) ARTIST I study: æ¯”è¼ƒD2 gastrectomyå¾Œæ¥å—postoperative XP ä¸­é–“åŠ ä¸Š RT(XRT) æˆ–XP aloneçš„æ•ˆæœï¼Œæ•´é«”é›–æ²’æœ‰çœ‹åˆ° DFSå’ŒOSçš„é¡¯è‘—å¥½è™•ï¼Œä½†subgroup analysisæœ‰çœ‹åˆ°åœ¨node-positive disease ç—…äººæœ‰DFSé¡¯è‘—å¥½è™•(77.5 vs. 72.3%, p-0.0365)ï¼Œä¹Ÿæ‰æœ‰å¾ŒçºŒARTIST II studyæ¯”è¼ƒè¡“å¾Œnode-positive disease ç—…äººæ¥å—S-1 vs. SOX vs. SOXRTæœ‰ç„¡å¥½è™•å·®ç•°ï¼Œä½†æ²’æœ‰çœ‹åˆ°postoperative chemoradiationçš„DFS benefitã€‚",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 97,
    "question": "é—œæ–¼ç¬¬ä¸€ç·šç³»çµ±æ€§æ²»ç™‚(systemic therapy)åœ¨é£Ÿé“ç™Œçš„è§’è‰²ï¼Œä¸‹åˆ—æè¿°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰? \r\n(1) CheckMate 648 trialé¡¯ç¤ºnivolumab plus chemotherapy or ipilimumabå°æ–¼chemotherapy alone æœ‰æ›´ä½³çš„tumor response rateã€progressive-free survival and overall survivalï¼Œå°¤å…¶æ˜¯PD-L1 expression (TPSâ‰¥1 or CPSâ‰¥10)çš„ç—…æ‚£æœ‰æ›´é¡¯è‘—çš„è‡¨åºŠç™‚æ•ˆã€‚\r\n(2) KEYNOTE-590 trialé¡¯ç¤ºpembrolizumab plus chemotherapyå°æ–¼chemotherapy æœ‰æ›´ä½³çš„ tumor response rateã€progressive-free survival and overall survivalï¼Œå°¤å…¶æ˜¯PD-L1 expression (CPSâ‰¥10)çš„ç—…æ‚£æœ‰æ›´é¡¯è‘—çš„è‡¨åºŠç™‚æ•ˆã€‚\r\n(3) KEYNOTE-590 trial subgroup analysisé¡¯ç¤ºpembrolizumabå°æ–¼é±—ç‹€ä¸Šçš®ç™Œçš„ç™‚æ•ˆå„ªæ–¼è…ºç™Œæ‚£è€…ã€‚\r\n(4) CheckMate 648 trial subgroup analysisé¡¯ç¤ºnivolumabå°æ–¼é±—ç‹€ä¸Šçš®ç™Œçš„ç™‚æ•ˆå„ªæ–¼è…ºç™Œæ‚£è€…ã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "è€ƒfirst-line treatment of advanced or metastatic esophageal cancerã€‚\r\n\r\nCheckMate 648\r\n*æ”¶éŒ„å°è±¡ä¸»è¦æ˜¯SCCï¼Œç¿»trialçš„protocolï¼ŒæŠŠadenocarcinomaåˆ—ç‚ºexclusion criteria (figure 1)ã€‚\r\n*åœ¨OSæ–¹é¢ï¼Œnivolumab+CT åœ¨æ•´é«”æˆ–PD-L1 expressionâ‰¥1%éƒ½å„ªæ–¼å–®æ‰“CTï¼›nivo+ipiåœ¨æ•´é«”æˆ–PD-L1 expressionâ‰¥1%ä¹Ÿéƒ½å„ªæ–¼å–®æ‰“CT (figure 2)ã€‚\r\n*åœ¨PFSæ–¹é¢ï¼Œnivolumab+CT in PD-L1 expressionâ‰¥1%å„ªæ–¼å–®æ‰“CTï¼Œä½†åœ¨æ•´é«”ç—…äººä¸­PFSæ²’æœ‰é”çµ±è¨ˆå­¸å·®ç•°ï¼›nivo+ipi vs. CT in PD-L1 expressionâ‰¥1%æ²’æœ‰çµ±è¨ˆå­¸å·®ç•°ï¼Œnivo+ipi vs. CTåœ¨æ•´é«”ç—…äººä¸­æ²’æœ‰çµ±è¨ˆæ•¸å­— (figure 3)ã€‚\r\n*åœ¨tumor response rateæ–¹é¢ï¼Œåœ¨PD-L1 expressionâ‰¥1%ç—…äººä¸­ï¼Œnivolumab+CTèˆ‡nivo+ipiçš„ORRéƒ½å„ªæ–¼å–®æ‰“CTï¼›åœ¨æ•´é«”ç—…äººä¸­ï¼Œnivolumab+CTçš„ORRå„ªæ–¼å–®æ‰“CTï¼Œnivo+ipièˆ‡å–®æ‰“CTçš„ORRå·®ä¸å¤š (figure 4)ã€‚\r\n\r\n\r\nKEYNOTE-590\r\n*æ”¶éŒ„å°è±¡æœ‰ESCCä¹Ÿæœ‰EAC (figure 5)ã€‚\r\n*åœ¨OSæ–¹é¢ï¼Œpembolizumab+CTåœ¨æ•´é«”ã€ESCCã€CPSâ‰¥10éƒ½å„ªæ–¼å–®æ‰“CTï¼Œå°¤å…¶åœ¨ECC CPSâ‰¥10ç—…äººä¸­è¡¨ç¾æ›´å¥½ (figure 6)ã€‚\r\n*åœ¨PFSæ–¹é¢ï¼Œpembolizumab+CTåœ¨æ•´é«”ã€ESCCã€CPSâ‰¥10éƒ½å„ªæ–¼å–®æ‰“CTï¼Œå°¤å…¶åœ¨CPSâ‰¥10ç—…äººä¸­è¡¨ç¾æ›´å¥½ (figure 7)ã€‚\r\n*åœ¨tumor response rateæ–¹é¢: all randomised patients: 45.0% vs. 29.3%, estimated percentage difference (15.8% [95% CI 9.0â€“22.5]; p<0.0001)ã€‚\r\n*pembolizumab+CT åœ¨ESCCè·ŸEACçš„æ¯”è¼ƒ-> OS: ESCC 12.6å€‹æœˆ, EAC 11.6å€‹æœˆï¼›PFS: ESCC 6.3å€‹æœˆ, EAC 6.3å€‹æœˆ (figure 8)ã€‚",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/097/explain_figures/figure1.jpg",
      "/qabank/097/explain_figures/figure2.jpg",
      "/qabank/097/explain_figures/figure3.jpg",
      "/qabank/097/explain_figures/figure4.jpg",
      "/qabank/097/explain_figures/figure5.jpg",
      "/qabank/097/explain_figures/figure6.jpg",
      "/qabank/097/explain_figures/figure7.jpg",
      "/qabank/097/explain_figures/figure8.jpg"
    ]
  },
  {
    "id": 98,
    "question": "45æ­²å¥³æ€§å› å¥åº·æª¢æŸ¥æ„å¤–ç™¼ç¾èƒ°è‡Ÿé ­æœ‰å°è…«ç˜¤ï¼Œç¶“èƒƒé¡è¶…éŸ³æ³¢åˆ‡ç‰‡æª¢æŸ¥é¡¯ç¤ºwell differentiated neuroendocrine tumorã€Grade 1ã€Ki67 <3%ï¼Œç—…äººçš„å…¶ä»–å½±åƒæª¢æŸ¥ä¸¦æ²’æœ‰é ç«¯æˆ–æ·‹å·´è½‰ç§»ã€‚æ ¹æ“šNCCN Guidelines 2024ï¼Œä¸‹åˆ—å¾ŒçºŒæ²»ç™‚å»ºè­°ä¸­ï¼Œåˆå®œçš„æœ‰ï¼Ÿ\r\n(1) è‹¥ç—…äººæ˜¯éåŠŸèƒ½æ€§çš„ï¼Œä¸”è…«ç˜¤ < 1cmï¼Œå¯ä»¥å…ˆè§€å¯Ÿã€‚\r\n(2) è‹¥ç—…äººæ˜¯åŠŸèƒ½æ€§çš„(æœ‰carcinoid syndrome)ï¼Œä¸”è…«ç˜¤ < 1cmï¼Œä¹Ÿå¯ä»¥å…ˆè§€å¯Ÿæˆ–æ‰“ somatostatin analogã€‚\r\n(3) è‹¥ç—…äººæ˜¯éåŠŸèƒ½æ€§çš„ï¼Œä¸”è…«ç˜¤ > 2cmï¼Œå»ºè­°pancreatectomyã€‚\r\n(4) è‹¥ç—…äººæ˜¯MEN1ï¼Œä¸ç®¡è…«ç˜¤å¤§å°ï¼Œéƒ½å»ºè­°pancreatectomyã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "åƒè€ƒNCCN Guideline - Neuroendocrine Tumors of the Pancreas (Well-Differentiated Grade 1/2)\r\n\r\n(1) è‹¥ç—…äººæ˜¯éåŠŸèƒ½æ€§çš„ï¼Œä¸”è…«ç˜¤ < 1cmï¼Œå¯ä»¥å…ˆè§€å¯Ÿ (figure 1)ã€‚\r\n(3) è‹¥ç—…äººæ˜¯éåŠŸèƒ½æ€§çš„ï¼Œä¸”è…«ç˜¤ > 2cmï¼Œå»ºè­°pancreatectomy (figure 1)ã€‚\r\n(2) functional panNET: ä¸ç®¡å¤§å°ï¼Œéƒ½å»ºè­°åˆ‡é™¤ã€‚(figure 2-7)\r\n(4) PanNET with MEN1 å»ºè­°æ‰‹è¡“çš„æƒ…æ³: functional tumor, å°è—¥ç‰©æ²»ç™‚ç„¡æ•ˆã€tumor å¤§æ–¼2å…¬åˆ†ã€tumoråœ¨6-12å€‹æœˆé–“é•·å¤ªå¿« (figure 8)ã€‚\r\né †æ‰‹è¤‡ç¿’MEN1, MEN2 (figure 9)ã€‚",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/098/explain_figures/figure1.jpg",
      "/qabank/098/explain_figures/figure2.jpg",
      "/qabank/098/explain_figures/figure3.jpg",
      "/qabank/098/explain_figures/figure4.jpg",
      "/qabank/098/explain_figures/figure5.jpg",
      "/qabank/098/explain_figures/figure6.jpg",
      "/qabank/098/explain_figures/figure7.jpg",
      "/qabank/098/explain_figures/figure8.jpg",
      "/qabank/098/explain_figures/figure9.jpg"
    ]
  },
  {
    "id": 99,
    "question": "Which of the following statements about management of advanced or metastatic gastrointestinal stromal tumor (GIST) are (is) correct?\r\n(1) Imatinib is the standard first line therapy, and could achieve a progression-free survival (PFS) around 2-3 years and an overall survival (OS) around 5-6 years.\r\n(2) Avapritinib is highly effective in GIST patients with PDGFRA exon 18 D842V mutation.\r\n(3) Sunitinib is the standard second line therapy and is effective against tumors with KIT exon 13/14 mutant.\r\n(4) Ripretinib is the standard fourth line therapy.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "(1) å¾UpToDateçš„ä¸€æ®µï¼Œå¼•ç”¨è‡ªMohammadi M, IJzerman NS, Hollander DD, et al. Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data. Target Oncol. 2023;18(3):415-423.â€œSubsequent retrospective registry studies of patients with advanced GIST treated with imatinib have reported a median progression-free survival of 33 months and overall survival of 68 months.â€\r\n\r\n(2) æœ‰PDGFRA exon 18 D842Vï¼Œè¦ç”¨avapritinibï¼Œå°imatinibæœ‰æŠ—è—¥æ€§ (figure 1)ã€‚\r\n\r\n(3) ç¬¬äºŒç·š: sunitinib (figure 1)ã€‚å°æ–¼secondary KIT exon 13/14 mutationsçš„æ•ˆæœå„ªæ–¼secondary KIT exon 17/18 mutationsã€‚\r\nHeinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26(33):5352-5359. â€œBoth PFS and OS were significantly longer for patients with secondary KIT exon 13 or 14 mutations than for those with exon 17 or 18 mutations (PFS: 7.8 vs. 2.3 months; OS: 13 vs. 4 months).â€\r\n\r\n(4) ç¬¬å››ç·š: ripretinib (figure 1)ã€‚\r\n<æ ¡ç¨¿è£œå……> Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:923-934.\r\n-- æ”¶éŒ„ç—…äºº: Advanced GIST, progression on at least imatinib, sunitinib, and regorafenib or documented intolerance to any of these treatments\r\n-- Ripretinibæ¯”èµ·å®‰æ…°åŠ‘ï¼Œæ˜é¡¯æ”¹å–„mPFSã€æœ‰acceptable safety. \r\n significantly improved median progression-free survival compared with placebo and had an acceptable safety profile in patients with advanced gastrointestinal stromal tumours who were resistant to approved treatments.",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/099/explain_figures/figure1.jpg"
    ]
  },
  {
    "id": 100,
    "question": "Regarding the diagnosis and staging of biliary tract cancer, which of the following statements are (is) correct?\r\n(1) For resectable intrahepatic cholangiocarcinoma, resection and regional lymphadenectomy is necessary for accurate staging and treatment.\r\n(2) For isolated intrahepatic mass (imaging characteristics consistent with malignancy but not consistent with hepatocellular carcinoma), tumor biopsy is mandatory for diagnosis and molecular testing.\r\n(3) Testing for MSI or MMR deficiency is recommended in patients with unresectable or metastatic gallbladder cancer, intrahepatic CCA.\r\n(4) Comprehensive molecular profiling is recommended for patients with unresectable or metastatic BTC who are candidates for systemic therapy.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "(1)(2) è©³è¦‹figure 1, 2ã€‚\r\n(3) å¾è¡¨æ ¼å»ºè­°çš„molecular testingï¼Œä¸è«–æ˜¯gallbladder cancerã€intrahepatic CCAæˆ–extrahepatic CCAï¼Œéƒ½å»ºè­°æ¸¬MSI-H/dMMRã€‚FGFR fusion/rearrangementå’ŒIDH1 mutationåœ¨gallbladder cancer ä¸å»ºè­°æ¸¬ï¼Œå› ç‚ºç™¼ç”Ÿç‡å¾ˆä½ (figure 3, 4)ã€‚\r\n(4) ç›´æ¥è¤‡è£½è²¼ä¸Šguidedlineä¸Šçš„æ–‡å­—æ•˜è¿° (figure 5)ã€‚",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/100/explain_figures/figure1.jpg",
      "/qabank/100/explain_figures/figure2.jpg",
      "/qabank/100/explain_figures/figure3.jpg",
      "/qabank/100/explain_figures/figure4.jpg",
      "/qabank/100/explain_figures/figure5.jpg"
    ]
  },
  {
    "id": 101,
    "question": "Regarding the treatment choice of advanced pancreatic adenocarcinoma, which of the following statements are (is) correct?\r\n(1) Induction chemotherapy preferred 4-6 months followed by chemoradiation in selected locally advanced without systemic metastatic disease.\r\n(2) Recommended adjuvant therapy options apply to patients who do not receive prior neoadjuvant therapy.\r\n(3) First line treatment for metastatic disease could be FOLFIRINOX or NALIRIFOX (liposomal irinotecan, oxaliplatin, leucovorin, and fluorouracil).\r\n(4) For known BRCA1/2 or PALB2 mutation first line treatment for metastatic disease could be gemcitabine + albumin-bound paclitaxel.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "(1) Induction chemotherapy preferred 4-6 months followed by chemoradiation in selected locally advanced without systemic metastatic disease.\r\nCorrect\r\n*NCCN Guidelines Version 2.2025. PANC-6 (Figure1)\r\n-In patients with locally advanced, unresectable disease \r\n-- Good or intermediate performance status\r\n--> initial systemic chemotherapy for 4-6 months \r\n--> In selected patients (good performance status+ no systemic metastases): consolidation chemoradiation or SBRT\r\n-- Poor PS: single agent chemotherapy or palliative RT \r\n\r\nåƒè€ƒtrial\r\n*LAP07 Trial (Hammel et al., JAMA Oncology, 2016): no clear survival benefit with the addition of conventional chemoradiation following gemcitabine monotherapy. Chemoradiation may improve local control and delay the need for resumption therapy\r\n\r\n\r\n(2) Correct, Recommended adjuvant therapy options apply to patients who do not receive prior neoadjuvant therapy.\r\n*NCCN Guidelines Version 2.2025. PANC-6ã€PANC-8ã€PANC-F (2 OF 13) (Figure2)(Figure3)\r\n- Recommended adjuvant therapy options apply to patients who did not receive prior neoadjuvant therapy.\r\n-- For those who received prior neoadjuvant therapy, the adjuvant therapy options are dependent on the response to neoadjuvant therapy and other clinical considerations.\r\n(å»ºè­°çš„è¼”åŠ©æ²»ç™‚é¸é …é©ç”¨æ–¼æœªæ¥å—neoadjuvantçš„æ‚£è€…ã€å°æ–¼æ›¾æ¥å—neoadjuvantçš„æ‚£è€…ï¼Œè¼”åŠ©æ²»ç™‚é¸é …éœ€è€ƒæ…®å°neoadjuvantçš„åæ‡‰ä»¥åŠå…¶ä»–è‡¨åºŠè€ƒé‡å› ç´ ã€‚)\r\n- Adjuvant treatment should be administered to patients who have adequately recovered from surgery; treatment should be initiated ideally within 12 weeks\r\n\r\n(3) Correct, First line treatment for metastatic disease could be FOLFIRINOX or NALIRIFOX (liposomal irinotecan, oxaliplatin, leucovorin, and fluorouracil).\r\n*NCCN Guidelines Version 2.2025. PANC-F 5 OF 13\r\n- recommended first line therapy\r\n--â€¢FOLFIRINOX (category 1) or modified FOLFIRINOX (*a)\r\n--â€¢Gemcitabine + albumin-bound paclitaxel (category 1) (*b)\r\n--â€¢NALIRIFOX (category 1) (*c)\r\n\r\nåƒè€ƒtrial (3ç¯‡)\r\n*a Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-1825. \r\n*a-1 ç ”ç©¶æ–¹æ³• \r\n-- éš¨æ©Ÿåˆ†é… 342 åECOG 0 æˆ– 1 çš„æ‚£è€…ï¼Œæ¥å— FOLFIRINOX æˆ– gemcitabine æ²»ç™‚ã€‚\r\n(FOLFIRINOX= oxaliplatin, 85 mg/m2; irinotecan, 180 mg/m2; leucovorin, 400 mg/m2; and fluorouracil, 400mg/m2 bolus + 2400mg/m2 46-houré€£çºŒè¼¸æ³¨, Q2wks)\r\n(Gemcitabine 1000 mg/m2 Qwk, 7 of 8 weeks and then Qwk for 3 of 4 weeks) æ¯é€±çµ¦è—¥7å‘¨ã€ç¬¬8å‘¨ä¼‘æ¯ï¼Œå†ä¾†æ¯é€±çµ¦è—¥3å‘¨ã€ç¬¬4å‘¨ä¼‘æ¯\r\n-- ç™‚ç¨‹6å€‹æœˆ(who had a response)\r\n-- The primary end point= overall survival.\r\n*a-2 ç ”ç©¶çµæœ\r\n-- mOS: FOLFIRINOX çµ„ç‚º 11.1 å€‹æœˆï¼ŒGemcitabine çµ„ç‚º 6.8 å€‹æœˆ(hazard ratio for death, 0.57ï¼ŒP<0.001)(Figure4)\r\n-- mPFS: FOLFIRINOX çµ„ç‚º 6.4 å€‹æœˆï¼ŒGemcitabine çµ„ç‚º 3.3 å€‹æœˆ(hazard ratio for disease progression, 0.47ï¼ŒP<0.001)(Figure5)\r\n-- ORR: FOLFIRINOX çµ„ç‚º 31.6%ï¼ŒGemcitabine çµ„ç‚º 9.4% (P<0.001)\r\n-- ä¸è‰¯äº‹ä»¶: FOLFIRINOX çµ„è¼ƒå¤šï¼Œå…¶ä¸­ 5.4% Febrile Neutropenia \r\n-- 6å€‹æœˆæ™‚çš„ç”Ÿæ´»å“è³ªæ˜é¡¯ä¸‹é™: FOLFIRINOX çµ„31%ï¼Œè€Œ gemcitabine çµ„å‰‡ç‚º 66% (hazard ratio, 0.47; P<0.001).(Figure6)\r\n*a-3 çµè«–\r\nAs compared with gemcitabine, FOLFIRINOX was associated with a survival advantage and had increased toxicity. FOLFIRINOX is an option for the treatment of patients with metastatic pancreatic cancer and good performance status.\r\n\r\n\r\n*b Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-1703.\r\n*b-1 ç ”ç©¶æ–¹æ³• \r\néš¨æ©Ÿåˆ†é… Karnofsky performance-status 70 åˆ†ä»¥ä¸Šçš„metastatic pancreatic canceræ‚£è€…æ¥å— nab-paclitaxel+gemcitabine æˆ–æ˜¯gemcitabine monotherapy\r\n(nab-paclitaxel 125 mg/m2èˆ‡ Gemcitabine 1000 mg/m2ï¼Œæ–¼æ¯ 4 é€±çš„ç¬¬ 1ã€8 å’Œ 15 å¤©çµ¦äºˆ)\r\n(Gemcitabine 1000 mg/m2å–®ç”¨ï¼Œåœ¨ç¬¬ 1 å€‹ç™‚ç¨‹ä¸­ï¼Œæ¯é€±æ‰“ï¼Œ7 é€±å¾Œåœ1é€±ï¼Œå¾ç¬¬ 2 å€‹ç™‚ç¨‹èµ·ï¼Œæ¯ 4 é€±çš„ç¬¬ 1ã€8 å’Œ 15 å¤©çµ¦äºˆ)\r\n-- ç™‚ç¨‹æ‰“åˆ°disease progression\r\n-- The primary end point= OS.\r\n-- The secondary end point= PFS and overall response rate.\r\n\r\n*b-2 ç ”ç©¶çµæœ\r\n-- 431 vs 430äºº\r\n-- mOS: Nab-paclitaxelâ€“gemcitabine çµ„ 8.5 å€‹æœˆï¼ŒGemcitabine çµ„å‰‡ç‚º 6.7 å€‹æœˆ(hazard ratio for death, 0.72ï¼›P<0.001)(Figure7)\r\n--1 å¹´OSï¼šnab-paclitaxelâ€“gemcitabine çµ„ç‚º 35%ï¼ŒGemcitabine çµ„ç‚º 22%ã€‚\r\n--2 å¹´OSï¼šnab-paclitaxelâ€“gemcitabine çµ„ç‚º 9%ï¼ŒGemcitabine çµ„ç‚º 4%ã€‚\r\n-- mPFS: Nab-paclitaxelâ€“gemcitabine çµ„ 5.5 å€‹æœˆï¼ŒGemcitabine çµ„å‰‡ç‚º 3.7 å€‹æœˆ(hazard ratio for disease progression or death, 0.69ï¼›P<0.001)(Figure8)\r\n-- ORR: Nab-paclitaxelâ€“gemcitabine çµ„ç‚º 23%ï¼ŒGemcitabine çµ„ç‚º 7%ï¼ˆP<0.001ï¼‰\r\n-- 3 ç´šæˆ–ä»¥ä¸Šæœ€å¸¸è¦‹çš„ä¸è‰¯äº‹ä»¶ï¼šNab-paclitaxelâ€“gemcitabine çµ„æ¯”è¼ƒå¤š --> Neutropenia (38% vs. 27%)ã€Fatigue (17% vs7%)ã€Neuropathy(17% vs1%)\r\n-- å…¶ä»–ä¸è‰¯äº‹ä»¶: Febrile neutropenia(3% vs. 1%)\r\n\r\n*b-3 çµè«–\r\nIn patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased.\r\n\r\n\r\n\r\n*c Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 2023;402:1272-1281.\r\n*c-1 ç ”ç©¶æ–¹æ³•\r\n-- randomised, open-label, phase 3 study\r\n-- mPDACï¼Œä¸”ECOG 0 æˆ– 1ã€‚æ‚£è€…ä»¥ 1:1 çš„æ¯”ä¾‹éš¨æ©Ÿåˆ†é…è‡³NALIRIFOX çµ„æˆ–Nab-paclitaxel + Gemcitabine çµ„\r\n(NALIRIFOX çµ„ï¼šLiposomal irinotecan 50 mg/mÂ², Oxaliplatin 60 mg/mÂ², Leucovorin 400 mg/mÂ², Fluorouracil 2400 mg/mÂ² 46 å°æ™‚æŒçºŒè¼¸æ³¨ã€‚æ¯ 28 å¤©é€±æœŸçš„ç¬¬ 1 å¤©èˆ‡ç¬¬ 15 å¤©)\r\n(Nab-paclitaxel + Gemcitabine çµ„ï¼šNab-paclitaxel 125 mg/mÂ², Gemcitabine 1000 mg/mÂ²ã€‚æ¯ 28 å¤©é€±æœŸçš„ç¬¬ 1ã€8 å’Œ 15 å¤©çµ¦äºˆ)\r\n-- The primary end point= OS.\r\n\r\n*c-2 ç ”ç©¶çµæœ\r\n-- 383 vs 387äºº\r\n-- mOS: NALIRIFOX 11.1 å€‹æœˆã€Nab-paclitaxel + Gemcitabine çµ„ 9.2 å€‹æœˆã€(hazard ratio for death, 0.83ï¼›p=0.036)(Figure9)(Figure10)\r\n-- 3 ç´šæˆ–ä»¥ä¸Šæ²»ç™‚ç›¸é—œä¸è‰¯äº‹ä»¶: NALIRIFOX çµ„ 87%ã€Nab-paclitaxel + Gemcitabine çµ„ 86% \r\n-- æ²»ç™‚ç›¸é—œæ­»äº¡ï¼ˆTreatment-related deathsï¼‰ï¼šå…©çµ„å‡ç‚º2%\r\n\r\n*c-3 çµè«–\r\nThe use of the NALIRIFOX regimen as a possible reference regimen for first-line treatment of mPDAC.\r\n\r\n\r\n\r\n(4) Incorrect, For known BRCA1/2 or PALB2 mutation first line treatment for metastatic disease could be gemcitabine + albumin-bound paclitaxel.\r\næ‡‰ä¿®æ­£ç‚ºGem-Cis\r\n*NCCN Guidelines Version 2.2025. PANC-F 5 OF 13 (Figure11)\r\n- Only for known BRCA1/2 or PALB2 mutations:\r\n--â€¢FOLFIRINOX (category 1) or modified FOLFIRINOX (è¦‹é¸é …3çš„*a trial)\r\n--â€¢Gemcitabine + cisplatin (*d)\r\n\r\nåƒè€ƒtrial\r\n*d O'Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol 2020;38:1378-1388.\r\n\r\n*d-1 ç ”ç©¶æ–¹æ³•\r\n-- æœªç¶“æ²»ç™‚çš„gBRCA/PALB2 é™½æ€§ pancreas adenocarcinoma with measurable stage III to IV, ECOG 0 to 1.\r\n-- åˆ†åˆ¥æ¥å— A çµ„ Cisplatin+Gemcitabine å¦ä¸€çµ„ B çµ„ Cis+Gem+Veliparib 80mg\r\n(A çµ„Cisplatin 25 mg/mÂ² + Gemcitabine 600 mg/mÂ²ï¼Œæ–¼ ç¬¬ 3 å¤©å’Œç¬¬ 10 å¤©çµ¦è—¥)\r\n(B çµ„èˆ‡ A çµ„ç›¸åŒï¼Œå†åŠ ä¸Š Veliparib 80 mgï¼Œæ¯æ—¥å£æœå…©æ¬¡ï¼Œå¾ç¬¬ 1 å¤©è‡³ç¬¬ 12 å¤©ï¼Œæ¯3 é€±ç‚º 1 å€‹æ²»ç™‚é€±æœŸ)\r\n-- The primary end point= response rate (RR)\r\n-- Secondary end points: PFS, disease control rate (DCR), OS, safety, and correlative analyses.\r\n\r\n*d-2 ç ”ç©¶çµæœ\r\n-- RR: 74.1% vs 65.2% (P = 0.55) å…©çµ„å‡è¶…éé å…ˆè¨­å®šçš„ç™‚æ•ˆé–¾å€¼ã€‚(Figure12)\r\n-- DCR: 100% vs 78.3%(P = 0.02)\r\n-- mPFS: 10.1 å€‹æœˆ vs 9.7 å€‹æœˆ(P = 0.73)\r\n-- mOS: 15.5 å€‹æœˆ vs 16.4 å€‹æœˆ(P = 0.6)\r\n-- 2yr OS(entire cohort) 30.6%ã€3yr OS(entire cohort) 17.8% \r\n-- 3 è‡³ 4 ç´šè¡€æ¶²å­¸æ¯’æ€§ A çµ„è¼ƒå¤š: Neutropenia 13(48%) vs 7(30%)ã€Thrombocytopenia 15(55%) vs 2(9%)ã€Anemia 14(52%) vs 8(35%)\r\n\r\n*d-3 çµè«–\r\nCisplatin and gemcitabine is an effective regimen in advanced gBRCA/PALB2+ PDAC. Concurrent veliparib did not improve RR.",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/101/explain_figures/Figure1.jpg",
      "/qabank/101/explain_figures/Figure10.jpg",
      "/qabank/101/explain_figures/Figure11.jpg",
      "/qabank/101/explain_figures/Figure12.jpg",
      "/qabank/101/explain_figures/Figure2.jpg",
      "/qabank/101/explain_figures/Figure3.jpg",
      "/qabank/101/explain_figures/Figure4.jpg",
      "/qabank/101/explain_figures/Figure5.jpg",
      "/qabank/101/explain_figures/Figure6.jpg",
      "/qabank/101/explain_figures/Figure7.jpg",
      "/qabank/101/explain_figures/Figure8.jpg",
      "/qabank/101/explain_figures/Figure9.jpg"
    ]
  },
  {
    "id": 102,
    "question": "Regarding the treatment of advanced hepatocellular carcinoma, which of the following statements are (is) correct?\r\n(1) Preferred first line treatment choice for Child Pugh A HCC patient is atezolizumab + bevacizumab or tremelimumab + durvalumab.\r\n(2) Subsequent-line systemic therapy for disease progression option could be cabozantinib, regorafenib, lenvatinib or sorafenib.\r\n(3) Subsequent-line systemic therapy for disease progression could be ramucirumab for those with AFP â‰¥400 ng/mL.\r\n(4) Immune checkpoint inhibition has shown clinical benefit in HCC patients without selection for microsatellite instability (MSI), mismatch repair (MMR), tumor mutational burden (TMB), or programmed death ligand 1 (PD-L1) testing status.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "(1) Preferred first line treatment choice for Child Pugh A HCC patient is atezolizumab + bevacizumab or tremelimumab + durvalumab.\r\nCorrect! (for unresectable HCC)\r\n*NCCN Guidelines Version 4.2024,  HCC-5ã€ HCC-I 1 OF 2 (Figure1)\r\n-First-Line Systemic Therapy\r\n--Preferred Regimens\r\n--â€¢ Atezolizumabd + bevacizumab (category 1) (*a: Updated IMbrave150)\r\n--â€¢ Tremelimumab-actl + durvalumab (category 1) (*b: HIMALAYA trial) \r\n-- Caution: æ‰€åˆ—çš„æ²»ç™‚æ–¹å¼åœ¨ Child B or C liver function çš„safety dataå¾ˆæœ‰é™\r\n\r\n*ç›¸é—œtrial (2ç¯‡)\r\n*a Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022;76:862-873.\r\n*a-1ç ”ç©¶æ–¹æ³•\r\n-- open-label, phase III study\r\n-- æœªæ¥å—éå…¨èº«æ€§æ²»ç™‚ä¸”ä¸å¯åˆ‡é™¤çš„HCC\r\n-- 2:1çš„æ¯”ä¾‹éš¨æ©Ÿåˆ†é…è‡³ï¼šAtezolizumab+bevacizumab æˆ–æ˜¯ Sorafenibçµ„åˆ¥\r\n(Atezolizumab 1,200 mg + Bevacizumab 15 mg/kg Q3wk)\r\n(Sorafenib 400 mg BID)\r\n-- Co-primary endpoints= OS and PFS\r\n-- Secondary efficacy endpoints= objective response rates(ORR)ã€exploratory subgroup efficacy analyses.\r\n\r\n*a-2ç ”ç©¶çµæœ\r\n--å…±501ç—…äºº(ITT)ï¼ŒA+B(n = 336)ã€Sorafenib(n = 165)(Figure2)\r\n--mOS: 19.2 å€‹æœˆ vs 13.4 å€‹æœˆï¼ŒHR 0.66, descriptive p <0.001\r\n--mPFS: 6.9 å€‹æœˆ vs 4.3 å€‹æœˆï¼ŒHR 0.65, descriptive p <0.001\r\n--æ²»ç™‚ç›¸é—œçš„ 3/4 ç´šAE: 143 äºº(43%ï¼Œn = 329) vs 72 äºº(46%ï¼Œn = 156)\r\n--æ²»ç™‚ç›¸é—œçš„ 5 ç´šAE: 6 äºº(2%) vs 1 äºº(<1%)\r\n--Objective response: 97äºº(30%) vs 18äºº(11%)(Figure3)\r\n\r\n*a-3çµè«–\r\nIMbrave150 (Published May 13, 2020 N Engl J Med 2020;382:1894-1905)çš„ä¸»è¦åˆ†æé¡¯ç¤ºï¼ŒA+Bç›¸è¼ƒæ–¼Sorafenibï¼Œåœ¨advanced HCC æ‚£è€…ä¸­å…·æœ‰é¡¯è‘—æ›´å¤§çš„ç™‚æ•ˆå„ªå‹¢ï¼Œä½†ç•¶æ™‚survival dataå°šæœªæˆç†Ÿã€‚åœ¨12 å€‹æœˆå¾Œé€²è¡Œçš„æ›´æ–°åˆ†æä¸­ï¼Œé¡¯ç¤ºA+Bçµ„çš„mOSè¼ƒ Sorafenib çµ„å»¶é•· 5.8 å€‹æœˆï¼Œä¸”æ²»ç™‚ç›¸é—œAEçš„åš´é‡ç¨‹åº¦èˆ‡å…ˆå‰çµæœç›¸ä¼¼ã€‚é€™äº›æ›´æ–°çµæœé€²ä¸€æ­¥ç¢ºèªï¼ŒA+Bå·²æˆç‚ºadvanced HCCçš„ä¸€ç·šæ¨™æº–æ²»ç™‚\r\n\r\n*b Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022;1:EVIDoa2100070.\r\n*b-1ç ”ç©¶æ–¹æ³•\r\n-- open-label, phase 3 trial\r\n-- æœªæ¥å—éå…¨èº«æ€§æ²»ç™‚ä¸”ä¸å¯åˆ‡é™¤çš„HCC\r\n-- éš¨æ©Ÿåˆ†é…è‡³3çµ„: Tremelimumab+Durvalumabã€å–®ç”¨durvalumabã€Sorafenib\r\n(Tremelimumab 300 mg å–®æ¬¡çµ¦è—¥+ Durvaluma 1500 mg q4wks)= STRIDE (Single Tremelimumab Regular Interval Durvalumab) \r\n(å–®ç”¨durvalumab 1500 mg q4wks)\r\n(Sorafenib 400 mg BID)\r\n-- The primary endpoint= OS for STRIDE vs Sorafenib\r\n-- The secondary objective= Noninferiority for OS for Durvalumab versus Sorafenib\r\n\r\n*b-2ç ”ç©¶çµæœ\r\n--N=1171ï¼šSTRIDE(n = 393)ã€Durvalumab(n = 389)ã€æˆ–Sorafenib(n = 389)\r\n--mOS: 16.43å€‹æœˆ vs 16.56 å€‹æœˆ vs 13.77 å€‹æœˆ (Figure4)\r\n--> STRIDE æ¯”èµ· Sorafenibï¼ŒOSçš„HR= 0.78ã€P=0.0035\r\n--> Durvalumab monotherapyä¸äºæ–¼ (noninferior to) sorafenib (HR, 0.86; 95.67% CI, 0.73 to 1.03; noninferiority margin, 1.08)\r\n--Overall survival at 36 months: 30.7% vs 24.7% vs 20.2%\r\n--mPFS: ä¸‰çµ„æ²’æœ‰å·®ç•°(Figure5)\r\n--æ²»ç™‚ç›¸é—œçš„ 3/4 ç´šAE: 50.5% vs 37.1% vs 52.4%\r\n \r\n*b-3çµè«–\r\nFor unresectable HCC\r\n--STRIDE significantly improved OS versus sorafenib. \r\n--Durvalumab monotherapy was noninferior to sorafenib.\r\n\r\n\r\n(2) Subsequent-line systemic therapy for disease progression option could be cabozantinib, regorafenib, lenvatinib or sorafenib.\r\nCorrect! \r\n*NCCN Guidelines Version 4.2024, HCC-I 1 OF 2\r\n- Subsequent-Line Systemic Therapy if Disease Progression\r\n-- Options \r\n-- â€¢ Cabozantinib (category 1) (*c)\r\n-- â€¢ Regorafenib (category 1) (*d) \r\n-- â€¢ Lenvatinib \r\n-- â€¢ Sorafenib\r\n-- 1ç·šæ²»ç™‚ä¹‹å¾Œï¼Œç›®å‰ç¼ºä¹æ¯”è¼ƒæ•¸æ“šä¾†ç¢ºå®šæœ€ä½³æ²»ç™‚é¸æ“‡\r\n\r\n\r\n*ç›¸é—œtrial (2ç¯‡)\r\n*c Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379:54-63.\r\n*c-1ç ”ç©¶æ–¹æ³•\r\n-- Randomized, double-blind, phase 3 trial\r\n-- æ”¶éŒ„æ›¾æ¥å—Sorafenibæ²»ç™‚ï¼Œç”¨é1-2ç·šå…¨èº«æ²»ç™‚å¾Œprogressionçš„ç—…äºº\r\n-- Cabozantinib æŠ‘åˆ¶tyrosine kinases (åŒ…å«VEGFR 1, 2, and 3, MET, and AXL)\r\n-- N= 707, éš¨æ©Ÿ2:1åˆ†é…è‡³ Cabozantinib (60 mg QD) æˆ– Placebo\r\n-- The primary end point= OS\r\n-- The secondary end point= PFS, ORR\r\n\r\n*c-2ç ”ç©¶çµæœ\r\n--mOS: 10.2 å€‹æœˆ vs 8.0 å€‹æœˆ (HR for death, 0.76; P=0.005)(Figure6)\r\n--mPFS: 5.2 å€‹æœˆ vs 1.9 å€‹æœˆ (HR for disease progression or death, 0.44; P<0.001)(Figure7)\r\n--ORR: 4% vs <1% (P=0.009)\r\n--Grade 3 or 4 AEs: Cabozantinibå¤šæ–¼å®‰æ…°åŠ‘çµ„åˆ¥ 68% vs 36%\r\n--> palmarâ€“plantar erythrodysesthesia (17% vs. 0%), hypertension (16% vs. 2%), ASTä¸Šå‡ (12% vs. 7%), fatigue (10% vs. 4%), and diarrhea (10% vs. 2%).\r\n\r\n*c-3çµè«–\r\n--åœ¨å…ˆå‰æ¥å—éæ²»ç™‚çš„advanced HCC, Cabozantinib æ¯”èµ·å®‰æ…°åŠ‘æœ‰æ›´é•·çš„OSèˆ‡PFSï¼Œä½†ä¹Ÿæœ‰æ›´å¤šçš„high-grade AE (ç´„ç‚º2å€)\r\n\r\n\r\n*d Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomized, double blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.\r\n\r\n*d-1ç ”ç©¶æ–¹æ³•\r\n--Randomised, double-blind, parallel-group, phase 3 trial\r\n--æ”¶éŒ„under Sorafenibæ²»ç™‚(â‰¥400 mg/day for â‰¥20 of last 28 days of treatment)ï¼Œå»PDçš„ç—…äººï¼Œéœ€ Child-Pugh A\r\n--éš¨æ©Ÿ2:1åˆ†é…è‡³ å£æœ Regorafenib æˆ– å¦ä¸€çµ„ å®‰æ…°åŠ‘ ï¼Œå…©çµ„éƒ½æœ‰æœ€ä½³æ”¯æŒæ²»ç™‚(BSC)\r\n(Regorafenib 160 mg QDï¼Œåƒä¸‰å‘¨ä¼‘ä¸€å‘¨ï¼Œ4å‘¨ç‚ºä¸€å¾ªç’°)\r\n-- The primary end point= OS\r\n\r\n*d-2ç ”ç©¶çµæœ\r\n--N=573éš¨æ©Ÿåˆ†é…ï¼ŒRegorafenib 379ã€Placebo 194 (For efficacy analyses)\r\n--N=567æ¥å—æ²»ç™‚ï¼ŒRegorafenib 374ã€Placebo 193 (For safety analyses)\r\n--mOS: 10.6 å€‹æœˆ vs 7.8 å€‹æœˆ (HR 0.63;one-sided p<0Â·0001) (Figure8)\r\n--AEs: 100% vs 93%\r\n--Grade 3 or 4 AEs: Regorafenibçµ„å¤šæ–¼Placebo\r\n--> hypertension 57(15%) vs 9(5%)ï¼Œ handâ€“foot skin reaction 47(13%) vs 1(1%), fatigue 34(9%) vs 9(5%), and diarrhoea 12(3%) vs 0\r\n--æ²»ç™‚ç›¸é—œæ­»äº¡(Grade 5 AE): å…±ç™¼ç”Ÿ88ä¾‹(50 vs 38)ï¼Œå…¶ä¸­æœ‰9ä¾‹è¢«èªç‚ºèˆ‡è©¦é©—è—¥ç‰©ç›¸é—œï¼ŒRegorafenib çµ„ 7 ä¾‹(2%)ã€å®‰æ…°åŠ‘çµ„ 2 ä¾‹(1%ã€ç‚ºè‚è¡°ç«­)\r\n\r\n*d-3Interpretation\r\nRegorafenib is the only systemic treatment shown to provide survival benefit in HCC patients progressing on sorafenib treatment.\r\n\r\n(3) Subsequent-line systemic therapy for disease progression could be ramucirumab for those with AFP â‰¥400 ng/mL.\r\nCorrect!\r\n*NCCN Guidelines Version 4.2024, HCC-I 1 OF 2 (Figure9)\r\n- Subsequent-Line Systemic Therapy if Disease Progression\r\n-- Useful in Certain Circumstances\r\n-- â€¢ Ramucirumab (AFP â‰¥400 ng/mL) (category 1) (*e =REACH-2 trial)\r\n-- â€¢ Nivolumab \r\n-- â€¢ For MSI-H/dMMR tumors: Dostarlimab-gxly (category 2B) \r\n-- â€¢ For RET gene fusion-positive tumors: Selpercatinib (category 2B)\r\n\r\n*ç›¸é—œtrial (1ç¯‡)\r\n*e Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased Î±-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20:282-296.\r\n\r\n*e-1ç ”ç©¶æ–¹æ³•\r\n--Randomised, double-blind, placebo-controlled, phase 3 trial\r\n--ç¬¦åˆæ¢ä»¶éœ€è¦å¹´æ»¿ 18 æ­²ï¼Œä¸¦ä¸”å…·å‚™ä»¥ä¸‹æ¢ä»¶ï¼š\r\n--1.ç¶“çµ„ç¹”å­¸æˆ–ç´°èƒå­¸ç¢ºè¨ºç‚ºHCCï¼Œæˆ–è‚ç¡¬åŒ–åˆä½µ HCC\r\n--2.BCLC B æœŸæˆ– C æœŸç–¾ç—…\r\n--3.Child-Pugh A ç´šè‚åŠŸèƒ½\r\n--4.ECOG 0 æˆ– 1\r\n--5.AFP â‰¥400 ng/mL\r\n--6.æ›¾æ¥å— Sorafenib ä¸€ç·šæ²»ç™‚\r\n--éš¨æ©Ÿåˆ†é…2:1è‡³ Ramucirumab çµ„(8 mg/kg Q2wks)æˆ– å®‰æ…°åŠ‘çµ„ï¼Œå…©çµ„å‡æœ‰æœ€ä½³æ”¯æŒæ²»ç™‚(BSC)\r\n--The primary end point= OS\r\n--The secondary endpoints= PFSã€ORRã€time to radiographic progression, safety, time to deterioration in scores on the Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8 (FHSI-8), and time to deterioration in ECOG\r\n--æ­¤ç ”ç©¶é‚„åˆä½µåˆ†æäº† REACH-2 åŠ REACH(NCT01140347)è©¦é©—ä¸­ AFP æ¿ƒåº¦ â‰¥400 ng/mL çš„æ‚£è€…å€‹é«”æ•¸æ“š\r\n\r\n*e-2ç ”ç©¶çµæœ\r\n--N=292, Ramucirumab 197ã€Placebo 95\r\n--Ramucirumab çµ„ç›¸è¼ƒæ–¼å®‰æ…°åŠ‘çµ„ï¼ŒOSå’ŒPFSå‡é¡¯è‘—æ”¹å–„\r\n--mOS: 8.5 å€‹æœˆ vs 7.3 å€‹æœˆï¼ŒHR 0.710ã€p = 0.0199 (Figure10)\r\n--PFS: 2.8 å€‹æœˆ vs 1.6 å€‹æœˆï¼ŒHR 0.452ã€p < 0.0001\r\n--ORRæœªé”çµ±è¨ˆå­¸å·®ç•°: 9 äºº(5%) vs 1 äºº(1%)ã€p = 0.1697\r\n--FHSI-8 ç¸½åˆ†æƒ¡åŒ–æ™‚é–“æœªé”çµ±è¨ˆå­¸å·®ç•°: 3.7 å€‹æœˆ vs 2.8 å€‹æœˆã€HR 0.799ã€p = 0.238\r\n--ECOG æƒ¡åŒ–æ™‚é–“æœªé”çµ±è¨ˆå­¸å·®ç•°: HR 1.082ã€p = 0.77\r\n--3 ç´šä»¥ä¸Šæ²»ç™‚ç›¸é—œä¸è‰¯äº‹ä»¶(ç™¼ç”Ÿç‡ â‰¥5%): é«˜è¡€å£“ 25 ä¾‹(13%) vs 5 ä¾‹(5%)ã€ä½éˆ‰è¡€ç—‡ 11 ä¾‹(6%) vs 0 ä¾‹ã€ASTå‡é«˜ 6 ä¾‹(3%) vs 5 ä¾‹(5%)\r\n--ä»»ä½•ç´šåˆ¥çš„åš´é‡ä¸è‰¯äº‹ä»¶(SAEsï¼Œç„¡è«–åŸå› ): 68 ä¾‹(35%) vs 28 ä¾‹(29%)\r\n--èˆ‡æ²»ç™‚ç›¸é—œçš„æ­»äº¡äº‹ä»¶: Ramucirumab çµ„æœ‰3ä¾‹åˆ¤å®šç‚ºèˆ‡è©¦é©—æ²»ç™‚ç›¸é—œï¼šAKIã€hepatorenal syndromeã€Renal failure \r\n \r\n*e-3çµè«–\r\n--Ramucirumab ç›¸è¼ƒæ–¼å®‰æ…°åŠ‘èƒ½æ”¹å–„ æ›¾æ¥å— Sorafenib æ²»ç™‚ä¸” AFP æ¿ƒåº¦è‡³å°‘ 400 ng/mL ä¹‹HCCæ‚£è€…çš„OSã€‚\r\n--Ramucirumab was well tolerated, with a manageable safety profile\r\n\r\n\r\n(4) Immune checkpoint inhibition has shown clinical benefit in HCC patients without selection for microsatellite instability (MSI), mismatch repair (MMR), tumor mutational burden (TMB), or programmed death ligand 1 (PD-L1) testing status.\r\nCorrect!\r\n-In Nivolumab, ç›¸é—œtrial=CheckMate 040 æŒ‡å‡º All responses occurred early in treatment. Responses were observed regardless of baseline etiology and PD-L1 status.(Figure11)\r\n-In A+B, ç›¸é—œtrial=IMbrave150 æŒ‡å‡º The predictive value of PDL1 status for the efficacy of PDL1 and PD1 inhibitors or combination therapies has not been clearly shown in the case of HCC.\r\n-MSI and MMR Deficiency: MSI-high tumorsåœ¨HCCä¸å¸¸è¦‹(<3%)ï¼ŒMSI is not a practical biomarker for predicting responses to ICIs in HCC patients. (Figure12)\r\n-TMB: HCCé€šå¸¸è¡¨ç¾low tumor mutational burden (TMB). This low TMB suggests that it is unlikely to serve as a relevant biomarker for ICI response in the majority of HCC patients. (Figure13)\r\n*ç›¸é—œtrial\r\n--CheckMate 040: Efficacy and Safety of Nivolumab + Ipilimumab in Patients With Advanced HCC Previously Treated With Sorafenib \r\n--IMbrave150 \r\n--Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma, Curr. Oncol. 2023, 30(9), 8665-868",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/102/explain_figures/Figure1.jpg",
      "/qabank/102/explain_figures/Figure10.jpg",
      "/qabank/102/explain_figures/Figure11.jpg",
      "/qabank/102/explain_figures/Figure12.jpg",
      "/qabank/102/explain_figures/Figure13.jpg",
      "/qabank/102/explain_figures/Figure2.jpg",
      "/qabank/102/explain_figures/Figure3.jpg",
      "/qabank/102/explain_figures/Figure4.jpg",
      "/qabank/102/explain_figures/Figure5.jpg",
      "/qabank/102/explain_figures/Figure6.jpg",
      "/qabank/102/explain_figures/Figure7.jpg",
      "/qabank/102/explain_figures/Figure8.jpg",
      "/qabank/102/explain_figures/Figure9.jpg"
    ]
  },
  {
    "id": 103,
    "question": "Regarding the treatment choice of unresectable and metastatic biliary tract adenocarcinoma, which of the following statements are (is) correct?\r\n(1) Durvalumab + gemcitabine + cisplatin or pembrolizumab + gemcitabine + cisplatin is preferred first-line systemic therapy regimens.\r\n(2) The most common therapeutic targets (more than 10%) are FGFR2 fusion or rearrangement and IDH1 mutation in common bile duct adenocarcinoma.\r\n(3) For MSI-H/dMMR tumors pembrolizumab treatment could be recommended.\r\n(4) Germline testing is recommended for all patients with unresectable or metastatic BTC who are candidates for systemic therapy.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1) Durvalumab + gemcitabine + cisplatin or pembrolizumab + gemcitabine + cisplatin is preferred first-line systemic therapy regimens.\r\nCorrect!\r\n*NCCN Guidelines Version 6.2024, BIL-C 2 OF 5 (Figure1)\r\n-Primary Treatment for Unresectable and Metastatic Disease\r\n--Preferred Regimens\r\n--â€¢ Durvalumab + gemcitabine + cisplatin (category 1) (*a=TOPAZ-1 trial)\r\n--â€¢ Pembrolizumab + gemcitabine + cisplatin (category 1) (*b=KEYNOTE-966)\r\n--è£œå……\r\n--> Durvalumab + gemcitabine + cisplatin ä¹Ÿé©ç”¨æ–¼åœ¨æ ¹æ²»æ€§æ‰‹è¡“å¾Œè¶…é6å€‹æœˆä¸”adjuvant therapy å®Œæˆå¾Œè¶…é6å€‹æœˆå¾©ç™¼çš„æ‚£è€…\r\n--> è‹¥ä½œç‚ºå¾Œç·šæ²»ç™‚ä½¿ç”¨ï¼Œæ‡‰é™æ–¼æœªæ›¾æ¥å—écheckpoint inhibitoræ²»ç™‚çš„æ‚£è€…ï¼Œå› ç‚ºç›®å‰ç¼ºä¹é‡å°å·²æ¥å—checkpoint inhibitorå¾Œå†ä½¿ç”¨immunotherapyçš„ç›¸é—œæ•¸æ“šã€‚\r\n\r\n\r\nç›¸é—œtrial (2ç¯‡)\r\n*a Oh DY, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022;1:EVIDoa2200015. \r\n*a-1ç ”ç©¶æ–¹æ³•\r\n--double-blind, placebo-controlled, phase 3 study\r\n--å…ˆå‰æœªæ¥å—æ²»ç™‚çš„ä¸å¯åˆ‡é™¤æˆ–è½‰ç§»æ€§è†½é“ç™Œæ‚£è€…ï¼Œæˆ–å¾©ç™¼æ€§ç–¾ç—…æ‚£è€…\r\n--1:1 éš¨æ©Ÿåˆ†é…ï¼Œæ¥å—Durvalumab æˆ–å®‰æ…°åŠ‘ï¼Œå…©çµ„å‡åˆä½µgemcitabine + cisplatinæ²»ç™‚ï¼Œæœ€å¤šå…«å€‹é€±æœŸï¼Œéš¨å¾Œå–®ç¨ä½¿ç”¨durvalumab æˆ–å®‰æ…°åŠ‘until disease progression or unacceptable toxicity.\r\n--The primary objective= OS\r\n--The secondary end points= PFS, ORR, Safety.\r\n\r\n*a-2ç ”ç©¶çµæœ\r\n--N=685ï¼ŒDurvalumabçµ„(n=341)ã€Placeboçµ„(n=344)\r\n--Data cutoffæ™‚ï¼ŒDurvalumab çµ„198åæ‚£è€…(58.1%)å’Œå®‰æ…°åŠ‘çµ„226åæ‚£è€…(65.7%)å·²æ­»äº¡\r\n--mOS: 12.8å€‹æœˆ vs 11.5å€‹æœˆï¼ŒHR for OS= 0.80ï¼ŒP=0.021 (Figure2)\r\n--mPFS: 7.2å€‹æœˆ vs 5.7å€‹æœˆï¼ŒHR for PFS= 0.75ï¼ŒP=0.001\r\n--ORR: 26.7% vs 18.7% (Figure3)\r\n--3æˆ–4ç´šAE: 75.7% vs 77.8%\r\n\r\n*a-3çµè«–\r\n--Durvalumab + chemotherapyé¡¯è‘—æé«˜OSï¼Œä¹Ÿæ”¹å–„PFS and ORR. å…©çµ„çš„safety profilesæ²’æœ‰å·®ç•°\r\n\r\n\r\n*b Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;401:1853-1865.\r\n*b-1ç ”ç©¶æ–¹æ³•\r\n--Randomised, double-blind, placebo-controlled, phase 3 trial\r\n--æ”¶éŒ„æ»¿18æ­²ã€æœªæ¥å—éæ²»ç™‚çš„ã€ä¸å¯åˆ‡é™¤çš„locally advanced or metastaticè†½é“ç™Œï¼›ECOG 0 æˆ– 1\r\n--ä¾ 1:1 éš¨æ©Ÿåˆ†é…è‡³Pembrolizumabçµ„ æˆ– å®‰æ…°åŠ‘çµ„ï¼Œå…©è€…å‡Q3wks (æœ€å¤š 35 å€‹ç™‚ç¨‹)ï¼Œä¸”å…©çµ„å‡åˆä½µGemcitabine+Cisplatin\r\n(Pembrolizumab 200mg Q3wk)\r\n(Gemcitabine 1000 mg/mÂ²ï¼Œæ–¼ç¬¬ 1 å¤©å’Œç¬¬ 8 å¤©çµ¦äºˆï¼ŒQ3wksï¼Œç„¡æœ€é«˜æ²»ç™‚é™åˆ¶)\r\n(Cisplatin 25 mg/mÂ²ï¼Œæ–¼ç¬¬ 1 å¤©å’Œç¬¬ 8 å¤©çµ¦äºˆï¼ŒQ3wksï¼Œæœ€å¤š 8 å€‹ç™‚ç¨‹)\r\n--The primary objective= OS (ITT)\r\n--The secondary endpoint= Safety (as-treated)\r\n\r\n*b-2ç ”ç©¶çµæœ\r\n--N=1069ï¼ŒPembrolizumabçµ„(n=533)ã€Placeboçµ„(n=536)\r\n--mOS: 12Â·7å€‹æœˆ vs 10Â·9å€‹æœˆï¼ŒHR= 0Â·83ï¼Œone-sided p=0Â·0034 [significance threshold, p=0Â·0200] (Figure4)\r\n--3æˆ–4ç´šAE: 420(79%) vs 400(75%)\r\n--Treatment-related 3æˆ–4ç´šAE: 369(70%) vs 367(69%)\r\n--å› ç‚ºAEè€Œæ­»äº¡: 31(6%) vs 49(9%) [å…¶ä¸­ 8(2%) vs 3(1%) è¢«èªå®šèˆ‡æ²»ç™‚ç›¸é—œ]\r\n\r\n*b-3çµè«–\r\n--Pembrolizumab plus gemcitabine and cisplatinæ”¹å–„OSï¼Œä¸”æ²’æœ‰æ–°çš„safety signals--> a new treatment option for patients with previously untreated metastatic or unresectable BTC.\r\n\r\n\r\n(2) The most common therapeutic targets (more than 10%) are FGFR2 fusion or rearrangement and IDH1 mutation in common bile duct adenocarcinoma.\r\nIncorrect! FGFR2 fusion or rearrangement, IDH1 mutationå‡æ˜¯åœ¨ intrahepatic CCAså¤šï¼Œå…¶ä»–subsitesç‚ºrareè¡¨ç¾\r\n*NCCN Guidelines Version 6.2024, BIL-B 1-3 OF 8\r\n-Molecular profiling in BTCs: Comprehensive molecular profiling is recommended for patients with unresectable or metastatic BTC who are candidates for systemic therapy. If tissue is too scant or not available, consider repeat biopsy depending on tumor accessibility, safety, and clinical context. A cell-free DNA (cfDNA) test may also be considered for identifying gene mutations. This technique may not reliably identify gene fusions or rearrangements depending on the panel used and the specific partner gene. \r\n(Figure5,6,7)\r\n--NTRK fusion: <1%\r\n--MSI-H/dMMR: 1%â€“3%\r\n--TMB-H: <5%\r\n--BRAF V600E mutation: 1%â€“5% \r\n--FGFR2 fusion or rearrangement: 9%â€“15% of intrahepatic CCAs and rare in other subsites\r\n--IDH1 mutation: 10%â€“20% of intrahepatic CCAs and rare in other subsites\r\n--HER2 (ERBB2) overexpression and/or amplification: 5%â€“20% of CCAs, 15%â€“30% of gallbladder cancer\r\n--RET fusion: <1%\r\n--KRAS G12C mutation: 1%\r\n\r\n\r\n(3) For MSI-H/dMMR tumors pembrolizumab treatment could be recommended.\r\nCorrect!\r\n*NCCN Guidelines Version 6.2024, BIL-B 4 OF 8, BIL-C 3 OF 5 (Figure8)\r\n-åœ¨unresecatble or metastatic gallbladder cancer, intrahepatic CCA, or extrahepatic CCA å»ºè­°è¦é©—MSI/dMMR\r\n-- è‹¥ç‚ºMSI-H/dMMR tumorsï¼Œç¬¬ä¸€ç·šTargeted Txå»ºè­°Pembrolizumabã€Subsequent-Line å»ºè­°Pembrolizumabã€Dostarlimab-gxly (category 2B)\r\n\r\nç›¸é—œtrial (2ç¯‡)\r\n*c Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1-10.\r\n*c-1ç ”ç©¶æ–¹æ³•\r\n--Histologically/cytologically confirmed MSI-H/dMMR\r\n--Advanced noncolorectal cancer + å…ˆå‰æ²»ç™‚å¤±æ•—\r\n--ç¬¦åˆä¸Šè¿°æ¢ä»¶çš„ç—…äººæ¥å—pembrolizumab 200 mg Q3wks for 2 years (æˆ–ç›´åˆ°PDã€ç„¡æ³•è€å—çš„toxicityã€ç—…äººwithdrawal)\r\n--Median follow up was 13.4 months. \r\n--The primary end point= ORR\r\n\r\n*c-2ç ”ç©¶çµæœ\r\n--N=233, å­å®®å…§è†œç™Œã€èƒƒç™Œã€è†½ç®¡ç™Œå’Œèƒ°è…ºç™Œæœ€ç‚ºå¸¸è¦‹ (å…¨éƒ¨27ç¨®tumor types)\r\n--ORR= 34.3% (Figure9)\r\n--mPFS= 4.1å€‹æœˆã€mOS= 23.5å€‹æœˆ\r\n--TRAE= 151=(64.8%)\r\n--- Gr3-5= 34(14.6%)ã€ç„¡å…¶ä»–èˆ‡æ²»ç™‚ç›¸é—œçš„è‡´å‘½ä¸è‰¯äº‹ä»¶\r\n\n-- Cholangiocarcinoma cohort: \n-- ORR= 40.9%, mPFS= 4.2å€‹æœˆã€mOS= 24.3å€‹æœˆ\n\r\n*c-3çµè«–\r\n--å°æ–¼å…ˆå‰æ¥å—æ²»ç™‚çš„ä¸å¯åˆ‡é™¤æˆ–è½‰ç§»æ€§MSI-H/dMMRéçµç›´è…¸ç™Œæ‚£è€…ï¼ŒAntiâ€“PD1 (pembrolizumab) å…·æœ‰è‡¨åºŠç›Šè™•ã€‚å…¶æ¯’æ€§èˆ‡ä¹‹å‰ä½¿ç”¨pembrolizumabçš„ç¶“é©—ä¸€è‡´ã€‚\r\n\r\n\r\n*d Maio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: Updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022;33:929-938.\r\n*d-1ç ”ç©¶æ–¹æ³•\r\n--èˆ‡å‰ä¸€ç¯‡å‡ç‚ºKEYNOTE-158 study\r\n--Longer follow-up: previously treated advanced MSI-H/dMMR noncolorectal cancers\r\n--Median time from first dose to database cut-off 37.5 å€‹æœˆ\r\n\r\n*d-2ç ”ç©¶çµæœ\r\n--ORR= 30.8%(Figure10)\r\n--mPFS= 3.5 å€‹æœˆã€mOS= 20.1 å€‹æœˆå€‹æœˆ\r\n--Median duration of response= 47.5 months\r\n--TRAE= 227(64.7%)\r\n--- Gr3-4= 39(11.1%)ã€Gr5= 3(0.9%)\r\n\n-- Cholangiocarcinoma cohort: \n-- ORR= 40.9%, mPFS= 4.2å€‹æœˆã€mOS= 19.4å€‹æœˆ\n\r\n*d-3çµè«–\r\n--Pembrolizumab demonstrated clinically meaningful and durable benefit, with a high ORR of 30.8%, long median duration of response of 47.5 months, and manageable safety across a range of heavily pretreated, advanced MSI-H/dMMR noncolorectal cancers, providing support for use of pembrolizumab in this setting.\r\n\r\n\r\n(4) Germline testing is recommended for all patients with unresectable or metastatic BTC who are candidates for systemic therapy.\r\nIncorrect!\r\n*NCCN Guidelines Version 6.2024, BIL-B 1 OF 8\r\n Recommendations:\r\n--Germline testing in hepatobiliary cancers\r\n--> æ˜¯å¦è¡Œgermline testingå°šç„¡è¶³å¤ è­‰æ“šå¯ç”¨æ–¼åˆ¶å®šæ˜ç¢ºçš„æ¨™æº–ï¼Œä¹Ÿç„¡è­‰æ“šæ”¯æŒé€²è¡Œuniversal germline testingã€‚\r\n--> è‹¥æ‚£è€…å…·å‚™ä»¥ä¸‹ä»»ä¸€ç‰¹å¾µï¼Œå¯ä»¥è€ƒæ…®æª¢æ¸¬ï¼šè¨ºæ–·æ™‚å¹´é½¡è¼ƒè¼•ã€å€‹äººæˆ–å®¶æ—ç™Œç—‡ç—…å²é¡¯è‘—ã€ç„¡å·²çŸ¥liver diseaseå±éšªå› å­ï¼Œæˆ–è…«ç˜¤åŸºå› æª¢æ¸¬ä¸­ç™¼ç¾å¯èƒ½ç‚ºgermline alterationsã€‚\r\n--> å·²çŸ¥æ”œå¸¶èˆ‡cancer predisposing syndromeç›¸é—œçš„germline mutationçš„æ‚£è€…ï¼ˆå¦‚Lynch syndrome or hereditary breast and ovarian cancer syndromeï¼‰ï¼Œç›®å‰ä»ç¼ºä¹è¶³å¤ è­‰æ“šæ”¯æŒé‡å°è†½é“æƒ¡æ€§è…«ç˜¤é€²è¡Œç¯©æª¢ã€‚\r\n\r\n(åŸæ–‡: Evidence remains insufficient for definitive recommendations regarding specific criteria to guide genetic risk assessment in hepatobiliary cancers or for universal germline testing in these tumors. In BTCs, genetic counseling referral and potential germline testing should be considered in patients with any of the following characteristics: young age at diagnosis; a strong personal or family history of cancer; no known risk factors for liver disease; or presence of mutations identified during tumor testing that are suspected to be possible germline alterations. For patients who do harbor a known germline mutation associated with a cancer predisposing syndrome (ie, Lynch syndrome or hereditary breast and ovarian cancer syndrome), there is currently insufficient evidence to support screening for biliary tract malignancies.)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/103/explain_figures/Figure1.jpg",
      "/qabank/103/explain_figures/Figure10.jpg",
      "/qabank/103/explain_figures/Figure2.jpg",
      "/qabank/103/explain_figures/Figure3.jpg",
      "/qabank/103/explain_figures/Figure4.jpg",
      "/qabank/103/explain_figures/Figure5.jpg",
      "/qabank/103/explain_figures/Figure6.jpg",
      "/qabank/103/explain_figures/Figure7.jpg",
      "/qabank/103/explain_figures/Figure8.jpg",
      "/qabank/103/explain_figures/Figure9.jpg"
    ]
  },
  {
    "id": 104,
    "question": "ä¸‹åˆ—é—œæ–¼å¤§è…¸ç›´è…¸ç™ŒHER2-amplificationçš„æ•˜è¿°ï¼Œæ­£ç¢ºçš„æœ‰ï¼Ÿ\r\n(1) åœ¨å¤§è…¸ç›´è…¸ç™Œï¼ŒHER2é«˜è¡¨ç¾çš„ç—…æ‚£ç´„æœ‰2-5%ï¼Œä¸”å¯èƒ½èˆ‡anti-EGFR è—¥ç‰©ä½¿ç”¨çš„æŠ—è—¥æ€§æœ‰é—œã€‚\r\n(2) åœ¨å…©ç·šåŒ–å­¸æ²»ç™‚å¤±æ•—å¾Œï¼Œåœ¨HER2é«˜è¡¨ç¾ï¼ŒRAS-wild type çš„å¤§è…¸ç›´è…¸ç™Œç—…æ‚£ï¼Œå¯è€ƒæ…®ä½¿ç”¨trastuzumab + tucatinibã€‚\r\n(3) æ ¹æ“šDESTINY-CRC02ï¼Œå–®ç¨ä½¿ç”¨T-DXdç„¡è«–RAS-mutantæˆ–wild typeï¼Œå…¶response rate ç´„ç‚º35%ã€‚\r\n(4) æ ¹æ“šDESTINY-CRC01ï¼Œåœ¨low HER2 (IHC2+/ISH-æˆ–IHC1+) çš„ç—…æ‚£ä½¿ç”¨T-DXdä¾ç„¶æœ‰ç´„40%çš„response rateã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": null,
    "explanation": "(1) åœ¨å¤§è…¸ç›´è…¸ç™Œï¼ŒHER2é«˜è¡¨ç¾çš„ç—…æ‚£ç´„æœ‰2-5%ï¼Œä¸”å¯èƒ½èˆ‡anti-EGFR è—¥ç‰©ä½¿ç”¨çš„æŠ—è—¥æ€§æœ‰é—œã€‚\r\nCorrect!\r\n*NCCN Guidelines Version 1.2025 MS-49 (Figure1)\r\n--HER2 is rarely amplified/overexpressed in CRC(approximately 3% overall), but the prevalence is higher in RAS/BRAFâ€“wild type tumors (reported at 5%â€“14%).\r\n--ç›®å‰ç„¡è­‰æ“šè­‰å¯¦ HER2 overexpressionåœ¨é å¾Œçš„è§’è‰²\r\n--é™¤äº†æ˜¯HER2-targeted therapyçš„predictive marker, HER2 amplification/overexpressionä¹Ÿèˆ‡EGFR-targeting monoclonal antibodiesçš„æŠ—è—¥æ€§æœ‰é—œ!\r\n\r\n*åƒè€ƒtrial: Raghav K, Loree JM, Morris JS, et al. Validation of HER2 Amplification as a Predictive Biomarker for Antiâ€“Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precision Oncology 2019:1-13. \r\n--ç ”ç©¶å°è±¡ï¼š98 å RAS/BRAFâ€“wild type mCRC\r\n--ä¸ä½¿ç”¨ EGFR inhibitoræ™‚ï¼Œç„¡è«– HER2 ç‹€æ…‹å¦‚ä½•ï¼Œmedian PFSç›¸ä¼¼ã€‚\r\n--ä½¿ç”¨ EGFR inhibitoræ™‚ï¼ŒHER2 amplificationæ‚£è€…çš„ PFS é¡¯è‘—è¼ƒçŸ­(2.8 å€‹æœˆ vs. 8.1 å€‹æœˆ)ã€‚\r\n--HRï¼š7.05(95% CI, 3.4â€“14.9)ã€‚\r\n--P < .001\r\n--çµè«–ï¼šin RAS/RAF wild-type mCRCï¼ŒHER2 amplificationèˆ‡anti-EGFRab therapyçš„æŠ—è—¥æ€§/ç™‚æ•ˆæœ‰é—œã€‚\r\n\r\n(2) åœ¨å…©ç·šåŒ–å­¸æ²»ç™‚å¤±æ•—å¾Œï¼Œåœ¨HER2é«˜è¡¨ç¾ï¼ŒRAS-wild type çš„å¤§è…¸ç›´è…¸ç™Œç—…æ‚£ï¼Œå¯è€ƒæ…®ä½¿ç”¨trastuzumab + tucatinibã€‚\r\nCorrect!\r\n*NCCN Guidelines Version 1.2025, COL-D 2 OF 12 (Figure2)\r\n\r\n*åƒè€ƒtrial: Strickler JH, Cercek A, Siena S, et al. Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC [abstract]. Ann Oncol 2022;33:S808-S869.\r\n-ç ”ç©¶æ–¹æ³•\r\n--æ”¶éŒ„18æ­²ä»¥ä¸Šã€chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic CRC\r\n--Cohort A: Tucatinib (300 mgBID) + intravenous trastuzumab(8 mg/kg loading, then 6 mg/kg Q3wks)->æ‰“åˆ°progression\r\n--ä¸­é€”æœ‰æ“´å¤§æ‹›å‹Ÿ: ä»¥4:3åˆ†è‡³å…©çµ„\r\n--> Cohort B= tucatinib + trastuzumab \r\n--> Cohort C= tucatinib monotherapy\r\n--The primary endpoint= objective response rate for cohorts A and B combined and was assessed in patients in the full analysis set (ie, patients with HER2-positive disease who received at least one dose of study treatment).\r\n-çµæœ\r\n--114 äºº HER2 é™½æ€§ä¸¦æ¥å—æ²»ç™‚(Cohort A: 45, B: 39, C: 30)\r\n--ORR: 38.1%(Figure3)\r\n--AE: \r\n--> A+B: è…¹ç€‰(64%)ã€3 ç´šä»¥ä¸Šï¼šé«˜è¡€å£“(7%)ã€3%(3/86) tucatinib ç›¸é—œåš´é‡ä¸è‰¯äº‹ä»¶ï¼ˆæ€¥æ€§è…æå‚·ã€çµè…¸ç‚ã€ç–²å‹)\r\n--> C: è…¹ç€‰(33%)ã€3 ç´šä»¥ä¸Šï¼šALTã€AST å‡é«˜(å„ 7%)ã€1 äºº(3%) tucatinib ç›¸é—œåš´é‡ä¸è‰¯äº‹ä»¶ï¼ˆè—¥ç‰©éé‡ï¼‰ã€\r\n\r\n-çµè«–\r\n--Tucatinib+trastuzumab: FDA approved for mCRC and is an important new treatment option for chemotherapy-refractory HER2-positive mCRC.\r\n\r\n(3) æ ¹æ“šDESTINY-CRC02ï¼Œå–®ç¨ä½¿ç”¨T-DXdç„¡è«–RAS-mutantæˆ–wild typeï¼Œå…¶response rate ç´„ç‚º35%ã€‚\r\nIncorrect! åœ¨subgroupåˆ†æä¸­ï¼ŒRAS-Wild-typeçš„ORRå„ªæ–¼RAS-mutantï¼Œå¯ä»¥çœ‹ç›´æ¥ä¸‹æ–¹**Subgroupç ”ç©¶çš„è³‡æ–™ (Figure4,5,6)\r\n\r\n*ç›¸é—œtrial: Kanwal Raghav, et al.Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial, The Lancet Oncology,Volume 25, Issue 9, 2024,1147-1162 \r\n-ç›®çš„: æ¢è¨ Trastuzumab deruxtecan ä¸åŒåŠ‘é‡(5Â·4 mg/kg and 6Â·4 mg/kg)åœ¨å…ˆå‰æ²»ç™‚éçš„HER2(+), RAS wild-type or mutant mCRCï¼Œæ‰¾å‡ºé©åˆçš„åŠ‘é‡\r\n-æ–¹æ³•\r\n-- æ”¶éŒ„å¹´æ»¿ 18 æ­²æˆ– 20 æ­²(ä¾åœ°å€è€Œå®š)ã€å…ˆå‰æ²»ç™‚éçš„unresectable,recurrent, or metastatic HER2-positive, and RAS wild-type or mutant colorectal cancer (å…ˆå‰æ²»ç™‚chemotherapy, and anti-EGFR, anti-VEGF, or anti-PD-L1 therapy)\r\n-- Stage 1: 1:1 çš„æ¯”ä¾‹è¢«éš¨æ©Ÿåˆ†é…è‡³æ¥å— 5.4 mg/kg æˆ– 6.4 mg/kg çš„ trastuzumab deruxtecan, Q21d\r\n-- Stage 2: æ‰€æœ‰æ‚£è€…å‡è¢«åˆ†é…è‡³ 5.4 mg/kg çš„æ²»ç™‚çµ„\r\n-- The primary endpoint= ORR\r\n-ç ”ç©¶çµæœ\r\n-- The confirmed ORR= 37Â·8% (5Â·4 mg/kg) vs 27Â·5% (6Â·4 mg/kg)\r\n-- Gr3 ä»¥ä¸Šdrug-related AE 34 (41%) vs 19 (49%) \r\n-- **Subgroupç ”ç©¶\r\n--> åœ¨5Â·4 mg/kgçµ„åˆ¥çš„ORR: 39.7% (RAS wild-type) vs 28.6% (RAS mutant)\r\n--> åœ¨6Â·4 mg/kgçµ„åˆ¥çš„ORR: 32.4% (RAS wild-type) vs 0% (RAS mutant)\r\n-çµè«–: åœ¨å…ˆå‰æ²»ç™‚éçš„HER2-positive mCRC (æœ‰åŒ…å«RAS mutations, æˆ–å…ˆå‰æ¥å—anti-HER2 therapy)ï¼Œtrastuzumab deruxtecan å–®ç”¨ï¼Œ5Â·4 mg/kgæ˜¯æœ€ä½³çš„åŠ‘é‡\r\n\r\n(4) æ ¹æ“šDESTINY-CRC01ï¼Œåœ¨low HER2 (IHC2+/ISH-æˆ–IHC1+) çš„ç—…æ‚£ä½¿ç”¨T-DXdä¾ç„¶æœ‰ç´„40%çš„response rateã€‚\r\nIncorrect! ORRç‚º0\r\n*ç›¸é—œtrial: Salvatore Siena MD, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. The Lancet Oncology,Volume 22, Issue 6, 2021,779-789\r\n\r\n-ç›®çš„: æ¢è¨ Trastuzumab deruxtecançš„anti-tumor activityèˆ‡å®‰å…¨æ€§ï¼Œåœ¨HER2(+)çš„mutant mCRC\r\n-æ–¹æ³•\r\n-- éœ€å¹´æ»¿ 18 æ­²ï¼ˆæ—¥æœ¬ç‚º 20 æ­²ä»¥ä¸Šï¼‰\r\n-- HER2-expressing metastatic colorectal cancerã€ä¸”å·²æ¥å—å…©ç¨®ä»¥ä¸Šå…ˆå‰æ²»ç™‚å¾Œæƒ¡åŒ–(å¯æ¥å—é™¤äº†trastuzumab deruxtecanä»¥å¤–çš„HER2-targeted therapies)ã€ä¸” RAS and BRAFV600E wild-type\r\n-- ä¾ç…§ HER2 è¡¨ç¾ç¨‹åº¦ åˆ†ç‚º3å€‹cohort\r\n--> Cohort Aï¼šHER2 é™½æ€§ï¼ˆå³ IHC3+ æˆ– IHC2+ ä¸” ISH é™½æ€§ï¼‰\r\n--> Cohort Bï¼šHER2 ä½è¡¨ç¾ï¼ˆIHC2+ ä¸” ISH é™°æ€§ï¼‰\r\n--> Cohort Cï¼šHER2 ä½è¡¨ç¾ï¼ˆIHC1+ï¼‰\r\n-- æ‰€æœ‰æ‚£è€…æ¥å— 6.4 mg/kg trastuzumab deruxtecan Q3wkï¼Œç›´è‡³ç–¾ç—…é€²å±•ã€å‡ºç¾ä¸å¯æ¥å—çš„ä¸è‰¯åæ‡‰ã€withdrawalï¼Œæˆ–æ­»äº¡ã€‚\r\n--The primary endpoint= ORR in cohort Aã€safety\r\n\r\n-ç ”ç©¶çµæœ\r\n-- ORR= 24(45.3%) in cohort A\r\n-- 3 or worse treatment-emergent adverse events that occurred in at least 10% of all participants\r\n-- **å°æ–¼Cohort B and Cohort Cçš„åˆ†æ (Figure7)\r\n--> å‡ç„¡æ‚£è€…é”åˆ°å®¢è§€ç·©è§£(ORR)\r\n--> mPFS åœ¨cohort B and Cç›¸ä¼¼: 1.3 å€‹æœˆ and 1.4 å€‹æœˆ\r\n--> mOS åœ¨cohort B and C: not reached\r\n--> PD or Death: Cohort B (4å)ã€Cohort C (14å)\r\n----\r\n\r\næ­¤é¡Œè¦ºå¾—ç­”æ¡ˆç‚º(1)(2)\n(å¯©ç¨¿é™„è­°)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/104/explain_figures/Figure1.jpg",
      "/qabank/104/explain_figures/Figure2.jpg",
      "/qabank/104/explain_figures/Figure3.jpg",
      "/qabank/104/explain_figures/Figure4.jpg",
      "/qabank/104/explain_figures/Figure5.jpg",
      "/qabank/104/explain_figures/Figure6.jpg",
      "/qabank/104/explain_figures/Figure7.jpg"
    ]
  },
  {
    "id": 105,
    "question": "ä¸€ä½ 47 æ­²ç—…æ‚£è¨ºæ–·ç‚º cT3N2M1 ä¹‹ sigmoid colon adenocarcinomaï¼Œæœ‰å¤šè™•è‚ºè½‰ç§»åŠè‚è‡Ÿ è½‰ç§»ï¼Œç‚ºç„¡æ³•æ‰‹è¡“ä¹‹ç–¾ç—…(unresectable)ï¼Œç—…ç†æª¢æ¸¬ç‚º RASwtã€BRAFwtã€pMMRï¼Œç—…æ‚£ä¹‹ ECOG PS 0 ä¸”ç„¡è…¸é˜»å¡ã€å‡ºè¡€ç­‰ç—‡ç‹€ã€‚ä¸‹åˆ—å°æ–¼æ­¤ç—…æ‚£çš„æ²»ç™‚å»ºè­°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰? \r\n\r\n(1)  æ ¹æ“š FIRE-3 studyï¼Œcetuximab + FOLFIRI ç›¸è¼ƒæ–¼ bevacizumab + FOLFIRIï¼Œå…¶ OS benefit åªæœ‰åœ¨ RAS-wild type ä¸”è…«ç˜¤ä½æ–¼å·¦å´å¤§è…¸æ™‚æ‰é¡¯è‘—ã€‚ \r\n(2)  Cetuximab + FOLFIRI åœ¨ RAS-wild type ä¸”è…«ç˜¤ä½æ–¼å·¦å´å¤§è…¸çš„ç—…æ‚£ï¼Œå…¶ response rate ç´„ç‚º 7 æˆï¼Œä¸”å…¶ early tumor shrinkage åŠ depth of response çš†å„ªæ–¼ bevacizumab + FOLFIRIã€‚ \r\n(3)  ç•¶ç—…æ‚£åœ¨ä¸€ç·šä½¿ç”¨ bevacizumab + FOLFOXï¼Œå¯åœ¨ç–¾ç—…æƒ¡åŒ–æ™‚ä½¿ç”¨ FOLFIRI åŠ ä¸Š ramucirumab æˆ–æ˜¯ç¹¼çºŒä½¿ç”¨ bevacizumabã€‚ \r\n(4)  Panitumumab ç›¸è¼ƒæ–¼ cetuximab æœ‰è¼ƒå¤šçš„ Grade 3 ä»¥ä¸Šçš„ infusion reactionï¼Œä½†æœ‰è¼ƒå°‘ çš„ hypomagnesaemia é¢¨éšªã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "(1)(2) æ­£ç¢ºï¼Œåœ¨ FIRE-3 çš„å¾ŒçºŒå ±å‘Šä¸­ï¼ŒRAS wild type mCRC çš„ median OS åœ¨å·¦å¤§è…¸ä¸”æ¥å— FOLFIRI + Cetuximab çš„çµ„åˆ¥å¯é”åˆ° 38.2 å€‹æœˆï¼Œ FOLFIRI + Bevacizumab åªæœ‰ 28.2 å€‹æœˆã€‚â€œFOLFIRI plus cetuximab resulted in a significantly higher ORR and longer OS compared to FOLFIRI plus bevacizumab among patients with left-sided tumoursâ€ (fig1)\r\n \r\nåƒè€ƒåŒç¯‡è«–æ–‡ appendixï¼ŒRAS-wild type left-sided mCRCï¼Œåœ¨ FOLFIRI + Cetuximab çš„çµ„åˆ¥æ¯”èµ· FOLFIRI + Bevacizumab æœ‰è¼ƒä½³çš„ ORR (69% vs 62%), early tumor shrinkage (71% vs 50%), depth of response (50% vs 33%)ã€‚(fig2)\r\n \r\nRef: British Journal of Cancer (2021) 124:587â€“594; https://doi.org/10.1038/s41416-020-01140-9 \r\n\r\n(3) æ­£ç¢ºï¼Œæ ¹æ“š NCCN guideline ver. 1.2025 Colon cancerâ€œAnother meta-analysis showed an OS and PFS benefit to continuing an anti-angiogenic agent after progression on an anti- angiogenic agent in first-line â€œï¼Œåœ¨ MS-68 ä¸­å…§æ–‡æåˆ°å¹¾å€‹ clinical trial ç ”ç©¶ contiuation of bevacizumab plus another chemotherapy regimen following progression on bevacizumab\r\nâ€œOverall, these data (along with data from the VELOUR trial, discussed below) show that the continuation of VEGF blockade in second-line therapy offers a very modest but statistically significant OS benefit. â€œ\r\nRamucirumab çš„éƒ¨åˆ†ï¼Œå‰‡åƒè€ƒ phase III RAISE studyï¼ŒOS æœ‰é”åˆ°çµ±è¨ˆå­¸ä¸Šé¡¯è‘—å·®ç•°ï¼ŒFOLFIRI + Ramucirumab versus FOLFIRI + placebo (13.3 vs 11.7å€‹æœˆ; HR: 0.844)ã€‚(fig3)(fig4)\r\n \r\n\r\n(4) éŒ¯èª¤ï¼Œæ­¤é¸é …å¯ä»¥å¾è—¥ç‰©æ©Ÿè½‰åˆªé™¤ã€‚â€œCetuximab and panitumumab are monoclonal antibodies directed against EGFR that inhibit its downstream signaling pathways. Panitumumab is a fully human monoclonal antibody, whereas cetuximab is a chimeric monoclonal antibody. â€â€œ Administration of either cetuximab or panitumumab has been associated with severe infusion reactions, including anaphylaxis, in 3% and 1% of patients, respectively. â€œ\r\nç”±æ–¼ Cetuximab æ˜¯ chimeric antibodyï¼Œå¸¶æœ‰ä¸åŒç‰©ç¨®çš„åˆ†å­ï¼Œå› æ­¤è¼ƒå®¹æ˜“é€ æˆéæ•åæ‡‰ï¼Œçµ¦è—¥æ™‚å®¹æ˜“æœ‰è¼¸æ³¨åæ‡‰ (infusion reaction)ï¼›ç›¸è¼ƒ panitumumab éƒ½æ˜¯äººé¡çš„åˆ†å­ï¼Œéæ•çš„æ©Ÿç‡å°±ä½å¾ˆå¤šã€‚\r\nè‡³æ–¼anti-EGFR monoclonal antibody é€ æˆçš„ä½è¡€é‚ï¼Œæœ‰æ–‡ç»æŒ‡å‡ºé€™èˆ‡ blockade of the EGFR in the kidney ç›¸é—œã€‚æ²’æœ‰æ‰¾åˆ°å…©ç¨®è—¥ç‰© head to head æ¯”è¼ƒçš„è‡¨åºŠè©¦é©—ï¼Œä¸éæ˜¯æœ‰æ‰¾åˆ°ä¸€ç¯‡ systematic reivew ç•¶ä¸­ pooled analysisï¼Œçœ‹åˆ° cetuximab ç™¼ç”Ÿä½è¡€é‚çš„æ¯”ä¾‹æ¯”èµ· panitumumab é‚„è¦é«˜ã€‚(fig5)\r\n \r\nRef: \r\n1. NCCN guideline v1.2025 Colon cancer MS-61\r\n2. Petrelli, F. et al. (2011) â€˜Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studiesâ€™, Expert Opinion on Drug Safety, 11(sup1), pp. S9â€“S19. doi: 10.1517/14740338.2011.606213.",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/105/explain_figures/fig1.png",
      "/qabank/105/explain_figures/fig2.png",
      "/qabank/105/explain_figures/fig3.jpg",
      "/qabank/105/explain_figures/fig4.png",
      "/qabank/105/explain_figures/fig5.png"
    ]
  },
  {
    "id": 106,
    "question": "ä¸‹åˆ—é—œæ–¼ Appendiceal neoplasm çš„æ•˜è¿°ï¼Œæ­£ç¢ºçš„æœ‰? \r\n(1)  ç—…ç†ä¸‹å¯åˆ†ç‚º low-grade/high-grade mucinous neoplasm, appendiceal adenocarcinoma åŠ neuroendocrine tumorã€‚ \r\n(2)  Signet ring mucinous adenocarcinoma çš„é å¾Œå¾ˆå·®ã€‚ \r\n(3)  è‹¥è…¹è†œè½‰ç§»çš„ç—…æ‚£å¯ä½¿ç”¨ PCI (peritoneal cancer index)è©•ä¼°æ˜¯å¦å¯æ‰‹è¡“åˆ‡é™¤ï¼Œè‹¥å¯æ‰‹è¡“åˆ‡é™¤ï¼Œå¯åœ¨è¡“å‰æ¥å—å…­å€‹æœˆçš„å‰å°æ€§åŒ–å­¸æ²»ç™‚ä¸¦éš¨å¾ŒåŠ ä¸Š HIPEC (hyperthermic intraperitoneal chemotherapy)ã€‚ \r\n(4)  ç„¡æ³•æ‰‹è¡“çš„ç—…æ‚£ï¼Œæ‡‰æ¥å—èˆ‡å¤§è…¸ç™Œç›¸åŒçš„åŸºå› æª¢æ¸¬(RAS, BRAF, MMR, HER2)åŠæ²»ç™‚é¸æ“‡ã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "é€™æ®µæ–‡å­—å‡ºè‡ª NCCN version 1.2025 colon cancer MS-9ï½MS-13\r\n(1) æ­£ç¢ºï¼Œâ€Appendiceal neoplasms can be histopathologically classified as neuroendocrine neoplasms (NENs), mucinous neoplasms, goblet cell adenocarcinomas (GCAs), colonic-type adenocarcinomas (non- mucinous), and signet ring cell carcinomas (epithelial origin).â€\r\n\n(2) æ­£ç¢ºï¼Œâ€It has been well-established that the presence of signet ring cells leads to a poorer prognosis; 10% to 40% of patients with G3 (poorly differentiated) mucinous adenocarcinoma with signet ring cells have a 5-year OS.â€\r\n\n(3) æ­£ç¢ºï¼Œâ€In select patients diagnosed with metastatic spread to the peritoneum, CRS and HIPEC have the potential to be curative.â€\r\nâ€œThe intent of CRS is to achieve maximum cytoreduction before the initiation of HIPEC. Because of this, presurgical evaluation of peritoneal involvement is recommended and can be achieved through laparoscopy and the peritoneal carcinomatosis index (PCI) scoring system. The PCI quantifies the distribution of tumors throughout 13 regions of the abdomen and pelvis along with a lesion size score.â€ â€œOnce an individual is deemed a candidate for CRS/HIPEC they should continue chemotherapy for up to 6 months, preferably in the neoadjuvant setting.â€\r\n\n(4) æ­£ç¢ºï¼Œâ€Cytotoxic chemotherapy with efficacy against CRC is used to treat AA. It is reasonable to use other targeted therapy options for MSI-high (MSI-H), BRAF mutation, or HER2 status, which is consistent with recommendations within the NCCN Guidelines for Colon Cancer and NCCN Guidelines for Rectal Cancer. There is no clear evidence for anti-epidermal growth factor receptor (EGFR) therapy even if the patientâ€™s tumor is RAS/RAF wild-type.â€",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 107,
    "question": "42 æ­²ç”·æ€§ï¼Œç¶“è¨ºæ–·è‚›é–€ç·£ä¸Š 1.5cm Low rectal adenocarcinoma, cT4aN2aM0, circumferential resection margin involved, stage IIICï¼ŒIHC ç™¼ç¾ MLH1/PMS2 loss, preserved MSH2/6ï¼ŒRASwt åŠ BRAFwtï¼Œæ­¤ç—…æ‚£ä¹‹ ECOG PS ç‚º 0ï¼Œç„¡é˜»å¡æˆ–å‡ºè¡€ç—‡ç‹€ï¼Œé—œæ–¼æ­¤ç—…æ‚£çš„æ²»ç™‚å»ºè­°ï¼Œ ä¸‹åˆ—æ•˜è¿°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰? \r\n(1)  ç—…æ‚£å¯å…ˆä½¿ç”¨ dostarlimab å…­å€‹æœˆä¸¦æ ¹æ“šè©•ä¼°å¾Œæ±ºå®šæ˜¯å¦æ¥å— chemoradiation (CRT) åŠæ‰‹è¡“ã€‚ \r\n(2)  åœ¨ CRT å¾Œæ¥å—åŒ–å­¸æ²»ç™‚ä¸¦å¾Œæ‰‹è¡“ï¼Œç›¸è¼ƒæ–¼å…ˆæ¥å—åŒ–å­¸æ²»ç™‚å¾Œ CRT å†æ‰‹è¡“ï¼Œæœ‰æ›´é«˜çš„ pCR æ©Ÿç‡ã€‚ \r\n(3)  clinical CR çš„å®šç¾©ç‚º:å…§è¦–é¡ä¸‹è…¸å£å…‰æ»‘ä¸” MRI T2W ä¸‹åªæœ‰ dark signal ä¸”ç„¡>5mm lymph nodeã€‚ \r\n(4)  å°æ–¼ Total neoadjuvant therapy å¾Œé”åˆ° cCR çš„ç—…æ‚£ï¼Œå¯è€ƒæ…® watch-and-wait è€Œä¸é€²è¡Œæ‰‹è¡“ã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "(1) æ­£ç¢ºï¼Œç—…æ‚£ç‚º dMMR locally advanced stage IIIC rectal cancerï¼Œæ ¹æ“š NCCN guideline å¯ä»¥å…ˆé€²è¡Œ neoadjuvant immune chekcpoint inhibitor å…­å€‹æœˆï¼Œè©•ä¼°ç™‚æ•ˆã€‚(fig1)\r\n \r\n(2) æ­£ç¢ºï¼ŒCAO/ARO/AIO-12 é€™ç¯‡ randomized phase II trialï¼Œå›æ‡‰äº†optimal sequence of chemoradiotherapy (CRT) and chemotherapy before total mesorectal excision surgery for total neoadjuvant therapy in rectal cancerã€‚\r\n\r\nThis secondary analysis of a randomized clinical trial showed that CRT followed by chemotherapy resulted in higher pathological complete response without compromising disease-free survival, toxicity, QoL, or stool incontinence and is thus proposed as the preferred total neoadjuvant therapy sequence if organ preservation is a priority.\n\r\nRef:  JAMA Oncol. 2022;8(1):e215445. doi:10.1001/jamaoncol.2021.5445\r\n\r\n(3) æ­£ç¢ºï¼ŒClinical complete responseï¼Œæ ¹æ“šNCCN version 2025.1 colon cancer page REC-H 1 OF 2 çš„å®šç¾©å¦‚ fig2ã€‚\r\n \r\n(4) æ­£ç¢ºï¼Œåœ¨æ¥å— total neoadjuvant therapy å¾Œå¦‚æœé”åˆ° clinical complete responseï¼Œå¯ä»¥è€ƒæ…® active surveillance (fig3)ï¼Œç›®çš„æ˜¯æ¸›å°‘æ‰‹è¡“å¾Œå¯èƒ½ä¼´éš¨çš„åŠŸèƒ½å–ªå¤±ï¼Œä¾‹å¦‚ incontinence, permanent colostomy ç­‰ç­‰ã€‚ç›®å‰æ”¯æŒ active surveillance çš„ç ”ç©¶å¤šåŠæ˜¯ phase II trialã€‚",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/107/explain_figures/fig1.png",
      "/qabank/107/explain_figures/fig2.png",
      "/qabank/107/explain_figures/fig3.png"
    ]
  },
  {
    "id": 108,
    "question": "ä¸‹åˆ—é—œæ–¼å¤§è…¸ç›´è…¸ç™Œ RAS çªè®Šçš„æ•˜è¿°ï¼ŒéŒ¯èª¤çš„æœ‰?\r\n(1) æœ€å¸¸è¦‹çš„ KRAS çªè®Šç‚º KRAS G12Dã€‚\r\n(2) åœ¨ FIRE-3 è‡¨åºŠè©¦é©—ä¸­ï¼Œæ¬¡æ—ç¾¤åˆ†æç™¼ç¾ RAS çªè®Šä¹‹å¤§è…¸ç™Œç—…æ‚£æ¥å— cetuximab + FOLFIRI ç›¸è¼ƒæ–¼ bevacizumab + FOLFIRI æœ‰æ›´å·®çš„PFSã€‚\r\n(3) åœ¨ CodeBreaK300 ä¸­ï¼Œsotorasib + panitumumab ç›¸è¼ƒæ–¼ triflufluridine- tipiracil æˆ– regorafenib æœ‰è¼ƒä½³çš„ PFSã€‚\r\n(4) åœ¨ KRYSTAL-1 ä¸­ï¼Œadagrasib + cetuximab ç›¸è¼ƒæ–¼ triflufluridine-tipiracil æˆ– regorafenib æœ‰è¼ƒä½³çš„ PFSã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 3,
    "explanation": "(1) æ­£ç¢ºï¼Œæ ¹æ“š NCCN v.2025.1 MS-47 colon cancer çš„æè¿°\r\nâ€œStudies have reported that around 40% of mCRC have KRAS mutations in codons 12 and 13. Of these mutations, KRAS G12D was mostly commonly found (36%), followed by G12V (21.8%), and G13D (18.8%). KRAS G12C has been reported in around 17% of KRAS-mutated mCRC cases.â€\n\r\n(2) æ­£ç¢ºï¼Œæ ¹æ“š FIRE-3 appendixï¼ŒRAS-mutant population æ¥å— cetuximab + FOLFIRI ç›¸è¼ƒæ–¼ bevacizumab + FOLFIRI çš„ median PFS ç‚º 7.5å€‹æœˆæ¯”ä¸Š9.6å€‹æœˆã€‚(fig1)\r\n \r\n(3) æ­£ç¢ºã€‚CodeBreaK 300 ç ”ç©¶å¸¶æœ‰ KRASG12C çªè®Šä¹‹è½‰ç§»æ€§å¤§è…¸ç™Œåœ¨æ¥å—å‰ç·šåŒ–å­¸è—¥ç‰©æ²»ç™‚å¤±æ•—å¾Œ(åŒ…å«fluoropyrimidine, irinotecan, oxaliplatin)ï¼Œä½¿ç”¨ sotorasib + panitumumab æ¯”ä¸Š trifluridine/tipiracil æˆ– regorafenib ï¼ŒPrimary endpoint ç‚ºPFS (ç ”ç©¶è¨­è¨ˆå¦‚ä¸‹)ã€‚çµæœé¡¯ç¤º sotorasib + panitumumab æ¯”èµ· standard care æœ‰è¼ƒä½³çš„ PFS (fig2-4)ã€‚   \r\n \r\n(4) éŒ¯èª¤ï¼ŒKRYSTAL-1 æ˜¯ä¸€ç¯‡ phase 1-2 studyï¼Œç ”ç©¶ Adagrasib åœ¨ KRASG12C mutant tumor çš„æ•ˆæœï¼Œå…¶ä¸­åŒ…å« NSCLC, CRC and other solid tumors ä¸‰å€‹ cohortã€‚åœ¨å¤§è…¸ç™Œçš„ç ”ç©¶ä¸­ï¼ŒAdagrasib + Cetuximab æ¯”èµ· Adagrasib monotherapy æœ‰è¼ƒå¥½çš„ ORR (46% v s 19%)ã€duration of response (7.6 months vs 4.3 months)ã€PFS (6.9 months vs 5.6 months)ã€‚(fig5:å·¦ç‚º Adagrasib + cetuximabï¼›å³ç‚º adagrasib monotherapy)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/108/explain_figures/fig1.png",
      "/qabank/108/explain_figures/fig2.jpg",
      "/qabank/108/explain_figures/fig3.png",
      "/qabank/108/explain_figures/fig4.png",
      "/qabank/108/explain_figures/fig5.png"
    ]
  },
  {
    "id": 109,
    "question": "Which of the following statements about thromboembolism in cancer patients are (is) correct? \r\n(1)  Direct oral anticoagulants (DOACs), LMWH, and warfarin have all been used to treat \r\n     thromboembolism. Select regimen based on renal function, hepatic function, inpatient/ \r\n     outpatient status, approval, cost, patient preference, ease of administration, monitoring,  \r\n     bleeding risk assessment, and ability to reverse anticoagulation.  \r\n(2)  For acute DVT of proximal lower extremity, the first recommended treatment is IVC filter \r\n     instead of anticoagulant.  \r\n(3)  For symptomatic catheter-associated DVT, consider anticoagulation treatment for at least \r\n     3 months or as long as the catheter is in place. \r\n(4)  For acute DVT of subclavian vein closed to the port-A, the first priority is remove the \r\n     port-A.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1)æ­£ç¢ºï¼›Guideline: National Comprehensive Cancer Network 2020 å…¶ä¸­çš„Recommendations \"Choice of anticoagulation regimen should be based on individual risk of thrombosis and bleeding, renal and hepatic function, inpatient/outpatient status, FDA approval status, ease of administration, cost, burden of laboratory monitoring, agent reversibility, and patient preferences.\"ï¼Œå’Œæ­¤é¸é …å¹¾ä¹ç›¸åŒ\r\n(2)éŒ¯èª¤ï¼›æ ¹æ“šVenous thromboembolism in cancer patients: ESMO Clinical Practice Guideline (2023)ï¼Œèµ·å§‹æ²»ç™‚ä»æ˜¯ä»¥anticoagulant ç‚ºä¸»ï¼Œå†æ—©ä¸€é»çš„guidelineæœƒå»ºè­°æœ‰anticoagulant contraindicationæ™‚ï¼Œæ‰è€ƒæ…®filter ä½¿ç”¨\r\n(3)æ­£ç¢ºï¼›Guideline: International Initiative on Thrombosis and Cancer 2019ï¼Œé‡å°CVC thrombosis treatmentï¼ŒæåŠ\"For the treatment of symptomatic CVC thrombosis, anticoagulation is recommended for a minimum of 3 months and as long as the CVC is in place\"ï¼Œå’Œæ­¤é¸é …å¹¾ä¹ç›¸åŒ (è£œå……ï¼šNCCN guideline DVT-3 å°‡\"and\" æ”¹æˆ \"or\")\r\n(4)éŒ¯èª¤ï¼›æ ¹æ“šNCCN guidelineå…§æ–‡ï¼Œ\"For patients with catheter-related DVT, in the absence of contraindication, anticoagulation is recommended. Anticoagulation without catheter removal is the preferred option for initial treatment, even for patients with asymptomatic DVT, provided that the catheter is necessary, functional, and free of infection.\"ï¼Œä½¿ç”¨anticoagulantè®“ç®¡è·¯ä¸ç”¨è¢«ç§»é™¤ï¼Œæ˜¯è™•ç½®çš„å„ªå…ˆç›®æ¨™ï¼Œè‹¥æœ‰contraindicationæ‰è€ƒæ…®ç§»é™¤\r\n\r\næ•…ç­”æ¡ˆé¸B\r\n\r\nRef:\r\n1. Streiff MB, Abutalib SA, Farge D, Murphy M, Connors JM, Piazza G. Update on Guidelines for the Management of Cancer-Associated Thrombosis. Oncologist. 2021 Jan;26(1):e24-e40. doi: 10.1002/onco.13596.\r\n2. Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, Lecumberri R, Mandala M, Maraveyas A, Pabinger I, Sinn M, Syrigos K, Young A, Jordan K; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023 May;34(5):452-467. doi: 10.1016/j.annonc.2022.12.014.\r\n3. NCCN guideline v1.2025 Cancer associated venous thromboembolism disease DVT-3/MS-17",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 110,
    "question": "ä¸€ä½30æ­²å¥³æ€§å› å³å´ä¹³ç™Œæ¥å—åˆ‡é™¤æ‰‹è¡“ï¼Œè¡“å¾Œ8å€‹æœˆå³æ‰‹è‡‚é€æ¼¸è…«èµ·ä¾†ï¼Œä¸‹åˆ—æ•˜è¿°ä¸­ï¼Œ \r\næ­£ç¢ºçš„æœ‰? \r\n(1) æœ‰æ¥å—æ¶²ä¸‹æ·‹å·´çµæ¸…é™¤è¡“è€…ï¼Œæ¯”èµ·æ¥å—å“¨å…µæ·‹å·´çµåˆ‡é™¤è€…ï¼Œæ·‹å·´æ°´è…«æ©Ÿæœƒé«˜10å€ã€‚\r\n(2) è¶Šç˜¦çš„äººï¼Œè¡“å¾Œè¶Šå¯èƒ½æœ‰æ·‹å·´æ°´è…«ã€‚ \r\n(3) èˆ‰é‡ç‰©æœƒå¢åŠ æ·‹å·´æ°´è…«çš„ç¨‹åº¦èˆ‡æ©Ÿæœƒã€‚ \r\n(4) è¡›æ•™å¥¹æ·‹å·´æ°´è…«ä¸æœƒç—Šç™’ã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 3,
    "explanation": "Breast cancer-related lymphedema (BCRL)\r\n(1)éŒ¯èª¤ï¼›æ ¹æ“šæ–‡ç»å…§æåŠï¼Œéå¾€ç ”ç©¶axillary lymph node dissection (ALND) æ¯”èµ·sentinel lymph node biopsy (SLNB)ï¼Œç™¼ç”ŸBCRLçš„æ¯”ç‡æ˜¯19.9% (95% CI: 13.5â€“28.2)åŠ 5.6%ï¼Œæ¯”ç‡ç´„ç‚º4å€ï¼Œé10å€\r\n(2)éŒ¯èª¤ï¼›æ ¹æ“šæ–‡ç»å…§æåŠï¼Œéå¾€ç ”ç©¶ç™¼ç¾èˆ‡æ²»ç™‚ç„¡é—œçš„BCRL risk factors ç‚ºobesityã€subclinical edemaåŠcellulitisï¼Œæ‰€ä»¥ç˜¦çš„ç—…äººç™¼ç”Ÿæ©Ÿæœƒæ¯”è¼ƒä½\r\n(3)éŒ¯èª¤ï¼›æ–‡ç»å…§æåˆ°ï¼Œ\"there is no limitation on the maximum amount of weight that can be lifted as long as weight-lifting exercises are supervised and progressive\"ï¼Œèˆ‰é‡ç‰©åŠå…¶æœ€å¤§é‡é‡ä¸¦æ²’æœ‰è¢«é™åˆ¶ï¼Œé–“æ¥è¡¨ç¤ºèˆ‡BCRLç„¡é—œã€‚\r\n(4)æ­£ç¢ºï¼›National cancer institute åœ¨lymphedemaé é¢ï¼Œæœ‰æåˆ°\"it is a chronic condition that cannot be cured but can be treated to relieve swelling and improve your ability to function day to day\"ï¼›å¦æ ¹æ“šJohns Hopkins Medicine ç¶²ç«™å…§\"Breast cancer lymphedema after treatment\"æ–‡ç« ï¼Œæåˆ°\"Itâ€™s a chronic (ongoing) condition that has no cure\"\r\n\r\n\r\nRef: \r\n1.Gillespie TC, Sayegh HE, Brunelle CL, Daniell KM, Taghian AG. Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. Gland Surg. 2018 Aug;7(4):379-403. doi: 10.21037/gs.2017.11.04.\r\n2.https://www.hopkinsmedicine.org/health/conditions-and-diseases/breast-cancer/breast-cancer-lymphedema-after-treatment\r\n3.https://www.cancer.gov/about-cancer/treatment/side-effects/lymphedema",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 111,
    "question": "é™¤äº†æ‰‹è¡“æ²»ç™‚ã€åŒ–å­¸æ²»ç™‚å¤–ï¼Œæœ‰äº›ç™Œç—‡å¯ç¶“ç”±ç¬¬ä¸€ç·šæ”¾å°„ç·šæ²»ç™‚ä¾†æ²»ç™’ã€‚ä¸‹åˆ—ç™Œç—‡ä¸­ï¼Œ \r\næ­£ç¢ºçš„æœ‰ï¼Ÿ \r\n(1) ç¬¬ä¸€æœŸå–‰ç™Œ \r\n(2) ç¬¬ä¸€æœŸèƒƒé»è†œç›¸é—œæ·‹å·´çµ„ç¹”æ·‹å·´ç™Œ \r\n(3) ç¬¬ä¸€æœŸé¼»å’½ç™Œ \r\n(4) ç¬¬ä¸€æœŸèƒ°è‡Ÿç™Œ",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "1. ç¬¬ä¸€æœŸå–‰ç™Œï¼Œå³ç‚ºGlottic cancer stage I (T1N0M0)ï¼Œæ ¹æ“šNCCN guidelineå¯ç¬¬ä¸€ç·šRT\r\n2. ç¬¬ä¸€æœŸèƒƒé»è†œç›¸é—œæ·‹å·´çµ„ç¹”æ·‹å·´ç™Œï¼Œå³ç‚ºExtranodal marginal zone lymphoma of stomach stage I (T1-3N0M0), æ ¹æ“šNCCN guidelineå¯ç¬¬ä¸€ç·šRT\r\n3. ç¬¬ä¸€æœŸé¼»å’½ç™Œï¼Œå³ç‚ºNasopharygeal carcinoma stage I (T1N0M0) ï¼Œæ ¹æ“šNCCN guidelineå¯ç¬¬ä¸€ç·šRT\r\n4. ç¬¬ä¸€æœŸèƒ°è‡Ÿç™Œï¼Œè¦–ç‚ºPancreatic adenocarcinoma stage I (T1-2N0M0)ï¼Œ æ ¹æ“šNCCN guidelineï¼ŒResectable è€…å»æ‰‹è¡“ã€non-resectableè€…Good PS å¯åšneoadjuvant managementã€non-resectableè€…Poor PSè€ƒæ…®BSC or palliative RTï¼Œé\"å¯æ²»ç™’æ”¾å°„æ²»ç™‚\"\r\n\r\næ•…ç­”æ¡ˆé¸(1)(2)(3) ->A\r\n\r\nRef: \r\n1. NCCN guideline v2.2025 Head and Neck cancer GLOT-2\r\n2. NCCN guideline v2.2025 B-cell lymphomas EMZLG-2\r\n3. NCCN guideline v2.2025 Head and Neck cancer NASO-2\r\n4. NCCN guideline v2.2025 Pancreatic adenocarcinoma PANC-6",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 112,
    "question": "åˆä½µåŒ–å­¸æ²»ç™‚å’Œæ”¾å°„ç·šæ²»ç™‚æ˜¯å­å®®é ¸ç™Œæœ€å¸¸è¦‹çš„æ²»ç™‚æ–¹å¼ï¼Œå­å®®é ¸ç™Œå…¶æ”¾å°„ç·šæ²»ç™‚ \r\nçµ¦äºˆæ–¹å¼æ˜¯å…ˆå¯¦æ–½éª¨ç›†æ²»ç™‚å¾Œè¿½åŠ è¿‘è·æ²»ç™‚ (brachytherapy)ï¼Œè¿‘è·æ²»ç™‚é ˆè©•ä¼°ä¸‹åˆ— \r\né‚£äº›(ä½•è€…)å±æ€¥å™¨å®˜(organ at risk)æœƒè¢«æ”¾å°„ç·šæ²»ç™‚è€Œå½±éŸ¿ï¼Ÿ \r\n(1) è†€èƒ±åŠ‘é‡ \r\n(2) è…è‡ŸåŠ‘é‡ \r\n(3) ç›´è…¸åŠ‘é‡ \r\n(4) è¼¸å°¿ç®¡åŠ‘é‡",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "Organ at risk: Healthy tissue or organ received radiation also during brachytherapy. \r\nEMBRACE trialã€ABSã€CCO recommendation çš†åˆ—å‡ºç­‰OAR \"rectumã€bladderã€sigmoid\" çš„å»ºè­°åŠ‘é‡\r\nå¼•ç”¨æ–‡ç»å…§æ–‡ä¸­æåˆ°å‚³çµ±OARæ˜¯rectumåŠbladderï¼Œæ•…ç­”æ¡ˆé¸B\r\n\r\nRef: Owrangi AM, Prisciandaro JI, Soliman A, Ravi A, Song WY. Magnetic resonance imaging-guided brachytherapy for cervical cancer: initiating a program. J Contemp Brachytherapy. 2015 Oct;7(5):417-22. doi: 10.5114/jcb.2015.55541",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/112/explain_figures/figure 1.png"
    ]
  },
  {
    "id": 113,
    "question": "é—œæ–¼ç™Œç—‡è‡¨åºŠè©¦é©—è¨­è¨ˆï¼ˆdesignï¼‰ï¼Œä¸‹åˆ—æ•˜è¿°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰ï¼Ÿ \r\n(1) Phase II trialså¦‚æœéš¨æ©Ÿåˆ†æ´¾æˆå¯¦é©—çµ„æ²»ç™‚vs.å°ç…§çµ„æ²»ç™‚ï¼Œå«åšrandomized screening designã€‚ \r\n(2) Phase II trialså¦‚æœéš¨æ©Ÿåˆ†æ´¾æˆå¯¦é©—çµ„æ²»ç™‚1 vs.å¯¦é©—çµ„æ²»ç™‚2ï¼Œå«åšrandomized selection designã€‚ \r\n(3) Phase III trialså¦‚æœselective biomarkeré™½æ€§ã€é™°æ€§çš„ç—…æ‚£éƒ½éš¨æ©Ÿåˆ†æ´¾æˆå¯¦é©—çµ„æ²»ç™‚vs. å°ç…§çµ„æ²»ç™‚ï¼Œå«åšbiomarker stratified designã€‚ \r\n(4) Phase III trialså¦‚æœåªæœ‰selective biomarkeré™½æ€§çš„ç—…æ‚£éš¨æ©Ÿåˆ†æ´¾æˆå¯¦é©—çµ„æ²»ç™‚vs.å°ç…§çµ„æ²»ç™‚ï¼Œå«åšbiomarker enrichment designã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "(1)æ­£ç¢º\r\n(2)æ­£ç¢º\r\n(3)æ­£ç¢º\r\n(4)æ­£ç¢º (è£œå……: Auxiliary-variable-enriched biomarker stratified designï¼Œåˆ©ç”¨è¼ƒä¾¿å®œçš„è¼”åŠ©biomarkerä¾†å”åŠ©ç¯©é¸ç—…äººï¼Œå¯ä»¥é™ä½ä½¿ç”¨true biomarkerä¾†ç¯©é¸ç—…äººçš„è²»ç”¨ï¼Œèˆ‡biomarker enrichment designç›¸åŒä¹‹è™•ç‚ºåªç´å…¥biomarkeré™½æ€§çš„ç—…äººé€²å…¥trial)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 114,
    "question": "æœ‰é—œNon-small cell lung cancerçš„ rare mutationsåŠå…¶ç›¸å°æ‡‰çš„æ²»ç™‚è—¥ç‰©ï¼Œä¸‹åˆ—é…å°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰ï¼Ÿ \r\n(1) RET fusionâ€“positive NSCLC: Selpercatinib \r\n(2) NTRK fusion: Entrectinib  \r\n(3) EGFR exon 20 insertion mutation: Amivantamab  \r\n(4) BRAF V600E: Dactolisib",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4),(5)"
    ],
    "correctAnswer": 0,
    "explanation": "(1)æ­£ç¢º\r\n(2)æ­£ç¢º (Entrectinibåœ¨NTRK 1/2/3 fusion NSCLC and ROS1 rearrangement NSCLCä¸­éƒ½å¯ä»¥ä½¿ç”¨)\r\n(3)æ­£ç¢º\r\n(4)éŒ¯èª¤ï¼ŒDactolisibç‚ºinhibitor of mTOR complex 1/2 and pan-PI3K; BRAF V600E NSCLCå¯ä»¥ä½¿ç”¨çš„è—¥ç‰©ç‚ºDabrafenib/trametinib, Encorafenib/binimetinib and Vemurafenib",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 115,
    "question": "æœ‰é—œAntibody-conjugate Drug (ADC) è—¥ç‰©ï¼Œä¸‹åˆ—æ•˜è¿°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰ï¼Ÿ \r\n(1) Trastuzumab deruxtecan (T-DXd) è—‰ç”± selectively cleavable by lysosomal histone proteases linkerï¼Œå¸¶è‘— anti-topoisomerase 1 inhibitor çš„payloadã€‚ \r\n(2) Sacituzumab govitecanæ˜¯FDA approvedæ–¼Trop-2éåº¦è¡¨ç¾ä¹‹è½‰ç§»å¾©ç™¼TNBCã€‚ \r\n(3) Trastuzumab deruxtecan (T-DXd) ä¸åªæ˜¯ä½œç”¨æ–¼HER2+ metastatic breast cancer(MBC)ï¼Œä¹Ÿè­‰å¯¦æ–¼ low-HER2 expression MBC (HR+/HR-)ä¸€æ¨£æœ‰ä¸éŒ¯æ•ˆæœã€‚ \r\n(4) Enfortumab vedotinå·²ç¶“approvedæ–¼æ²»ç™‚ç„¡æ•ˆå¾©ç™¼è½‰ç§»nectin-4è¡¨ç¾colon adenocarcinomaã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1)æ­£ç¢ºï¼ŒT-DXdçš„çµæ§‹ä¸­å«æœ‰cleavable tetrapeptide-based linkerï¼Œè¢«lysosomal enzymes (ex. cathepsins)åˆ†è§£å¾Œï¼Œé‡‹æ”¾å‡ºpayload anti-topoisomerase 1 inhibitor\r\n(2)éŒ¯èª¤ï¼Œèˆ‡single agent chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine)ç›¸æ¯”ï¼ŒSGå¯å¢åŠ PFS and OS of relapsed or refractory metastatic triple-negative breast cancer (ä¹³ç™Œç´°èƒçš„Trop-2è¡¨ç¾é‡>90%)(ASCENT trial)ï¼Œé©ç”¨æ–¼æ‰€æœ‰çš„TNBCï¼Œä¸éœ€è¦æª¢é©—Trop-IIè¡¨ç¾é‡\r\n(3)æ­£ç¢ºï¼Œåœ¨HER2-low metastatic breast canceræ—ç¾¤ (HER2-low: IHC 1+ or IHC 2+ with FISH negative)ï¼Œèˆ‡physicianâ€™s choice of chemotherapyç›¸æ¯”ï¼ŒT-DXdå¯å¢åŠ PFS and OS (DESTINY-Breast04 trial)\r\n(4)éŒ¯èª¤ï¼Œç›®å‰Enfortumab vedotin (EV)åªæœ‰è¢«æ ¸å‡†ä½¿ç”¨æ–¼urothelial carcinoma (ä¸”ä¸éœ€è¦ç‰¹åˆ¥é©—nectin-4è¡¨ç¾é‡)ï¼Œå¯ä»¥ä½¿ç”¨çš„æƒ…å¢ƒæœ‰ä¸€ç·š(EV with pembrolizumabï¼ŒEV-302 trial)åŠå¾Œç·š(EVå–®ç”¨ï¼ŒEV-301 trial) ï¼ŒEVåœ¨colon adenocarcinomaçš„è§’è‰²ç›®å‰é‚„åœ¨è‡¨åºŠè©¦é©—ç•¶ä¸­",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 116,
    "question": "æœ‰é—œAntibody-conjugate Drug (ADC) è—¥ç‰©çš„æ•˜è¿°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰ï¼Ÿ \r\n(1) ADCï¼Œä¾‹å¦‚TDM1ï¼Œåœ¨æ¥è¿‘target cellæ™‚ï¼Œlinkerå°±æœƒrelease payloadï¼ŒåŸ·è¡ŒcytotoxicityåŠæ˜é¡¯bystander effectã€‚ \r\n(2) ADCæœ‰ç²¾æº–target ä½œç”¨ï¼Œæ•…å¾ˆå°‘ myelotoxicity, nausea, or vomitingã€‚ \r\n(3) Trastuzmab deruxtecan éœ€è¦æœ‰ HER2 over-expression æ‰èƒ½åŸ·è¡Œtarget cell binding åŠinternalizationã€‚ \r\n(4) Enfortumab vedotin ä¸»è¦targetæ˜¯nectin-4ã€‚",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 3,
    "explanation": "(1)éŒ¯èª¤ï¼ŒADCèˆ‡ç™Œç´°èƒè¡¨ç¾çš„markerçµåˆä¹‹å¾Œè¢«åå™¬é€²å…¥ç™Œç´°èƒï¼Œlinker partåœ¨ç™Œç´°èƒå…§è¢«lysosomal enzymeåˆ†è§£ï¼Œé‡‹æ”¾å‡ºpayloadï¼Œé”åˆ°æ¯’æ®ºç´°èƒçš„æ•ˆæœ (ä¸¦éåœ¨ç´°èƒé™„è¿‘é‡‹æ”¾payload)\r\n(2)éŒ¯èª¤ï¼ŒADCä»ç„¶æœƒæœ‰myelotoxicity, nausea and vomitingé€™äº›å‰¯ä½œç”¨ (æ¯”ä¾‹ä¸Šä¹Ÿä¸å°‘)ï¼Œä»¥EV-301ç‚ºä¾‹ï¼Œany grade nausea (EV) 22.6% vs (chemothrapy) 21.6%; decreased appetite (EV) 30.7% vs (chemotherapy) 23.4%; leukopenia (EV) 5.4% vs (chemotherapy) 10.7%\r\n(3)éŒ¯èª¤ï¼ŒTrastuzumab Deruxtecan åœ¨HER2-lowæ—ç¾¤ä¾èˆŠæœ‰ä¸€å®šçš„æ•ˆæœ (DESTINY-Breast04 trial)\r\n(4)æ­£ç¢º",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 117,
    "question": "æœ‰é—œImmune checkpoint inhibitor æ²»ç™‚çš„æ•˜è¿°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰ï¼Ÿ \r\n(1) GI cancers with mismatch-repair deficiency, which has been hypothesized to result in increased numbers of tumor somatic mutations that would produce neoantigen targets, exhibit good response and tumor control to immune checkpoint blockade. \r\n(2) Clinical tumor response after immunotherapy should be assessed by conventional RECIST. \r\n(3) The major limitation to development of combinations has been the inability to identify the critical mechanisms of resistance to anti-CTLA-4 or to PD-1/ PD-L1 antagonists and as a result, accurate biomarkers to select patients for treatment with specific combination regimens are not yet available \r\n(4) The most common side effects observed (irAEs) were renal failure, cardiomyopathy and encephalitis, especially heart failure.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1) æè¿°æ­£ç¢ºã€‚MMR deficiencyæ˜¯ä¸€ç¨®Tumor agnosticsã€‚MMR proteinæ˜¯åƒèˆ‡DNAä¿®å¾©çš„è›‹ç™½è³ªï¼ŒMMR deficiencyæœƒå°è‡´DNAä¿®å¾©ç•°å¸¸ï¼Œå› è€Œå®¹æ˜“åœ¨è…«ç˜¤ç´°èƒä¸­ç”¢ç”Ÿå„å¼çªè®Šï¼Œé€²è€Œç”¢ç”ŸNeoantigensï¼Œè®“å…ç–«ç´°èƒæ›´å®¹æ˜“è¾¨è­˜åˆ°è…«ç˜¤ã€‚å› æ­¤ï¼Œè…«ç˜¤å°æ–¼Immune checkpoint blockadeçš„æ•ˆæœè¼ƒå¥½ï¼Œåƒæ˜¯åœ¨Colorectal cancer, cholangiocarcinomaç­‰GI cancersä¸­ï¼Œè‡¨åºŠè©¦é©—å‡è­‰å¯¦MMRdå°æ–¼ICIsæœ‰ä¸éŒ¯çš„æ•ˆæœ\r\n(2) æ­¤é¸é …éŒ¯èª¤ã€‚Conventional RECISTæ˜¯ç”¨æ–¼è©•ä¼°å‚³çµ±åŒ–ç™‚ã€target therapyçš„treatment responseã€‚ç”±æ–¼ICIsçš„Response patternä¸åŒæ–¼å‚³çµ±åŒ–ç™‚ã€target therapy (èˆ‰ä¾‹ä¾†èªªï¼ŒICIsçš„responseåŒ…å«Pseudoprogression, ç”¢ç”ŸResponseæ‰€éœ€æ™‚é–“å¯èƒ½è¼ƒä¹…ã€Responseå¯ä»¥ç¶­æŒè¼ƒä¹…ç­‰)ï¼Œå› æ­¤è©•ä¼°ICIs responseä¸èƒ½ä½¿ç”¨å‚³çµ±RECISTï¼Œè€Œæ˜¯è¦ç”¨Immune-specific related response criteriaï¼ŒåŒ…å«irRC, iRECIST, irRECIST, imRECIST \r\n(3) æè¿°æ­£ç¢ºã€‚é›–ç„¶ç›®å‰é©—Tumor PD-L1 expression, MMR deficiency/MSI-H, Tumor mutation burden (TMB)ç­‰æŒ‡æ¨™èƒ½éƒ¨åˆ†é æ¸¬è…«ç˜¤å°æ–¼ICIsçš„æ•ˆæœï¼Œä½†ç›®å‰ç¢ºå¯¦ä»ç¼ºä¹ç²¾ç¢ºçš„Biomarkersä¾†é æ¸¬ç™‚æ•ˆ \r\n(4) æ­¤é¸é …éŒ¯èª¤ã€‚æœ€å¸¸è¦‹çš„IrAEsæ˜¯Dermatitis, å…¶ä»–å¸¸è¦‹çš„åŒ…å«Colitis, Hepatitis, Pneumonitis, Endocrinopathy (Thyroiditis, Hypophysitis)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 118,
    "question": "æœ‰é—œendocrine therapyæ²»ç™‚è—¥ç‰©æ©Ÿè½‰èˆ‡ç–¾ç—…çš„æ•˜è¿°ä¸­ï¼Œæ­£ç¢ºçš„æœ‰ï¼Ÿ \r\n(1) Unlike other CDK4/6 inhibitors, abemaciclib has significant single-agent activity in hormone-refractory and chemotherapy-refractory metastatic ER-positive metastatic breast cancer. \r\n(2) Abiraterone, one of anti-androgen agents, is commonly associated with gynecomastia and elevated transaminase levels requiring frequent monitoring. \r\n(3) Raloxifene is a SERM originally developed to treat osteoporosis. Large placebo-controlled  randomized trials demonstrated reduced rates of osteoporosis and a reduction in new breast cancers. \r\n(4) Octreotide and lanreotide are somatostatin analogs used to treat post-menopausal syndrome.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1) æè¿°æ­£ç¢ºã€‚Abemaciclib monotherapyåœ¨MONARCH1 (phase 2 single-arm trial)å’ŒnextMONARCH(phase 2 RCT)å‡è­‰å¯¦å…¶å°æ–¼HR+, HER2- MBCçš„ç™‚æ•ˆ\r\n(2) æè¿°éŒ¯èª¤ã€‚Abirateroneæ˜¯ä¸€ç¨®anti-androgen agentsï¼Œæ©Ÿåˆ¶æ˜¯æŠ‘åˆ¶Androgen synthesisã€‚å¸¸è¦‹å‰¯ä½œç”¨ç¢ºå¯¦åŒ…å«AST/ALTä¸Šå‡ï¼Œä½†ä¸åŒæ–¼å‚³çµ±Anti-androgenï¼ŒAbirateroneä¸¦ä¸å¸¸è¦‹gynecomastiaã€‚(Ref: Oncology. 2013;84(2):92-9. doi: 10.1159/000343821.)\r\n(3) æè¿°æ­£ç¢ºã€‚Raloxifeneæ˜¯SERMï¼Œç”¨æ–¼æ²»ç™‚Osteoporosisã€‚æ ¹æ“šMORE trial (multicenter, randomized, double-blind trial)ï¼Œ3å¹´Ramoxifeneç›¸è¼ƒæ–¼Placeboå¯ä»¥æ¸›å°‘76%ç”¢ç”Ÿä¹³ç™Œçš„é¢¨éšª (Ref: JAMA. 1999 Jun 16;281(23):2189-97. doi: 10.1001/jama.281.23.2189.)\r\n(4) æè¿°éŒ¯èª¤ã€‚Octreotideå’Œlanreotideæ˜¯somatostatin analogsæ²’éŒ¯ï¼Œä¸éä»–å€‘æ˜¯ç”¨ä¾†æ²»ç™‚Neuroendocrine tumor (NET), carcinoid syndrome, acromegalyç­‰ç–¾ç—…ï¼Œè€Œéç”¨æ–¼æ²»ç™‚Post-menopausal syndromeã€‚Post-menopausal syndromeçš„æ²»ç™‚å¯ä»¥åˆ†ç‚ºHormone therapy (estrogens)å’Œnon-hormone therapy (ex. fezolinetantç”¨æ–¼æ§åˆ¶Vasomotor syndromeï¼›Ospemifene, DHEAç”¨æ–¼æ§åˆ¶genitourinary syndrome of menopause)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 119,
    "question": "About cancer genetic alterations, which of the following statements are (is) correct? \r\n(1)  Prof. Vogelsteinâ€™s research has shown that tumors from patients with HNPCC requires the accumulation of many genetic events, a process takes decades from polyp to adenoma and finally invasive carcinoma.  \r\n(2)  Circulating tumor DNA fragments contain the identical genetic defects as the tumor themselves; thus, the blood can reveal tumor point mutations, rearrangements, as well as amplifications. \r\n(3)  Major types of somatic mutations for oncogene present in malignant tumors include nucleotide substitutions, small insertions and deletions (indels), chromosomal rearrangements, and copy number alterations. \r\n(4)  The drug-resistant EGFR mutation is structurally analogous to the mutated gatekeeper residue T315I in BCR-ABL, T670I in c-Kit, and L1196M in EML4-ALK, which have been shown previously to confer resistance kinase inhibitors.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 3,
    "explanation": "(1) æè¿°éŒ¯èª¤ã€‚Prof. Vogelsteinâ€™sæ˜¯ç ”ç©¶\"Spontaneous\" CRCç™¼å±•æˆCarcinomaçš„åŸºå› è®ŠåŒ–ï¼Œè€ŒéHNPCC (Ref: N Engl J Med 1988;319:525-532. DOI: 10.1056/NEJM198809013190901)ã€‚HNPCCæ˜¯éºå‚³æ€§çš„å¤§è…¸ç™Œï¼Œè‡´ç—…æ©Ÿè½‰èˆ‡MMR deficiencyç›¸é—œ\r\n(2) æè¿°éŒ¯èª¤ã€‚ctDNAä¸æœƒåŒ…å«æ‰€æœ‰Tumorçš„DNA fragmentsï¼Œå› æ­¤ctDNAé€šå¸¸ç„¡æ³•å®Œå…¨åµæ¸¬Tumor genetic mutationã€‚èˆ‰ä¾‹ä¾†èªªï¼Œæ–‡ç»æŒ‡å‡ºä½¿ç”¨ctDNAæˆ–Tissueæª¢æ¸¬NSCLC EGFR variantsï¼Œconcordance rateç´„70%-90%ï¼Œè€Œé100% (Journal of Clinical Oncology. Volume 36, Number 16. https://doi.org/10.1200/JCO.2017.76.8671)\r\n(3) è€å¯¦èªªï¼Œæˆ‘ä¸çŸ¥é“é€™å€‹é¸é …éŒ¯åœ¨å“ª\r\n(4) æè¿°æ­£ç¢ºã€‚\r\næˆ‘è¦ºå¾—(3)(4)éƒ½æ˜¯æ­£ç¢ºçš„é¸é …ï¼Œä¸éå› ç‚ºé¸é …åªæœ‰(4)ï¼Œæ‰€ä»¥æˆ‘é¸D",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 120,
    "question": "The identification of drivers versus the passenger gene mutation from NGS is of utmost relevance and remains a pressing challenge in cancer genetics. Which of the following scenarios are (is) in favor of a driver mutation?\r\n(1) mutations that frequently occur on different patients\r\n(2) mutations may have characteristics like those causing Mendelian disease when inherited in the germ line\r\n(3) mutations that affect locations that have previously been shown to be cancer causing in protein members of the same gene family\r\n(4) mutations with nonsynonymous single nucleotide polymorphisms with high minor allele frequencies",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "åœ¨è…«ç˜¤å½¢æˆçš„éç¨‹ä¸­æœƒç´¯ç©å¤šç¨®çªè®Šï¼Œå¤§éƒ¨åˆ†çš„çªè®Šä¸¦ä¸æœƒè³¦äºˆè…«ç˜¤ç´°èƒç”¢ç”Ÿç”Ÿé•·å„ªå‹¢ï¼Œç¨±ä¹‹ç‚ºPassenger mutationï¼›åä¹‹ï¼Œå°‘éƒ¨ä»½çš„çªè®Šæœƒè³¦äºˆè…«ç˜¤ç´°èƒç”¢ç”Ÿç”Ÿé•·å„ªå‹¢ï¼Œå› æ­¤ç¨±ç‚ºDriver mutationã€‚\r\n(1) é«˜æ¯”ä¾‹ç—…äººæœ‰é€™å€‹çªè®Š â†’ è©²çªè®Šæ¯”è¼ƒæœ‰å¯èƒ½æ˜¯Driver mutation\r\n(2) è©²çªè®Šå…·æœ‰å­Ÿå¾·çˆ¾åŸºå› éºå‚³æ¨¡å¼ â†’ ä»£è¡¨åªè¦æœ‰é€™å€‹çªè®Šå°±æœƒç™¼ç—… â†’ æ¯”è¼ƒæœ‰å¯èƒ½æ˜¯Driver mutation\r\n(3) çªè®Šç™¼ç”Ÿçš„è›‹ç™½è³ªï¼Œæœ‰å·²çŸ¥èˆ‡è©²è›‹ç™½åŒä¸€å®¶æ—çš„å…¶ä»–è›‹ç™½è³ªçªè®Šæœƒç›´æ¥å°è‡´ç™Œç—‡ â†’ æœ‰å¯èƒ½æ˜¯Driver mutation\r\n(4) Non-synonymous single nucleotide polymorphisms (nsSNPs)æ˜¯æŒ‡æœƒå½±éŸ¿è½‰è­¯è›‹ç™½è³ªamino acid sequenceçš„SNP. Minor allel freqency (MAF)æ˜¯æŒ‡æ•´å€‹æ—ç¾¤ä¸­ç¬¬äºŒå¸¸è¦‹çš„åŸºå› è®Šç•°ç™¼ç”Ÿçš„æ¯”ä¾‹ (èˆ‰ä¾‹ä¾†èªª:æŸå€‹SNPåœ¨æ—ç¾¤ä¸­æœ€å¸¸è¦‹çš„nucleotideæ˜¯T(ä½”50%)ï¼Œç¬¬äºŒå¸¸è¦‹çš„æ˜¯C(ä½”40%)ï¼Œå‰‡è©²SNPçš„MAFå°±æ˜¯40%)ã€‚å› æ­¤ï¼Œæ­¤é¸é …æè¿°çš„High minor allele frequenciesçš„nsSNPsï¼Œåªèƒ½èªªè©²nsSNPsç¬¬äºŒå¸¸è¦‹çš„è®Šç•°ä½”æ•´å€‹æ—ç¾¤çš„æ¯”ä¾‹æ˜¯é«˜çš„ï¼Œä¸¦æœªæåŠèˆ‡æŸç–¾ç—…çš„é—œè¯ï¼Œå› æ­¤ä¸å¤ªå¯èƒ½æ˜¯Driver mutation",
    "questionFigures": [],
    "explainFigures": []
  }
]